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Diabetes is a worldwide condition that affects millions of people of all ages and 
backgrounds. It strikes the rich and the poor, old and young, healthy and sick. Diabetes 
is one of the largest global health emergencies of the 21st century, where some regions 
of the world have a much higher occurrence than others. Diabetes occurs when there 
are increased levels of glucose in the blood due to the lack of insulin, or the inability of 
the body’s cells to respond to insulin. Type 2 diabetes accounts for approximately 90% 
of all cases of diabetes worldwide and continues to rise across all world regions.  
The goal of our research was to investigate two families of heterocyclic compounds that 
have potential as anti-diabetic agents. We postulated that an anti-diabetic effect might 
be achieved through the inhibition of complex I of the electron transport chain, which 
would make oxidative phosphorylation less efficient, and therefore require increased 
glucose uptake from the blood in order to maintain ATP levels. This would consequently 
lower blood glucose levels and the inhibitor would thus have a hypoglycaemic effect.   
Building on findings of previous members of our own research group and collaborators, 
we developed two families of compounds and evaluated them for their anti-diabetic 
biological activity. The first family investigated was the arylpiperazine family, which 
consisted of analogues of the hit compound RTC1. Here, structural variations were 
performed at five sites on RTC1. The second family explored was the 
pyrazolopyrimidinone bicycle family, which consisted of analogues of the hit compound 
RTC53. In this case, structural variations were carried out at two principle sites on RTC53.  
Hydrophobic, steric, and electronic effects were all explored for both families through 
the systematic structural modifications. 
One of the aims of the project, in addition to access a large number of compounds, was 
to develop improved methods for the synthesis of both families. For the arylpiperazine 
family, a simpler and higher yielding procedure for their synthesis was achieved.  This 
method no longer required anhydrous conditions or elaborate work-up procedures. For 
the pyrazolopyrimidinone bicycle family, method development focused on establishing 
a “one-pot” microwave-assisted synthesis of the pyrazolopyrimidinone bicycle. This 
2 
 
avoided the need to isolate and purify intermediates, and reduced total reaction times 
down to just over 2 hours.  
Full characterisation of all compounds synthesised was carried out using techniques 
such as 1H and 13C NMR spectroscopy, including 2D-NMR experiments, X-ray crystal 
analysis, infrared spectroscopy, and high-resolution mass spectrometry.  
A structure activity relationship study was performed by testing compounds from both 
families in (i) a whole cell, functional, glucose uptake assay and (ii) a complex I inhibition 
assay. The glucose uptake assay measured the amount of tritiated (3H) deoxy-2-glucose 
taken up by C2C12 mouse muscle cells and quantified the fold change using a protein 
assay to determine the number of cells present. The complex I assay determined a 
compound’s ability to inhibit NADH dehydrogenase, complex I of the electron transport 
chain, by measuring the change in ubiquinone absorbance. Using both these assays, we 
were able to establish active compounds, which had the potential of developing into 
anti-diabetic agents, and obtained a better understanding of the influence of structure 












Diabetes Mellitus, more simply called diabetes, is a chronic condition that occurs when 
there are increased levels of glucose in the blood. Diabetes is a global worldwide issue. 
It kills and disables, strikes people at their most productive age, impoverishes families, 
and reduces the life expectancy of older people. Diabetes is a shared threat that does 
not respect borders or social class. No country is immune from diabetes and the 
epidemic is anticipated to continue. The burden of diabetes drains national healthcare 
budgets, reduces productivity, decreases economic growth, causes catastrophic 
expenditure for vulnerable households, and overwhelms healthcare systems.1,2 
Diabetes is classed as a metabolism disorder. Metabolism refers to the way the body 
breaks down digested food into carbohydrates, fats, and proteins, which then makes its 
way into our bloodstream.3 Glucose is a form of carbohydrate used by cells for energy 
and growth. However, cells cannot use glucose without insulin being present. Insulin is 
a hormone that is produced in the pancreas. It is an essential hormone as it plays a key 
role in the transport of glucose from the bloodstream into the body’s cells where the 
glucose is converted into energy. The lack of insulin, or the inability of the cells to 
respond to insulin, leads to high levels of blood glucose, known as hyperglycaemia, 
causing diabetes.1 
There are three main types of diabetes: type 1 diabetes, type 2 diabetes, and gestational 
diabetes. There are also some less common types of diabetes which include monogenic 
diabetes and secondary diabetes.1 While type 1 and type 2 diabetes are caused by 
contributions of multiple genes and environmental factors, monogenic diabetes is the 
result of a single genetic mutation in an autosomal dominant gene. Neonatal diabetes 
mellitus and maturity-onset diabetes of the young (MODY) are examples of monogenic 
diabetes. Around 1-5% of all diabetes cases are due to monogenic diabetes.4 Secondary 
diabetes arises as a complication of other diseases such as hormone disturbances, drugs, 
or diseases of the pancreas.1 
Recent research has shown that diabetes has been increasing in patients with cystic 
fibrosis, occurring in 20 % of adolescents and up to 50 % of adults. Cystic fibrosis-related 
diabetes (CFRD) is a unique clinical entity but shares features of type 1 and type 2 
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diabetes. The complexity of management of CFRD is increased by other factors such as 
elevated energy expenditure, glucagon deficiency, and liver dysfunction.5  
The most common symptoms of diabetes include fatigue, weight gain, cuts and bruises 
that do not heal, frequent urination, increased thirst and hunger, male sexual 
dysfunction, numbness and tingling in hands and feet. The risk of developing type 2 
diabetes is elevated among those who are overweight, physically inactive, and have an 
unhealthy diet.6  
Diabetic patients are typically advised to follow a healthy eating plan, perform adequate 
exercise and lose weight, take insulin regularly, and test their blood glucose levels 
regularly. Type 2 diabetics are also sometimes recommended to take oral medication to 
control their blood glucose levels.6 
When diabetes is badly controlled, many complications can occur. These complications 
can affect the eye (glaucoma, cataracts, and diabetic retinopathy), leg/foot (ulcers), 
nerves (diabetic neuropathy), skin, heart, stomach (gastroparesis), and kidney 
(nephropathy). Complications from diabetes may also result in hypertension, hearing 
loss, gum disease, infections and stroke.7,2,8 Acute complications can include diabetic 
ketoacidosis, hyperosmolar hyperglycaemic state, or death.9   
In Ireland, recent research among children has shown that the risk of type 2 diabetes 
increases among obese children and adolescents. The extent of obesity has also been 
found to correlate with insulin resistance and occurrence of non-alcoholic 
steatohepatitis. Cardio-metabolic risk factors found in conjunction with obesity include 
impaired fasting glucose tolerance, impaired fasting blood glucose, as well as 
hypertension, low high-density lipoproteins, and high triglycerides.10  
Prediabetes is a condition that normally develops into type 2 diabetes. It is diagnosed 
when blood glucose levels are higher than normal, but not high enough to merit a 
diabetes diagnosis. The cells in the body are gradually becoming resistant to insulin. 
Studies have indicated that even at the prediabetes stage, some damage to the 




 Types of diabetes 
As previously mentioned, there are several types of diabetes. However, there are three 
main types of diabetes: type 1 diabetes, type 2 diabetes, and gestational diabetes.    
Type 1 diabetes tends to be diagnosed in childhood or early adult life, and always 
requires treatment with insulin injections. It is caused by the body’s own immune system 
destroying the β-cells of the pancreas, whose function is to make insulin. As a result, the 
body produces none to very little insulin with a relative or absolute deficiency of insulin. 
The causes of this destructive process are not fully comprehended, but a combination 
of genetic susceptibility and environmental triggers have been suggested, such as viral 
infection, toxins or some dietary factors. People with type 1 diabetes need daily insulin 
injections in order to maintain a glucose level in the proper range.1,12  
Type 2 diabetes usually develops slowly in adulthood and is commonly caused by 
excessive body weight and insufficient exercise. It begins with insulin resistance, where 
cells fail to respond to insulin properly, and may develop into a lack of insulin as the 
disease advances. It is progressive and can sometimes be treated with diet and exercise, 
but more frequently type 2 diabetes may require anti-diabetic medicine and/or insulin 
injections.6,13 
Gestational diabetes is the third main form of diabetes, and occurs when women have 
very high levels of glucose in their blood during their pregnancy. In such a case, their 
bodies are unable to produce enough insulin to transport sufficient levels of glucose into 
their cells, resulting in progressively increasing levels of blood glucose. This is a result of 
the action of insulin being diminished (insulin resistance) due to hormone production by 
the placenta. Risk factors for gestational diabetes include older age, overweight or 
obesity, or a family history of diabetes. The majority of gestational diabetes patients can 





 Diabetes prevalence globally  
Diabetes is one of the largest global health emergencies of the 21st century. It is among 
the top ten causes of death globally and together with the other three major non-
communicable diseases (NCDs) (cardiovascular disease, cancer, and respiratory disease) 
accounts for over 80% of all premature NCD deaths. A major contributor to the challenge 
of diabetes is that 80% of people with diabetes are undiagnosed.15 
The occurrence of diabetes is increasing worldwide, but there is huge variation by 
country with some regions of the world having much higher occurrence than others 
(Figure 1). The reasons for this are unclear but an interplay between genetic and 
environmental factors is suspected.1 
 
Figure 1: Number of people with diabetes worldwide and per region in 2017 and 2045        
(20-79 years) (International Diabetes Federation – 8th Edition 2017).1 
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About 425 million people worldwide, or 8.8% of adults aged 20-79 years old, are 
estimated to have diabetes. From those, an estimated 79% live in low and middle 
income countries. If these trends continue, by 2045, 629 million people aged 20-79 years 
old are expected to have diabetes. The largest increases will take place in regions where 
economies are moving from low income to middle income levels.1  
In high income countries, an estimated 10% of all diabetes cases are type 1 diabetes. In 
total, over one million of children and adolescents below 20 years of age are estimated 
to have type 1 diabetes globally. The United States, India, and Brazil have the largest 
incidence and prevalence of children with type 1 diabetes under 15 years old.1   
Type 2 diabetes accounts for approximately 90% of all cases of diabetes worldwide and 
continues to rise across all world regions. This rise is likely fuelled by an aging population, 
economic development and increasing urbanisation, leading to more sedentary 
lifestyles and greater consumption of unhealthy foods linked with obesity.16,17 
The International Diabetes Federation (IDF) 2017 (8th edition) showed that in 2017, 
China had the most number of people with diabetes aged 20-79 years old with 114.4 
million people. Whereas by 2045, it is expected that India will have the most number of 
people for that age group with 134.3 million people. Other countries among the top ten 
in the world for the prevalence of diabetes included the United States of America, 
Indonesia, Brazil, and Egypt. This report also showed that the prevalence of diabetes for 
women aged 20-79 years old is estimated to be 203.9 million, which is slightly lower 
than among men, with 221.0 million. However, it has been estimated that approximately 
212.4 million people (50%) of that age group are undiagnosed.1  
It is estimated by the IDF that for 21.3 million (16.2%) live births in 2017, the mother had 
some form of hyperglycaemia in pregnancy. An estimated 86.4% of those cases were 
due to gestational diabetes, 6.2% due to diabetes detected prior to pregnancy, and 7.4% 
due to other types of diabetes first detected in pregnancy.1 
The IDF also stated how diabetes shows high prevalence in people older than 65 years 
old. In 2017, it was estimated that 122.8 million people (18.8%) aged 65-99 years old 
were living with diabetes. If the trends continue, this number is expected to become 
253.4 million people by the year 2045. The number of deaths due to diabetes from age 
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65 years and above currently stands at 3.2 million, which counts for more than 60% of 
all deaths attributable to diabetes among  adults in total.1 
As mentioned before, diabetes kills. According to the IDF, diabetes accounts for 10.7% 
of global all-cause mortality among people in the age of 20-79 years old. In 2017 alone, 
approximately 4 million people of this age group are estimated to have died from 
diabetes. This is higher than the combined number of deaths from infectious diseases, 
such as HIV, tuberculosis, and malaria. The continent which resulted in most deaths from 
diabetes before the age of 60 was Africa with 77% proportion of the deaths according 
to diabetes.1 
According to the IDF, in 2017, Ireland had an estimate of 141,500 people aged 20-79 
years old suffering from diabetes (prevalence of 4.3% of the population). Among those, 
an estimated 50,600 people (34%) are undiagnosed. People with type 1 diabetes 
account for approximately 15,000 people (11%) of the total diabetes population. It is 
estimated that there are over 15,600 people over 80 years of age living with type 2 
diabetes. Ireland was ranked ninth in the top ten countries for the incidence rates of 




 Cost of diabetes  
The economic burden of diabetes on the Irish health care system is becoming a major 
challenge for the government and the Health Service Executive (HSE). The CODEIRE 
study published in 2006 was an international accredited study and examined the cost of 
treating type 2 diabetes in Ireland during Nov-Dec 1999.18 This study suggested that 10% 
of the national health budget was being consumed treating diabetes alone. Of the 
overall cost, 50% was spent on hospitalization for complications and wages; 42% on drug 
costs; and 8% on ambulatory care and attending non-diabetes specialists for diabetes-
related complications.18 Globally, according to the IDF, diabetes results in $727 billion 
US dollars being spent annually by people with diabetes on healthcare alone, which 




 Treatments for diabetes 
The first-line therapy for diabetes is diet and exercise plus hypoglycaemic drugs, as 
recommended by the American Diabetes Association (ADA) and European Association 
for the Study of Diabetes (EASD).19 Regular monitoring of blood glucose levels for 
diabetic patients is essential, especially those who are overweight and obese. In order 
to save lives and prevent devastating complications resulting from diabetes, the IDF has 
suggested early detection, diagnosis and cost-effective treatment of diabetes.1,19   
When inadequate glycaemic control prevails, pharmaceutical intervention in the form 
of an anti-diabetic oral agent is needed. There are currently seven distinct classes of 
hypoglycaemic agents with different mechanisms of action, adverse effect profiles, and 
toxicities. They are sulfonylureas, biguanides, meglitinides, thiazolidinediones, α-






Sulfonylureas consist of first generation sulfonylureas (acetohexamide, chlorpropamide, 
tolbutamide and tolazamide), which are no longer in use due to undesirable 
cardiovascular effects, and second generation sulfonylureas (glipizide, gliclazide (Figure 
2), glibenclamide, glimepiride) which are widely used worldwide. Sulfonylureas are used 
to enhance insulin secretion and improve insulin activity. They stimulate insulin release 
from the pancreatic β-cells, displaying a more pronounced action in the presence of 
glucose. They do so by inhibiting an adenosine triphosphate-dependent potassium 
channel that results in cell membrane depolarization.22 This leads to calcium influx and 
release of stored insulin from secretory granules within the cell. The net outcome is 
increased responsiveness of β-cells to both glucose and non-glucose secretagogues, 
resulting in more insulin being released at all blood glucose concentrations.19,21  
 
Figure 2: Structure of gliclazide.  
The second generation sulfonylureas have a potency that allows them to be given in 
much lower doses than the first generation sulfonylureas. Due to the mechanism of 
action of sulfonylureas, studies have suggested concern with respect to patients with 
acute myocardial infarction (heart attack).19 Sulfonylureas can be used as monotherapy, 
or in combination with insulin or other oral hypoglycaemic drugs. Sulfonylurea 
compounds have several adverse side-effects such as hypoglycaemia and 
hyponatraemia, or less severe side-effects such as headaches, dizziness, and 
gastrointestinal issues. Sulfonylureas are not suggested as first choice for obese patients 
as they have been associated with weight gain.19,20,22,23 Sulfonylureas are also not 





Biguanides are a class of anti-hyperglycaemic agents that have been used in the control 
and treatment of type 2 diabetes for many years. They work by reducing hepatic glucose 
output and enhancing insulin sensitivity in hepatic and peripheral tissues.  Originally 
three biguanides were used: metformin, phenformin and buformin. However metformin 
is the only drug of this class still administered to patients today as it does not cause lactic 
acidosis, unlike phenformin and buformin.19  
1.1.4.2.1 Metformin 
Metformin (Figure 3) is indicated either as a monotherapy or in combination with a 
sulfonylurea. Sulfonylureas and metformin cause a similar decrease in fasting blood 
glucose levels in diabetic patients. However, unlike sulfonylureas, metformin does not 
cause weight gain and does not directly stimulate insulin secretion. Its major effects are 
to increase insulin-mediated glucose utilization in peripheral tissues (such as muscle and 
liver), improve insulin action, and to decrease hepatic glucose output. It also reduces 
substrate availability for gluconeogenesis as it has an anti-lipolytic effect that lowers 
serum free fatty acid concentrations.25 Furthermore, it decreases insulin resistance, 
which is often a problem in patients with type 2 diabetes, by increasing insulin 
sensitivity. Importantly, it is an anti-hyperglycaemic agent and not a hypoglycaemic 
agent, as are the sulfonylureas, as it decreases the blood glucose level of diabetic 
patients but not that of non-diabetic patients.19,20  
 
Figure 3: Structure of metformin. 
Metformin undergoes almost no hepatic metabolism and is 90-100% excreted by the 
kidneys.  Metformin has therefore proved effective and safe. It has been used in Europe 
for over thirty years, and in the United States for over twenty years. Metformin is 
commonly prescribed to type 2 diabetic patients, unless contraindicated.19,20  
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Although the exact mechanism by which metformin exerts its anti-diabetic effect in the 
body is not fully known, it has been found to activate adenosine monophosphate-
activated protein kinase (AMPK). AMPK is a heterotrimeric protein complex that is 
involved in cellular energy homeostasis where it regulates energy levels by monitoring 
the amounts of adenosine triphosphate (ATP) and adenosine monophosphate (AMP). 
AMPK also regulates lipid and glucose metabolism. Activation of AMPK by small 
molecules such as metformin has shown to reduce hepatic gluconeogenesis and to 
stimulate the uptake of glucose by skeletal muscles. A commonly proposed mechanism 
for the metformin induced activation of AMPK is the inhibition of mitochondrial 
respiration by acting at complex I of the electron transport chain.26,27 
Recently, metformin was found to lower the increase in enzyme activity exhibited by the 
pancreatic mitochondrial complex I, in both type 1 and type 2 diabetes, in response to 
nicotinamide adenine dinucleotide (NAD+) versus NADH (reduced form) redox 
imbalance, as well as NADH overload of complex I.28 Recent research has also shown 
that metformin does not produce the mitochondrial damage observed with more 
hydrophobic guanide-containing drugs. Instead, it was found to inhibit the mitochondria 
by a distinctive mechanism resulting in oxidation of the NADH/NAD+ couple. It inhibits 
the energy transduction by selectively suppressing efficient coupling of the redox and 
proton transfer domains of complex I. In addition, unlike other biguanides, metformin 
does not exhibit any toxic properties nor induce lactic acidosis, but it does suppress 
weight gain.29 
Metformin is available as tablet and liquid formulations. Metformin tablet formulations 
are either immediate release or extended release. The most common side-effects of 
metformin are gastrointestinal, including diarrhoea, nausea, and mild anorexia. These 
effects are usually mild and brief. They can be managed by dose reduction or 
discontinuation of the drug.19 The use of metformin in the elderly has been associated 
with adverse events such as hyporexia, gastrointestinal intolerance, dysgeusia, and 
vitamin B12 deficiency.24 Metformin extended release causes fewer gastrointestinal 
side-effects than metformin IR.30  
Metformin cannot be administered to patients who have certain conditions such as 
acute heart failure, tissue hypoxia, respiratory failure, hepatic impairment, or a risk of 
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functional renal failure. The usefulness of metformin has been found to be highly limited 
in patients with anorexia and low weight. Five percent of patients who use metformin 
have been found to discontinue using it due to poor gastrointestinal tolerance. This rate 
has been reported to be higher in elderly patients.24 
Metformin is commonly prescribed for women with gestational diabetes as it is 
associated with lower gestational weight gain, displays a reduced risk of hypoglycaemia, 
and shows no compromise of the motor and linguistic development. Despite all these 
benefits however, up to half of the women with gestational diabetes require insulin 





The meglitinides (repaglinide (Figure 4) and nateglinide) are short-acting glucose-
lowering drugs for treatment of patients with type 2 diabetes, where they can be used 
alone or in combination with metformin. They were designed to achieve more 
physiologic insulin release and less risk for hypoglycaemia. Their mechanism of action 
closely resembles that of sulfonylureas. They also act by regulating ATP-dependent 
potassium channels in pancreatic β-cells, which leads to depolarization of cell 
membrane, opening of calcium channels, and consequently releasing insulin. However, 
they are structurally different than sulfonylureas and they stimulate the release of 
insulin from the pancreatic β-cells through a different binding site than the “sulfonylurea 
receptor”. Meglitinides also have a shorter onset and duration of action compared with 
sulfonylureas, due to their weaker binding affinity and faster dissociation.19,21 
 
Figure 4: Structure of repaglinide. 
Nateglinide is hepatically metabolized, with renal excretion of active metabolites. 
Repaglinide is the drug of choice in patients with impaired renal function as it is 
principally metabolized by the liver. Hypoglycaemia is the most common side effect 





Thiazolidinediones (pioglitazone (Figure 5)) are another class of drugs for type 2 diabetes 
which act by increasing peripheral insulin sensitivity. Thiazolidinediones provide longer-
lasting glycaemic control than sulfonylureas and metformin.24 They improve glycaemia 
by reducing insulin resistance and preserving pancreatic β-cell function with a different 
mechanism of action than biguanides. They act mainly by improving peripheral uptake 
and utilization of glucose in muscle and fat, to decrease liver glucose production.19,21  
 
Figure 5: Structure of pioglitazone. 
Pioglitazone does not produce hypoglycaemia and acts favourably on the lipid profile. 
The drug has also been shown to histologically improve non-alcoholic steatohepatitis in 
patients with prediabetes. However, pioglitazone has various adverse effects that limit 
its use in the elderly, such as weight gain, dilutional anaemia, salt and fluid retention, 
increased risk of fractures, and increased risk of heart failure.24 
Thiazolidinediones are among the most expensive oral agents and therefore are not 
generally indicated over metformin for initial therapy of type 2 diabetes. 
Thiazolidinediones have been reported to have anti-inflammatory, anti-thrombotic, and 
anti-atherogenic properties. However, thiazolidinediones have also been found to cause 
severe side-effects.  They were reported to increase the risk of heart attack in many 
patients. They cause weight gain due in part by fluid retention, but also from the 
proliferation of new adipocytes. They also have an effect on bone metabolism through 
the activation of peroxisome proliferator-activated receptor (PPAR), so a relationship 





1.1.4.5 α-Glucosidase inhibitors 
α-Glucosidase inhibitors (acarbose and miglitol (Figure 6)) act on the α-glucosidase 
enzyme which is found in brush border cells of the small intestine and cleaves more 
complex carbohydrates into simpler sugars. α-Glucosidase inhibitors prevent the 
breakdown and absorption of carbohydrates. The largest impact of α-glucosidase 
inhibitors is on postprandial hyperglycaemia and on fasting plasma glucose (FPG) 
levels.19,21  
 
Figure 6: Structure of miglitol. 
The main side-effects of α-glucosidase inhibitors are abdominal discomfort, flatulence, 
bloating, and diarrhoea. Although hypoglycaemia is not typically associated with 
monotherapy with α-glucosidase inhibitors, it can occur in combination with other 
drugs.19 Although α-glucosidase inhibitors can be potentially useful for some elderly 
diabetic patients, their use can be limited by their low efficacy and high rate of adverse 





1.1.4.6 Incretin mimetics 
Incretins are enteroendocrine hormones released into bloodstream from L and K cells 
dispersed throughout the gastrointestinal tract. Examples of incretins are Glucagon Like 
Peptide-1 (GLP-1) and Glucose Dependent Insulinotropic Polypeptide (GIP).  GLP-1 is 
secreted in response to nutrients and its levels are decreased in type 2 diabetes. It acts 
by stimulating glucose-dependent insulin release from the pancreatic islets and 
therefore prevents hypoglycaemia, which is the major advantage over sulfonylureas. It 
also slows gastric emptying, inhibits inappropriate post-meal glucagon release, and 
reduces food intake.19,21,32  
Therapy with GLP-1 and its analogues is associated with weight loss, owing in part to the 
effects of GLP-1 on slowed gastric emptying and its well-recognized side-effects of 
nausea and vomiting.19 GLP-1 analogue therapy has also been shown recently to 
decrease proinflammatory macrophages and reduce inflammation in type 2 diabetes.33 
GLP-1 can also regulate invariant natural killer T (iNKT) cells, which are a rare subset of 
innate T cells involved in the regulation of macrophage and adipose tissue biology.32,34 
GLP-1 exhibits a short half-life of 1-2 minutes due to N-terminal degradation by the 
enzyme DPP-IV. Research has focused on analogues of GLP-1 (incretin mimetics) that 
are resistant to DPP-IV degradation, and on agents that increase GLP-1 via inhibition of 
DPP-IV. Experimental studies have suggested that GLP-1 stimulate proliferation of 
developed β-cells and inhibits β-cell apoptosis, suggesting a potential role of incretin-
mimetics in vivo in limiting β-cells dysfunction, which typically occurs in people with type 
2 diabetes.19,21  
1.1.4.6.1 Exenatide  
Exenatide is a 39-amino acid peptide incretin mimetic that exhibits glucose regulatory 
activities like those observed with human GLP-1 but with increased resistance to 
deactivation by DPP-IV. Exenatide binds to the GLP-1 receptor, stimulates glucose-
dependent insulin secretion, reduces gastric emptying, suppresses glucagon secretion, 
and lowers food intake. More interestingly, exenatide appears to have beneficial effects 
on β-cell function as it normalizes the loss of first-phase insulin secretion as well as 
20 
 
hypersecretion of glucagon from α-cells, thereby lowering hepatic glucose production 
in the postprandial state.19,21  
Commonly reported adverse effects of exenatide are nausea, diarrhoea, weight loss and 
vomiting. Hypoglycaemic events are mainly observed when combinations are used, such 




1.1.4.7 Dipeptidyl peptidase-IV inhibitors 
Dipeptidyl peptidase IV (DPP-IV) is a 110 kDa plasma membrane-spanning cell surface 
glycoprotein ectopeptidase. It is ubiquitously expressed in tissues such as liver, kidney, 
lung, lymphocytes, and endothelial cells. As previously discussed, DPP-IV rapidly 
degrades and inactivates GLP-1, GIP, and other peptides in vivo via cleavage of the N-
terminal amino acids. Inhibition of DPP-IV therefore leads to an increase in circulating 
endogenous GLP-1 and GIP levels. DPP-IV inhibitors are therefore not incretin mimetics, 
but incretin enhancers. DPP-IV inhibitors can be administered orally, unlike other GLP-1 
based therapies.19,21  
 
Figure 7: Structure of sitagliptin. 
DPP-IV inhibitors (sitagliptin (Figure 7), vildagliptin and saxagliptin) can be used as a 
second agent if a single agent, such as a sulfonylurea, metformin or a thiazolidinedione, 
does not provide enough of a response. They can also be used as a third agent when 
dual therapy with metformin and a sulfonylurea does not provide adequate glycaemic 
control. These oral drugs are well tolerated, safe, and effective in the short and long 
term, in elderly and young diabetic patients. They have no effect on gastric emptying, 
do not induce reduced central intake, and do not cause gastrointestinal intolerance or 
weight loss.24  
DPP-IV inhibitors mimic the therapeutic effects of incretin mimetics including inhibition 
of glucagon secretion, stimulation of insulin secretion, and inhibition of apoptosis. These 
drugs are weight neutral and have a low potential for hypoglycaemia when used as 
monotherapy. One safety concern involves the potential of DPP-IV inhibitors to interfere 
with immune functions causing infections and headaches. Other adverse effects 




1.2 ATP Production  
Glucose in the blood acts as the main source of energy for our bodies. A major part of 
the use of the energy from glucose oxidation is the conversion of adenosine diphosphate 
(ADP) to adenosine triphosphate (ATP), which can be further used as the energy 
currency of the cell. ATP is produced in a process known as cellular respiration (Figure 
8), which is a cumulative process that consists of glycolysis, Krebs’ cycle, and oxidative 
phosphorylation.35  
 
Figure 8: Overview of Cellular Respiration (Campbell's Biology, 5th Edition).  
In eukaryotic cells, glycolysis takes place in the cytosol, whereas the Krebs’ cycle and 
oxidative phosphorylation occur within the mitochondrion. In prokaryotic cells, these 
reactions take place in the cytoplasm. Glycolysis and the Krebs’ cycle catabolically break 
down glucose and other organic substances. Redox reactions are key processes of both 
glycolysis and the Krebs’ cycle.35  
Glycolysis is the process where glucose is converted into smaller molecules through 
many chemical transformations. It occurs in two phases, known as the energy 
investment phase and the energy pay-off phase. It produces two molecules of ATP, two 
molecules of pyruvate and two electron-carrying molecules of NADH.35  
The Krebs’ cycle (also known as the citric acid cycle) oxidizes a pyruvate derivative to 
acetyl Coenzyme A and carbon dioxide. Through a series of intermediate steps, NAD+ 
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and flavin adenine dinucleotide (FAD), are produced along with two ATP molecules.  
NAD+ and FAD molecules are capable of storing hydride electrons and are reduced in the 
process. The reduced forms, NADH and FADH2, carry the hydride electrons to the next 
stage; oxidative phosphorylation (Figure 9).35 
 
Figure 9: Oxidative Phosphorylation (Campbell Biology 7th Edition).  
During the oxidative phosphorylation step, NADH and FADH2 unload their electrons in 
the electron transport chain (ETC) and return to their original forms, NAD+ and FAD. The 
electrons then move across the ETC to release energy. The major function of the ETC is 
to establish a proton gradient. The ETC ends when oxygen accepts the electrons and 
bonds with protons, forming water. The protons produced in the proton gradient return 
to the matrix via an enzyme called ATP synthase, which synthesises ATP in a process 
known as chemiosmosis. ATP synthase is an integral protein consisting of several 
different subunits. This protein is directly responsible for the production of ATP via 
chemiosmotic phosphorylation. It uses the proton gradient created by several of the 
other carriers in the ETC to drive a mechanical rotor, whose energy is then used to 
phosphorylate ADP to ATP. This couples the redox reactions of the ETC to ATP synthesis.  
Prokaryotic cells may yield a maximum of 38 ATP molecules, while eukaryotic cells may 
have a net yield of 36 ATP molecules.35,36 
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 The Electron Transport Chain (ETC) 
The ETC consists of a series of proteins, which exist in multi-protein complexes 
numbered I-IV. Tightly bound to these proteins are prosthetic groups, which are non-
protein components essential for the catalytic functions of certain enzymes. In 
eukaryotes, the ETC components are found in the inner mitochondrial membrane. In 
prokaryotes, the ETC components are found in the plasma membrane.35   
The ETC is an energy converter that uses the exergonic flow of electrons from NADH and 
FADH2 to pump protons across the membrane. Electron carriers alternate between 
reduced and oxidized states as they accept and donate electrons. Each component of 
the chain reduces when it accepts electrons from its uphill neighbour and oxidizes when 
it passes electrons to its downhill neighbour. There are four complexes in the ETC, which 
are complex I (NADH reductase), complex II (succinate dehydrogenase), complex III 
(cytochrome reductase) and complex IV (cytochrome oxidase).35,36 
Complex I, also known as NADH-ubiquinone oxidoreductase, or simply as NADH 
reductase, is an important protein that receives electrons in the form of hydride ions 
from NADH and passes them on to ubiquinone (Q). Complex II, also known as succinate 
dehydrogenase, is a peripheral protein that receives electrons from succinate (an 
intermediate metabolite of the Krebs’ cycle) to yield fumarate and FADH2. Electrons are 
received from succinate by FAD, which then becomes FADH2. The electrons then pass 
onto ubiquinone.36 
Ubiquinone is a small hydrophobic molecule which resides within the membrane and is 
the only member of the electron transport chain that is not a protein. It receives 
electrons from complex I and complex II, becomes the reduced form, ubiquinol, and 
passes its electron off to complex III.  Complex III, also known as cytochrome reductase, 
is a vital protein that receives electrons from ubiquinol and passes them on to complex 
IV. Complex IV, also known as cytochrome c oxidase, is an essential protein that receives 
electrons from complex III and transfers them to oxygen, producing water within the 
mitochondria matrix. Cytochrome c is found within the intermembrane space but 
only transfers electrons from complex III to complex IV.36,37  
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The driving force of the ETC is the fact that each electron carrier has a higher standard 
reduction potential than the one that it accepts electrons from. Standard reduction 
potential is a measure of the ability to accept or donate electrons. Oxygen has the 
highest standard reduction potential which means that it is most likely to accept 









1.2.1.1 Complex I of the ETC 
Complex I of the ETC, also known as NADH reductase, is an essential protein that 
receives electrons in the form of hydride ions from NADH and passes them on to 
flavoprotein, then to an iron-sulphur (FeS) protein, and then onto ubiquinone (Q) (Figure 
10). Flavoprotein has a prosthetic group attached called flavin mononucleotide (FMN).38 
 
Figure 10: Simplified structure of complex I of the ETC.38 
Electrons enter the ETC via complex I or complex II, as mentioned before. Electrons pass 
from complex I to ubiquinone (Q), which is embedded by itself in the membrane. From 
ubiquinone, electrons are then passed to complex III, which is associated with another 
proton translocation event. The path of electrons is therefore from complex I to 
ubiquinone to complex III.  
Complex II is a separate starting point and is not a part of the NADH pathway. From 
succinate, the sequence is complex II (by-passing complex I) to ubiquinone to complex 
III to cytochrome c to complex IV. Thus there is a common electron transport pathway 
beyond the entry point, i.e. beyond either complex I or complex II.38 
Complex I is one of the largest known membrane proteins. This mitochondrial enzyme 
consists of about 44 different subunits, divided into 30 accessory subunits and 14 core 
subunits. The 30 accessory subunits are thought to form a protective shell around the 
core, although some may have a specialized functional role. The simpler prokaryotic 
version of complex I normally comprises of just the 14 core subunits, highly conserved 
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from bacteria to humans, suggesting that the mechanism also conserves. Both enzymes 
contain equivalent redox components and have a similar L-shaped structure, formed by 
the hydrophilic and membrane domains.39  
The structure of an entire, intact complex I was published for the first time by Sazanov 
et al. in 2013 (Figure 11).40 They reported that the structure of the 536-kDa complex, 
from Thermus thermophiles, comprises 14 different subunits, with a total of 64 
transmembrane helices and nine iron–sulphur clusters.40  
 
Figure 11: Structure of the entire complex I from T. thermophilus. FMN and Fe–S 
clusters shown as magenta and red–orange spheres, respectively, with cluster N2 
labelled.40 
They found that the core fold of subunit Nqo8 (ND1 in humans) was unexpectedly similar 
to a half-channel of the antiporter-like subunits. Small subunits nearby form a linked 
second half-channel, which completes the fourth proton-translocation pathway. They 
also reported that the ubiquinone-binding site was unusually “long, narrow and 
enclosed” and that the quinone head group binds at the deep end of this chamber, near 
iron–sulphur cluster N2.40 The iron–sulphur cluster participates in the oxidative half 
reaction by accepting an electron from FAD, which is in a reduced state because it 
participates in the reductive half reaction with the substrate.41 The chamber links to the 
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fourth channel by a “funnel” of charged residues. The link continues over the entire 
membrane domain as a flexible central axis of charged and polar residues, and probably 
has “a leading role in the propagation of conformational changes, aided by coupling 
elements”. This structure suggested that a unique, out-of-the-membrane quinone-
reaction chamber enables the redox energy to drive concerted long-range 
conformational changes in the four antiporter-like domains, resulting in translocation of 
four protons per cycle.40 
The primary electron acceptor, FMN, is within electron transfer distance of cluster N3, 
leading to the main redox pathway, and of the distal cluster N1a, which is a possible 
antioxidant. The terminal cluster N2 coordinates, uniquely, by two consecutive 
cysteines. The novel subunit Nqo15 has a similar fold to the mitochondrial iron 
chaperone frataxin, and it may be involved in iron-sulphur cluster regeneration in the 
complex.39 
In literature, research focused on complex I and its inhibition has mainly focused on two 
binding sites: the NADH binding site and the ubiquinone binding site. Some of the 
inhibitors currently targeting complex I such as rotenone, piericidin and pyridaben are 
considered to bind at the ubiquinone binding site.42,43 It has been found that 
hydrophobic inhibitors like rotenone or piericidin most likely disrupt the electron 
transfer between the terminal FeS cluster N2 and ubiquinone. Some of the common 
complex I inhibitors, e.g. rotenone and metformin, have some unwanted side-effects, 
such as hepatotoxicity.42   
Previous work by the Stephens group established the inhibition of complex I as a 
possible method of targeting diabetes, leading to AMP-activated protein kinase 
activation and subsequent increased glucose uptake by the cells, as measured in the 
mouse C2C12 muscle cell line. They also discovered that inhibiting complex I does not 
shut down the ETC, nor affects the ADP: ATP ratio. Instead, the cell maintains its levels 
of ATP production, perhaps via increased levels of succinate which is the alternative 
route for the electron entry. In order to generate sufficient levels of succinate, the cell 
increases its uptake of glucose (via Glut4) and hence lowers blood glucose levels.44 
Recent research involving restoring the NADH/NAD+ redox balance and attenuating 
oxidative stress has proven that complex I could be a promising therapeutic target for 
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diabetes.28 Building on this work, the aim of this project was to synthesise compounds 
which could increase glucose uptake by inhibiting complex I and therefore act as 
potential anti-diabetic agents.  
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1.3 Discovery of hit compounds  
Previous work in this project involved computational techniques and biological assays in 
order to determine the hit compounds with potential as anti-diabetic agents.45 
The initial biological mechanism targeted was the inhibition of a protein-protein 
interaction between retinol binding protein 4 (RBP4) and transthyretin (TTR).  
The retinol transporter, RBP4, has been shown to have the potential to be used as a 
target for the control and treatment of type 2 diabetes. RBP4 has been reported to have 
a possible involvement in preventing cellular responses to insulin, generating insulin 
resistance and the development of type 2 diabetes.46,47 
RBP4 is a member of the lipocalin family of proteins which are extracellular proteins that 
bind small, typically hydrophobic molecules, such as retinoids and steroids. RBP4 is 
composed of an N-terminal coil, eight anti-parallel β-strands, which form a β-barrel, and 
a short α-helix near the C-terminus. There are four highly variable loops that connect 
the β-strands A and B, C and D, E and F, and G and H (Figure 12).46  
 
Figure 12: Structure of holo-RBP4 with ROH bound.47 
The 21 kDa monomeric RBP4 is synthesised primarily in the liver but also in adipose 





Figure 13: Structure of ROH. 
During transportation, the vitamin molecule, ROH, is accommodated within the β-barrel 
of RBP4. The protein cavity is lined with hydrophobic residues that make specific 
interactions with ROH, thus stabilising the vitamin within the β-barrel.47  
Holo-RBP4 is RBP4 with ROH bound inside the β-barrel. Holo-RBP4 is released from the 
liver complexed to a second homotetrameric protein, transthyretin (TTR). TTR is a 
thyroid binding hormone, synthesised in hepatic tissues, whose purpose is to distribute 
thyroids. It is a 55 kDa protein that binds to holo-RBP4 and stabilises the RBP4-ROH 
complex. The absence of ROH from the RBP4 β-barrel results in a weaker interaction 
between RBP4 and TTR. As holo-RBP4 is small enough to be removed from circulation 
by renal filtration, the formation of the 76 kDa RBP4-TTR complex prevents this renal 
filtration due to its increased size.47  
The presence of ROH is very important in the formation of the RBP4-TTR complex and 
demonstrates that replacing ROH with an alternative ligand may disrupt the formation 
of the RBP4-TTR complex, which will result in the renal filtration of RBP4. Thus, the 
serum levels of RBP4 will be reduced and may improve the diabetic condition.47  
Computational techniques were used to identify ligands that could bind to RBP4 and 
involved the use of the eHiTS (electronic High Throughput Screening) software package 
(SimBioSys Inc.). The eHiTS software docked flexible ligands within the RBP4 receptor 
and rapidly and systematically counted mappings of interacting atoms between the 
RBP4 receptor and the ligand database using an exhaustive search algorithm. The 
binding pocket was first determined from the X-ray crystal structure of RBP4. The 
binding mode for each conformation was determined and a binding score was assigned 
based on binding affinity for RBP4.45 
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From a database of 57,576 compounds, three compounds were uncovered, two of which 
are RTB70 and RTB69 (Figure 14). These compounds passed Lipinski’s guidelines (< 5 
hydrogen bond donors; < 10 hydrogen bond acceptors; molecular weight < 500; logP < 
5), which indicated that the compound had potential to be used as a bioavailable and 
orally administered drug. The compounds were purchased from Maybridge 
(www.Maybridge.com) and tested in the surface plasmon resonance (SPR) assay to 
elucidate if they were capable of disrupting the RBP4-TTR complex formation.45  
 
Figure 14: Structure of RTB70 and RTB69. 
The SPR assay is an optical method used for measuring molecular interactions by 
immobilizing a binding molecule (e.g. holo, His-RBP4) onto the surface of a sensor chip. 
Next, a certain concentration of test compound is injected over the chip surface in a 
solution of SPR running buffer. This is followed by an injection of another binding 
molecule (e.g. untagged TTR). Binding of molecules (i.e. formation of a complex) causes 
a change in mass on the sensor chip resulting in changes in the refractive index of the 
SPR running buffer. Changes to the refractive index indicate if binding has occurred and 
appears as an increase in resonance units. This assay showed that RTB70 and RTB69 are 
capable of docking within the β-barrel of RBP4 and disrupting/preventing the formation 




 Glucose tolerance test (GTT) and an insulin tolerance test (ITT) 
As discussed previously in section 1.3, the ability to disrupt the RBP4-TTR complex, thus 
lowering serum RPB4, is linked to improvements in insulin resistance. The use of the 
retinoid like compound Fen has shown this to be true as its use prevents high-fat diet 
(HFD) induced obesity, and the development of insulin resistance in mice, through the 
lowering of serum RBP4 levels.45,48  
Following this logic, the next investigation was focused on the ability of RTB70 and 
RTB69 to control and reduce insulin resistance in mice. A study examining the effects of 
these compounds on a group of mice exposed to a HFD was thus performed by our 
collaborators in the Biology department in Maynooth University, and the results were 
published.45,49 
This study focused on two tests, a glucose tolerance test (GTT) and an insulin tolerance 
test (ITT). GTT examined how quickly glucose is cleared from the blood after a bolus of 
glucose is administered, whereas ITT examined insulin sensitivity. With regards to mice 
treated with RTB70, GTT showed improved glucose handling and the ability to clear 
glucose more rapidly was observed, as well as improved insulin sensitivity from ITT. With 
regards to mice treated with RTB69, GTT also showed improved glucose handling and 
the ability to clear glucose more rapidly, but not as effective in the ITT as RTB70.45,49 
As well as showing improved insulin and glucose profiles, the mice treated with RTB70 
also exhibited a reduced weight gain over the eight-week period when compared to a 
control. Although RTB69 was not as effective at reducing weight gain as RTB70, a 




 Discovery of RTC1 and RTC53 
The results from the SPR assay and animal studies stimulated an effort to optimise 
RTB70 so as to improve its anti-diabetic properties. A small number of compounds were 
synthesised by removing functional groups from RTB70 and tested using SPR, 
fluorometric binding assay, and glucose uptake (GU) assay. From the compounds 
synthesised, RTC1 (compound 1, Figure 15) was shown to be the most active. 
 
Figure 15: Structure of RTC1, compound 1.  
Results of the SPR assay showed that RTC1 was a highly effective disruptor of the RBP4-
TTR complex with results indicating that it was more potent than RTB70. The 
fluorometric binding assay quantitatively measures a compounds ability to dock within 
apo-RBP (i.e. RBP4 without ROH bound inside the β-barrel), by measuring the level of 
tryptophan fluorescence quenching that occurs. RTC1 was found to show an increase in 
fluorescence due to conformational changes at or around the tryptophan residue. This 
may also indicate some level of interaction between RTC1 and RBP4.48  
The glucose uptake assay measures the amount of tritiated (3H) deoxy-2-glucose taken 
up by muscle cells. Tritiated deoxy-2-glucose is used as its biochemical properties allow 
for it to be easily traced and measured within a cell.50 The glucose uptake assay is 
independent of RBP4. Therefore, one would not have expected the hit compounds to 
be active in this assay. However, RTC1 was very active, more so than RTB70. This 
suggested that a different mechanism of action was occurring that results in glucose 
uptake.   
RTC53 (Figure 16), a member of the pyrazolopyrimidinone bicycle family and a derivative 




Figure 16: Structure of RTC53.  
 Alternative mechanism of action: effect of RTC1 on complex I  
A concerted effort was undertaken, with our collaborators, to determine the mechanism 
of action. Recent work published with our collaborators in Maynooth University has 
shown the effect of RTC1 on inhibiting complex I (NADH:ubiquinone oxidoreductase), 
which can counteract many of the cellular abnormalities associated with type 2 
diabetes. During this research, they compared RTC1 with the current leading therapy for 
type 2 diabetes, metformin. The result of their research showed that RTC1 
demonstrated a superior effect at much lower concentrations in amending in vitro 
representations of the type 2 diabetes phenotype. They established that RTC1 
stimulates the inhibition of complex I, which leads to the activation of AMPK, and an 
increase in glucose uptake at much lower concentrations than the common anti-diabetic 
therapy.51  
It was predicted that the superior influence of RTC1 may lie with the structural 
differences of the compound, which could favour binding of RTC1 to distinctive regions 
of the enzyme complex, and could occupy a similar binding pocket to that discussed in 
section 1.2.1.1. They concluded that although metformin is substantially more 
hydrophilic and reliant on organic cation transporters to enter the cell, RTC1 has 
lipophilic properties (logP value of 4.79), which might also allow easier target 
engagement. They also concluded that the cell was able to maintain its energy status as 
the ATP levels remained within normal levels.51  
Overall, they demonstrated from this study that RTC1 can prevent weight gain, restore 
normal glucose uptake, and augment insulin sensitivity in a murine diet-induced model 
of type 2 diabetes. They concluded that RTC1 can act as an insulin sensitizer as well as 
an insulin substitute, through its potent influence on complex I and AMPK activation.51 
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1.4 Aims of this Project  
Building on from all the previous work mentioned, this project was focused on 
expanding both families of compounds in order to create a large library of compounds 
that could potentially develop into novel small anti-diabetic agents. The first family is an 
arylpiperazine family with variations on five different sites of RTC1 (compound 1, Figure 
17). These sites are the aryl group (site A), the piperazine ring (site B), the carbonyl group 
(site C), the alkyl chain (site D), and the thiophene ring (site E).  
 
Figure 17: Structure of RTC1 with variations at five sites, A-E. 
The second family is a pyrazolopyrimidinone bicycle family where analogues of RTC53 
were synthesised with variations at the R and R1 groups (Figure 18).  
 
Figure 18: Structure of RTC53 and general structure of pyrazolopyrimidinone bicycle 
with variations at R and R1 groups.  
A structure activity relationship (SAR) study of both families was conducted in order to 
explore the effect the key functional groups had on biological activity. Full 
characterisation of all the compounds synthesised was carried out using techniques such 
as melting point, nuclear magnetic resonance (NMR) spectroscopy, including 1H, 13C 
NMR and 2D-NMR experiments, infrared (IR) spectroscopy, high-resolution mass 
spectrometry (HR-MS), and X-ray crystal analysis when appropriate. Variations were 
made with electron donating and electron withdrawing groups and adding/removing 
certain elements of the parent active structure to determine source of activity.  
37 
 
Another aim of the project was to develop an improved method for synthesising both 
families. This was carried out in the arylpiperazine family by developing a less laborious 
method of synthesis that does not require any anhydrous conditions and employs a 
simplified work-up. In the pyrazolopyrimidinone bicycle family, method development 
focused around microwave synthesis of the pyrazole starting materials and the 
pyrazolopyrimidinone bicycle final compounds. This involved the development of a 
“one-pot” synthesis for these compounds.  
Active compounds from both families were identified using the glucose uptake assay 
and complex I assay. The complex I assay can determine a compound’s ability to inhibit 
NADH dehydrogenase in complex I of the electron transport chain by measuring the 
change in ubiquinone absorbance. Using both these assays, we were able to establish 











2.1 Introduction  
Arylpiperazine compounds consist of a piperazine moiety bonded to an aryl group. They 
are commonly used in the development of novel drugs. To access the necessary 
arylpiperazine derivative, various synthetic approaches can be utilised such as 
nucleophilic aromatic substitutions (SNAr) reactions, metal catalysed reactions, and 
cyclocondensation reactions.52,53 Asymmetric synthesis of arylpiperazines has been 
widely reported and includes resolution of racemic materials, separation of 
diastereomers, and diastereoselective reduction at the benzylic position.32  
Arylpiperazines have been used for many years in various applications. For example, (i) 
m-chlorophenylpiperazine was patented by American Cyanamid in the 1960s as an 
appetite suppressant, (ii) 2-chloro-6-(piperazin-1-yl)pyrazine, the pyrazine isoster of m-
chlorophenylpiperazine, was patented by Merck & Co. for its anorectic effect in the 
1970s, and (iii) 1-(4-fluoro-3-(trifluoromethyl)phenyl)piperazine has also been patented 
as an anorectic agent in the early 1970s (Figure 19).52  
 
Figure 19: Structure of arylpiperazines found in literature.52 
More recently, arylpiperazines are used in antidepressant drugs which act as 
monoamine neurotransmitter reuptake inhibitors and exhibit antidepressant activity. 
Some of these drugs include trazodone, which is a serotonin reuptake inhibitor and is 
comparatively safer than conventional antidepressants, and buspirone, which can cause 
metabolic acidosis in diabetic patients (Figure 20).54 
 
Figure 20: Structure of trazodone and buspirone.54 
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Studies have shown that compounds with arylpiperazine moieties have anti-
proliferative properties. Naftopidil (Figure 21), an arylpiperazine ether derivative, has 
been shown to induce apoptosis in malignant mesothelioma cell lines, as well as exert 
an anticancer effect and inhibit prostate cancer cell growth by arresting the G1 cell cycle 
phase.54,55 
 
Figure 21: Structure of naftopidil.54 
More recently, other arylpiperazine derivatives have been reported to act as novel anti-
cancer agents as they have been shown to exhibit in vitro strong cytotoxic activity 
against prostate cancer cell lines. These compounds were derivatives of naftopidil and 
their synthesis consisted of a four-step reaction (Scheme 1). This consisted of (i) a 
reduction reaction of the carboxylic acid starting material into an alcohol, (ii) a 
nucleophilic substitution reaction, (iii) activation of the primary alcohol via a tosylation 




Scheme 1: Synthesis of naftopidil derivatives.54 
An efficient protocol for the synthesis of various substituted arylpiperazines was 
recently reported using sulfolane as solvent (Scheme 2).54 Sulfolane is an aprotic, 
dipolar, high boiling and recoverable solvent, and can be used as a substitute for 
common organic solvents. The developed protocol was clean, high yielding and products 
were obtained in high purities. The final products were precipitated as hydrochloride 
salts and could be obtained by filtration, thus making the new protocol also fast and 
convenient.54  
 
Scheme 2: The synthesis of arylpiperazines using sulfolane as solvent.54 
The synthesis of an amide bond is one of the most important reactions in biochemistry, 
as it is the bond that links amino acids together in peptides and proteins. It is a common 
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feature in small and complex molecules, whether naturally-occurring or synthetically 
made.56 Carboxamides are compounds which contain an amide functional group and 
have been reported to appear in more than 25% of known drugs, such as Penicilline G 
(Figure 22).57 This is due to carboxamides being neutral and stable as well as having both 
hydrogen-bond accepting and donating properties. 
 
Figure 22: Structure of Penicilline G. 
The amide bond is commonly synthesised using coupling reagents to activate the 
carboxylic acid in situ. Coupling reagents are used to generate more reactive 
intermediates such as acid chlorides, anhydrides, carbonic anhydrides or activated 
esters.56 The N-acylpiperazine moiety consists of a piperazine bonded to a carbonyl 
group through an amide bond. This moiety is also found in many drugs with various 
medicinal uses such as antibacterial, antiulcer, anticancer and as nootropic agents.58 
The arylpiperazine family that I worked with consisted of novel analogues of the lead 
compound of 4-(thiophen-2-yl)-1-(4-(4-(trifluoromethyl)phenyl)piperazin-1-yl)butan-1-
one (RTC1) (compound 1) (Figure 23). My family of arylpiperazine compounds were 
added to a family of arylpiperazines that had been generated by a previous group 
member.45 This combination resulted in a larger library of arylpiperazines, which 
underwent biological evaluation and allowed for a more comprehensive investigation of 
the SAR. RTC1 was systematically modified at five different sites, A-E (Figure 23). This 
allowed us to investigate the importance of the aryl substituent and the nature of the 
aryl group (site A), the piperazine ring (site B), the carbonyl group (site C), the length and 
nature of the alkyl chain (site D), as well as the terminal group (site E), on anti-diabetic 
activity.  
 
Figure 23: Structure of RTC1 with variations at five sites, A-E.  
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2.2 Synthesis of 4-(thiophen-2-yl)-1-(4-(4-
(trifluoromethyl)phenyl)piperazin-1-yl)butan-1-one (RTC1) 1  
The previously reported procedure for the generation of the amide bond in 4-(thiophen-
2-yl)-1-(4-(4-(trifluoromethyl)phenyl)piperazin-1-yl)butan-1-one (RTC1) 1 and its 
analogues, consisted of coupling the starting aryl piperazine, 1-(4-
(trifluoromethyl)phenyl)piperazine (MK17) 2, with the corresponding carboxylic acid, 4-
(2-thienyl)butyric acid, under rigorous air-free conditions.44,45 The reaction was carried 
out using coupling reagent (e.g. hydroxybenzotriazole (HOBt) and N,N,N′,N′-
tetramethyl-O-(benzotriazol-1-yl)uronium tetrafluoroborate (TBTU) combination, or 
benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP)), 
anhydrous dimethylformamide (DMF), anhydrous triethylamine (NEt3), in an oven-dried 
Schlenk tube, and overnight stirring at rt under a N2 atmosphere (Scheme 3).44,45 
 
 
Scheme 3: Synthesis of RTC1, (i) HOBt, TBTU, anhydrous DMF, anhydrous NEt3, N2, rt, 
overnight, 80% yield.44,45 
A somewhat elaborate work-up procedure was then followed, including evaporation 
under reduced pressure, acidification, extraction, base wash, brine wash, drying, and 
finally column chromatography.    
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 Method development for the synthesis of arylpiperazines  
The original procedure for the preparation of RTC1 was somewhat cumbersome and as 
a result a study was undertaken to identify improved reaction conditions. We first 
explored the need for anhydrous reaction conditions. To achieve this, we did not dry 
reactants, reagents, or solvents (i.e. non-anhydrous). We also avoided Schlenk 
conditions and carried out the reaction in a normal air atmosphere and round-bottom 
flask. Furthermore, we postulated that the work-up procedure could be simplified and 
upon reaction completion, move straight from evaporation under reduced pressure to 
column chromatography. This greatly reduced the amount of sample manipulation and 
removed the acidification, washing, extraction, and drying steps.  
A comparison of the two methods was performed using the synthesis of methyl 9-oxo-
9-(4-(4-(trifluoromethyl)phenyl)piperazin-1-yl)nonanoate (MK16) 3 (Scheme 4).  
 
Scheme 4: Synthesis of compound 3 using: (i) the old method of BOP, anhydrous NEt3, 
anhydrous dichloromethane (DCM), nitrogen (N2) atmosphere, rt, overnight, 43% 
yield; versus (ii) the new method of BOP, NEt3, DCM, rt, air atmosphere, overnight, 
55% yield. 
The old method consisted of coupling methyl hydrogen azelate with compound 2 using 
BOP, anhydrous NEt3 and anhydrous dichloromethane (DCM) in an oven-dried two-neck 
flask under a nitrogen (N2) atmosphere with overnight stirring. Purification of the 
reaction mixture consisted of acidification using 0.1 M aqueous hydrochloric acid (HCl), 
extraction using DCM, wash with aqueous sodium hydrogen carbonate (NaHCO3), wash 
45 
 
with brine, and drying using magnesium sulfate (MgSO4). The residue was purified using 
column chromatography to give compound 3 as an off-white solid in a 43% yield. 
The new method involved coupling methyl hydrogen azelate with compound 2 using 
BOP, non-anhydrous NEt3, and non-anhydrous DCM in a round-bottom flask and stirred 
at room temperature overnight. Purification of the crude product consisted of 
evaporation under reduced pressure followed by column chromatography to give 
compound 3 as an off-white solid in a 55% yield. 
Most of the compounds were synthesised using this improved method and HOBt/TBTU 
coupling reagents, with non-anhydrous DMF as the solvent. However, because DMF is a 
reproductive toxin (category 1B) with a high boiling point (153 °C), an alternative solvent 
was sought. DCM was used instead as it has a much lower boiling point (39.6 °C) and is 
less toxic than DMF. This resulted in the synthesis of arylpiperazine derivatives with 
similar, and in some cases higher yields, than when using DMF as before.  
For example, the original synthesis of 1-(4-cyclohexylpiperazin-1-yl)-4-(thiophen-2-
yl)butan-1-one (MK43) 4 (Figure 24) using anhydrous conditions and anhydrous DMF 
resulted in a 70% yield.45 Using the new method and DCM, the yield increased to 82%. 
A more significant difference was observed with the synthesis of 4-(1H-Pyrazol-4-yl)-1-
(4-(4-(trifluoromethyl)phenyl)piperazin-1-yl)butan-1-one (MK69) 5 (Figure 24), which 
consisted of a 10% yield with the original synthesis method45 and a 93% yield with the 
new synthesis method.  
 
Figure 24: Structure of compound 4 and compound 5. 
The new method was therefore adopted and employed in the synthesis of most of the 




 Mechanism for the synthesis of RTC1 (compound 1) and RTC1 
analogues 
The coupling of the carboxylic acid starting material with compound 2 is suggested to 
take place using the following general mechanism (Scheme 5):  
 
Scheme 5: Mechanism for the synthesis of RTC1. 
The mechanism begins with a general base catalysis where NEt3 deprotonates the 
carboxylic acid while the carboxylic acid attacks the electrophilic carbon of TBTU. This 
step creates an activated ester with a more electrophilic carbonyl group. This in turn can 
get attacked by HOBt which gets deprotonated at the same time via general base 
catalysis, generating a tetrahedral intermediate, with a better leaving group. The 
carbonyl group is then reformed and the 1,1,3,3-tetramethylurea group is eliminated. 
Finally, the carbonyl group of the resulting ester gets attacked by the arylpiperazine 
nucleophile to give a tetrahedral intermediate, which subsequently gets deprotonated 
and eliminates -OBT leaving group to generate the final product.   
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 Characterisation of RTC1, compound 1  
All compounds synthesised in the arylpiperazine family were characterised using 1H 
NMR, 13C NMR, HR-MS and IR spectroscopy. Some of the compounds containing a 
trifluoromethyl group were also characterised using 19F NMR spectroscopy. Proton and 
carbon signals were assigned with the aid of DEPT and 2D-NMR experiments such as 1H 
– 1H COSY, 1H – 13C HSQC, and 1H – 13C HMBC. The numbering scheme shown below 
(Figure 25) will be used in the following discussion on the structural characterisation of 
RTC1.  
 





2.2.3.1 The 1H NMR spectrum of RTC1  
The 1H NMR spectrum of RTC1 is shown below (Figure 26). The spectrum consists of ten 
signals in two main regions; four signals in the more deshielded aromatic region and six 
signals in the more shielded aliphatic region.  
 







2.2.3.1.1  Aromatic region of the 1H NMR spectrum of RTC1 
The four signals in the aromatic region (Figure 27) of the 1H NMR spectrum of RTC1 
integrate to 7H and account for the four protons of the aromatic ring and the three 
protons of the thiophene ring.  
 
Figure 27: Aromatic region of the 1H NMR spectrum of RTC1. 
The most downfield signal is a doublet at 7.50 ppm and can be assigned as the two H2 
protons of the aromatic ring. They are ortho to the electron withdrawing trifluoromethyl 
group (CF3) and therefore appear as the most deshielded signals. A plane of symmetry 
exists through the aromatic ring and hence the signal at 7.50 ppm integrates for both 
protons ortho to the trifluoromethyl group. The coupling constant (J value) is a measure 
of the coupling interaction between a pair of protons.  This signal appears as a doublet 
with a J value of 8.5 Hz as it couples with the neighbouring protons on the aromatic ring, 
H3. The signal for the two other protons in the aromatic ring (H3) should also appear as 
a doublet as they are only coupled with protons H2. However, they overlap with one of 
the protons of the thiophene ring (H10) and therefore appear as a multiplet in the region 
of 6.94 – 6.89 ppm integrating for three protons.  
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Without the overlap, the signal for H10 of the thiophene ring was expected to appear as 
a double of doublets (dd) as it is coupled to two non-equivalent protons, H9 and H11. 
Both H9 and H11 signals must therefore appear as doublets as they are both coupled to 
H10. The signal for H11 is more deshielded as it is adjacent to the electron withdrawing 
sulphur group and therefore appears more downfield. Its multiplicity is that of a doublet 
and occurs at 7.13 ppm with a J value of 4.9 Hz. The signal for H9 is more upfield as it is 
further away from the sulphur group and appears as a doublet at 6.81 ppm with a J value 
of 2.2 Hz.  
The assignment of the aromatic region of the 1H NMR spectrum is further supported by 
a 2D-NMR experiment known as 1H–1H Homonuclear Correlation Spectroscopy (1H-1H 
COSY) (Figure 28), which is used to identify protons coupled to each other. COSY spectra 
show two types of signals; diagonal signals and cross signals. Diagonal signals have the 
same frequency coordinate on each axis and appear along the diagonal of the plot, 
while cross signals have different values for each frequency coordinate and appear off 
the diagonal. Diagonal signals correspond to the signals in a 1D-NMR experiment, while 
the cross signals indicate couplings between pairs of nuclei. Using a 1H–1H COSY 
spectrum it is possible to map the coupling network in the molecule.  
 
            Figure 28: The aromatic region of the 1H-1H COSY spectrum of RTC1. 
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In the aromatic region of the 1H – 1H COSY spectrum of RTC1, the aromatic ring protons 
H2 and H3 are confirmed to be coupled to each other (green square). Proton H10 of the 
thiophene ring can also be seen to be coupled to both H11 (purple square) and H9 (blue 
square).  
2.2.3.1.2  Aliphatic region of the 1H NMR spectrum of RTC1  
The aliphatic region of the 1H NMR spectrum (Figure 29) of RTC1 consists of six different 
signals integrating for the eight protons of the piperazine ring and the six protons of the 
alkyl chain (H5 – H7). The three most deshielded multiplet signals in this region, 
resonating at 3.85 – 3.72 ppm, 3.64 – 3.49 ppm and 3.31 – 3.17 ppm, are due to the 
eight protons of the piperazine ring. The signals at 3.85 – 3.72 ppm and 3.64 – 3.49 ppm 
can be assigned as the HB/HB’ protons of the piperazine ring, whereas the signal at 3.31 
– 3.17 ppm can be assigned as the HA/HA’ protons of the piperazine ring (this 
assignment was confirmed using the 1H-13C Heteronuclear Multiple Bond Correlation 
(1H-13C HMBC) spectrum, section 2.2.3.2.1). The signals for the HB/HB’ protons appear 
as two separate signals due to the anisotropy effect with respect to the carbonyl oxygen. 
These signals appear downfield as they are deshielded by the electronegative nitrogen 
adjacent to them. The remaining three signals in the aliphatic region can be assigned to 
the six protons from the alkyl chain with each signal integrating to two.  
 
Figure 29: Aliphatic region of the 1H NMR spectrum of RTC1. 
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The triplet signal resonating at 2.93 ppm can be assigned to the protons (H7) adjacent 
to the thiophene ring. This assignment was confirmed using the 1H-13C HMBC spectrum, 
section 2.2.3.2.1. The signal appears as a triplet as it is coupled to two equivalent 
protons (i.e. H6) with a J value of 7.2 Hz. This signal is the most deshielded signal of the 
alkyl chain as it is adjacent to an electron withdrawing thiophene ring. Similarly, the 
signal at 2.40 ppm also appears as a triplet with a J value of 7.4 Hz and can be assigned 
to the two protons at H5. The H5 protons are deshielded due to the adjacent carbonyl 
group and are coupled to two equivalent protons at H6 (hence appear as a triplet). This 
assignment was also confirmed using the 1H-13C HMBC spectrum, section 2.2.3.2.1. The 
two protons in the middle of the alkyl chain (H6) are therefore coupled to both H5 and 
H7 and appear as a quintet in the region of 2.13 – 2.00 ppm.   
The coupling network of the signals can be clearly seen in the aliphatic region of the 1H–
1H COSY spectrum of RTC1 (Figure 30).   
 
Figure 30: Aliphatic region of the 1H–1H COSY spectrum of RTC1. 
The piperazine protons (HA/HA’ and HB/HB’) are coupled to each other as expected (red 
square). The protons in the middle of the alkyl chain, H6, can be seen to couple to both 
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the protons adjacent to the thiophene ring, H7, (blue square) and the protons adjacent 
to the carbonyl group, H5 (green square).  
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2.2.3.2 The 13C NMR spectrum of RTC1 
The 13C NMR spectrum of RTC1 is shown below (Figure 31). For ease of explanation, this 
spectrum can be divided into three regions; A, B, and C.  
 





2.2.3.2.1  Region A of the 13C NMR spectrum of RTC1 
Region A of the 13C NMR spectrum of RTC1 consists of three signals for three quaternary 
carbons; the carbonyl carbon (C=O), the ipso carbon of the aromatic ring (C4), and the 
ipso carbon of the thiophene ring (C8) (Figure 32).  
 
Figure 32: Region A of the 13C NMR spectrum of RTC1. 
These signals were identified using the 2D-NMR 1H-13C HMBC spectrum (Figure 33), 
which correlates chemical shifts of 1H and 13C nuclei separated from each other by two 
or more chemical bonds. HMBC spectra are particularly useful in identifying the 
connectivity of a molecule. The most deshielded quaternary carbon signal is due to the 
carbonyl carbon (C=O) and resonates at 171.1 ppm. This chemical shift is characteristic 
of a carbonyl carbon found in an amide. The 1H-13C HMBC spectrum (Figure 33) shows 
this carbon signal coupling to the two B/B’ piperazine proton signals but is not coupled 
to the other A/A’ piperazine proton signals, as they are too many bonds away. It is also 
coupled to the H5 and H6 proton signals from the alkyl chain (red lines), which are within 
two bonds (H5) or three bonds (H6) of the carbonyl carbon. Noticeably, it is not coupled 




Figure 33: The 1H-13C HMBC spectrum of RTC1 showing the assignment of the three 
quaternary carbon signals. 
The second signal in region A of the 13C NMR spectrum at 152.9 ppm is assigned to the 
ipso quaternary carbon of the aromatic ring (C4). In the 1H-13C HMBC spectrum (Figure 
33), this carbon is coupled to the aromatic protons (H2 and H3), as well as the piperazine 
A/A’ protons adjacent to it (blue lines). It is not coupled to the other piperazine B/B’ 
protons as they are too many bonds away.  
The third signal in region A of the 13C NMR spectrum at 144.4 ppm is assigned to the ipso 
quaternary carbon of the thiophene ring (C8). This signal can be seen in the 1H-13C HMBC 
spectrum (Figure 33) to be coupled to the three protons from the thiophene ring (H9, 
H10, H11), as well as protons from the alkyl chain (H6 and H7) which are 2-3 bonds away 
(green lines). It is not coupled to H5 protons of the alkyl chain as they are four bonds 






2.2.3.2.2  Region B of the 13C NMR spectrum of RTC1 
Region B of the 13C NMR spectrum (Figure 34) of RTC1 consists of multiple signals that 
can be assigned to seven carbons. The tertiary carbons of the thiophene ring appear as 
singlet signals at 126.9 ppm (C10), 124.6 ppm (C9) and 123.3 ppm (C11). The two tertiary 
carbons of the aromatic ring (C3), which are meta to the trifluoromethyl group, are 
equivalent and appear as a single singlet at 115.0 ppm.  
 
Figure 34: Region B of the 13C NMR spectrum of RTC1. 
The three other signals present in region B of the 13C NMR spectrum of RTC1 appear as 
quartets due to the coupling between the 13C nucleus and the NMR-active 19F nucleus, 
which is the third most receptive NMR nucleus and has a nuclear spin of a half.59 The 
carbon spectra generated are not fluorine-19 decoupled so coupling between 13C-19F 
was observed. The signal of the tertiary carbon ortho to the trifluoromethyl group (C2) 
appears as a quartet at 126.6 ppm with a J value of 3.7 Hz. The signal of the 
trifluoromethyl carbon appears as a quartet at 125.6 ppm with a J value of 271.3 Hz. The 
signal of the quaternary carbon bonded to the trifluoromethyl group (C1) appears as a 
quartet at 121.2 ppm with a J value of 32.8 Hz.  
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The assignment of the quaternary carbons in region B of the 13C NMR spectrum 
employed a Distortionless Enhancement of Polarization Transfer (DEPT) experiment. 
This experiment uses a 135-degree decoupler pulse (DEPT-135) to produce a carbon 
spectrum with positive signals for methyl (CH3) and methine (CH) carbons, and negative 
signals for methylene (CH2) carbons. As the quaternary carbons are not bonded to any 
protons, they can be identified due to their absence from the DEPT-135 spectrum of 
RTC1 (Figure 35). The tertiary carbons of the aromatic ring (C2 & C3) and thiophene ring 
(C9, C10 and C11) all appear as positive signals in the DEPT-135 spectrum as they are 
each bonded to one proton. 
 
Figure 35: DEPT-135 spectrum of region B of the 13C NMR spectrum of RTC1. 
The assignment of the tertiary carbon signals in region B was also confirmed using a 1H-
13C Heteronuclear Single Quantum Correlation (1H-13C HSQC) experiment (Figure 36) 
which is a 2D-NMR technique that correlates chemical shifts of directly bound nuclei (i.e. 
1H with 13C). Using the information already obtained from the 1H NMR spectrum (section 
2.2.3.1), the tertiary carbons from region B of the 13C NMR spectrum were assigned by 
correlating their 13C signal with the corresponding 1H signal in the HSQC spectrum. For 
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example, the carbon signal at 123.3 ppm was identified as C11 as it correlates with the 
H11 proton signal at 7.13 ppm (red lines) (Figure 36).  
 
Figure 36: Region B of the 1H-13C HSQC spectrum of RTC1. 
The assignments made using the DEPT and 1H-13C HSQC experiments were also 
confirmed using the 1H-13C HMBC experiment (Figure 37) which shows long range 1H-13C 
coupling. The quaternary ipso carbon (C1) was shown to couple with the aromatic 
protons (H2 & H3) (red lines) while the quaternary carbon from the trifluoromethyl 
group coupled to just H2 (blue lines). The tertiary carbons were all coupled to the 
neighbouring protons which were 2-3 bonds away from them. For example, C10 of the 
thiophene ring was observed to couple to H9 and H11, and weakly to H7 of the alkyl 
chain (green lines). H7 of the alkyl chain was observed to be strongly coupled to C9 as it 











2.2.3.2.3  Region C of the 13C NMR spectrum of RTC1 
Region C of the 13C NMR spectrum of RTC1 consists of seven signals that can be assigned 
to the secondary carbons of the piperazine ring and the alkyl chain (Figure 38).  
 




These seven signals all appear negative in the DEPT-135 spectrum (Figure 39) as the 
carbons they represent are bonded to two hydrogens. 
 




These signals were assigned using the 2D-NMR 1H–13C HSQC spectrum (Figure 40). Here, 
the four signals resonating most downfield (48.3, 48.1, 45.0, and 41.1 ppm) are the 
secondary carbons of the piperazine (CA/CA’ and CB/CB’) and show a coupling to the 
piperazine protons (HA/HA’ and HB/HB’). The signal at 32.0 ppm can be assigned to C5, 
the signal at 29.3 ppm to C7, and the signal at 27.0 ppm to C6. Again, in the HSQC, clear 
coupling can be seen with their corresponding proton signals. 
 




The assignments made using the DEPT and 1H-13C HSQC experiments were confirmed 
using the 1H-13 C HMBC experiment (Figure 41) which show long range 1H-13C coupling. 
Each carbon signal was shown to be coupled with the neighbouring protons within 2-3 
bonds. For example, C6 of the alkyl chain was observed to be coupled to H5 and H7 (red 
lines). Similarly, C5 was coupled to H6 and H7. The carbon of the alkyl chain closest to 
the thiophene ring, C7, did not only couple to H5 and H6 of the alkyl chain, but also 
coupled to H9 of the thiophene ring, as it was three bonds away (blue lines). The other 
protons of the thiophene ring, H10 and H11, were more than three bonds away and 
therefore no coupling was observed. The piperazine carbons showed coupling to the 
piperazine protons as expected.   
 







2.2.3.3 The 19F NMR spectrum of RTC1 
As mentioned previously, fluorine has an NMR-active 19F isotope with a nuclear spin of 
a half (I = ½). It is the third most receptive NMR nucleus with many applications in 
medicinal chemistry and chemical biology.60 The 19F spectrum is 1H and 13C decoupled in 
order to just show the signals arising from the fluorine atoms in the compounds. For the 
19F spectrum of RTC1 (Figure 42), a singlet signal was observed at -61.4 ppm for the three 
equivalent fluorines of the trifluoromethyl group.  
 




A 2D-NMR experiment known as 1H-19F Heteronuclear Overhauser Effect Spectroscopy 
(HOESY) can be used to assess the spatial proximity between two heteronuclei such as 
1H and 19F. The 1H-19F HOESY spectrum of RTC1 (Figure 43) shows that the fluorine of 
the trifluoromethyl group is in close spatial proximity to the protons of the aromatic ring 
(H2 and H3) as well as the piperazine protons (HA/HA’).  
 
Figure 43: The 1H-19F HOESY spectrum of RTC1. 




2.2.3.4 Mass spectrum of RTC1  
Mass spectrometry (MS) is a powerful analytical technique used to quantify known 
materials, to identify unknown compounds within a sample, and to help elucidate the 
structure of molecules. A typical process of mass spectrometry involves the conversion 
of the sample into gaseous ions, with or without fragmentation, which are then 
characterized by their mass to charge ratios (m/z) and relative abundances. Mass 
spectrometry was used in the characterisation of our compounds to further confirm the 
presence or absence of the target compounds. The mass (m/z) obtained for each 
compound was within 5 ppm of the calculated mass for that compound.  
The mass spectrum (Figure 44) of RTC1 showed that the high-resolution mass obtained 
for C19H22F3N2OS, the protonated version of the product (i.e. [M + H]+), is 383.1398 m/z, 
which is -0.26 ppm from the calculated mass of 383.1399 m/z. It also found the mass for 
C19H21F3N2OSNa, the product plus a sodium cation (i.e. [M + Na]+), was found to be 
405.1228 m/z, which is 2.2 ppm different from the calculated mass of 405.1219 m/z .   
 






2.2.3.5 Infrared spectrum of RTC1  
Infrared (IR) spectroscopy is an optical technique that detects molecular bond vibrations 
and rotations upon absorption of infrared light.61 IR spectroscopy can be used for 
chemical structure analysis, chemical fingerprinting, and chemical imaging as different 
chemical functional groups absorb IR light at different frequencies. An IR spectrum 
displays transmittance on the vertical axis versus wavelength on the horizontal axis, and 
can be obtained using a fourier-transform infrared (FTIR) spectrometer. Liquid samples 
can be tested using sodium chloride plates, whereas solid samples are typically grinded 
with potassium bromide (KBr) to form KBr disks.  
More recently, test compounds can be analysed by the more efficient attenuated total 
reflection (ATR) method, which enables samples to be examined directly in the solid or 
liquid state without further preparation.62 ATR-FTIR operates by measuring the changes 
that occur in an internally reflected IR beam when it encounters the test sample. The 
way this takes place is that an IR beam is directed onto an optically dense crystal with a 
high refractive index at a certain angle. This internal reflectance creates an evanescent 
wave that extends beyond the surface of the crystal onto the sample held in contact 
with the crystal.63 In regions of the IR spectrum where the sample absorbs energy, the 
evanescent wave will be attenuated. The attenuated beam then returns to the crystal, 
exits the opposite end of the crystal, and is directed onto the detector in the IR 
spectrometer. The detector records the attenuated IR beam as an interferogram signal, 
which can be used to generate an IR spectrum.63 
The IR spectrum of RTC1 (Figure 45) showed an absorption band of 2925 cm-1 
characteristic of the aliphatic C-H bonds, 1652 cm-1 characteristic of the carbonyl group 
C=O stretch, 1612 cm-1 characteristic of the C=C bond stretch, and 1329 cm-1 for the C-F 
bond stretch. These characteristic functional groups further confirmed the successful 




Figure 45: IR spectrum of RTC1. 
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2.3 Synthesis of compounds with structural variations at site A: the aryl 
group 
As mentioned previously, structure modifications were carried out on RTC1 (Figure 46) 
at five different sites in order to explore the relationship between structure and 
biological activity. The first site examined was site A, where variations were made on 
the aryl group. For RTC1, site A consisted of an aromatic ring with a para substituted 
trifluoromethyl group. 
 
Figure 46: Structure of RTC1 showing site A – the aryl group. 
Fluorine is the most electronegative element and has its 2s and 2d electrons close to the 
nucleus.64,65 It has been found that a strong bond between carbon and fluorine leads to 
high thermal and chemical stabilities of fluorinated compounds.64 These compounds 
also have a low dielectric constant due to the low polarizability of the C–F bond along 
with its hydrophobic character.65 The trifluoromethyl (CF3) group is significantly electron 
withdrawing and is often described as being intermediate between the 
electronegativities of fluorine and chlorine.66 The CF3 group has been used in many 
medicinal agents due to its unique chemical and physiological stability67, and has been 
widely reported to result in pharmacological and chemotherapeutic effects.68 Agents 
containing the trifluoromethyl group include anaesthetic, antidepressant, antiviral, and 
diuretic agents.64 It has also been found in the selective PPAR-δ agonist 
pyridyloxybenzene-acylsulfonamides, which is a potential novel agent for the treatment 
of type 2 diabetes.69  
Compounds containing variations at site A were synthesised using the new method 
discussed in section 2.2.1. This involved the coupling of the corresponding 
arylpiperazine with 4-(2-thienyl)butyric acid using HOBt/TBTU coupling reagents and  
NEt3. The reaction mixture in DMF or DCM was stirred at room temperature overnight 




Scheme 6: General reaction of compounds made with variations at site A.  
The acid derivative, 4-(2-thienyl)butyric acid, was commercially available and all the 
corresponding arylpiperazine starting materials were commercially available, with the 
exception of 1-(2-chloro-4-(trifluoromethyl)phenyl)piperazine (MK21) 6. The synthesis 
of this starting material consisted of dissolving 3-chloro-4-fluorobenzotrifluoride and 
piperazine in N-methyl-2-pyrrolidone (NMP) and heating the reaction at 200 °C for 30 
minutes in a microwave (MW) reactor (Scheme 7). The reaction mixture was purified 
using column chromatography to give the product as an orange oil in a 63% yield. 
 
Scheme 7: Synthesis of compound 6, 63% yield. 
Structure variations of the aryl group (site A) of RTC1 consisted of removing the CF3 
group, i.e. an unsubstituted phenyl ring (compound 7), moving the CF3 group to the 
ortho position (compound 8), and adding a second CF3 group, i.e. the bistrifluoromethyl 
substitution pattern (compound 9). Compounds were also made that replaced the para 
trifluoromethyl group with another electron withdrawing group, a nitro group 
(compound 10), and an electron donating group, an amine group (compound 11). We 
also wanted to explore the addition of a second halogen substituent and this resulted in 
the chlorine substituted compound 12. Additionally, we examined if replacing the 
aromatic ring with a heterocyclic ring would affect the biological activity. To do this, we 
synthesised the pyridine-containing compounds 13 and 14 (Table 1).  
Triflouromethyl groups are hydrophobic in nature. Hence, we were interested to know 
if replacing the para CF3 aromatic ring with other hydrophobic groups, e.g. cyclohexyl 
(compound 4) or methyl (compound 15), would have a negative effect on biological 
activity (Table 1).  
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Table 1: Compounds synthesised with variations at site A.  
 




























15 (MK36) Me 70% 
 
All yields for the final step were in the range of 70 – 90%, except for 1-(4-(4-
aminophenyl)piperazin-1-yl)-4-(thiophen-2-yl)butan-1-one (MK70) 11. The synthesis of 
this compound consisted of a reduction reaction of 1-(4-(4-nitrophenyl)piperazin-1-yl)-




Scheme 8: Synthesis of compound 11 by the reduction of compound 10 using H2 gas 
and PtO2 (Adam's catalyst), 35% yield. 
This reduction reaction was carried out using platinum oxide (PtO2), also known as 
Adam’s catalyst, in methanol (MeOH) with overnight stirring under an atmosphere of H2 
gas. The reaction mixture was passed through a bed of Celite to remove the platinum 
oxide and the filtrate was concentrated under reduced pressure, before purification 
using column chromatography. The lower yield of this compound was not totally 




 Structural characterisation of compounds made with variations at site 
A 
Structural characterisation of compounds 4, 7-15 was carried out in the same manner 
as for RTC1, whose structural characterisation was explained in detail in section 2.2.3, 
and employed 1H, 13C, 19F, and 2D-NMR spectroscopy, IR spectroscopy, and mass 
spectrometry. 
2.3.1.1 Structural characterisation of 1-(4-phenylpiperazin-1-yl)-4-(thiophen-
2-yl)butan-1-one (compound 7) 
 
Figure 47: Structure of compound 7. 
Compound 7 (Figure 47) only differs from RTC1 at the aromatic ring. Hence, the 
spectroscopic data for compound 7 is very similar to RTC1 and only significantly differs 
for the aromatic signals. The aromatic region of the 1H NMR spectrum for this compound 
contains four signals. The thiophene ring generates a doublet signal at 7.11 ppm and a 
multiplet signal in the range of 6.77 – 6.83 ppm, both integrating for 1H as expected. 
The multiplet signal in the range of 7.23 – 7.30 ppm, integrating for 2H, is assigned to 
the aromatic ring. The remaining multiplet signal in the range of 6.85 – 6.95 ppm is 
assigned to the three remaining hydrogens of the aromatic ring, and the remaining 
hydrogen of the thiophene ring. This signal integrates for 4H as expected. 
The 13C NMR spectrum also contains some differences compared to that for RTC1. We 
no longer see splitting due to F atoms and an additional CH signal can be observed at 
116.6 ppm. The three 13C CH signals for the aromatic ring in compound 7 occur at 129.2 
ppm, 126.8 ppm, and 116.6 ppm. In addition, the signal at 1328 cm-1 for the C-F bond 
stretch in the IR spectrum of RTC1 is absent from the IR spectrum of this compound. The  




2.3.1.2 Structural characterisation of 4-(thiophen-2-yl)-1-(4-(2-
(trifluoromethyl)phenyl)piperazin-1-yl)butan-1-one (compound 8)  
 
Figure 48: Structure of compound 8. 
The 1H NMR spectrum of compound 8 (Figure 48) contains all the expected signals, many 
of which are again similar to those found for RTC1. The 1H NMR signals of note occur in 
the aromatic region and were typical of an ortho substituted aromatic ring. The key 1H 
NMR signals of the aromatic ring occur as a doublet at 7.64 ppm, integrating for 1H, a 
multiplet in the range of 7.48 – 7.56 ppm, also integrating for 1H, and a multiplet in the 
range of 7.21 – 7.33 ppm, integrating for 2H.  
The 13C NMR spectrum also displayed the expected signals along with 13C-19F splitting 
due to the presence of F atoms. The aromatic carbon ipso to the piperazine now appears 
as a doublet at 151.7 ppm due to 13C-19F splitting instead of the singlet signal in RTC1. 
Quartet signals appear at 123.9, 127.4, and 127.2 ppm for the trifluoromethyl group 
carbon (CF3), the carbon bonded to the trifluoromethyl group (C-CF3), and the CH carbon 
ortho to the trifluoromethyl group (C-C-CF3), respectively. Singlet signals appear at 
132.8, 124.0, and 123.1 ppm for the remaining carbons in the para, meta, and ortho 
position (relative to the piperazine) of the aromatic ring, which are four or more bonds 
away from the F atoms and therefore appear as singlet signals.  The IR and MS data also 
confirmed the generation of compound 8.  
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2.3.1.3 Structural characterisation of 1-(4-(3,5-
bis(trifluoromethyl)phenyl)piperazin-1-yl)-4-(thiophen-2-yl)butan-1-
one (compound 9) 
 
Figure 49: Structure of compound 9. 
The 1H NMR spectrum of compound 9 (Figure 49) differs from the 1H NMR spectrum of 
RTC1 at the aromatic ring signals due to the bistrifluoromethyl substitution pattern. The 
1H NMR spectrum for this compound contains two singlet signals for the aromatic ring 
protons at 7.33 ppm and 7.24 ppm, representing the proton at the para position and the 
two protons at the ortho position of the aromatic ring (relative to the piperazine). The 
carbons bonded to these protons have corresponding signals in the 13C spectrum at 
112.7 ppm and 115.1 ppm, respectively, both appearing as multiplets due to 13C-19F 
coupling with the two trifluoromethyl groups. For the same reason, the signal for the 
trifluoromethyl carbon (CF3) and the signal for the carbons bonded to the 
trifluoromethyl groups (C-CF3) appear as quartets at 123.5 ppm and 132.5 ppm, 
respectively. The IR and MS data also confirmed the generation of compound 9. 
2.3.1.4  Structural characterisation of 1-(4-(4-nitrophenyl)piperazin-1-yl)-4-
(thiophen-2-yl)butan-1-one (compound 10)  
 
Figure 50: Structure of compound 10. 
Compound 10 (Figure 50) showed differences from RTC1 in the 1H and 13C NMR spectra 
as well as the IR spectrum due to the presence of the para nitro group in the aromatic 
ring. An important 1H NMR signal is a doublet at 8.14 ppm, which is part of a double of 
doublets, and is assigned to the two aromatic protons ortho to the nitro group. This 
signal is more downfield than that for the corresponding CH signals in RTC1 due to the 
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deshielding effect caused by the electron withdrawing nitro group (Scheme 9). The 
aromatic ring signals appear as a double of doublets as the two pairs of protons on the 
aromatic ring are in different chemical environments. The other doublet signal of the 
aromatic ring is overlapping with a thiophene CH signal and hence appears as a multiplet 
in the range of 6.78 – 6.86 ppm, integrating for 3H as expected.  
 
Scheme 9: Resonance structures for an aromatic ring with a para substituted nitro 
group. 
The IR spectrum of compound 10 showed that the absorbance band for the C-F stretch 
from RTC1 was absent and an absorbance band at 1321 cm-1 for an NO2 group was 
present. The MS data also confirmed the generation of compound 10.    
2.3.1.5 Structural characterisation of 1-(4-(4-aminophenyl)piperazin-1-yl)-4-
(thiophen-2-yl)butan-1-one (compound 11) 
 
Figure 51: Structure of compound 11. 
While the 1H NMR spectrum of compound 10 shows that the aromatic protons meta to 
the piperazine appear more downfield than in RTC1, due to the electron withdrawing 
nitro group, the 1H NMR spectrum of compound 11 (Figure 51) shows the opposite 
effect. This is due to the presence of an electron donating para substituted amino group 
causing a shielding effect. The aromatic protons meta to the piperazine now appear as 
a multiplet more upfield in the 1H NMR spectrum in the range of 6.77 – 6.82 ppm. As 
with compound 10, the aromatic protons are expected to appear as a double of doublets 
due to the two pairs of protons being in different chemical environments. This can be 
explained by considering the resonance structures shown in Scheme 10, where 
electrons are delocalised into the aromatic ring from the amino group. For compound 
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11, the expected double of doublets appears as a somewhat poorly resolved double of 
multiplets.   
 
Scheme 10: Resonance structures for an aromatic ring with a para substituted amino 
group. 
The IR spectrum shows an absorbance band at 3337 cm-1, which is characteristic of a N-
H bond stretch, and did not contain the C-F bond stretch that was found in the IR 
spectrum of RTC1. The MS data also confirmed the generation of compound 11.    




Figure 52: Structure of compound 12. 
Compound 12 (Figure 52) showed differences from RTC1 in the 1H and 13C NMR spectra 
as well as the IR spectrum, due to the presence of the ortho chloro substituent on the 
aromatic ring. In the 1H NMR spectrum, the aromatic protons appear as three signals 
due to the absence of a plane of symmetry, as expected. The most deshielded signal at 
7.64 ppm was assigned to the proton between the electron withdrawing CF3 and 
chlorine substituents, which was further deshielded due to the electron withdrawing 
properties of the neighbouring chlorine substituent.  
This signal appears as a doublet (J = 1.7 Hz) due to long range coupling with the proton 
in the meta position (relative to the piperazine), which is four bonds away from it. This 
coupling is common in aromatic rings and is known as meta coupling or “W-coupling” 
(Figure 53). The signal at 7.48 ppm was assigned to the other meta proton (relative to 
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the piperazine) which appears as a double of doublets (J = 8.4, 1.7 Hz) due to coupling 
to two non-equivalent protons (Figure 53). The third signal is a doublet at 7.05 ppm, 
which results from the ortho proton (relative to the piperazine) and has a coupling 
constant of J = 8.4 Hz. 
 
Figure 53: Long-range meta (“W”) coupling between the meta protons (J = 1.7 Hz) and 
short-range coupling between the ortho and meta protons (J = 8.4 Hz) of the aromatic 
ring. 
The 13C NMR spectrum of compound 12 also confirms its synthesis as it contains two 
extra signals when compared to the 13C spectrum of RTC1. The first signal is a quaternary 
13C signal at 128.8 ppm for the CH carbon bonded to the chlorine. The second signal is a 
quartet at 128.0 ppm for the carbon between the CF3 and Cl groups. In the IR spectrum, 
an absorbance band at 694 cm-1, which can be assigned to the C-Cl bond. The MS data 
also confirmed the generation of compound 12. 




Figure 54: Structure of compound 13. 
The 1H NMR spectrum of compound 13 (Figure 54) shows three pyridine signals in the 
aromatic region. The proton adjacent to the nitrogen of the pyridine ring appears most 
deshielded at 8.41 ppm due to the electron withdrawing effect of the nitrogen, as 
expected, with a multiplicity of a singlet. The other proton adjacent to the 
trifluoromethyl group, in the meta position relative to the piperazine, appears as a 
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double of doublets at 7.66 ppm. The multiplicity is due to coupling with the other meta 
proton (long-range “W” coupling as before) and also with its neighbouring proton (ortho 
to the piperazine). The third pyridine proton in the ortho position appears most upfield 
at 6.64 ppm and is a doublet due to coupling with the neighbouring proton. The key 13C 
NMR signals appear as a quartet at 145.8 ppm for the CH carbon bonded to the nitrogen, 
a quartet at 134.7 ppm for the other meta carbon relative to the piperazine coupling 
with CF3, and a singlet at 105.7 ppm for the CH carbon in the ortho position, relative to 
the piperazine. The IR and MS data also confirmed the generation of compound 13.  
2.3.1.8  Structural characterisation of 1-(4-(3-chloro-5-
(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)-4-(thiophen-2-yl)butan-
1-one (compound 14) 
 
Figure 55: Structure of compound 14. 
Similar to compound 13, compound 14 (Figure 55) also contained a pyridine. However, 
compound 14 also had an ortho substituted chlorine, which resulted in only two pyridine 
signals in the 1H NMR spectrum. These signals appear more deshielded than the 
corresponding signals in RTC1 as expected. This is due to the electron withdrawing 
effects of the nitrogen and chlorine. As with compound 13, the first proton appears as a 
singlet at 8.40 ppm, which represents the proton adjacent to the nitrogen. The second 
proton also appears as a singlet at 7.79 ppm, which represents the proton between the 
CF3 and chlorine. The carbons bonded to these protons appear as quartets in the 13C 
NMR spectrum at 143.0 ppm (J = 4.2 Hz) and 136.1 ppm (J = 3.3 Hz), respectively. In the 
IR spectrum, an absorbance band at 847 cm-1 can be observed for the C-Cl bond stretch. 
The MS data also confirmed the generation of compound 14.  
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2.3.1.9 Structural characterisation of 1-(4-cyclohexylpiperazin-1-yl)-4-
(thiophen-2-yl)butan-1-one (compound 4) 
 
Figure 56: Structure of compound 4. 
The 1H and 13C NMR spectra of compound 4 (Figure 56) are significantly different from 
the spectra of RTC1 due to the replacement of the aromatic ring with a cyclohexyl group. 
The 1H NMR spectrum for compound 4 shows five additional multiplet signals in the 
aliphatic region. The proton signal for CH attached to the piperazine appears in the range 
of 2.25 – 2.32 ppm, integrating for 1H, and is most deshielded due to its close proximity 
to an electronegative nitrogen. The protons in the 2- and 3-positions appear in the range 
of 1.73 – 1.93 ppm and 1.14 – 1.31 ppm respectively, each signal integrating for 4H. The 
protons in the 4-position appear as two multiplet signals in the range of 1.56 – 1.69 ppm 
and 1.04 – 1.14 ppm, each integrating for 1H.  
The 13C NMR spectrum contains four signals for the cyclohexyl carbons. The most 
downfield signal at 63.6 ppm is for the CH carbon bonded to the piperazine ring, which 
is the most deshielded cyclohexyl carbon as it is directly bonded to the electronegative 
nitrogen. The signals for the carbons in the 2, 3 and 4-position appear at 28.8 ppm, 25.8 
ppm, and 26.2 ppm, respectively. The IR and MS data also confirmed the generation of 




2.3.1.10 Structural characterisation of 1-(4-methylpiperazin-1-yl)-4-
(thiophen-2-yl)butan-1-one (compound 15) 
 
Figure 57: Structure of compound 15 
The final compound in the group with variations at site A is compound 15 (Figure 57), 
and also shows some differences in the 1H and 13C NMR spectra when compared to those 
of RTC1. Similar to compound 4, the 1H and 13C NMR spectra of course do not contain 
any signals for the aromatic ring as found with RTC1. Instead, an extra singlet signal for 
the methyl group protons appears at 2.29 ppm, integrating for 3H, while the 
corresponding carbon appears at 46.0 ppm in the 13C NMR spectrum. The IR and MS 
data also confirmed the generation of compound 15.   
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2.4 Synthesis of compounds with structural variations at site B: the 
piperazine ring 
The second site of variation examined was the piperazine ring (site B) (Figure 58). It is 
important to have variations at this site to establish whether a nitrogen-containing 
heterocyclic ring, such as a piperazine ring or indeed a piperidine ring, is needed for 
activity, or if instead a simple amide linkage can maintain biological activity. The 
piperidine ring will also indicate the importance of having the second nitrogen of the 
piperazine ring on biological activity. 
 
Figure 58: Structure of RTC1 showing site B – the piperazine ring. 
The piperazine ring contains two nitrogen atoms in a 1,4-relationship within a 6-
membered heterocyclic ring. It has many medicinal applications such as antiviral70, 
antiobesity52, antidepressant71, antibacterial72, and antiulcer72 (Figure 59). It has many 
uses as an antithelmintic agent where it works to paralyze parasites that may invade the 
host body and cause disease73, and act as a gamma-amino-butyric acid receptor agonist 
in nematodes.74 It has also been associated with network formation and 
photoluminescence in copper(I) halide complexes.75 Medicines containing piperazine 
are used to treat diseases such as ascariasis or enterobiasis.73 
 
Figure 59: Structure of piperazine-based analogues that act as an antiviral (A)70 or 
antidepressant (B)71 agents. 
Two derivatives of RTC1 were synthesised with variations at the piperazine ring (site B). 
For compound 16, the piperazine ring was replaced by a piperidine ring and for 
compound 17, the piperazine ring was replaced by an NH (amine linkage).  
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 Synthesis and structural characterisation of 4-(thiophen-2-yl)-1-(4-(4-
(trifluoromethyl)phenyl)piperidin-1-yl)butan-1-one (compound 16)  
Compound 16 was synthesised using the new method discussed in section 2.2.1. Again, 
coupling of 4-(4-(trifluoromethyl)phenyl)piperidine with 4-(2-thienyl)butyric acid, using 
HOBt/TBTU coupling reagents and  NEt3, was utilised (Scheme 11). The reaction mixture, 
in DMF, was stirred at room temperature for 24 hours and purified using column 
chromatography (3:2, ethyl acetate (EtOAc):n-hexane) to give an off-white solid in a 67% 
yield. 
 
Scheme 11: Synthesis of compound 16, 67% yield. 
This compound has different 1H and 13C NMR spectra in comparison with RTC1 due to 
the replacement of the piperazine ring with a piperidine ring, most noticeably in the area 
where the piperazine signals occurred. Seven signals appear in the 1H NMR spectrum 
due to the piperidine ring. The protons bonded to the carbons adjacent to the 
electronegative nitrogen appear as four separate signals; two doublet signals at 4.82 
and 3.92 ppm, and two triplet signals at 3.10 ppm and 2.63 ppm. These four signals were 
shown to couple with the quaternary carbonyl carbon at 170.9 ppm in the 1H-13C HMBC 
spectrum (Figure 60).  
The four protons further from the nitrogen appear as two multiplet signals in the range 
of 1.84 – 1.93 ppm and 1.52 – 1.68 ppm. The proton furthest to the nitrogen appears as 
a multiplet in the range of 2.74 – 2.85 ppm, integrating for 1H. These three signals 
coupled to the quaternary carbon of the aromatic ring at 149.2 ppm in the 1H-13C HMBC 
spectrum (Figure 60). The carbons bonded to these protons appear in the 13C NMR 
spectrum at 46.0 ppm and 42.2 ppm for the carbons bonded to the nitrogen, at 33.7 
ppm and 32.6 ppm for the carbons further from the nitrogen, and 42.7 ppm for the ipso 





Figure 60: The 1H-13C HMBC spectrum of compound 16 
 Synthesis and structural characterisation of 4-(thiophen-2-yl)-N-(4-
(trifluoromethyl)phenyl)butanamide (compound 17) 
Compound 17 was also synthesised using the new method discussed in section 2.2.1. 
Once more, coupling 4-(trifluoromethyl)aniline with 4-(2-thienyl)butyric acid was 
carried out using HOBt/TBTU coupling reagents and  NEt3 (Scheme 12). The reaction 
mixture, in DMF, was stirred at room temperature for 20 hours and purified using 
column chromatography (3:2, EtOAc:n-hexane) to give a white solid in a 90% yield. 
 
Scheme 12: Synthesis of compound 17, 90% yield. 
The replacement of the piperazine ring in RTC1 with a NH results in significantly different 
1H and 13C NMR spectra. For compound 17 there are no piperazine signals present. 
Instead, a broad singlet at 7.29 ppm is observed in the 1H NMR spectrum, which is 
assigned as the proton of the amide. Furthermore, the IR spectrum shows an 
absorbance band at 3304 cm-1, which also confirms the presence of the amide linkage. 
The MS data also confirmed the generation of compound 17.  
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2.5 Synthesis of compounds with structural variations at site C: the carbonyl 
group 
The third site of variation examined on RTC1 was the carbonyl group (site C) (Figure 61). 
We deemed it important to establish the affect this group was having on biological 
activity.  
 
Figure 61: Structure of RTC1 showing site C – the carbonyl group. 
A carbonyl group consists of a carbon atom double bonded to an oxygen atom. It is found 
in several functional groups such as aldehydes, ketones, anhydrides, and carboxylic 
acids. As oxygen is more electronegative than carbon, compounds containing a carbonyl 
group are polar, which results in an increase in the melting and boiling points as well as 
influencing their solubility. The polarity of the carbonyl bond allows it to partake in a 
variety of chemical reactions as nucleophilic reagents react at the carbonyl carbon atom 
(e.g. addition-elimination reactions), whereas electrophilic reagents, such as Lewis acid, 
interact with the carbonyl oxygen. It is found in many medicines due to its ability to 
participate in many non-covalent interactions with protein targets such as hydrogen-




 Synthesis and structural characterisation of 1-(4-(thiophen-2-yl)butyl)-
4-(4-(trifluoromethyl)phenyl)piperazine (compound 18) 
A single derivative was generated with the carbonyl group (site C) removed, 1-(4-
(thiophen-2-yl)butyl)-4-(4-(trifluoromethyl)phenyl)piperazine (MK34) (compound 18). 
The synthesis of this compound consisted of a three-step process involving (i) a 
reduction reaction, (ii) a mesylation reaction, and (iii) a nucleophilic substitution 
reaction (Scheme 13). 
 
Scheme 13: Synthetic route to compound 18 using reduction, mesylation and 
nucleophilic substitution reactions.  
The first reaction consists of the synthesis of 4-(thiophen-2-yl)butan-1-ol (MK32) 19 via 
the reduction of 4-(2-thienyl)butyric acid using lithium aluminium hydride (LiAlH4) in 
anhydrous tetrahydrofuran (THF). After quenching the reaction mixture using deionised 
water (H2O), and a work-up using HCl and EtOAc, the product was dried over MgSO4 and 
under reduced pressure. The product was obtained as a pure orange oil in a 58% yield.  
The second reaction, the mesylation reaction of compound 19, used methanesulfonyl 
chloride and NEt3 in anhydrous DCM. Work-up of this reaction also consisted of several 
washes using HCl and EtOAc, purification using column chromatography, and drying 
under reduced pressure, to obtain the product (compound 20) as a colourless oil in a 
46% yield.  
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The mesylation reaction converts the hydroxy group of the alcohol into a good leaving 
group, the methanesulfonyl group. The mesylation mechanism (Scheme 14) begins with 
the elimination of HCl from sulfonyl chloride to give the sulfene intermediate, followed 
by the nucleophilic attack of compound 19 to give 4-(thiophen-2-yl)butyl 
methanesulfonate (MK33) 20.  
 
Scheme 14: Proposed mechanism for the synthesis of compound 20. 
The final reaction is a nucleophilic substitution reaction of compound 20 using the 
arylpiperazine as the nucleophile, and sodium carbonate (Na2CO3) as base. The reaction 
mixture in acetonitrile was refluxed for 22 hours with vigorous agitation and under a 
nitrogen atmosphere. After purification using column chromatography, the product, 
compound 18, was obtained as a white solid in a 77% yield. 
Compound 18 showed the expected differences in the 1H and 13C NMR spectra, and IR 
spectra from those of RTC1. The 13C NMR spectrum no longer has a signal at 171.1 ppm 
due to the absence of the carbonyl carbon. Also, an extra proton signal at 2.87 ppm in 
the 1H NMR spectrum and corresponding 29.8 ppm in the 13C NMR spectrum is 
observed. These signals can be assigned to the CH2 group that has replaced the carbonyl 
group. Furthermore, the IR spectrum does not contain a carbonyl absorbance band at 
1652 cm-1, as found in the IR spectrum of RTC1. The MS data also confirmed the 




2.6 Synthesis of compounds with structural variations at site D: the alkyl 
chain 
The fourth site of variation examined was the alkyl chain (site D) (Figure 62) which links 
the carbonyl group to the thiophene ring.  
 
Figure 62: Structure of RTC1 showing site D – the alkyl chain. 
The length and nature of the alkyl chain could have a significant effect on biological 
activity. Hence, investigating the optimum length for this alkyl chain was considered 
important, as was varying the nature of the linking chain.  
Five compounds (compounds 21-25) were made as part of this study (Table 2). 
Compounds 21, 22, 24, and 25 were synthesised using the optimised method as 
discussed in section 2.2.1. Again, coupling of compound 2 with the corresponding 
carboxylic acid derivative was performed using HOBt/TBTU as coupling reagents 
(Scheme 15). Purification was carried out using column chromatography.  
 
Scheme 15: General reaction for the synthesis of compounds 21, 22, 24, and 25. 
Compound 23 was synthesised using the old method consisting of anhydrous conditions, 
HOBT/TBTU, oven-dried Schlenk tube and under nitrogen atmosphere at the beginning 
of this project and not repeated under the improved conditions. 
Structure variations of RTC1 on the alkyl chain (site D) consisted of compounds without 
an alkyl chain (compound 21), a shorter alkyl chain (compound 22), and a longer alkyl 
chain (compound 23). Further variations on the alkyl chain consisted of substituting the 
CH2 group adjacent to the thiophene ring with a carbonyl group (compound 24), or a 
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sulphur atom (compound 25). Yields of 60-84% were obtained for compounds 21-25 
(Table 2).   
Table 2: Compounds made with variations at site D of RTC1 at the alkyl chain. 
 
Compound X Yield 
21 (MK37) - 69% 
22 (MK47) CH2 82% 







 Structural characterisation of thiophen-2-yl (4-(4-
(trifluoromethyl)phenyl)piperazin-1-yl) methanone (compound 21) 
 
Figure 63: Structure of compound 21. 
As expected, the 1H and 13C NMR spectra of compound 21 (Figure 63) do not contain any 
alkyl chain signals. Instead, both spectra just contain the typical signals for the para CF3 
substituted aromatic ring and the thiophene ring, as well as the signals for the piperazine 
motif. The IR and MS data also confirmed the generation of compound 21.  
 Structural characterisation of 2-(thiophen-2-yl)-1-(4-(4-
(trifluoromethyl)phenyl)piperazin-1-yl)ethanone (compound 22) 
 
Figure 64: Structure of compound 22. 
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The three signals for the alkyl chain of RTC1 are also absent in the 1H NMR spectrum of 
compound 22 (Figure 64). Instead, just one singlet signal at 3.96 ppm appears for the 
single CH2 group, integrating for 2H. The carbon signal for this CH2 group appears at 35.2 
ppm in the 13C NMR spectrum. The expected 1H and 13C NMR signals for the para CF3 
substituted aromatic ring, the thiophene ring, and the piperazine ring are all present. 
The IR and MS data also confirmed the generation of compound 22. 
 Structural characterisation of 5-(thiophen-2-yl)-1-(4-(4-
(trifluoromethyl)phenyl)piperazin-1-yl)pentan-1-one (compound 23) 
 
Figure 65: Structure of compound 23. 
Compound 23 (Figure 65) contains an alkyl chain with four repeating CH2 units. The 1H 
NMR spectrum contains three signals for the alkyl chain, with one of the signals, a 
multiplet in the range of 1.68 – 1.81 ppm, integrating for four protons and the remaining 
two signals integrating for two protons each. The extra CH2 group also shows an extra 
carbon signal in the 13C NMR spectrum at 31.4 ppm, which further confirms the synthesis 
of this compound. The IR and MS data also confirmed the generation of compound 23. 
 Structural characterisation of 1-(thiophen-2-yl)-1-(4-(4-
(trifluoromethyl)phenyl)piperazin-1-yl)butan-1,4-dione (compound 24)  
 
Figure 66: Structure of compound 24. 
Compound 24 (Figure 66) contains one less signal in the 1H NMR spectrum, when 
compared to that of RTC1, due to the replacement of one of the CH2 groups with an 
electron withdrawing carbonyl group. This second carbonyl group causes the signals for 
the two CH2 groups to be deshielded and appear as an unresolved multiplet in the range 
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of 3.25 – 3.27 ppm and a triplet at 2.82 ppm. Both signals integrate for 2H. The 13C NMR 
spectrum for compound 24 also confirms its synthesis as it has one less CH2 signal in the 
aliphatic region, when compared to the 13C NMR spectrum of RTC1, and instead has an 
extra quaternary carbonyl carbon signal at 191.9 ppm. Furthermore, the IR spectrum 
shows a second carbonyl group absorbance band at 1647 cm-1. The MS data also 
confirmed the generation of compound 24. 
 Structural characterisation of 3-(thiophen-2-ylthio)-1-(4-(4-
(trifluoromethyl)phenyl)piperazin-1-yl)propan-1-one (compound 25) 
 
Figure 67: Structure of compound 25. 
Similar to compound 24, compound 25 (Figure 67) also has a one less signal in the 1H 
NMR spectrum, when compared to that of RTC1. This is due to the replacement of one 
of the CH2 groups with an electronegative sulphur atom. This also causes the signals of 
the two CH2 groups to be deshielded, occurring at 2.68 ppm and 3.12 ppm. Both signals 
appear as triplets and integrate for 2H. The 13C NMR spectrum also showed one CH2 
signal less when compared to the spectrum for RTC1. The IR and MS data also confirmed 




2.7 Synthesis of compounds with structural variations at site E: the 
thiophene ring 
The final site of variation examined on RTC1 was the thiophene ring (site E) (Figure 68).  
 
Figure 68: Structure of RTC1 showing variations at site E – the thiophene ring. 
The thiophene ring is a planar five-membered heterocyclic ring, which is present in many 
agrochemicals, pharmaceuticals and dyes, with applications in many areas such as 
material science, coordination chemistry, and organic synthesis.78,79 Many molecules 
incorporating the thiophene ring have shown important pharmacological activities.79 It 
can partake in many reactions such as oxidation, halogenation, acylation, alkylation and 
polymerisation, and has many useful applications as an electron acceptor, a hydrogen-
poor heterocycle, or an organic conductors.80,81 It can react with oxidising agents, 
nucleophilic reagents, bases and radical agents.81 
Structure variations of RTC1 at the thiophene ring (site E) consisted of just one derivative 
where the thiophene ring was replaced with a different heterocycle, namely the 
nitrogen containing pyrazole ring (compound 5) (Figure 69).  
 
Figure 69: Structure of compound 5. 
 Synthesis and structural characterisation of 4-(1H-pyrazol-4-yl)-1-(4-(4-
(trifluoromethyl)phenyl)piperazin-1-yl)butan-1-one (compound 5) 
The synthesis of compound 5 consisted of using the new method as discussed in section 
2.2.1. Again, coupling of the arylpiperazine with 4-(1H-pyrazol-4-yl-)butanoic acid was 
94 
 
carried out using HOBt/TBTU as coupling reagents (Scheme 16). Purification using 
column chromatography generated the desired product as a brown solid in a 93% yield.  
 
Scheme 16: Synthesis of compound 5, (i) HOBt, TBTU, DCM, NEt3, 24 hrs, rt, 93% yield. 
Compound 5 contains two different signals in the 1H NMR spectrum in comparison with 
RTC1 due to the replacement of the thiophene ring with a pyrazole ring. These signals 
are a singlet at 7.43 ppm representing the two C-H protons, and a broad singlet at 5.57 
ppm representing the N-H proton of the pyrazole ring. The C-H carbons of the pyrazole 
ring also show a signal at 132.9 ppm in the 13C NMR spectrum. Furthermore, the IR 
spectrum shows an absorbance band for the N-H at 3055 cm-1, with the MS data also 




2.8 Synthesis of compounds with structural variations at multiple sites 
After making individual changes to the five different sites of RTC1 (Figure 70), additional 
compounds were synthesised that consisted of variations at multiple sites. These 
compounds were synthesised from the corresponding arylpiperazine and carboxylic acid 
using coupling chemistry.     
 
Figure 70: Structure of RTC1 with variation sites, A-E. 
 Synthesis of compounds with structural variations at site A and site B – 
compounds 26 and 27 
Two compounds were synthesised with variations at the aryl group (site A) and 
piperazine ring (site B) (Figure 71). Compound 26 was synthesised where the entire 
arylpiperazine motif of RTC1 was replaced by a dimethylamino group. For compound 27, 
the trifluoromethyl group of RTC1 was replaced with a hydrogen, and the piperazine ring 
replaced with a piperidine ring.  
 
Figure 71: Structure of compound 26 and compound 27.   
2.8.1.1  Synthesis and structural characterisation of N,N-dimethyl-4-
(thiophen-2-yl)butanamide (compound 26) 
Compound 26 was synthesised using the new method discussed in section 2.2.1 which 
involved coupling of dimethylamine with 4-(2-thienyl)butyric acid, using HOBt/TBTU 
coupling reagents and  NEt3 (Scheme 17). The reaction mixture, in DMF, was stirred at 
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room temperature for 16 hours and purified using column chromatography (3:2, 
EtOAc:n-hexane) to give a grey oil in a 43% yield. 
 
Scheme 17: Synthesis of compound 26, 43% yield. 
Compound 26 differed from the 1H and 13C NMR spectra of RTC1 in that it did not contain 
any signals for the aryl or piperazine groups. Instead a multiplet signal, due to bond 
rotation, appears in the 1H NMR spectrum in the range of 2.74 – 3.11 ppm for the two 
methyl groups of the dimethylamine group. The carbon signals for these methyl groups 
appear at 35.5 ppm and 37.3 ppm in the 13C NMR spectrum. The IR and MS data also 
confirmed the generation of compound 26. 
2.8.1.2  Synthesis and structural characterisation of 1-(4-phenylpiperidin-1-
yl)-4-(thiophen-2-yl)butan-1-one (compound 27) 
Compound 27 was also synthesised using the new method discussed in section 2.2.1. 
Again, HOBt/TBTU coupling reagents were used to couple 4-phenylpiperidine with 4-(2-
thienyl)butyric acid, and  NEt3 (Scheme 18). The reaction mixture, in DCM this time, was 
stirred at room temperature for 18 hours and purified using column chromatography 
(3:2, EtOAc:n-hexane) to give a clear oil in a 98% yield. 
 
Scheme 18: Synthesis of compound 27, 98% yield. 
Differences in the 1H and 13C NMR spectra of compound 27 compared to the spectra of 
RTC1 are due to the absence of the trifluoromethyl group, and the replacement of the 
piperazine ring with a piperidine ring. The aromatic region of the 1H NMR spectrum of 
this compound contains two signals for the phenyl ring. The first signal is for the ortho 
proton at 7.32 ppm which appears as a pseudo triplet instead of a double of doublet as 
expected due to short-range splitting with the proton in the meta position and long-
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range splitting with the proton in the para position. The second signal appears as a 
multiplet at 7.16 – 7.25 ppm integrating for 3H for the protons in the ortho and para 
positions. The carbons bonded to these protons appear in the 13C NMR spectrum as 
singlet signals at 126.5 ppm (ortho carbons), 126.8 ppm (meta carbons), and 128.6 ppm 
(para carbons). 
The piperidine ring results in multiple signals in the 1H and 13C NMR spectra. The 
piperidine CH proton appears at 2.73 ppm in the 1H NMR spectrum as a triplet of triplet 
signal as expected due to splitting with two sets of two adjacent protons. The carbon 
bonded to this proton appears at 42.8 ppm in the 13C NMR spectrum. The protons 
adjacent to the nitrogen results in 4 different signals; two triplet of doublet signals at 
2.63 ppm and 3.09 ppm, and two doublet signals at 3.91 ppm and 4.82 ppm. The carbons 
bonded to these protons appear in the 13C spectrum at 42.4 ppm and 46.2 ppm. The 
protons further from the nitrogen appear in the 1H NMR spectrum as multiplet signals 
in the range of 1.54 – 1.67 ppm and 1.84 – 1.93 ppm, each integrating for 2H. The 
carbons bonded to these protons appear at 32.9 ppm and 34.0 ppm in the 13C NMR 
spectrum. The IR and MS data also confirmed the generation of compound 27. 
2.8.1.3 Synthesis of compound with structural variations at site B and site D – 
1-(thiophen-2-yl)-4-(4-(4-(trifluoromethyl)phenyl)piperidin-1-
yl)butane-1,4-dione (compound 28) 
Compound 28 consisted of replacing the piperazine ring (site B) with a piperidine ring, 
and a methylene group on the alkyl chain (site D) with a carbonyl group. It was 
synthesised using the new method discussed in section 2.2.1 by coupling 4-(4-
trifluoromethyl)phenyl)piperidine with 4-oxo-4-(2-thienyl)butanoic acid,  using 
HOBt/TBTU coupling reagents, and NEt3 (Scheme 19). The reaction mixture, also in DCM, 
was stirred at room temperature for 19 hours and purified using column 
chromatography (4:1, EtOAc:n-hexane) to give a white solid in a 87% yield. 
 
Scheme 19: Synthesis of compound 28, 87% yield. 
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The 1H and 13C NMR spectra of compound 28 showed all the expected signals. The 
piperidine ring generated very similar signals in the 1H and 13C NMR spectra to those of 
compound 27. As anticipated, the extra carbonyl group results in one less signal in the 
aliphatic region of the 1H NMR spectrum in comparison to RTC1. Furthermore, the two 
signals of the alkyl chain of compound 28 appear as multiplet signals at 2.77 – 2.90 ppm 
and 3.14 – 3.23 ppm, more deshielded than the corresponding signals in RTC1. The alkyl 
carbonyl group also produces an extra quaternary carbon signal at 192.2 ppm in the 13C 




2.8.1.4 Synthesis of compounds with structural variations at site D and site E 
– compounds 3, 29 and 30 
The next set of compounds synthesised consisted of variations of RTC1 at both the alkyl 
chain (site D) and thiophene ring (site E). The first compound (compound 3) was 
previously discussed in the method development section 2.2.1. For compound 3, the 
alkyl chain is elongated with the thiophene heterocycle being replaced with a methyl 
ester group. The second compound (compound 29) also consisted of elongating the alkyl 
chain but this time the thiophene is replaced with a phenyl ring. The third compound 
(compound 30) consisted of replacing both the alkyl chain and the thiophene ring with 
a methyl group (Figure 72). 
 
Figure 72: Structure of compounds 3, 29 and 30.   
2.8.1.4.1  Synthesis and structural characterisation of methyl 9-oxo-9-(4-(4-
(trifluoromethyl)phenyl)piperazin-1-yl)nonanoate (compound 3) 
The synthesis of compound 3 was previously discussed in the method development 
section 2.2.1 which consisted of coupling methyl hydrogen azelate with 1-(4-
(trifluoromethyl)phenyl)piperazine (compound 2) using BOP and NEt3 in a round-bottom 
flask and stirred, in DCM, at room temperature overnight. Purification consisted of 
evaporation under reduced pressure followed by column chromatography to give the 




Scheme 20: Synthesis of compound 3, 55% yield. 
The 1H NMR spectrum of compound 3 contains three signals for the seven CH2 groups. 
The α-protons from the two CH2 groups adjacent to the two carbonyl groups appear 
most deshielded at 2.32 ppm and as a doublet of triplet signal, integrating for 4H. The 
next signal appears as a multiplet in the range of 1.58 – 1.69 ppm and can be assigned 
to the β-protons of the two CH2 groups further from the carbonyl groups.  
The third signal appears as a broad singlet at 1.34 ppm integrating for the 6H of the γ-
protons of the remaining three CH2 groups in the middle of the alkyl chain. The CH3 signal 
of the ester group appears as a multiplet in the range of 3.52 – 3.72 ppm. The 13C NMR 
spectrum for compound 3, in comparison with the spectrum of RTC1, also shows the 
expected additional signals for the elongated alkyl chain, as well as an extra carbonyl 
carbon signal at 174.3 ppm. The ester CH3 signal appears at 51.5 ppm. The MS and IR 
data for compound 3 also confirms its synthesis, with the IR spectrum showing an 
absorbance band at 1736 cm-1, characteristic of an ester carbonyl group.   
2.8.1.4.2  Synthesis and structural characterisation of 5-phenyl-1-(4-(4-
(trifluoromethyl)phenyl)piperazin-1-yl)pentan-1-one (compound 
29)  
The synthesis of compound 29 involved using the new method as discussed in section 
2.2.1 which consisted of coupling of the arylpiperazine with 5-phenylpentanoic acid 
using HOBt/TBTU as coupling reagents, and NEt3, and carrying the reaction in DMF  
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(Scheme 21). Purification using column chromatography (4:1, EtOAc:n-hexane) 
generated the desired product as an orange oil in a 65% yield.  
 
Scheme 21: Synthesis of compound 29, (i) HOBt, TBTU, DMF, NEt3, 21 hrs, rt, 65% 
yield. 
The 1H and 13C NMR spectra for compound 29 differ from those of RTC1 as expected. 
The 1H NMR spectrum contains a multiplet signal in the range of 1.65 – 1.75 ppm, which 
integrates for 4H instead of 2H as in RTC1, due to the extra CH2 group of compound 29.  
An extra carbon signal at 31.1 ppm can be found in the 13C NMR spectrum of compound 
29, again due to the extra CH2 group. The phenyl ring results in multiplet signals in the 
1H NMR spectrum in the range of 7.23 – 7.26 ppm and 7.13 – 7.19 ppm for the protons 
in the ortho position and meta position respectively. The carbons in the ortho, meta, 
and para position of the aromatic ring appear at 128.5 ppm, 128.4 ppm, and 125.8 ppm 
respectively, while the ipso carbon appears at 142.2 ppm. The IR and MS data also 
confirmed the generation of compound 29.  
2.8.1.4.3  Structural characterisation of 1-(4-(4-
(trifluoromethyl)phenyl)piperazin-1-yl)ethan-1-one (compound 30) 
Compound 30 was also synthesised using the new method as discussed in section 2.2.1 
by using HOBt/TBTU coupling reagents to couple the arylpiperazine with 1-(4-
(trifluoromethyl)phenyl)piperazine, using NEt3, and carrying the reaction in DMF  
(Scheme 22). Purification using column chromatography (4:1, EtOAc:n-hexane) 
generated the desired product as an off-white solid in a 73% yield.  
 
Scheme 22: Synthesis of compound 30, 73% yield. 
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The 1H and 13C NMR spectra of compound 30 does not contain any signals for the alkyl 
chain or thiophene ring of RTC1 as they have been replaced by a methyl group. Instead, 
a singlet signal at 2.14 ppm in the 1H NMR spectrum, integrating for 3H, and a signal at 
21.3 ppm in the 13C NMR spectrum, confirms the presence of the methyl group. The IR 
and MS data also confirmed the generation of compound 30. 
2.8.1.5 Synthesis and structural variation of compound 31 with structural 
variation at sites C, D and E – 1-methyl-4-(4-
(trifluoromethyl)phenyl)piperazine (compound 31) 
The final compound, 1-methyl-4-(4-(trifluoromethyl)phenyl)piperazine (MK35) 
(compound 31) consisted of completely removing the thiophene-linker motif, including 
the carbonyl carbon, of RTC1 and replacing it with a simple methyl group. The synthesis 
of compound 31 utilised the Eschweiler-Clarke reaction,82 a reductive amination, and 
consisted of dissolving compound 2 in ethanol (EtOH) and reacting it with formic acid 
and formaldehyde, under refluxing conditions for three hours (Scheme 23). After 
successful work-up and purification using column chromatography, the product 
appeared as a white solid in a 70% yield.  
 
Scheme 23: Synthesis of compound 31, 70% yield. 
The proposed mechanism for this reaction (Scheme 24) begins with the protonation of 
formaldehyde by formic acid to form a more electrophilic carbonyl carbon, which in turn 
undergoes nucleophilic attack by the arylpiperazine 2. After protonation and 
deprotonation, water is removed as the leaving group to form the electrophilic iminium 
intermediate. The formate then acts as a hydride donor with the iminium ion being 
reduced to an amine. Deprotonation of the amine reforms formic acid and compound 




Scheme 24: Proposed mechanism for the synthesis of compound 31. 
As with compound 30, the 1H and 13C NMR spectra of compound 31 does not contain 
any signals for the alkyl chain or thiophene ring of RTC1. Also, the quaternary carbonyl 
carbon signal is absent in the 13C NMR spectrum. The methyl group signals appear as a 
singlet signal at 2.35 ppm in the 1H NMR spectrum, integrating for 3H, and at 54.8 ppm 
in the 13C NMR spectrum. The IR and MS data also confirmed the generation of 




The arylpiperazine moiety is found in many medicinal agents and has multiple 
pharmacological applications. To access the arylpiperazine derivative, various synthetic 
approaches can be utilised such as nucleophilic aromatic substitutions (SNAr) reactions, 
metal catalysed reactions, and cyclocondensation reactions.52,53 Arylpiperazines have 
been used for many years in various applications such as an appetite suppressant, an 
anorectic agent, an antidepressant drug, and an anti-cancer agent.54,55    
The arylpiperazine family generated in this project consisted of analogues of RTC1 with 
variations at five sites, Figure 73. The purpose of generating this family was to explore 
the relationship between chemical structure and biological function (anti-diabetic 
effect) for this compound class.  The five sites of variation are the aryl group (A), 
piperazine ring (B), carbonyl group (C), alkyl chain (D), and thiophene ring (E). Additional 
compounds were also synthesised that contained variations at multiple sites.  
 
Figure 73: Structure of RTC1 with five sites of variation, A-E. 
Synthetic method development for this family involved using non-anhydrous conditions 
and removing the post-reaction work-up to provide a more facile and quicker method 
of synthesising the target compounds. This optimised method resulted in a reduction of 
time required to synthesise and purify target compounds as well as giving a higher yield. 
This method was therefore utilised for the synthesis of most compounds in this family.  
Each member of the arylpiperazine family was fully characterised using 1H and 13C NMR 
spectroscopy, including 2D-NMR spectroscopy, as well as IR spectroscopy, and accurate 
HR-MS. Some of the compounds containing a trifluoromethyl group were also 
characterised using 19F NMR spectroscopy. Compounds synthesised in this group were 
added to arylpiperazines generated by previous group members to create a large family 
of arylpiperazines.  
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Compounds from this larger family were then made available for biologically evaluation 
in order to explore the relationship between their structure and biological activity. This 
SAR type study was performed using a glucose uptake assay and a complex I assay in 










3.1 Introduction  
Members of the pyrazolopyrimidinone bicycle family are composed of a fused nitrogen-
containing heterocyclic bicycle system with substituents at R and R1 group, Figure 74.  
 
Figure 74: General structure for the pyrazolopyrimidinone bicycle family. 
This family is of interest due to its role as a basic core scaffold in many bioactive and 
pharmaceutically relevant compounds. Derivatives of the pyrazolopyrimidinone bicycle 
core structure have found use in the battle against several illnesses including cancer83 
(GSK), obesity84 (Pfizer), and cystic fibrosis85 (Vertex) (Figure 75).  
 
Figure 75: Structure of bioactive pyrazolopyrimidinones as agents for cancer83, 
obesity84 and cystic fibrosis85. 
They have also been found as KCNQ channel openers. KNCQ are a member of potassium 
channel proteins that belong to the 6-transmemberance gene family of ion channels86 
(Figure 76). Some derivatives have also been discovered to have anti-trypanosomal or 
anti-schistosomal activities, while others show potential activity against respiratory 
diseases.87 
 
Figure 76: Structures of bioactive pyrazolopyrimidinones as KCNQ channel openers.86 
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Due to the continuous discoveries of interesting biological properties of this ring system, 
research has been stimulated for new and efficient procedures of synthesising 
compounds containing this core scaffold. Solvent-free conditions for the synthesis of 
these compounds have been employed, particularly with cyclocondensation reactions, 
due to the drive towards clean technology in organic synthesis. This resulted in higher 
yields in most cases, while using benign synthetic procedures. Most methods found in 
literature for the synthesis of pyrazolopyrimidinones (or pyrazolo[1,5-a]pyrimidones) 
involve the reaction between 5-amino-1H-pyrazoles with 1,3-bis-electrophilic reagents, 
such as β-dicarbonyl, α,β-unsaturated carbonyl, alkoxy methylene-β-dicarbonyl, or β-
enaminone compounds.87 
The method by which we synthesise the pyrazolopyrimidinone bicycle compounds in 
this project is via a condensation reaction of the aminopyrazoles with the corresponding 
β-ketoesters. This method was recently reported by Azeredo et al. where they carried 
out this reaction under traditional reflux to produce the desired pyrazolo[1,5-
a]pyrimidinones in 71-93% yield after 5-16 hours reflux (Scheme 25).88 They then 
submitted these pyrazolopyrimidinones to a chlorodehydroxylation reaction with 
phosphorus oxychloride to produce the desired 7-chloro-pyrazolo[1,5-a]pyrimidines. 
These compounds underwent an aromatic nucleophilic substitution with the 
corresponding anilines to produce the target 7-arylaminopyrazolo[1,5-a]pyrimidines.88 
 
Scheme 25: Synthesis of pyrazolo[1,5-a]pyrimidinones.88 
Recent research published by Portilla et al. have reported the regioselective synthesis of 
fused pyrazolo[1,5-a]pyrimidines and pyrazolo[1,5-a]pyrimidones by reaction of 5-
amino-1H-pyrazoles and β-dicarbonyl compounds containing five-membered rings.87 
One of the reactions discussed in this research consisted of the synthesis of 
cyclopenta[d]pyrazolo[1,5-a]pyrimidones via a solvent-free cyclocondensation 
procedure using 3-substituted-5-amino-1H-pyrazoles and 2-
ethoxycarbonylcyclopentanone (Scheme 26). This reaction was performed using fusion 
and microwave irradiation methods in 2-3 minutes to yield 82-92% yield. This was a 
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higher yield in comparison with the traditional reflux method in EtOH for 15-20 hours 
with 19-27% yields.87 
 
Scheme 26: Synthesis of cyclopenta[d]pyrazolo[1,5-a]pyrimidones.87 
The pyrazolopyrimidinone bicycle RTC53 is one of our lead anti-diabetic compounds and 
showed good activity in the glucose uptake assay, Figure 77 and section 1.3.3.45 In order 
to better understand the potential of pyrazolopyrimidinones as anti-diabetic agents, it 
was necessary to synthesise and biologically evaluate a large family of 
pyrazolopyrimidinones.  
 
Figure 77: Structure of RTC53. 
Proposed structural variations of RTC53 were categorised as follows: (i) variations of the 
R group on the bicycle core (Figure 78) i.e. vary the 3,5-bistrifluoromethyl aryl 
substituent on RTC53; (ii) the R1 group on the bicycle core (Figure 78) i.e. vary the 
isopropyl substituent on RTC53; (iii) variations on both R and R1 groups.  
      
Figure 78: General structure for the pyrazolopyrimidinone bicycle family. 
By maintaining the bicycle core while varying the R and R1 groups, we hoped to gain a 
better understanding of how structure relates to biological activity (glucose uptake) for 




3.2 Retrosynthesis of the pyrazolopyrimidinone bicycle 
A retrosynthetic analysis of the pyrazolopyrimidinone bicycle is shown below (Scheme 
27), where we proposed that the synthesis could be achieved via a condensation 
reaction between the appropriate β-ketoester and corresponding aminopyrazole. Some 
of the β-ketoesters and aminopyrazoles were commercially available. When the β-
ketoester was not available, we considered forming it through the use of a coupling 
reaction of the corresponding carboxylic acid derivative with Meldrum’s acid. The 
carboxylic acid itself was not always commercially available however, and in such cases,  
we proposed its synthesis using Grignard formation from the starting bromide and 
subsequent quenching with carbon dioxide. When the aminopyrazole was not 
commercially available, we proposed its synthesis from the corresponding β-ketonitrile 
derivative and hydrazine. 
 






3.3 Synthetic method development for the pyrazolopyrimidinone bicycle 
family 
Due to the welcomed commercial availability of β-ketoesters, the key steps in the 
proposed synthetic route to the pyrazolopyrimidinones were considered to be the 
generation of the aminopyrazole and its subsequent reaction with the appropriate β-
ketoester. As such, synthetic method development for the pyrazolopyrimidinone bicycle 
family focused on generating efficient and effective reactions for both these steps. We 
also postulated that a “one-pot” method, incorporating both of these reactions in a 
single pot, for the synthesis of the pyrazolopyrimidinones may be possible. Such a “one-
pot” approach would remove the need to isolate and purify the intermediate 
aminopyrazole. In order to establish reaction conditions for this “one-pot” approach, we 
first turned our attention to developing general reaction conditions for the microwave-
assisted generation of the intermediate aminopyrazoles. Once these reaction conditions 
were established, we sought to use them as a starting point for developing the “one-






 Solvent screen for the synthesis of aminopyrazoles 
Typical methods for preparing aminopyrazoles require conventional heating of the 
appropriate β-ketonitrile in the presence of hydrazine monohydrate for 17 – 24 hours 
(Scheme 28).86,90  
 
Scheme 28: Synthesis of aminopyrazoles using conventional heating. 
The proposed mechanism for the synthesis of the aminopyrazole from the β-ketonitrile 
is shown below (Scheme 29). The synthesis begins with nucleophilic attack by hydrazine 
on the carbonyl carbon of the β-ketonitrile. This generates a tetrahedral intermediate. 
This intermediate cyclises via nucleophilic attack of the second nitrogen of the hydrazine 
on the electrophilic carbon of the nitrile group. After several proton transfers, and the 
elimination of water, the aminopyrazole is generated.  
 
Scheme 29: Proposed mechanism of the synthesis of aminopyrazoles from β-
ketonitrile. 
Method optimisation was carried out on the reaction of 3-oxo-3-phenylpropanenitrile 
with hydrazine monohydrate to form 3-phenyl-1H-pyrazol-5-amine (MK12) 32 (Scheme 
30).89 Under conventional reflux conditions, this reaction in MeOH takes 17 hours to go 
to completion with a 60% isolated yield. Under microwave conditions at 150 °C for only 




Scheme 30: Synthesis of compound 32 using optimised microwave conditions, 99% 
yield. 
Microwave-assisted synthesis is increasingly becoming a popular method in modern 
chemical synthesis and drug discovery as it has revolutionized chemical synthesis. 91,92 It 
can be used in organic, inorganic, polymer and peptide synthesis, as well as 
nanotechnology.93,94 It has also been extended to medicinal, analytical, environmental, 
and green chemistry as well as biochemistry and materials science.93,95 It allows fast 
heating of reaction mixtures to high pressures and temperatures far above the boiling 
point of the used solvent.95 Microwave-assisted synthesis reduces reaction times from 
several hours down to only a few minutes by employing closed vessel conditions.91,94 
This rate acceleration is based on the Arrhenius Law, which states that the reaction rate 
is doubled when increasing the reaction temperature by 10 °C.92 
Microwave-assisted synthesis has proven to be an interesting alternative for heating 
chemical reactions and offers considerable advantages over conventional heating 
methods.92 These include enhanced reaction rates, greater selectivity, simple 
purification procedures, and higher product purity as decomposition is minimized.91 By 
controlling the specific parameters such as temperature, pressure, and time, as well as 
choice of solvents, researchers can now achieve similar and often better results using 
microwave-assisted synthesis with experiments previously performed using 
conventional heating methods.93,94  
Microwave chemistry is based on the efficient heating of materials, particularly solvents, 
by dielectric heating effects. Dielectric heating works by two major mechanisms: dipolar 
polarization, and ionic conduction.91  
When the molecular structure of a substance is partly negatively charged and partly 
positively charged, it contains a dipole. The presence of a dipole is important for a 
substance to be able to generate heat when irradiated with microwaves. Since the 
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microwave field is oscillating, the dipoles in the field align to the oscillating field. This 
alignment causes rotation, which results in friction and ultimately in heat energy.91,92 
During ionic conduction, dissolved charged particles oscillate back and forth under the 
influence of microwave irradiation, which causes collisions of the charged particles with 
neighbouring molecules creating heat energy.91,92 
A material or solvent must possess certain dielectric properties in order to be efficiently 
heated in the microwave field. The heating characteristics of a particular substance 
under microwave irradiation conditions are dependent on its ability to convert 
electromagnetic energy into heat.94 Solvents such as MeOH, EtOH and formic acid are 
therefore useful for rapid heating in the microwave field. Although solvents such as 
chloroform, acetone, and toluene have low heating efficiencies, they can still be used 
for microwave-assisted synthesis.95  
Previous group members established the optimum temperature and time needed for 
the synthesis of aminopyrazoles to be 150 °C and five minutes respectively.89 To do this, 
they initially began with 120 °C and 40 minutes, as previously reported by Bagley et al.94, 
where they generated the product in 84% yield. Increasing the temperature to 130 °C 
and decreasing the time to 30 minutes resulted in a 96% yield of the product. 
Maintaining temperature at 130 °C but reducing the time to only five minutes decreased 
the yield to 53%. The penultimate attempt consisted of increasing the temperature to 
140 °C for 20 minutes, which produced 98% yield of the product. The final and most 
successful variation consisted of 150 °C for five minutes, which generated the product 




Table 3: Temperature and time variations for the synthesis of 3-phenyl-1H-pyrazol-5-
amine.89 
T (°C) Time (min) Yield (%) 
120 40 84 
130 30 96 
130 5 53 
140 20 98 
150 5 99 
The final parameter needed to be investigated for the synthesis of these aminopyrazoles 
was the optimum solvent. This was performed by myself by carrying out the reaction in 
different solvent, while keeping the reaction time constant at five minutes and the 
temperature constant at 150 °C. High yields were obtained for all solvents under 
microwave conditions, all with only five minutes reaction time. Results for the solvent 
screen can be found below (Table 4). Based on these results, MeOH was subsequently 
selected as the solvent of choice, due to the higher yield generated and the lower cost 
when compared with acetonitrile. When the same reaction was carried out under 









Petroleum Ether 88% 
EtOAc 92% 
Acetonitrile 96% 





3.4 Synthesis of aminopyrazoles  
Some of the aminopyrazoles used to synthesise the pyrazolopyrimidinone bicycle 
compounds were commercially available. When this was not the case, they were 
synthesised from the corresponding β-ketonitrile by reacting it with hydrazine 
monohydrate and MeOH solvent in the microwave at 150 °C for five minutes (Scheme 
31).  
 
Scheme 31: Synthesis of aminopyrazole from the corresponding β-ketonitrile. 
The aminopyrazoles synthesised in this project, and yields obtained, are shown in Table 
5, where the R1 substituent is an aromatic ring, a heterocyclic ring, or an alkyl group. 
Purification of these compounds consisted of evaporation under reduced pressure 
followed by column chromatography to give the product a solid in the yields reported 
below.  
Table 5: Synthesised aminopyrazoles with isolated yields. 
 





















38 (MK54) Et 54% 
39 (MK53) t-Butyl 77% 
Structural characterisation of these compounds consisted of 1H and 13C NMR analysis, IR 
spectroscopy, and HR-MS. An example is shown below of the full structural 
characterisation of compound 32. The same approach was carried out on all the 
remaining compounds.  
 Structural characterisation of 3-phenyl-1H-pyrazol-5-amine 
(compound 32) 
The numbering scheme shown below (Figure 79) will be used in the following discussion 
on the structural characterisation of compound 32 which consisted of 1H and 13C NMR 
analysis, IR spectroscopy, and HR-MS.  
 





3.4.1.1  The 1H NMR spectrum of compound 32 
The 1H NMR spectrum of compound 32 (Figure 80) shows four signals as expected in the 
aromatic region. The most deshielded signal was assigned for the H3 protons of the 
aromatic ring as a multiplet in the range of 7.51 – 7.54 ppm. The H2 protons which are 
meta to the pyrazole ring also appear as a multiplet in the range of 7.36 – 7.38 ppm. The 
third signal from the aromatic ring appears as a multiplet in the range of 7.28 – 7.33 ppm 
for the proton in the para position. The proton of the pyrazole ring appeared at 5.90 
ppm as a singlet signal.  
 




3.4.1.2  The 13C NMR spectrum of compound 32 
The 13C NMR spectrum of compound 32 (Figure 81) contained seven signals, one for 
each carbon. The quaternary carbon of the pyrazole ring bonded to the amine group 
appears at 154.5 ppm, whereas the other quaternary carbon of the pyrazole ring bonded 
to the aromatic ring appears at 145.6 ppm. The quaternary carbon of the aromatic ring, 
ipso to the pyrazole ring, appears at 130.3 ppm. The CH proton signals of the aromatic 
ring appear at 128.9 ppm, 128.3 ppm, and 125.4 ppm, for C2, C1, and C3 respectively. 
The CH pyrazole carbon signal appears at 90.5 ppm.  
 





3.4.1.3  Mass spectrum of compound 32 
Mass spectrometry was used in the characterisation of the aminopyrazoles to further 
confirm their successful synthesis. The high-resolution mass spectrum of compound 32 
showed the mass obtained for C9H10N3, the protonated version of the molecule (i.e. 
[M+H]+), to be 160.0872 m/z which is -1.9 ppm different from the calculated mass of 
160.0869 m/z. 
 
3.4.1.4  IR spectrum of compound 32 
IR spectroscopy identified key functional groups in the aminopyrazole which further 
confirmed its presence.  Some of these functional groups are labelled in the IR spectrum 
of compound 32 below (Figure 82). They include an absorption band at 3296 cm-1 and 
1564 cm-1 which are characteristic of an NH bond, and 1506 cm-1 and 1468 cm-1 for the 
C-C bond.  
 

















































3.5 “One-pot” synthesis of the pyrazolopyrimidinone bicycle family  
After developing a convenient and efficient method for the synthesis of aminopyrazoles, 
our attention focused on finding a “one-pot” synthesis of the pyrazolopyrimidinone 
bicycle using microwave-assisted synthesis as discussed earlier. Once established, such 
a method would eliminate the need to isolate and purify the intermediate 
aminopyrazole (Scheme 32). The synthesis begins with the appropriate β-ketonitrile 
reacting with hydrazine monohydrate, with MeOH as solvent, in the microwave at 150 
°C for five minutes. Without isolating the resultant intermediate aminopyrazole, the 
synthesis is then continued, in the same reaction vessel, by adding the appropriate β-
ketoester and acetic acid. The reaction mixture is then heated in the microwave at 150 
°C for a further two hours.  
 
Scheme 32: “One-pot” synthesis of pyrazolopyrimidinones. 
A comparative study was carried out using the synthesis of 2,5-diphenylpyrazolo[1,5-
a]pyrimidin-7(4H)-one (MK15) (compound 40). By conventional reflux heating (Scheme 
33), the first reaction to synthesise 3-phenyl-1H-pyrazol-5-amine (MK12) (compound 
32) required 17 hours to go to completion, and the second reaction to synthesise 
compound 40 required 18 hours to go to completion. Therefore, in total, using 
conventional reflux heating, the synthesis of this product took over 35 hours to 
complete. This method also required isolation and purification of the intermediate 
aminopyrazole. This method of synthesis resulted in 15% overall yield for the two steps.  
 
Scheme 33: Synthesis of compound 40 using conventional heating conditions. 
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Using microwave irradiation (Scheme 34), the first reaction to synthesise compound 32 
as shown previously required only five minutes for completion, and the second reaction 
to synthesise compound 40 required a further two hours for completion. Therefore, in 
total, using microwave irradiation, the synthesis of this product took just over two hours 
to complete. In addition to the higher yield, this method also involved a “one-pot” 
approach which eliminated the need to isolate the intermediate aminopyrazole.89 This 
method of synthesis resulted in 52% yield of the product over the two steps.  
 
Scheme 34: Synthesis of compound 40 using microwave conditions using a “one-pot” 
approach.89 
In direct comparison with the above microwave-assisted “one-pot” approach, we 
attempted a “one-pot” conventional heating reaction that employed the same times as 
the microwave heating conditions (i.e. five minutes for step one and two hours for step 
two). We did not isolate the intermediate aminopyrazole as per the microwave method.  
The final product was isolated in this case, but a complex mixture resulted. A further 
comparison was carried out using purified compound 32 and reacting it with the β-
ketoester, ethyl 3-oxo-3-phenylpropanoate, in acetic acid and MeOH using conventional 
reflux heating but for only two hours. This resulted in the product isolation, but only in 
an 11% yield. Another comparison consisted of also reacting compound 32 with the β-
ketoester, ethyl 3-oxo-3-phenylpropanoate, in acetic acid and MeOH, but using 
microwave heating for two hours, which resulted in 53% yield. The microwave-assisted 





3.6 Mechanism of the formation of the pyrazolopyrimidinone bicycle 
The formation of the pyrazolopyrimidinone bicycle from the appropriate β-ketoester 
and aminopyrazole can be explained through the following proposed mechanism 
(Scheme 35): 
 
Scheme 35: Proposed mechanism for the final step of the synthesis of the 
pyrazolopyrimidinone bicycle. 
The mechanism begins with a nucleophilic attack of the primary amine on the 
aminopyrazole to the first carbonyl group of the β-ketoester. Proton transfer step takes 
place to form an alcohol intermediate. The second cyclisation step occurs by another 
nucleophilic attack from the NH on the aminopyrazole to the second carbonyl group of 
the β-ketoester. Once the bicycle is formed, the carbonyl group is reformed by the 
elimination of EtOH. The hydroxyl group is protonated using acetic acid to form water, 
which is eliminated after the deprotonation of the α-hydrogen, resulting in the 
formation of the final pyrazolopyrimidinone bicycle product.  
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3.7 Structure variations on RTC53 
As mentioned previously, structure variations were performed on the hit compound 
RTC53 (Figure 83) in an effort to better understand the relation between chemical 
structure and biological activity in the glucose uptake assay.  
 
     Figure 83: Structure of RTC53. 
Variations in this family of compounds can be divided into three categories. Category 1 
consists of variations on both sides of the pyrazolopyrimidinone bicycle (both R and R1). 
Category 2 consists of variations of the R substituent on the left of the bicycle, i.e. the 
aromatic bis-CF3 group, while keeping the isopropyl group. Category 3 consists of 
maintaining the aromatic bis-CF3 group on the left and varying the R1 group on the right, 
i.e. the isopropyl group (Figure 84).  
 




 Category 1: Substituent variation on both sides of the 
pyrazolopyrimidinone core (R and R1) 
The first category of variations of RTC53 consisted of changing both the aromatic bis-CF3 
group on the left (R) and the isopropyl group on the right (R1) of the 
pyrazolopyrimidinone bicycle (Figure 85).  
 
Figure 85: Category 1 variations on both sites, R and R1.  
Compounds produced in this category of variations were synthesised using the “one-
pot” microwave-assisted method as described in section 3.5. Starting from the β-
ketonitrile, reaction with hydrazine generated the intermediate aminopyrazole and 
subsequent addition of the corresponding β-ketoester resulted in the desired 
pyrazolopyrimidinone bicycle (Scheme 36). After removing volatiles under reduced 
pressure, products were purified using column chromatography or trituration using a 
suitable solvent such as MeOH or EtOAc. 
 
Scheme 36: Synthesis of pyrazolopyrimidinones of group 1 using the “one-pot” 
synthesis. 
Twelve compounds were made in total with category 1 variations. The R group was 
maintained as an aromatic ring, be that a phenyl ring or a substituted aromatic ring.  
Substituent variations at the R1 site included alkyl groups, substituted aromatic rings, 
heterocyclic rings, and a phenyl ring. Aromatic ring substitutions included those at the 
ortho, meta and para positions of the aromatic rings, and consisted of electron donating 
(e.g. methyl and methoxy) and electron withdrawing groups (e.g. nitro group) (Table 6).  
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Table 6: Pyrazolopyrimidinone bicycles synthesised category 1 variations (at R and R1). 
 
Compound R R1 Yield 
41 (MK56) Ph 
 
50% 
42 (MK55) Ph 
 
40% 
43 (MK62) Ph Me 33% 
44 (MK59) Ph 
 
17% 
45 (MK58) Ph 
 
32% 
46 (MK7) Ph 
 
45% 
47 (MK8) Ph 
 
67% 
48 (MK9) Ph 
 
45% 
  40 (MK15) Ph Ph 29% 
   49 (MK61) 
 
Ph 30% 
   50 (MK66) 
 
Ph 16% 





 52 (MK2) 
 
Me 59% 
The successful synthesis of these compounds was confirmed by using 1H and 13C NMR 
spectroscopy, HR-MS, and IR spectroscopy. Section 3.7.1.1 details the approach taken 
for the structural characterisation of the pyrazolopyrimidinone family, using the furan 
substituted pyrazolopyrimidinone (compound 41) as an example. Common absorption 
bands found in the IR spectra of all these compounds appear at 3251 cm-1, which is 
characteristic of an N-H bond stretch, 3060 cm-1 for the aromatic C-H bonds, 1665 for 
the carbonyl C=O bond, and 1597 cm-1 for the aromatic C-C bonds. Each compound was 
analysed using HR-MS and the correct mass was found for all compounds with a 





3.7.1.1 Structural characterisation of 2-(furan-2-yl)-5-phenylpyrazolo[1,5-
a]pyrimidin-7(4H)-one (compound 41) 
The numbering scheme shown below (Figure 86) will be used in the following discussion 
on the structural characterisation of compound 41. Structural characterisation of this 
compound involved 1H and 13C NMR spectroscopy, IR spectroscopy, and mass 
spectrometry. The 1H and 13C NMR signals were assigned with the aid of 2D-NMR 
experiments such as 1H – 1H COSY, 1H – 13C HSQC, and 1H – 13C HMBC. Furthermore, an 
X-ray crystal structure of this compound was obtained in order to further confirm its 
formation.  
 






3.7.1.1.1  The 1H NMR spectrum of compound 41 
The 1H NMR spectrum of compound 41 (Figure 87) has eight signals.  
 
Figure 87: 1H NMR spectrum of compound 41. 
The most downfield signal at 12.58 ppm is a broad singlet for the NH signal, integrating 
for 1H. This signal appears deshielded as the hydrogen atom is directly bonded to an 
electronegative nitrogen. The most upfield signals appear as singlets with a chemical 
shift of 6.45 ppm, representing the pyrazole proton (H8), and 6.10 ppm, representing 
the α-proton (H6), each integrating for 1H.  
The next five signals appear in the aromatic region (Figure 88) and can be assigned to 
the protons of the phenyl and furan rings. The protons arising from the phenyl ring in 
the ortho position (H3) appear as a multiplet in the range of 7.85 – 7.90 ppm, integrating 
for 2H. The protons arising from the phenyl ring in the meta position (H2), and para 




Figure 88: The aromatic region of the 1H spectrum of compound 41. 
The signals arising from the furan ring appear at 6.66 ppm (H12), 7.04 ppm (H11), and 
7.84 ppm (H13). Each proton was split by two non-equivalent protons and therefore all 
appear a double of doublets. The J value was calculated for these 3 signals and helped 
distinguish which protons they represent. The J value due to the coupling between H11 
and H12 was calculated to be 3.3 Hz. The J value due to the coupling between H12 and 
H13 was found to be 1.7 Hz, and the longer-range coupling between H11 and H13 was 




3.7.1.1.1.1 The 1H–1H COSY 2D-NMR spectrum of compound 41 
As previously discussed in section 2.2.3.1.1, the 1H–1H COSY NMR is a 2D-NMR 
experiment which shows coupling between protons in the same coupling system. The 
1H – 1H COSY spectrum (Figure 89) of compound 41 showed the coupling systems within 
the aromatic region. The phenyl ring contained coupling between H3, H1 and H2 (red 
square), and the furan ring contained coupling between H13 and H12 (green square) as 
well as between H11 and H12 (blue square). The coupling between H11 and H13 was 
too weak to be observed in the 1H – 1H COSY spectrum but was evident from the splitting 
of the peaks (i.e. double of doublets). The 1H – 1H COSY spectrum confirms the 
assignment of H12 as it is coupled to both H11 and H13. The signal for H13 can be 
distinguished from H11 as it is more deshielded, as is expected for a furan ring since it is 
adjacent to the electronegative oxygen of the furan ring, unlike H11.  
 




3.7.1.1.2  The 13C NMR spectrum of compound 41 
Structural characterisation of compound 41 (Figure 90) also involved the use of a 13C 
NMR experiment. 
 
Figure 90: Structure of compound 41 with all protons and carbons numbered. 
The 13C NMR spectrum of compound 41 (Figure 91) generated 14 signals. These consist 
of six quaternary carbons and eight tertiary carbons. The assignment of these signals 
was confirmed by the 2D-NMR experiments 1H – 13C HSQC and 1H – 13C HMBC. 
 
Figure 91: 13C NMR spectrum of compound 41. 
Six quaternary carbons were identified; the carbonyl carbon at 156.7 ppm, the β-carbon 
(C5) at 150.5 ppm, the ipso carbon of the furan ring (C10) at 148.3 ppm, the carbon of 
the bicycle core bonded to the furan ring (C9) at 146.2 ppm, the bridgehead carbon of 




The carbon adjacent to the electronegative oxygen of the furan ring (C13) appears 
downfield at 144.2 ppm. The other two carbon signals of the furan ring appear at 112.4 
ppm (C12) and 109.0 ppm (C11). The carbon signals of the phenyl ring appear in close 
proximity to each other at 131.5 ppm (C1), 129.5 ppm (C2), and 127.7 ppm (C3). Finally, 
the most upfield signals consist of the signal for the α-carbon (C6) at 94.5 ppm, and for 
the pyrazole carbon of the bicycle core (C8) at 86.8 ppm.  
3.7.1.1.2.1 The 1H–13C HSQC 2D-NMR spectrum of compound 41  
As previously discussed in section 2.2.3.2.2, the 1H-13C HSQC experiment is a 2D-NMR 
technique that correlates chemical shifts of directly bound nuclei (i.e. 1H with 13C). The 
1H–13C HSQC spectrum (Figure 92) of compound 41 helped confirm the identity of the 
eight tertiary carbon signals already discussed. This was achieved by correlating each 13C 
NMR signal with the corresponding 1H signal in the 1H-13C HSQC spectrum. For example, 
the 1H NMR signal at 6.45 ppm representing H8 correlated with the 13C NMR signal at 
86.8 ppm, therefore the signal at 86.8 ppm was assigned to C8.  
 
Figure 92: 1H – 13C HSQC 2D-NMR spectrum of compound 41. 
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3.7.1.1.2.2 The 1H–13C HMBC 2D-NMR spectrum of compound 41 
Another useful 2D-NMR experiment that was employed used was the 1H–13C HMBC, 
which, as previously mentioned in section 2.2.3.2.1, correlates the 1H NMR signals with 
the 13C NMR signals generated by atoms that are two or three bonds away from each 
other. The 1H – 13C HMBC spectrum (Figure 93) of compound 41 further confirmed the 
assignment of the tertiary carbons but was essential for identification of the quaternary 
carbons.  
With regards to the tertiary carbons, an example is the signal for C12 at 112.4 ppm, 
which correlates with H11 at 7.04 ppm, and H13 at 7.84 ppm (red lines), as expected 
based on the proposed structure. In the same way, C11 at 109.0 ppm correlates with 
H12 at 6.66 ppm, and H13 at 7.84 ppm (green lines). The same technique was used to 
confirm the identity of C13 and the tertiary carbons of the phenyl ring. 
 
Figure 93: The 1H – 13C HMBC 2D-NMR spectrum of compound 41. 
The 1H – 13C HMBC spectrum was of critical importance for the assignment of the six 
quaternary carbons. The 13C signal at 156.7 ppm was assigned as the carbonyl carbon 
signal as it correlates with the H8 proton of the pyrazole at 6.45 ppm, and the α-proton 
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(H6) adjacent to it at 6.10 ppm (blue lines). The 13C signal at 150.5 ppm was assigned as 
the carbon β to the carbonyl (C5) as it correlates with the protons at the ortho position 
(H3) of the aromatic ring in the range of 7.89 – 7.90 ppm, and the α-proton (H6) at 6.10 
ppm (magenta lines).  
The 13C signal at 148.3 ppm was assigned as the ipso carbon of the furan ring (C10) as it 
correlates with all three protons of the furan ring (H11, H12 and H13). The 13C signal at 
146.2 ppm was assigned as the carbon of the bicycle core bonded to the furan ring (C9) 
as it correlates with the H8 proton of the pyrazole ring adjacent to it, and weakly with 
H11, which is three bonds away from it. The 13C signal at 143.6 ppm was assigned as the 
C7 carbon of the bicycle core as it only correlates with the H8 pyrazole proton adjacent 
to it. The final 13C signal at 133.0 ppm was assigned as the ipso carbon of the phenyl ring 





3.7.1.1.3  Mass spectrum of compound 41 
Mass spectrometry was used in the characterisation of these compounds to further 
confirm the presence or absence of the target compounds. The high-resolution mass 
spectrum (Figure 94) of compound 41 showed the mass obtained for C16H11N3O2Na, the 
ionised version of the molecule with a sodium cation (i.e. [M + Na]+), was found to be 
300.0757 m/z which is 4.70 ppm different from the calculated mass of 300.0743 m/z. It 
also found the mass of (C16H11N3O2)2Na (i.e. [2M + Na]+) ion to be 577.1615 m/z which 
is 3.47 ppm different from the calculated mass of 577.1595 m/z.  
 
Figure 94: Mass spectrum of compound 41. 
3.7.1.1.4  Infrared spectrum of compound 41 
IR spectroscopy identified key functional groups which further confirmed the presence 
of our target compound.  The IR spectrum (Figure 95) of compound 41 shows an 
absorption frequency of 3122 cm-1 characteristic of the secondary amine (N-H), 3059 
cm-1 for the aromatic C-H’s, and 1670 cm-1 for the carbonyl group (C=O stretch).  
 















































3.7.1.1.5  X-ray crystal structure of compound 41 
The final characterisation carried out for compound 41 was an X-ray crystal structure 
analysis which confirmed the correct structure of our compound. Recrystallization of the 
sample was performed using the solvent system 4:1, EtOH:H2O at room temperature. 
The X-ray crystal structure (Figure 96) obtained shows the phenyl ring on the left (C7 – 
C12), the pyrazolopyrimidinone bicycle core structure in the middle with the carbonyl 
oxygen (O1) and the three nitrogens (N1 – N3), and the furan ring on the right (C13 – 
C16) with the furan oxygen (O2).  
 




3.7.1.2 Structural characterisation of 5-phenyl-2-(thiophen-2-yl)pyrazolo[1,5-
a]pyrimidin-7(4H)-one (compound 42) 
 
Figure 97: Structure of compound 42. 
The compound containing a thiophene ring at the R1 site, compound 42 (Figure 97), 
generated three 1H NMR signals and five 13C NMR signals for the thiophene ring. The 1H 
NMR signal for the proton adjacent to the electronegative sulphur is the most 
deshielded signal and appears as a doublet at 7.61 ppm, as it is coupled to the 
neighbouring proton. The carbon bonded to this proton appears at 125.7 ppm in the 13C 
NMR spectrum.  
The proton furthest from the sulphur appears as a doublet at 7.53 ppm in the 1H NMR 
spectrum. It is also coupled to the neighbouring proton, with the carbon bonded to it 
appearing at 126.2 ppm in the in the 13C NMR spectrum. The remaining thiophene 
proton is coupled to two non-equivalent protons and therefore appears as a double of 
doublets at 7.13 ppm, with the carbon bonded to it appearing at 128.1 ppm in the 13C 
NMR spectrum. The quaternary ipso carbon of the thiophene ring appears at 148.3 ppm, 
and the quaternary carbon, of the bicycle core, directly bonded to the thiophene ring 
appears at 137.7 ppm. The phenyl substituted pyrazolopyrimidine core generated all the 
expected signals in both the 1H and 13C NMR spectra. The IR and MS data also confirmed 
the generation of compound 42. 
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3.7.1.3 Structural characterisation of 2-methyl-5-phenylpyrazolo[1,5-
a]pyrimidin-7(4H)-one (compound 43) 
 
Figure 98: Structure of compound 43. 
Compound 43 (Figure 98) contains a methyl group at the R1 site and a phenyl ring at the 
R site and generated all the expected NMR signals. The presence of the methyl group 
results in a singlet in the 1H NMR spectrum at 2.32 ppm. The same methyl group also 
generates a signal at 14.6 ppm in the 13C NMR spectrum. The quaternary carbon bonded 
to the methyl group appears at 152.6 ppm in the 13C NMR spectrum. The IR spectrum of 
this compound showed an absorbance band at 1327 cm-1, which is characteristic of an 
alkyl C-H bond. The MS data also confirmed the generation of compound 43. 
3.7.1.4 Structural characterisation of 2-(tert-butyl)-5-phenylpyrazolo[1,5-
a]pyrimidin-7(4H)-one (compound 44) 
 
Figure 99: Structure of compound 44. 
The compound containing a t-butyl group at the R1 site, compound 44 (Figure 99), like 
compound 43, also contained a singlet signal in the alkyl region of the 1H NMR spectrum. 
This time the signal occurs at 1.42 ppm and integrates for the nine protons of the t-butyl 
group. The carbon signal for the three equivalent methyl groups appears at 30.6 ppm in 
the 13C NMR spectrum. The carbonyl carbon appears at 165.2 ppm, the quaternary 
carbon bonded to the t-butyl group appears at 142.8 ppm, whereas the quaternary 
carbon of the t-butyl group appears at 32.9 ppm. The phenyl substituted 
pyrazolopyrimidinone generated all the expected 1H and 13C NMR signals. Similar to 
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before, the IR spectrum showed an absorbance band at 1324 cm-1, which is 
characteristic of an alkane C-H bond, and the MS data also confirmed the generation of 
compound 44.  
3.7.1.5 Structural characterisation of 2-(2-methoxyphenyl)-5-
phenylpyrazolo[1,5-a]pyrimidin-7(4H)-one (compound 45) 
 
Figure 100: Structure of compound 45. 
Compound 45 (Figure 100), contains an ortho methoxy substituted aryl ring at the R1 
site. The NMR spectra for compound 45 contains four aromatic proton signals in the 1H 
NMR spectrum and seven carbon signals in the 13C NMR spectrum. The most deshielded 
signal in the 1H NMR spectrum is a broad singlet at 7.99 ppm for the aromatic ring proton 
ortho to the pyrazolopyrimidinone bicycle core. The carbon attached to this proton 
appears at 128.9 ppm in the 13C NMR spectrum. The proton para to the bicycle core 
appears as a pseudo triplet at 7.30 ppm instead of the expected double of doublets 
shape as it is coupled by two non-equivalent protons. The carbon bonded to this proton 
appears at 129.4 ppm in the 13C NMR spectrum.  
The proton adjacent to the methoxy group (meta to the bicycle core) appears as 
multiplet in the range of 7.02 – 7.05 ppm, while the other meta proton appears as a 
multiplet in the range of 6.95 – 6.98 ppm. These protons appear more shielded than 
expected due to the presence of the methoxy group (Scheme 37). The corresponding 
carbons bonded to these protons appear at 112.3 ppm and 120.8 ppm, respectively. The 
protons from the methyl group appear as a singlet at 3.89 ppm, which was more 





Scheme 37: Resonance contributors of the methoxy substituted aromatic ring. 
The carbon of the methyl group appears at 56.0 ppm in the 13C NMR spectrum. The 
quaternary carbon bonded to the methoxy group appears at 157.4 ppm, the quaternary 
carbon bonded to the aromatic ring from the bicycle core appears at 152.0 ppm, and 
the quaternary ipso carbon from the aromatic ring appears at 123.3 ppm. The IR 
spectrum showed an absorbance band at 1248 cm-1, which is characteristic of the C-O 
bond stretch of the methoxy group. The MS data also confirmed the generation of 
compound 45. 
3.7.1.6 Structural characterisation of 2-(3-chlorophenyl)-5-
phenylpyrazolo[1,5-a]pyrimidin-7(4H)-one (compound 46) 
 
Figure 101: Structure of compound 46. 
The compound containing a meta substituted chlorine aryl ring at the R1 site, compound 
46 (Figure 101), generated four proton signals and six carbon signals for the aromatic 
ring. The most deshielded signal appearing as a singlet at 8.07 ppm in the 1H NMR 
spectrum was due to the proton in the ortho position adjacent to the electron 
withdrawing chlorine. The carbon bonded to this proton appears at 129.6 ppm in the 13C 
NMR spectrum. The other proton adjacent to the chlorine group in the para position 
appears as a doublet at 8.00 ppm in the 1H NMR spectrum, due to coupling with one 
non-equivalent proton, and the corresponding carbon at 129.2 ppm.  
The other two protons from the aromatic ring had overlapping signals and therefore 
appears as a multiplet in the range of 7.46 – 7.56 ppm, with corresponding carbons at 
126.2 ppm and 125.3 ppm in the 13C NMR spectrum. The quaternary carbon bonded to 
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the chlorine appears at 158.9 ppm, the quaternary carbon from the bicycle core bonded 
to the aromatic ring appears at 152.3 ppm, and the quaternary ipso carbon appears at 
128.1 ppm. The IR spectrum showed an absorbance band at 772 cm-1, which is 
characteristic of a C-Cl bond. The MS data also confirmed the generation of compound 
46. 
3.7.1.7 Structural characterisation of 2-(4-fluorophenyl)-5-
phenylpyrazolo[1,5-a]pyrimidin-7(4H)-one (compound 47) 
 
Figure 102: Structure of compound 47. 
Compound 47 (Figure 102) contains a para fluoro substituted aryl ring at the R1 site and 
a phenyl ring at the R site. There are two multiplet signals in the 1H NMR spectrum for 
the four protons of the aryl ring, as opposed to four signals. These signals occur in the 
range of 8.02 – 8.12 ppm for the protons ortho to the pyrazolopyrimidinone, and 7.31 – 
7.37 ppm for the protons meta to the pyrazolopyrimidinone. Each signal integrates for 
two protons. These signals appear more deshielded due to the effect of the electron 
withdrawing fluoro substituent.  
The multiplet shape of the peaks may have been due to coupling of the aromatic protons 
with the NMR-active 19F atom. The carbons bonded to these protons both appear as 
doublets in the 13C NMR spectrum due to bonding with fluorine at 128.8 ppm (JCF = 8.4 
Hz) and 116.2 ppm (JCF = 21.5 Hz) respectively. The quaternary carbon bonded to the 
fluorine also appears as a doublet at 163.1 ppm (JCF = 246.3 Hz) and the quaternary 
carbon of the bicycle core that is bonded to the fluoro aryl ring appears as a singlet at 
152.9 ppm. The fluoro aryl quaternary carbon ipso to the pyrazolopyrimidinone appears 
as a doublet at 129.4 ppm (JCF = 3.0 Hz). The IR and MS data also confirmed the 
generation of compound 43. 
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3.7.1.8 Structural characterisation of 5-phenyl-2-(p-tolyl)pyrazolo[1,5-
a]pyrimidin-7(4H)-one (compound 48)  
 
Figure 103: Structure of compound 48. 
The compound containing a para methyl aryl ring at the R1 site, compound 48 (Figure 
103), like for compound 47 has free rotation about the bond between the para methyl 
substituted aryl ring and the pyrazolopyrimidinone bicycle. As a result, one would expect 
the aryl ring to contain two sets of equivalent protons generating two signals in the 1H 
NMR spectrum. For compound 48, there are overlapping signals in the aromatic region 
of the 1H NMR spectrum. The 1H NMR spectrum contains a signal for the protons ortho 
to the pyrazolopyrimidinone as a multiplet in the range of 7.82 – 7.96 ppm, which 
overlapped with the ortho protons of the phenyl ring. The carbon bonded to this proton 
appears as a singlet at 129.5 ppm in the 13C NMR spectrum.  
The protons of the methyl substituted aromatic ring meta to the pyrazolopyrimidinone 
appear as a doublet (J = 7.8 Hz) in the 1H NMR spectrum at 7.30 ppm as they coupled 
with the neighbouring ortho protons. The carbons bonded to these protons appear at 
127.7 ppm in the 13C NMR spectrum. The methyl group protons appear as a singlet at 
2.37 ppm in the 1H NMR spectrum, and the methyl carbon appears at 21.4 ppm in the 
13C NMR spectrum. The quaternary carbon of the bicycle core that is bonded to the 
methyl substituted aromatic ring appears at 153.8 ppm, the quaternary carbon bonded 
to the methyl group appears at 138.9 ppm, and the quaternary carbon ipso to the 
pyrazolopyrimidinone appears at 130.1 ppm. The IR and MS data also confirmed the 
generation of compound 48. 
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3.7.1.9 Structural characterisation of 2,5-diphenylpyrazolo[1,5-a]pyrimidin-
7(4H)-one (compound 40) 
 
Figure 104: Structure of compound 40. 
Compound 40 (Figure 104) contains a phenyl ring at both the R and R1 sites. The 1H NMR 
spectrum showed two signals for the aromatic protons; a multiplet in the range of 7.94 
– 8.02 ppm, with an integration of two, for the ortho protons, and a multiplet in the 
range of 7.55 – 7.63 ppm, with an integration of three, for the meta and para protons. 
The 13C NMR spectrum showed the ortho carbon at 131.1 ppm, meta carbon at 128.7 
ppm, and the para carbon at 128.9 ppm. The quaternary carbon of the bicycle core 
bonded to the phenyl group at R1 appears at 143.2 ppm, and the quaternary carbon ipso 
to the pyrazolopyrimidinone appears at 132.3 ppm. The IR and MS data also confirmed 




3.7.1.10 Structural characterisation of 5-(4-nitrophenyl)-2-
phenylpyrazolo[1,5-a]pyrimidin-7(4H)-one (compound 49) 
The next three compounds, compounds 49-51, all contain a phenyl group at the R1 site, 
with different aromatic rings at the R site.  
 
Figure 105: Structure of compound 49. 
Compound 49 (Figure 105) contains a para nitro substituted aromatic ring at the R site 
and a phenyl ring at the R1 site. There is free rotation about the bond between the para 
nitro substituted aryl ring and the pyrazolopyrimidinone core. This would be expected 
to result in two sets of equivalent protons. As such, in the 1H NMR spectrum, there are 
two doublet signals, as opposed to four signals, for the four protons of the aryl ring. The 
meta protons (meta to the pyrazolopyrimidinone) appear more deshielded as a doublet 
at 8.40 ppm, with a J value of 8.8 Hz, due to the electron withdrawing effect of the nitro 
group (see Scheme 9, section 2.3.1.4). 
The ortho protons (ortho to the pyrazolopyrimidinone), are less shielded and appear as 
a doublet at 8.14 ppm, with a matching J value of 8.8 Hz. The carbons bonded to the 
meta protons appear at 128.7 ppm in the 13C NMR spectrum, whereas the ortho carbons 
appear at 123.9 ppm. The quaternary carbon of the bicycle core bonded to the para 
nitro aryl ring appears at 148.9 ppm and the quaternary carbon bonded to the nitro 
group itself appears at 147.7 ppm. The quaternary carbon of the para nitro aryl ring ipso 
to the pyrazolopyrimidinone appears at 138.6 ppm. The IR and MS data also confirmed 
the generation of compound 49. 
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3.7.1.11 Structural characterisation of 5-(4-methoxyphenyl)-2-
phenylpyrazolo[1,5-a]pyrimidin-7(4H)-one (compound 50) 
 
Figure 106: Structure of compound 50. 
Compound 50 (Figure 106) contained a para methoxy aryl ring at the R site and a phenyl 
ring at the R1 site. As previously discussed for other para substituted aryl systems, it was 
expected that the para methoxy aryl ring would generate twos sets of 1H NMR signals, 
as a double of doublets. This was indeed the case. The meta protons (meta to the 
pyrazolopyrimidinone) appear as a more deshielded doublet at 7.85 ppm due to the 
electron withdrawing effect of the oxygen, with a J value of 8.8 Hz. The ortho protons 
(ortho to the pyrazolopyrimidinone) appear as a doublet at 7.14 ppm, with a matching 
coupling constant of 8.8 Hz. The carbons bonded to the meta protons appear at 114.4 
ppm in the 13C NMR spectrum, whereas the ortho carbons appear at 128.7 ppm.  
The protons of the methoxy group appear as a singlet at 3.86 ppm in the 1H NMR 
spectrum, and the carbon of the methoxy group appears at 55.5 ppm in the 13C NMR 
spectrum. The quaternary carbon bonded to the methoxy group appears at 161.5 ppm, 
the quaternary carbon of the bicycle core bonded to the para methoxy aryl ring appears 
at 130.7 ppm, and the quaternary carbon of the para methoxy aryl ring ipso to the 
pyrazolopyrimidinone bicycle appears at 124.4 ppm. The IR and MS data also confirmed 
the generation of compound 50. 
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Figure 107: Structure of compound 51. 
Compound 51 (Figure 107) generated a more complex set of NMR spectra due to the 
presence of the four 19F NMR active atoms. The single proton of the fluorinated aromatic 
ring at the R site generated a multiplet signal in the region of 7.87 – 7.94 ppm in the 1H 
NMR spectrum due to 1H-19F coupling. The carbon bonded to this proton appears as a 
doublet in the 13C NMR spectrum at 113.3 ppm with a coupling constant of 19.3 Hz.  
Interestingly, the α-proton on the pyrazolopyrimidinone core, no longer appear as a 
singlet at approximately 6.1 ppm. Instead, it appears as a doublet signal at 6.01 ppm 
with a coupling constant of 0.8 Hz due to long-range coupling with one of the fluorine 
atoms. In the 13C NMR spectrum, the quaternary carbon of the pyrazolopyrimidinone 
core bonded to the fluorinated aromatic ring appears at 156.2 ppm and the quaternary 
carbon of the fluorinated aromatic ring ipso to the pyrazolopyrimidinone core appears 
at 143.5 ppm. The 19F NMR spectrum shows four multiplet peaks at -140.2, -141.8, -
154.9 and -156.9 ppm. The IR spectrum shows an absorbance band at 1089 cm-1, which 




3.7.1.13 Synthesis and characterisation of 5-(3,5-dimethylphenyl)-2-
methylpyrazolo[1,5-a]pyrimidin-7(4H)-one (compound 52) 
 
Figure 108: Structure of compound 52. 
Almost all the compounds in category 1 were synthesised using the “one-pot” 
microwave-assisted approach described previously. The only exception was compound 
52 (Figure 108) which contains a 3,5-dimethyl substituted aryl ring at the R site, and a 
phenyl ring at the R1 site. The synthesis of this compound was performed by the 
conventional reflux heating of ethyl 3-(3,5-dimethylphenyl)-3-oxopropanoate (MK1) 
(compound 53) with 3-amino-5-methylpyrazole in acetic acid for 21 hours. After 
volatiles were removed under reduced pressure, the product was purified by column 
chromatography (100 % DCM) to generate the product as a beige solid with 59% yield 
(Scheme 38). The starting β-ketoester, compound 53, was not commercially available 
and had to be synthesised. The synthesis of this compound and other β-ketoesters is 
discussed in detail in section 3.7.2. 
 
Scheme 38: Synthesis of compound 52, 59% yield. 
The 1H NMR spectrum of compound 52 shows two signals for the aromatic ring, both 
appearing as singlets, one at 7.42 ppm for the ortho protons and 7.26 ppm for the para 
proton. The carbons bonded to these protons appear in the 13C NMR spectrum at 124.5 
ppm and 132.3 ppm respectively. The CH proton of the pyrazole ring appears as a singlet 
at 6.13 ppm and the α-proton appears as a singlet at 6.05 ppm. The three methyl groups 
had overlapping signals and appear as overlapping singlets in the range of 2.34 – 2.53 
ppm in the 1H NMR spectrum, and their carbons appear at 19.9 ppm in the 13C NMR 
spectrum. The IR and MS data also confirmed the generation of compound 52.  
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 Category 2: Substituent variations at the R site only (the bis-CF3 aryl 
site)  
The second category of RTC53 analogues consisted of only varying the R, bis-CF3 aryl, 
group of RTC53 (Figure 109).  
  
Figure 109: Category 2 - variations at the R site. 
The synthesis of the pyrazolopyrimidinone bicycles in the category was carried out by 
reaction of the corresponding β-ketoester with the commercially available 3-isopropyl-
1H-pyrazol-5-amine in acetic acid using microwave irradiation (Scheme 39). For some 
compounds, conventional heating at reflux was employed instead of microwave 
irradiation.  
 
Scheme 39: Synthesis of category 2 pyrazolopyrimidinones. 
The β-ketoesters starting materials used in the synthesis of the category 2 
pyrazolopyrimidinone bicycles were not always commercially available and therefore 
had to be synthesised. This was achieved via a coupling type reaction of the 
corresponding benzoic acid starting materials with Meldrum’s acid, using the coupling 
reagent N,N'-dicyclohexylcarbodiimide (DCC). The β-ketoesters synthesised in this group 




Table 7: β-ketoesters made for the synthesis of pyrazolopyrimidinone bicycles. 
 







   55 (MK10) 
 
37% 
     56 (MK11) 
 
11% 
The proposed mechanism for the synthesis of these β-ketoesters (Scheme 40) begins 
with nucleophilic attack of the benzoic acid on to DCC to generate an ester with a more 
electrophilic carbonyl carbon. General base catalysis occurs where Meldrum’s acid is 
deprotonated by the base 4-dimethylaminopyridine (DMAP), which removes the acidic 
α-proton, and the deprotonated Meldrum’s acid acts as a nucleophile and attacks the 
electrophilic carbonyl carbon to generate the tetrahedral intermediate. Removal of 
N,N′-dicyclohexylurea (DCU) leaving group regenerates the carbonyl group. The second 
carbonyl group gets protonated using para-toluenesulfonic acid (p-TSA) to generate a 
more electrophilic carbonyl carbon which gets attacked by EtOH. A hydroxyl group is 
generated by protonation of the oxygen by p-TSA. The second carbonyl group is 
regenerated by deprotonation using p-TSA and the cleavage of the bond to the hydroxyl 
group. The final step of the synthesis involves decarboxylation which generates the 
product as two tautomers, keto and enol tautomers, with carbon dioxide and acetone 




Scheme 40: Mechanism of the synthesis of β-ketoesters using Meldrum’s acid and 
DCC. 
The benzoic acid starting material used in the synthesis of the β-ketoesters was 
commercially available for all compounds except one of the target compounds. 
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Compound 54, ethyl 3-(3,5-diethylphenyl)-3-oxopropanoate (MK4), contains a diethyl 
meta substituted aryl ring, whose incorporation required the use and synthesis of 3,5-
diethylbenzoic acid (MK3) (compound 57). We proposed the synthesis of benzoic acid 
57 via the generation of the corresponding aryl Grignard and its subsequent reaction 
with carbon dioxide. The synthesis of 3,5-diethylbenzoic acid 57 was successfully 
completed via the formation of the aryl Grignard from 1-bromo-3,5-diethylbenzene 
using magnesium turnings and iodine in THF (Scheme 41). Subsequent reaction with 
carbon dioxide and acidic work-up gave the desired benzoic acid in a 93% yield. 
 
Scheme 41: Synthesis of benzoic acid 57, 93% yield. 
After successfully synthesising the required β-ketoesters, the four corresponding 
pyrazolopyrimidinone bicycles were made, see Table 8.  
Table 8: Pyrazolopyrimidinone bicycles synthesised with category 2 variations (at R 
site). 
 









     60 (MK13) 
 
18% 
      61 (MK49) 
 
13% 
The synthesis of the first three pyrazolopyrimidinone bicycles (compounds 58, 59 and 
60) was performed towards the beginning of my PhD studies by reaction of the 
corresponding β-ketoester with the commercially available 3-isopropyl-1H-pyrazol-5-
amine in acetic acid, with overnight conventional heating at reflux (Scheme 42).  
 
Scheme 42: Synthesis of compounds 58 – 60. 
The synthesis of 5-(3,5-dinitrophenyl)-2-isopropylpyrazolo[1,5-a]pyrimidin-7(4H)-one 
(MK49) (compound 61), was carried out at a later stage and hence employed the “one-
pot” microwave assisted approach described previously in section 3.5. This synthesis 
consisted of reaction of the commercially available β-ketonitrile, 4-methyl-3-
oxopentanenitrile with hydrazine monohydrate, in the microwave at 150 °C for five 
minutes to synthesise the intermediate aminopyrazole, 3-isopropyl-1H-pyrazol-5-
amine. This was followed by addition of the previously synthesised β-ketoester, ethyl 3-
(3,5-dinitrophenyl)-3-oxopropanoate (MK11) (compound 56) and acetic acid and 
microwave heating at 150 °C for a further two hours (Scheme 43). 
 
Scheme 43: Synthesis of compound 61, 13% yield. 
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Structural characterisation of these four pyrazolopyrimidinone bicycles employed 1H 
and 13C NMR spectroscopy, HR-MS, and IR spectroscopy.  DEPT and 2D-NMR 
experiments, such as 1H-1H COSY, 1H-13C HSQC and 1H-13C HMBC, were used to help 
assign the 1H and 13C NMR signals.  
Common signals were present in the 1H NMR and 13C NMR spectra arising from the 
bicycle core structure and the isopropyl group of all four compounds. For compound 58, 
a broad singlet signal at 9.51 ppm in the 1H NMR spectrum is assigned to the NH, a 
multiplet signal at 6.00 ppm for the pyrazole proton and the α-proton of the bicycle core, 
a septet signal at 3.10 ppm for the single proton of the isopropyl group, and a doublet 
signal at 1.28 ppm for the two methyl groups of the isopropyl group. The single proton 
of the isopropyl group is coupled to six equivalent protons from the two methyl groups 
and therefore appears as a septet.  
The 13C NMR spectrum for the same compound contained quaternary signals for the 
bridgehead carbon adjacent to the amine at 139.1 ppm, and the carbon bonded to the 
aromatic ring at 132.8 ppm. Tertiary carbon signals appear at 94.6 ppm for the carbon 
α to the carbonyl group, 86.7 ppm for the pyrazole carbon, and 28.6 ppm for the 
isopropyl CH carbon. The carbon signals for the two methyl groups of the isopropyl 
group appear at 22.5 ppm.  
All four compounds were analysed by high-resolution mass spectrometry where an 
accurate mass was obtained for each compound which was less than 5 ppm from the 
calculated expected mass.  
An IR spectrum was obtained for all these compounds. With regards to the bicycle core 
and isopropyl group, the IR spectrum shows absorbance bands at 3199 cm-1 and 1595 
cm-1 characteristic of the amine (N-H) bond, 3081 cm-1 for the aromatic C-H bond and 




3.7.2.1 Structural characterisation of 5-(3,5-dimethylphenyl)-2-
isopropylpyrazolo[1,5-a]pyrimidin-7(4H)-one (compound 58) 
 
Figure 110: Structure of compound 58. 
The 1H and 13C NMR data was as expected for the compound containing an aromatic ring 
on the R site with two meta substituted methyl groups, compound 58 (Figure 110). The 
signals for the aromatic ring appear as singlets in the 1H NMR spectrum at 7.25 ppm (two 
protons ortho to the pyrazolopyrimidinone) and 7.13 ppm (para proton), and at 124.5 
ppm and 132.7 ppm in the 13C NMR spectrum for the carbons bonded to these protons 
respectively. The quaternary carbons of the aromatic ring appear in the 13C NMR 
spectrum at 157.7 ppm for the carbon ipso to the pyrazolopyrimidinone and at 141.6 
ppm for the carbon bonded to the methyl groups. The signal for the methyl groups 
appears as a singlet in the 1H NMR spectrum at 2.34 ppm integrating for the six 
equivalent protons, and at 21.3 ppm in the 13C NMR spectrum. The IR and MS data also 
confirmed the successful synthesis of compound 58. 
3.7.2.2 Structural characterisation of 5-(3,5-diethylphenyl)-2-
isopropylpyrazolo[1,5-a]pyrimidin-7(4H)-one (compound 59) 
 
Figure 111: Structure of compound 59. 
The same approach was taken for the compound containing an aromatic ring on the R 
site with two meta substituted ethyl groups, compound 59 (Figure 111). The aromatic 
proton signals appear similarly to the previous compound at 7.37 ppm and 7.12 ppm, 
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and 123.8 ppm and 130.5 ppm, for the two ortho C-H’s of the aromatic ring, and the 
para C-H respectively. The two ethyl groups appear as a quartet at 2.60 ppm, resonating 
for the two CH2 groups of the ethyl groups and integrating for four protons, and at 1.16 
ppm for the CH3 groups of the ethyl groups, integrating for six protons (overlap was 
observed with the isopropyl methyl groups). In the 13C NMR spectrum, the 
corresponding carbon signals for the CH2 of the ethyl groups resonated at 28.7 ppm, and 
at 15.3 ppm for the ethyl CH3 groups. The IR and MS data also confirmed the successful 
synthesis of compound 59.  
3.7.2.3 Structural characterisation of 5-(3,5-dimethoxyphenyl)-2-
isopropylpyrazolo[1,5-a]pyrimidin-7(4H)-one (compound 60) 
 
Figure 112: Structure of compound 60. 
For the compound containing an aromatic ring on the R site with two meta substituted 
methoxy groups, compound 60 (Figure 112), the aromatic proton signals in the 1H NMR 
spectrum appear more upfield at 7.08 ppm (two protons ortho to the 
pyrazolopyrimidinone) and 6.60 ppm (para proton). This was expected as the methoxy 
groups are electron donating groups due to resonance (Scheme 44). The corresponding 
13C signals appear in the 13C NMR spectrum at 105.4 ppm (two ortho C-H’s) and 102.1 
ppm (para C-H).  
 
Scheme 44: Resonance structures due to delocalisation of electrons from methoxy 
group into the aromatic ring. 
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The methoxy protons resonate as a singlet signal integrating for six protons at 3.83 ppm 
in the 1H NMR spectrum. The carbons of the methoxy groups resonate at 55.9 ppm in 
the 13C NMR spectrum. Both signals are downfield due to the deshielding effect of the 
electronegative oxygen. Finally, the IR and MS data also confirmed the successful 
synthesis of compound 60.  
3.7.2.4 Structural characterisation of 5-(3,5-dinitrophenyl)-2-
isopropylpyrazolo[1,5-a]pyrimidin-7(4H)-one (compound 61) 
 
Figure 113: Structure of compound 61. 
For the compound containing an aromatic ring on the R site with two meta substituted 
nitro groups, compound 61 (Figure 113), the opposite effect was observed in the 1H and 
13C NMR spectra to that which was observed to the dimethoxy substituted compound 
60. This was due to the electron withdrawing effect of the nitro groups which resulted 
in the aromatic proton and carbon signals being deshielded and appearing more 
downfield. The aromatic protons appear in the 1H NMR spectrum at 9.07 ppm and 8.92 
ppm for the ortho and para protons respectively. The corresponding carbon signals 
appear at 127.3 ppm and 119.8 ppm respectively, according to the 1H-13C HSQC 
spectrum. Furthermore, the presence of this compound was additionally confirmed by 
the MS data and IR spectrum, with absorbance bands of 1533 cm-1 and 1341 cm-1 which 





 Category 3: Substituent variations at R1 site only (the isopropyl group)  
The third category of variations of RTC53 consisted of changing the isopropyl group at 
the R1 site while maintaining the aromatic bis-CF3 group (Figure 114).  
 
Figure 114: Category 3 variations at the R1 site. 
Compounds produced in category 3 were synthesised using the “one-pot” microwave 
assisted method as described previously in section 3.5. This consisted of reacting a 
commercially available β-ketonitrile with hydrazine monohydrate in MeOH using 
microwave heating at 150 °C for five minutes. This was followed by addition of the 
commercially available β-ketoester, ethyl 3-(3,5-bis(trifluoromethyl)phenyl)-3-
oxopropanoate, along with acetic acid with microwave heating for a further two hours 
to yield the pyrazolopyrimidinone bicycle (Scheme 45).   
 
Scheme 45: General synthesis of category 3 pyrazolopyrimidinone bicycles using the 
“one-pot” microwave assisted method. 
In total, 15 compounds were made with category 3 variations at R1. Variations consisted 
of substituted aromatic rings or heterocyclic rings. The aromatic rings contained 
substitutions at the ortho, meta and para positions, with electron donating (e.g. methyl 
and methoxy) and electron withdrawing groups (e.g. nitro and halogens). Heterocyclic 
rings consisted of furan, thiophene, and pyridine (Table 9).  
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Table 9: Pyrazolopyrimidinone bicycles synthesised with category 3 variations. 
 
















































The isolated yields obtained for most of these compounds were poor due to a complex 
mixture being formed and the difficulty in isolation of the product. All these compounds 
were purified by column chromatography when other purification methods, such as 
filtration, recrystallisation, or trituration, were unsuccessful. The only exception was the 
compound containing the aromatic ring with the nitro group substituted at the para 
position, 5-(3,5-bis(trifluoromethyl)phenyl)-2-(4-nitrophenyl)pyrazolo[1,5-a]pyrimidin-
7(4H)-one (MK76) (compound 72), which was purified by trituration with cold MeOH.  
The synthesis of these compounds was confirmed as before using 1H and 13C NMR 
spectroscopy, HR-MS, and IR spectroscopy. DEPT and 2D NMR techniques were used to 
support signal assignments. The mass spectrum of each compound was analysed, and 
the correct mass was found for all compounds with a difference of less than 5.0 ppm 
from the calculated mass.  
Common signals in the NMR spectra for these compounds arose from the protons of the 
bis-CF3 substituted aromatic ring and bicycle core, which were present in all the 
compounds. Taking compound 62 as an example, the aromatic ring with the bis meta 
substituted trifluoromethyl groups generated 1H NMR signals at 8.73 ppm (ortho 
protons) and 8.15 ppm (para proton), and corresponding 13C NMR signals at 127.2 ppm 
and 122.1 ppm. The 13C NMR also displayed a signal at 152.9 ppm for the ipso quaternary 
carbon, a quartet at 130.9 ppm (J = 33.4 Hz) for the carbon of the trifluoromethyl group, 
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and a quartet at 124.0 ppm (J = 273.6 Hz) for the carbon bonded to the trifluoromethyl 
group. The IR spectrum also displayed absorbance bands at 1276 cm-1 and at 1126 cm-1, 
which are characteristic of the C-F bond stretches.  
The bicycle core of the same compound displayed 1H NMR signals at 6.69 ppm for the 
pyrazole proton adjacent to the R1 group, and at 6.33 ppm for the α-proton (α to the 
carbonyl group), with the corresponding 13C NMR signals at 94.8 ppm and 89.6 ppm, 
respectively. The 13C NMR spectra also displayed quaternary carbon signals arising from 
the bicycle core for the carbonyl group (159.1 ppm), the bridgehead carbon adjacent to 
the NH group (152.1 ppm), the carbon bonded to the R1 group (149.6 ppm), and the β-
carbon bonded to the bistrifluoromethyl substituted aryl ring (128.5 ppm).   
3.7.3.1 Structural characterisation of 5-(3,5-bis(trifluoromethyl)phenyl)-2-(2-
chlorophenyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one (compound 62) 
 
Figure 115: Structure of compound 62. 
Compound 62 (Figure 115) contains an ortho chloro substituted aromatic ring at R1. The 
proton of the chloro substituted aromatic ring ortho to the pyrazolopyrimidinone core 
appears as a doublet at 8.03 ppm, with a coupling constant of 8.4 Hz, in the 1H NMR 
spectrum and a corresponding signal in the 13C NMR spectrum at 131.6 ppm. The proton 
adjacent to the C-Cl bond also appears as a doublet at 7.61 ppm, with a coupling 
constant of 7.2 Hz, in the 1H NMR spectrum and a corresponding 13C NMR signal at 130.6 
ppm. This was expected due to the deshielding effect of the electron withdrawing 
chlorine atom. 
The remaining protons of the chloro substituted aromatic ring generate overlapping 
signals and appear as a multiplet between 7.42 – 7.56 ppm and integrate for two. The 
corresponding 13C signals occur at 129.6 ppm and 127.5 ppm. The IR and MS data also 
confirmed the generation of compound 62. 
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3.7.3.2 Structural characterisation of 5-(3,5-bis(trifluoromethyl)phenyl)-2-(2-
methoxyphenyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one (compound 63)  
 
Figure 116: Structure of compound 63. 
Compound 63 (Figure 116) contains an aromatic ring with an ortho methoxy substituent 
at R1 and generated the expected signals for the pyrazolopyrimidinone core and the 
bistrifluoromethyl aryl ring. The proton of the methoxy substituted aromatic ring ortho 
to the pyrazolopyrimidinone core resonates as a multiplet in the range of 8.04 – 8.15 
ppm as it overlapped with the proton in the para position of the other aromatic ring.  
The proton adjacent to the methoxy group appears as a doublet at 7.13 ppm with a 
coupling constant of 8.2 Hz as it was coupled with just one non-equivalent proton. The 
remaining two protons of the methoxy aryl ring might both have been expected to 
appear as a double of doublets, as they are each coupled to two non-equivalent protons. 
However, for each the double of doublets overlapped slightly and they appear as pseudo 
triplet at 7.02 ppm (meta proton) and 7.34 ppm (para proton). The meta proton is 
slightly more shielded than the para proton due to the effect of the methoxy group (see 
Scheme 37, section 3.7.1.5). 
The 13C NMR spectrum displays signals for the methoxy aryl ring at 129.7 ppm (carbon 
meta to pyrazolopyrimidinone), 129.5 ppm (carbon adjacent to OMe), 120.8 ppm (para 
C-H), and 112.4 ppm (ortho C-H). Quaternary signals consist of the carbon bonded to the 
methoxy group at 157.5 ppm and the ipso carbon at 123.1 ppm. The signal for the methyl 
group of the methoxy group appears as a singlet at 3.91 ppm in the 1H NMR spectrum 
and at 56.1 ppm in the 13C NMR spectrum. The IR and MS data also confirmed the 
generation of compound 63. 
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3.7.3.3 Structural characterisation of 5-(3,5-bis(trifluoromethyl)phenyl)-2-(3-
chlorophenyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one (compound 64) 
 
Figure 117: Structure of compound 64. 
The meta chloro aryl ring of compound 64 (Figure 117) generated four signals in both 
the 1H and 13C NMR spectra. The proton adjacent to the C-Cl bond, in the ortho position 
of the aromatic ring, appears as a singlet at 8.02 ppm in the 1H NMR spectrum, with a 
corresponding 13C signal at 125.8 ppm for the carbon bonded to it. This signal is 
deshielded due to the electron withdrawing effect of the chlorine atom as previously 
discussed. This signal was confirmed using 1H-1H COSY spectrum (see spectra of 
compound 64) as it did not couple with the other three proton signals of the aromatic 
ring. The protons in the para position and ortho position of the aromatic ring both 
appear as doublets at 7.92 ppm and 7.39 ppm respectively, as they are both coupled by 
the meta proton between them. The carbons bonded to these protons appear at 124.9 
ppm and 127.8 ppm respectively. Finally, the remaining meta proton appears as a 
pseudo triplet (resulting from slightly overlapped double of doublets) at 7.48 ppm, with 
a corresponding 13C NMR signal at 130.8 ppm for the carbon bonded to it. The IR 
spectrum shows an absorbance at 768 cm-1 which is characteristic of a C-Cl bond.  The 
MS data also confirmed the generation of compound 64.   
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3.7.3.4 Structural characterisation of 5-(3,5-bis(trifluoromethyl)phenyl)-2-(3-
methoxyphenyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one (compound 65)  
 
Figure 118: Structure of compound 65. 
The compound containing a meta methoxy aromatic ring at the R1 site, compound 65 
(Figure 118), generated all the expected 1H and 13C NMR signals. The two protons 
adjacent to the methoxy group on each side had overlapping signals in the 1H NMR 
spectrum and appear as a multiplet in the range of 7.49 – 7.61 ppm, and at 118.7 ppm 
and 111.5 ppm in the 13C NMR spectrum. The proton in the meta position of the 
aromatic ring appears as a pseudo triplet at 7.36 ppm (J = 7.8 Hz), with a corresponding 
13C signal at 130.0 ppm.  
The proton in the ortho position of the aromatic ring appears as a double of doublets at 
6.92 ppm with a coupling constant of 8.6 Hz and 2.1 Hz due to coupling with its 
neighbouring proton (meta proton), as well as a proton four bonds away (ortho or para 
proton) through aromatic long-range coupling or “W-coupling”. The carbon bonded to 
this proton appears at 114.2 ppm in the 13C NMR spectrum. Finally, the methyl group 
protons of the methoxy group appear as a singlet at 3.84 ppm in the 1H NMR spectrum 
with the corresponding carbon appearing at 55.6 ppm in the 13C NMR spectrum. The IR 
and MS data also confirmed the generation of compound 65.  
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3.7.3.5 Structural characterisation of 5-(3,5-bis(trifluoromethyl)phenyl)-2-(3-
nitrophenyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one (compound 66) 
 
Figure 119: Structure of compound 66. 
Compound 66 (Figure 119) contains a meta nitro substituted aryl ring at the R1 site. The 
1H NMR signals arising for the nitro substituted aromatic protons are quite deshielded 
as nitro is significantly electron withdrawing (see Scheme 9, section 2.3.1.4). The signal 
for the proton in the ortho position between the nitro group and the 
pyrazolopyrimidinone is most deshielded and appears as a singlet at 8.42 ppm, with the 
corresponding 13C NMR signal for the carbon bonded to it found at 120.4 ppm using 1H-
13C HSQC.  
The signal for the other proton adjacent to the nitro group (para to the 
pyrazolopyrimidinone) overlapped with the signal for the other ortho proton and 
appears as a multiplet in the range of 7.82 – 7.93 ppm, with corresponding 13C NMR 
signals at 132.5 ppm and 122.3 ppm, respectively. The remaining proton, in between 
these protons, appears as a pseudo triplet at 7.38 ppm, with a corresponding 13C NMR 
signal at 129.1 ppm. The IR spectrum for this compound showed an absorbance band at 
1347 cm-1, which is characteristic of a N-O bond stretch. The MS data also confirmed the 
generation of compound 66. 
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3.7.3.6 Structural characterisation of 5-(3,5-bis(trifluoromethyl)phenyl)-2-(p-
tolyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one (compound 67) 
 
Figure 120: Structure of compound 67. 
Compound 67 (Figure 120) contains a para methyl substituted aryl ring at R1.  The p-tolyl 
group generated the expected pair of doublets in the aromatic region of 1H NMR 
spectrum at 7.92 ppm and 7.32 ppm, for the protons ortho and meta to the 
pyrazolopyrimidinone respectively, with a matching coupling constant of 7.9 Hz for 
each. The carbons bonded to these protons appear in the 13C NMR spectrum at 126.7 
ppm and 129.8 ppm respectively, as identified using 1H-13C HSQC experiment. The 
protons from the p-tolyl methyl group appear as a singlet at 2.38 ppm in the 1H NMR 
spectrum, and the corresponding carbon appears at 21.4 ppm in the 13C NMR spectrum. 
The IR and MS data also confirmed the generation of compound 67.  
3.7.3.7 Structural characterisation of 5-(3,5-bis(trifluoromethyl)phenyl)-2-(4-
fluorophenyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one (compound 68) 
 
Figure 121: Structure of compound 68. 
The presence of the additional NMR active fluorine atom, of the para fluoro aryl ring, in 
compound 68 (Figure 121) resulted in a more complex set of NMR spectra. In 1H NMR 
spectrum, the protons ortho to the pyrazolopyrimidinone appear as a double of doublets 
at 8.02 ppm (J = 8.5, 5.7 Hz). The splitting pattern is due to coupling with the 
neighbouring meta protons and the fluorine atom.  The 13C NMR spectrum shows the 
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carbon bonded to the ortho protons as a doublet at 128.6 ppm. The splitting was due to 
the 13C-19F coupling and had a coupling constant of 8.0 Hz.  
The proton at the meta position of the aromatic ring appears as a pseudo triplet at 7.27 
ppm (J = 8.8 Hz), again due to coupling with the neighbouring protons, as well as the 
fluorine. This signal was expected to appear as a double of doublets but overlap of the 
two middle peaks resulted in a pseudo triplet appearance. The fluorine atom itself was 
expected to have a similar deshielding effect on the protons meta to the 
pyrazolopyrimidinone as before.  
The carbons bonded to the meta protons are equivalent and appear as a doublet in the 
13C NMR spectrum at 115.8 ppm due to 13C-19F coupling with a coupling constant of 21.6 
Hz. The quaternary carbon bonded to the fluorine also appears as a doublet at 162.7 
ppm (JCF = 245.6 Hz) and the carbon ipso to the pyrazolopyrimidinone appears as a 
quartet at 131.1 ppm (JCF = 33.0 Hz). The IR and MS data also confirmed the generation 
of compound 68. 
3.7.3.8 Structural characterisation of 5-(3,5-bis(trifluoromethyl)phenyl)-2-(4-
chlorophenyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one (compound 69) 
 
Figure 122: Structure of compound 69. 
Compound 69 (Figure 122) contains a para chloro substituted aromatic ring at R1. This 
aryl ring generated the expected pair of doublets in the aromatic region of the 1H NMR 
spectrum at 7.97 ppm and 7.48 ppm. These signals were assigned to the protons ortho 
and meta to the pyrazolopyrimidinone respectively. Both doublets have a matching 
coupling constant of 8.4 Hz. The deshielding effect of the chloro substituent is as 
expected and similar to that discussed previously. The carbons bonded to these protons 
appear as singlets in the 13C NMR spectrum at 128.1 ppm and 128.9 ppm respectively. 
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This assignment was supported by the HSQC spectrum. The IR spectrum shows an 
absorbance band at 806 cm-1, which is characteristic of the C-Cl bond stretch. The MS 
data also confirmed the generation of compound 69. 
3.7.3.9 Structural characterisation of 5-(3,5-bis(trifluoromethyl)phenyl)-2-(4-
bromophenyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one (compound 70)  
 
Figure 123: Structure of compound 70. 
The para bromo aryl substituted pyrazolopyrimidinone compound 70 (Figure 123) 
generated all the expected NMR signals. The para bromo aromatic ring itself produced 
two doublet aromatic signals in the 1H NMR spectrum at 7.94 ppm and 7.62 ppm, for 
the protons ortho and meta to the pyrazolopyrimidinone respectively. The doublets 
have matching coupling constants of 8.3 Hz. The deshielding effect of the bromo 
substituent is as expected and again similar to that discussed for the para fluoro 
derivative, compound 68. The carbons bonded to these protons appear as singlets in the 
13C NMR spectrum at 128.5 ppm and 131.8 ppm respectively, this was supported by 1H-
13C HSQC data. The IR and MS data also confirmed the generation of compound 70.  




Figure 124: Structure of compound 71. 
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Compound 71 (Figure 124) contains a para methoxy substituted aryl ring at R1. The 
methoxy aromatic ring did not generate the expected pair of doublets in the aromatic 
region of the 1H NMR spectrum. Instead a pair of multiplets are observed in the 1H NMR 
spectrum for the protons ortho and meta to the pyrazolopyrimidinone bicycle, and four 
corresponding carbon signals are observed in the 13C NMR spectrum. This led us to 
believe that the ortho and meta protons were not equivalent. The two protons in the 
meta position appear as a multiplet in the region of 7.82 – 7.90 ppm, with corresponding 
13C signals at 127.8 ppm and 127.9 ppm.  
Similarly, the two protons in the ortho position appear as a multiplet in the region of 
6.90 – 6.97 ppm with corresponding 13C signals at 114.1 ppm and 114.2 ppm. The 
quaternary carbon ipso to the pyrazolopyrimidinone appears at 152.9 ppm. The signals 
for the methyl group appear as a multiplet in the range of 3.74 – 3.80 ppm in the 1H 
NMR spectrum, and a corresponding signal in the 13C NMR spectrum for the carbon of 
the methyl group at 55.5 ppm. The IR spectrum shows an absorbance band at 1174 cm-
1 which is characteristic of the C-O bond stretch. The MS data also confirmed the 
generation of compound 71.  
3.7.3.11 Structural characterisation of 5-(3,5-bis(trifluoromethyl)phenyl)-
2-(4-nitrophenyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one (compound 72)  
 
Figure 125: Structure of compound 72. 
Compound 72 (Figure 125) contains a para nitro substituted aryl ring at R1. The electron 
withdrawing nature of a nitro group and its deshielding effect in NMR spectroscopy has 
already been discussed in for compound 66 (Scheme 9, section 2.3.1.4). For compound 
72, the para nitro aromatic ring generated the expected NMR data. The two 1H NMR 
aromatic signals for the nitro substituted aryl ring were overlapping with each other and 
with one of the protons from the bistrifluoromethyl aromatic ring and appear as a 
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multiplet in the range of 8.24 – 8.46 ppm, integrating for five hydrogens. The carbons 
bonded to the aromatic protons appear in the 13C NMR spectrum at 127.8 and 124.5 
ppm. The IR spectrum showed an absorbance band at 1364 cm-1, which is characteristic 
of the N-O symmetric bond stretch. The MS data also confirmed the generation of 
compound 72.  




Figure 126: Structure of compound 73. 
The compound containing the para trifluoromethyl aromatic ring at R1 (compound 73) 
(Figure 126) generated a somewhat complex set of NMR spectra due to the additional 
coupling with the NMR active fluorine atoms. The 1H NMR spectrum shows the proton 
meta to the pyrazolopyrimidinone resonating as a multiplet in the range of 8.14 – 8.20 
ppm and overlaps with a proton from the other aromatic ring. The ortho proton of the 
aromatic ring appears as a doublet at 7.77 ppm with a coupling constant of 8.1 Hz due 
to coupling with its neighbouring proton.  
The carbon bonded to the meta proton appears as a poorly resolved quartet at 125.6 
ppm in the 13C NMR spectrum due to coupling with the fluorine (13C-19F coupling) of the 
trifluoromethyl group, with a coupling constant of 6.9 Hz. The carbon attached to the 
ortho proton was too distant from the fluorine to display any coupling and therefore 
appears as a singlet at 126.9 ppm. However, the carbon ipso to the 
pyrazolopyrimidinone core appears as a poorly resolved quartet at 151.8 ppm (J = 32.8 
Hz), the carbon of the trifluoromethyl group appears as a quartet at 137.5 ppm (J = 313.3 
Hz), and the carbon bonded to the trifluoromethyl group appears as a quartet at 124.9 
ppm (J = 274.8 Hz). The IR and MS data also confirmed the generation of compound 73.  
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3.7.3.13 Structural characterisation of 5-(3,5-bis(trifluoromethyl)phenyl)-
2-(furan-2-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one (compound 74) 
 
Figure 127: Structure of compound 74. 
Compound 74 (Figure 127) contains a furan heterocyclic ring at R1. Clear signals for the 
furan ring could be observed in the 1H NMR spectrum. The proton adjacent to the 
oxygen appears as a broad singlet at 7.48 ppm, which was the most deshielded proton 
due to the electron withdrawing effect of oxygen. The proton furthest away from the 
oxygen also appears as a broad singlet at 6.89 ppm, while the middle proton appears as 
a broad singlet at 6.47 ppm. Although these three signals had a broad singlet 
appearance, the 1H-1H COSY spectrum (see spectra for compound 74) confirmed that 
they are coupled to each other but are poorly resolved. The 13C NMR signals for the 
carbons bonded to these protons appear at 142.5 ppm, 107.6 ppm, and 110.1 ppm 
respectively. These assignments were confirmed using the 1H-13C HSQC spectrum. The 
IR and MS data also confirmed the generation of compound 74.  
3.7.3.14 Structural characterisation of 5-(3,5-bis(trifluoromethyl)phenyl)-
2-(thiophen-2-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one (compound 75) 
 
Figure 128: Structure of compound 75. 
Compound 75 (Figure 128) also contained a heterocyclic ring at R1, this time a thiophene 
ring. The 1H NMR spectrum consists of three signals for the thiophene ring; a poorly 
resolved broad singlet for the proton adjacent to the sulphur at 7.55 ppm which was 
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confirmed by 1H-1H COSY spectrum (see spectra of compound 75), a doublet for the 
proton adjacent to the previous proton at 7.51 ppm, and a multiplet for the proton 
furthest away from the sulphur in the range of 7.10 – 7.16 ppm. The carbons bonded to 
these protons appear as singlets in the 13C NMR spectrum at 125.0 ppm, 125.8 ppm and 
128.0 ppm. The IR and MS data also confirmed the generation of compound 75.  
3.7.3.15 Structural characterisation of 5-(3,5-bis(trifluoromethyl)phenyl)-
2-(pyridin-3-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one (compound 76) 
 
Figure 129: Structure of compound 76. 
Compound 76 (Figure 129) had the nitrogen containing pyridine heterocycle at R1. The 
proton in the ortho position of the pyridine ring, and adjacent to the nitrogen, appears 
as a singlet at 9.20 ppm, being most deshielded due to the electron withdrawing effect 
of the nitrogen. The carbon bonded to this proton appears at 147.6 ppm in the 13C NMR 
spectrum. The other ortho proton appears as a double of doublets at 8.55 ppm as it 
coupled with its neighbouring proton and through long-range coupling to the proton in 
the para position, which itself appears as a multiplet in the range of 8.31 – 8.37 ppm. 
The carbons bonded to these protons appear at 149.2 ppm and 133.4 ppm respectively.  
The proton in the meta position was between these two protons and therefore coupled 
with both. It also shows a small coupling with the first ortho proton (adjacent to the 
nitrogen), which resulted in a multiplet signal at 7.46 – 7.50 ppm. The carbon bonded to 
this proton appears at 124.1 ppm in the 13C NMR spectrum. These assignments were 
supported by 1H-1H COSY and 1H-13C HSQC data. The IR and MS data also confirmed the 










The pyrazolopyrimidinone bicycle core is commonly found in many pharmaceutical and 
biomedical agents. Derivatives of this core structure can be found in medicines for the 
treatment of cancer, obesity, and cystic fibrosis. Other research groups have reported 
the synthesis of this pyrazolopyrimidinone bicycle core using conventional heating and 
microwave methods.  
A family of pyrazolopyrimidinones were synthesised in order to establish how structural 
variations can influence biological activity, namely their ability to stimulate glucose 
uptake and inhibit complex I.  The hit compound RTC53 was used as a starting point and 
a large number of RTC53 derivatives were synthesised using a selection of structural 
variations at R and R1, Figure 130.  
 
Figure 130: General structure for the pyrazolopyrimidinone bicycle family. 
These structural variations can be grouped in three categories. Category 1: derivatives 
of RTC53 where variations were made at both the R and R1 sites; Category 2: derivatives 
of RTC53 where variations were made at the R site only; Category 3: derivatives of RTC53 
where variations were made at the R1 site only. Variations included alkyl groups, phenyl 
ring, substituted aromatic rings, and heterocyclic rings. Aromatic ring substitutions 
included those at the ortho, meta, and para positions of the aromatic rings, and 
consisted of electron donating (e.g. methyl and methoxy) and electron withdrawing 
groups (e.g. nitro group). Heterocyclic rings consisted of furan, thiophene, and pyridine.  
Synthetic method development for this family consisted of developing a microwave-
assisted “one-pot” approach for the generation of the pyrazolopyrimidinone bicycles. 
The conventional reflux heating method for the synthesis of the intermediate 
aminopyrazole typically takes 17–24 hours and for the subsequent synthesis of 
pyrazolopyrimidinone takes a further 21–24 hours. This two step synthesis was reduced 
down to just over 2 hours using the “one-pot” microwave-assisted method. 
Furthermore, isolation and purification of the intermediate aminopyrazole could be 
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avoided as the second step of the synthesis could be conducted in the same reaction 
vessel (“one-pot”), by adding in the relevant β-ketoester to produce the required 
pyrazolopyrimidinone bicycle.  
Purification of some pyrazolopyrimidinones proved to be difficult with yields averaging 
between 30-50% for the three categories. Category 3 compounds where the most 
challenging group of compounds to isolate and purify, and here our focus moved to 
accessing sufficient quantities of pure material for biological evaluation, regardless of 
yield. For all categories, purification typically consisted of column chromatography with 
a solvent mixture, or in a few cases, trituration with the appropriate solvent.  
Structural characterisation of the pyrazolopyrimidinones employed 1H and 13C NMR 
spectroscopy, HR-MS, and IR spectroscopy. An X-ray crystal structure was also obtained 
for the furan-substituted pyrazolopyrimidinone. The 1H NMR and 13C NMR spectral 
assignments were confirmed using DEPT NMR experiments, as well as 2D-NMR 
experiments such as 1H-1H COSY, 1H-13C HSQC and 1H-13C HMBC. All compounds were 
analysed by high-resolution mass spectrometry to obtain a mass which was less than 
five ppm from the calculated mass of the compound. This also confirmed the presence 
of the desired compound. Finally, IR spectroscopy displayed absorption bands for the 
key functional groups present in each compound and further verified the successful 
synthesis of the target compound. The pure and fully characterised 












4.1 Introduction  
As previously mentioned, biological evaluation of the two families of compounds, the 
arylpiperazine family and the pyrazolopyrimidinone bicycle family, involved a glucose 
uptake assay and a complex I assay.  
The results presented in this chapter are for compounds synthesised by myself, and 
whose synthesis was discussed in the previous two chapters. In addition, some biological 
results are included for compounds that were synthesised by previous members of the 
Stephens group; Robert Devine and John Walsh. For clarity, compounds synthesised by 
Robert Devine will be assigned a subscript “a”, and compounds synthesised by John 
Walsh will be assigned a subscript “b”. All other compounds will have been synthesised 
by myself.  The biological evaluation itself was carried out by myself, Robert Devine, 
John Walsh, Darren Martin (collaborator), and Siobhan Leonard (also a previous 
member of the Stephens group). Biological data generated by another group member 
will be assigned a subscript “c” (all the complex I inhibition data, including that using the 
compounds I synthesised, was generated by Siobhan Leonard). All other biological data 
will have been generated by myself.  
The glucose uptake assay is a whole cell assay carried out on C2C12 mouse muscle cells. 
Cells were stimulated with the test compounds 16 hours before the glucose uptake 
assay was performed. The glucose uptake assay used was a radiolabelled assay that 
employed tritiated deoxy-2-glucose, see section 4.2. After 16 hours of stimulation of the 
cells with the test compounds or controls, tritiated (3H) deoxy-2-glucose was added. 
Tritium (3H) is a radioactive isotope of hydrogen. This allowed us to quantitatively 
measure how much radio labelled deoxy-2-glucose has been taken up by the cells after 
stimulation of the test compounds, in comparison with the controls. Deoxy-2-glucose is 
used, as opposed to glucose itself, as it is a derivative of glucose that cannot be 
metabolized and so will remain in the cell after uptake.50  
The glucose uptake assay is a whole cell assay, where the cell membrane and cell 
components are all in place. We used the glucose uptake assay as our first screening 
assay. This is because a whole cell assay more closely resembled what the compounds 
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will encounter in the body, as opposed to an enzyme inhibition assay (such as our second 
assay, complex I inhibition assay). Compounds that are active in enzyme inhibition 
assays have been known to be inactive in whole cell assays due to difficulties in passing 
through the cell membrane, and/or degradation by the cell components.96 
The second assay performed, a complex I inhibition assay, was performed on 
compounds that were active in the glucose uptake assay (we also evaluated some 
compounds that were inactive in the glucose uptake assay). This assay utilised isolated 
rat liver mitochondria. A liver extraction, washing, chopping, homogenization, 
centrifugation process was followed, see section 4.4, which resulted in a mitochondrial 
pellet with which the assay could be carried out. The pelleted mitochondria were then 
permeabilized and the reaction initiated with the addition of ubiquinone and the 
resulting decrease in absorbance of ubiquinone measured for 3 minutes. Varying 
concentrations of the test compounds were then added, and absorbance was measured 
for a further 3 minutes in each case. The effect of the compounds on complex I was 
determined by comparing activity before and after addition, relative to the vehicle 





4.2 Glucose Uptake Assay 
The glucose uptake assay was carried out on C2C12 mouse muscle cells, an immortalized 
myoblast cell line, which is derived from a subclone of a mouse cell line.97 Subcloning is 
the targeted transfer of a specific DNA sequence from the parent vector to the target 
one.98 C2C12 is a muscle tissue cell line, which exhibits mononucleated myoblast 
morphology. This cell line acts as a good transfection model, but can rapidly differentiate 
into contractile multinucleated myotubes, producing muscle-specific proteins. Due to 
this ability for rapid differentiation, these cells are ideal for in vitro studies in biomedical 
research and cell biology, especially of mammalian myoblast cells.97 C2C12 cells have 
been used to study the differentiation of myoblasts, osteoblasts, and myogenesis, to 
explore mechanistic biochemical pathways such as protein degradation99, gene 
expression100, and glucose transport101, and to express various target proteins.  
C2C12 cells used for the assay were stored in liquid nitrogen in DMSO in a process known 
as cryopreservation.102 This process preserves the cells at low temperatures (-196 °C) to 
prevent any enzymatic or chemical activity from occurring. All media, equipment, and 
reagents must be sterile during cell culture to prevent microbial growth. Once removed 
from liquid nitrogen, cells were split multiple times in a sterilised biosafety cabinet 
before being used for experiments.  
Splitting of the cells is an essential component of tissue culture as it allows for the cells 
to grow in a healthy and suitable environment. This process begins by rinsing the cells 
with phosphate-buffered saline to remove any dead cells, detaching cells from the 
bottom of the flask using trypsin, adding in fresh medium to transport the cells into a 
falcon tube, and spinning the cells down using a centrifuge. Cells can then be counted 
under a microscope using a haemocytometer, which is a glass plate accurately engraved 
with a grid of squares. New T75 flasks can be seeded with cells of the desired density. 
Once these cells become 80% confluent after 2-3 days, they can be split again into new 
flasks and the process continues until cells are no longer growing at the same rate as 
before.  
Cells were cultured in 6-, 12-, or 24-well plates using high-glucose Dulbecco’s Modified 
Eagle’s Medium (DMEM) containing 10% (v/v) fetal bovine serum, 2 mM L-glutamine, 
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and 100 μg/ml penicillin-streptomycin, and stored in 5% CO2 sterilised biosafety 
incubator with a constant temperature of 37 °C. When the myoblast cells reached 80 % 
confluence, differentiation into myotubes was induced by switching the growth medium 
to DMEM supplemented with 2% (v/v) horse serum for three days, after which the 
myotube cells were ready for use in the assay.  
Cells were stimulated with the test compounds 16 hours before the glucose uptake 
assay in a 0.1% (v/v) horse serum DMEM medium. Compounds were prepared by 
dissolution in 100 μL DMSO to achieve a 50 mM concentration stock solution, which was 
diluted down to 1 mM working solution in Krebs’ Ringer Buffer (KRB). KRB was prepared 
using 1 litre of distilled water containing sodium chloride (136 mM), Hepes (20 mM), 
potassium chloride (4.6 mM), magnesium sulfate (1 mM), calcium chloride (1 mM), 
sodium phosphate dibasic (4.05 mM), and sodium phosphate monobasic (0.95 mM). 
After the pH of KRB was adjusted to pH 7.4 using sodium hydroxide, it was sterilised 
filtered using a syringe and a 0.2 μM filter and stored at 4 °C.  
Two controls were prepared in all experiments. DMSO acted as the standard control, to 
which all the cells were compared with, and insulin (or in some cases metformin) acted 
as the positive control to ensure cells are performing correctly. Insulin was stimulated 
for only 30 minutes to the cells at a concentration of 100 nM. This was done by pipetting 
5 μL of a 10 μM working solution into 245 μL of 5 mM glucose solution inside the cells. 
The 10 μM working solution of insulin was prepared by pipetting 2.9 μL out of a 10 
mg/mL stock solution of insulin inside 500 μL of 5 mM glucose solution. The 5 mM 
glucose solution was prepared by dissolving 0.04504 g of glucose in 50 mL KRB solution 
and sterilise filtering it. Metformin was stimulated in the same concentration as the test 
compounds for 16 hours.   
After 16 hours of stimulation of the cells with the test compounds and controls, tritiated 
(3H) deoxy-2-glucose was added to quantitatively measure how much glucose has been 
taken up by the cells after stimulation of the test compounds, in comparison with the 
controls. Tritium (3H) is a radioactive isotope of hydrogen containing one proton and 
two neutrons with a half-life of over 12 years. It emits β-particles which cannot travel 
far through air and are incapable of passing through skin. Caution was taken while 
handling 3H deoxy-2-glucose and disposing its waste by carrying out swabs before and 
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after every experiment, using designated equipment and reagents in the radiation suite, 
reducing the amount of time exposed to tritium to a minimum, and carrying out all the 
work inside the safety cabinet or fume-hood.  
Following treatment of the cells with 3H deoxy-2-glucose, cells were incubated for 10 
minutes then washed three times in ice-cold KRB to stop any further uptake and 
solubilized in 0.1% (w/v) sodium dodecyl sulfate for 30-45 minutes. After this time, 
tritiated glucose uptake was evaluated via scintillation counting of the lysates diluted 
1:4 in β-scintillation fluid using a scintillation counter. A protein assay accompanied the 
glucose uptake assay by quantitatively measuring the protein concentration of each 
sample via the bicinchoninic acid assay method to account for the different number of 
cells present in each sample.103 A standard solution curve was made in this assay using 
distilled water and bovine serum albumin.  
Protein concentration of each sample was correlated with the corresponding counts 
from the glucose uptake assay to express the result as counts per minute per mg protein. 
Each result was compared with the control (DMSO) to generate the fold change. All data 
was expressed as means ± standard error of the means (SEM) of a number of 
experiments (n) performed for that sample. Statistical analysis was performed using 
one-way analysis of variance (ANOVA) using GraphPad Prism 5.0 with a threshold of 
significance defined as a p-value <0.05 (95% confidence in result) or a one star 
significance (*), p-value < 0.01 or two stars significance (**), and p-value < 0.0001 or 
three stars significance (***). Only compounds which received stars significance in the 
glucose uptake assay were considered “active” compounds as their results meant that 






4.3 Glucose uptake results of the arylpiperazine family 
As discussed in chapter 2, the arylpiperazine family consists of compounds synthesised 
by structural variation of RTC1 at five sites (Figure 131). Variations were carried out at 
the aryl group (site A), the piperazine ring (site B), the carbonyl group (site C), the alkyl 
chain (site D), and the thiophene ring (site E).  
 
Figure 131: Structure of RTC1 with variations sites, A-E. 
The results from the glucose uptake assay can be divided into the same 
sites/subfamilies, and hence allow the relationship between chemical structure and 
biological activity to be explored.  As previously mentioned, and in order to describe the 
complete compound library, some compounds have been included that were 
synthesised by previous group members. All the biological data was generated by 




  Glucose uptake results for structure variations at site A: the aryl group 
Glucose uptake data for compounds with variations at site A of RTC1 can be found in 
Table 10. The first entry in Table 10 is for the parent compound, RTC1, which was active 
and gave a glucose uptake result of 2.57 fold change over the vehicle control with three 
stars significance. The fold change value illustrates how active RTC1 was in comparison 
with the vehicle control (fold change of 1). This calculation is performed by combining 
the number of 3H deoxy-2-glucose counts (per minute) the cells contained after 
stimulation with RTC1, and the number of proteins (i.e. cells) these counts correspond 
to, in order to achieve the counts per minute per mg of protein. Three stars significance 
indicates that the results obtained from RTC1 have a p-value of less than 0.0001 and are 
therefore accurate and reliable, and RTC1 should be consistently active.  
Table 10: Glucose uptake results for site A variations of RTC1.  
 
Compound R Glucose Uptake Result 
  
Fold change ± 
SEM 
Active (Y) with 
stars significance, 
or inactive (N) 
1 (RTC1/MK24) 
 
2.57 ± 0.08 Y (***) 
7 (MK38)c 
 
0.96 ± 0.07 N 
8 (MK41)c 
 
0.85 ± 0.02 N 
9 (MK44)c 
 
1.42 ± 0.09 Y (*) 
10 (MK39)c 
 





1.32 ± 0.12 N 
RTC11a,c 
 
1.16 ± 0.09 N 
12 (MK20)c 
 
1.58 ± 0.15 Y (***) 
RTC62a,c 
 
1.02 ± 0.04 N 
13 (MK42)c 
 
1.00 ± 0.09 N 
RTC44a,c 
 
1.22 ± 0.10 N 
14 (MK45)c 
 
1.13 ± 0.02 Y (*) 
4 (MK43) 
 
1.29 ± 0.04 Y (***) 
15 (MK36) Me 0.84 ± 0.03 N 
aCompounds synthesised by Dr Robert Devine. 
cCompounds tested by Dr Siobhan Leonard. 
From these results, it is observed that changes to the trifluoromethyl group or its 
position may result in loss of activity. This was the case when the trifluoromethyl group 
was removed (compound 7), substituted in the ortho position instead of the para 
position (compound 8), or replaced by a nitro (compound 10), amine (compound 11), or 
fluorine (RTC11) groups. The result for compound 10 is interesting as replacement of a 
hydrophobic electron withdrawing group (CF3) with a considerable less hydrophobic 
electron withdrawing group (NO2) resulted in loss of activity. Activity was found with the 
compound containing two trifluoromethyl groups, meta substituted, (compound 9) but 
with a lower fold change and only one star significance in comparison with RTC1. From 
these results, it could be concluded that one trifluoromethyl group at the para position 
of the aromatic ring may play an important role in the biological activity of the 
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compounds. Trifluoromethyl groups are well known for the hydrophobic and lipophilic 
nature, and can aid transport across cell membranes as well as contribute to binding in 
hydrophobic enzyme pockets.68 
Some further changes to the aromatic ring also resulted in complete loss of activity, 
including those where an additional bromine ortho substituent was added (RTC62), 
where a para CF3 pyridine ring replaced the para CF3 aryl ring (compound 13), or a para 
CF3 pyridine ring with an additional chlorine meta substituent replaced the para CF3 aryl 
ring (RTC44). However, some changes could be somewhat tolerated, albeit with a drop 
in activity. When a chlorine group was added at the ortho position of the aromatic ring 
(compound 12), the glucose uptake fold change dropped but still showed activity with 
three stars significance. Similarly, an increase in glucose uptake over vehicle control was 
observed for compound 14, where the para CF3 pyridine ring had an additional chloro 
ortho substituent. Although, here the fold change was small but did have one star 
significance.   
An increase in glucose uptake over the vehicle control, with three stars significance, was 
observed for compound 4 where the hydrophobic para CF3 aryl ring was replaced by a 
hydrophobic cyclohexyl ring. This activity was not shown when the hydrophobic para 
CF3 aryl group was replaced with a simple methyl group (MK36) (compound 14). These 
results may suggest that a somewhat large hydrophobic group at site A may be 
important for biological activity. The presence of such a group could impact on transport 
across cell membranes and on binding in enzyme hydrophobic pockets. 
The results of each experiment were generated using a bar graph similar to the one 
shown below (Figure 132), which shows the activity of compounds 4 and 15, in 














































































Figure 132: Glucose uptake results of RTC1, compound 4, and compound 15 in 








  Glucose uptake results for structure variations at site B: the piperazine 
ring 
The next set of glucose uptake results are for site B variations, the piperazine ring of 
RTC1 (Table 11). 
Table 11: Glucose uptake results for site B variations of RTC1. 
 
Compound X Glucose Uptake Result 
  Fold change ± SEM 
Active (Y) with stars 




2.14 ± 0.30 Y (***) 
17 (MK90) NH 1.11 ± 0.08 N 
RTC21a,c (NH)2    1.24 ± 0.05 Y (**) 
aCompound synthesised by Dr Robert Devine. 
cCompounds tested by Dr Siobhan Leonard. 
It is observed from these results that good activity is maintained if the piperazine ring in 
RTC1 is replaced by a piperidine ring (compound 16), which had three stars significance 
and a 2.14 fold change over the vehicle control. Replacement of the piperazine ring with 
a hydrazine motif (RTC21) resulted in an active compound, albeit with lower fold change 
(two stars significance). Activity was lost when the piperazine ring was replaced by a 
secondary amine (compound 17). It can therefore be concluded that the piperazine ring 
appears to be important for biological activity and that changing to a piperidine ring is 
not optimal but does generate a compound with good activity. However, removal of the 
saturated six membered ring heterocycle altogether, as was the case with the hydrazine 





  Glucose uptake results for structure variations at site C: the carbonyl 
group 
The next glucose uptake result is for site C variations of RTC1, the carbonyl group (Figure 
133). Here, a single compound was made without the carbonyl group, 1-(4-(thiophen-2-
yl)butyl)-4-(4-(trifluoromethyl)phenyl)piperazine (MK34) (compound 18). This 
compound was active in the glucose uptake assay with a fold change value of 1.36 ± 0.09 
and three-star significance. This compound was tested by Dr Siobhan Leonard. 
 
Figure 133: Structure of compound 18. 
Although activity was still maintained without the carbonyl group, the fold change of 
this compound was lower than RTC1. It can therefore be concluded that the carbonyl 
group improves biological activity and its presence is important, but perhaps not 




  Glucose uptake results for structure variations at site D: the alkyl chain 
The following set of glucose uptake results are for site D variations of RTC1, the alkyl 
chain (Table 12). 
Table 12: Glucose uptake results for site D variations of RTC1. 
 
Compound X Glucose Uptake Result 
  Fold change ± SEM 
Active (Y) with stars 
significance or inactive 
(N) 
21 (MK37)c - 0.93 ± 0.07 N 
22 (MK47)c CH2 1.33 ± 0.04 Y (***) 
RTC532a,c C2H4 1.09 ± 0.08 N 
1 (RTC1) C3H6 2.57 ± 0.08 Y (***) 
23 (MK18) C4H8 1.78 ± 0.13 Y (***) 
RTC537a,c C5H10 1.33 ± 0.05 Y (***) 
24 (MK40)c 
 
1.19 ± 0.03 Y (***) 
RTC29a,c 
 
1.41 ± 0.04 Y (***) 
25 (MK22)c 
 
2.14 ± 0.23 Y (***) 
aCompounds synthesised by Dr Robert Devine. 
cCompounds tested by Dr Siobhan Leonard. 
The lead compound RTC1 has a three carbon alkyl chain linking the carbonyl carbon with 
the thiophene heterocycle. The results of the glucose uptake assay suggest that the alkyl 
chain in RTC1 is important for biological function, as activity was lost when the chain 
was completely removed (compound 21). Activity was also reduced when the alkyl chain 
was shortened but not fully removed, as was the case for compound 22 (low activity) 
and RTC532 (not active). Lengthening the alkyl chain (compound 23 and RTC537) also 
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resulted in a decrease in activity but not a complete loss in activity. One possible 
explanation is that a certain length of alkyl chain is required for the molecule to strongly 
bind to the active site. Too short or too long a chain may result in a poor fit and weak 
binding. Also, an entropy effect could also be considered for the longer chain 
compounds. Longer chain compounds will be more “floppy” in nature and be able to 
adopt a larger number of conformations when unbound. As such, upon binding there 
will a large increase in order, entropy cost, and hence the binding of such molecules may 
be less thermodynamically favourable when compare to shorter chained molecules.   
A large drop in activity levels was observed when an additional carbonyl group 
(compound 24) or when a hydroxyl group (RTC29) was placed at the γ-carbon. Carbonyl 
groups can act as H-bond acceptors via the lone pairs on the carbonyl oxygen.77 Hydroxyl 
groups can act as both H-bond acceptors and H-bond donors.104 Carbonyl groups and 
hydroxyl groups are also polar in nature. Hence, the addition of such groups may result 
in unfavourable H-bonding or electrostatic interactions between the molecule and the 
target protein. This could cause a weakening in binding and poorer biological function.   
When the γ-CH2 was replaced with a sulphur atom (compound 25), a small drop in 
activity was observed, but with a 2.14 fold change compared with the vehicle control 
and with three-star significance. Sulphur has two lone pairs, but is considered to be a 
significantly weaker H-bond acceptor that oxygen,105 and hence may not have large 
negative impact on binding strength. 
All the active compounds in this subfamily had activity with three stars significance, but 
with a lower fold change than RTC1. It could therefore be concluded that the alkyl chain 
in RTC1, which connects the carbonyl group to the thiophene ring, is important for 
biological activity. An optimal alkyl chain length appears to be three carbons in length, 
and that the addition of motifs to the chain that could result in additional substrate-





  Glucose uptake results for structure variations at site E: the thiophene 
ring 
The next set of glucose uptake results are for site E variations of RTC1, the thiophene 
ring (Table 13). 
Table 13: Glucose uptake results for site E variations of RTC1. 
  
Compound R Glucose Uptake Result 
  Fold change ± SEM 
Active (Y) with stars 




 1.35 ± 0.11 Y (**) 
RTC194a,c     CH3 1.28 ± 0.11 Y (**) 
aCompound synthesised by Dr Robert Devine. 
cCompounds tested by Dr Siobhan Leonard. 
It can be observed from these glucose uptake results that replacing the thiophene ring 
in RTC1 with a different heterocycle, a pyrazole ring (compound 5), or with an alkyl 
group, a methyl group (RTC194), caused a decrease in activity. However, both 
compounds did remain active, with two stars significance, and hence it could be 
suggested that a thiophene may be important but not be essential for activity, and that 
alternatives to a thiophene may result in reduced activity.   
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  Glucose uptake results for structure variations at a combination of sites 
The following sets of glucose uptake results are for compounds with a combination of 
variations of RTC1. Table 14 summaries the results for the first set, which contains 
compounds with variation at both site A, the aryl group, and site B, the piperazine. 
Table 14: Glucose uptake results for compounds with a combination of variations at 
sites A and B. 
 
Compound R X Glucose Uptake Result 
  
 
Fold change ± 
SEM 
Active (Y) with 




1.25 ± 0.12 Y (*) 
RTC1 acidc - OH 1.16 ± 0.04 Y (*) 
RTC19a,c - OMe 1.09 ± 0.04 N 
aCompound synthesised by Dr Robert Devine. 
cCompounds tested by Dr Siobhan Leonard. 
Removal of the CF3 group from RTC1 at the same time as replacing the piperazine ring 
with a piperidine ring (compound 27) resulted a large drop in activity. A reduction in 
activity may not be very surprising, if one considers the result for compound 7 where 
removal of the CF3 group alone, Table 10, resulted in complete loss of activity. What 
perhaps is more surprising is that activity was observed at all for compound 27, albeit at 
very low levels. Very low levels of activity were also observed when the starting material 
used in the synthesis of RTC1 (RTC1 acid) was evaluated in the glucose uptake assay. For 
both these compounds, the fold change was marginally above 1 (1.2-1.3, one star 
significance) and hence are not very promising candidates for development. 
When the aryl group and piperazine ring were both replaced by a methoxy group, 
activity was lost. This is not surprising as this molecule is significantly different from the 
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hit compound RTC1. This set of tests further suggests that having a para substituted 
trifluoromethyl aryl ring and a piperazine ring are important for biological activity.  
The next set of glucose uptake results are for a combination of site A (aryl group) and 
site D (alkyl chain) variations of RTC1 (Table 15). 
 
Table 15: Glucose uptake results for compounds with for a combination of variations 




R X Glucose Uptake Result 
   
Fold change ± 
SEM 
Active (Y) with 
stars significance 








1.26 ± 0.06 Y (*) 
RTC3a,c 
  
1.22 ± 0.06 N 
aCompounds synthesised by Dr Robert Devine. 
cCompounds tested by Dr Siobhan Leonard. 
Although active, all three compounds evaluated in this subfamily showed large drops in 
biological activity. Such a decrease in activity may not be that surprising if one considers 
the results for compound 13 and 14 in Table 10, where the same pyridine rings replaced 
the para trifluoromethyl aryl ring of RTC1, and a large drop in activity was also observed. 
These compounds reaffirm previous suggestions that compounds with chlorine 
substituted in the ortho position of a pyridine ring can result in an active compound but 
with much low levels of activity in comparison with RTC1.  
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The next glucose uptake result is for 1-(thiophen-2-yl)-4-(4-(4-
(trifluoromethyl)phenyl)piperidin-1-yl)butane-1,4-dione (MK88) (compound 28, Figure 
134). Here a combination of variations was employed at both site B (the piperazine ring) 
and site D (the alkyl chain).  
 
Figure 134: Structure of compound 28.  
As discussed earlier, compound 16, Table 11, replacing the piperazine ring by a 
piperidine ring seemed to maintain high levels of activity. However, adding an extra 
carbonyl group in the alkyl chain was observed to lower activity in the glucose uptake 
assay. As such, combining both these changes would be expected to show a reduction 
in activity but perhaps still some lower level of activity. This indeed turned out to be the 
case as the glucose uptake assay for this compound showed a fold change of 1.31 ± 0.05 
compared to the vehicle control, with three stars significance. 
The next set of glucose uptake results are for compounds with a combination of 
variations at site D (the alkyl chain) and site E (the thiophene ring) (Table 16). 
Table 16: Glucose uptake results for compounds with a combination of variations at 
sites D and E. 
 
Compound X R Glucose Uptake Result 
  
 
Fold change ± 
SEM 
Active (Y) with 
stars significance or 
inactive (N) 
30 (MK29) CH3 - 1.43 ± 0.09 Y (***) 
RTC535a,c C2H4 
 
1.11 ± 0.04 N 
29 (MK30) C4H8 Ph 1.95 ± 0.09 Y (***) 
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RTC533a,c C6H12 CH3   1.38 ± 0.05 Y (***) 
RTC15a,c C7H14 
 
   1.38 ± 0.06 Y (***) 
3 (MK16)c C7H14 
 
    1.08 ± 0.08 N 
RTC18a,c C7H14 
 
     2.35 ± 0.25 Y (***) 
aCompounds synthesised by Dr Robert Devine. 
cCompounds tested by Dr Siobhan Leonard. 
All the compounds in this subfamily contain changes in length of the alkyl chain 
compared to RTC1. Such changes would be expected to reduce, but perhaps not 
eliminate, biological activity in the glucose uptake assay, based on results shown for 
related compounds in Table 12. Changes to the thiophene ring, site E, Table 13, could 
also be expected to reduce, but not eliminate, activity. The results in Table 16 above are 
reflective of this, with lower activity resulting for all compounds. Compounds 3 and 
RTC35 both showed complete loss of activity. RTC18, on the other hand, is perhaps the 
surprise result from this subfamily as while the activity was lower than for RTC1, the 
drop was only marginal. 
The next set of glucose uptake results are for a combination of variations at site C (the 
carbonyl group), site D (the alkyl chain), and site E (the thiophene ring) (Table 17). 
Table 17: Glucose uptake results for a combination of variations at sites C, D, and E.  
 
Compound R Glucose Uptake Result 
  
Fold change ± 
SEM 
Active (Y) with 
stars significance or 
inactive (N) 
RTC1 aminec H 1.16 ± 0.06 Y (*) 
31 (MK35) CH3 0.92 ± 0.07 N 
cCompound tested by Dr Siobhan Leonard. 
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It can be observed from these glucose uptake results that the starting material of RTC1 
(RTC1 amine), which does not have a carbonyl group, alkyl chain, or thiophene ring show 
a very large drop in activity, as would be expected. It is perhaps surprising that any 
activity was observed, but it is worth noting that the activity level was very low at 1.2 
fold change compared with the vehicle control. Furthermore, if a methyl group is used 
to replace the carbonyl group, alkyl chain, and thiophene ring then activity is no longer 
observed. Again, this would be as expected. These results suggest the presence of an 
arylpiperazine alone is not sufficient for substantial levels of activity.   
For this compound family, RTC1 remained the most active compound in the glucose 
uptake assay. The presence of a para trifluoromethyl aryl piperazine motif appears 
essential for high levels of glucose uptake activity. An alkyl chain linker of three carbons 
also appears important. The terminal moiety appears to be variable to some extent, 
although a preference for the thiophene ring could be suggested.   
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4.4  NADH:ubiquinone oxidoreductase (complex I) assay, aryl piperazine 
family  
Compounds that were active in the glucose uptake assay were brought forward for 
testing in a second assay, the NADH:ubiquinone oxidoreductase (complex I) assay. This 
would allow us to evaluate the compounds ability to inhibit complex I of the electron 
transport chain. As discussed previously, the inhibition of complex I of the electron 
transport chain has been discovered to be a potential target for treatment of type 2 
diabetes.44 Recent research published by our group examined how compounds of the 
arylpiperazine family were able to inhibit complex I and restore the glucose-handling 
abilities of mice fed with a high-fat diet.44 The complex I assay used isolated rat liver 
mitochondria for the animal studies. Inhibition of complex I was shown to lead to 
activation of AMP-activated protein kinase (AMPK), which in turn increased glucose 
uptake by the cells.44 
Inhibition of complex I was shown to lead to activation of AMP-activated protein kinase 
(AMPK).44 AMPK is a heterotrimeric protein complex that is involved in cellular energy 
homeostasis where it regulates energy levels by monitoring the amounts of adenosine 
triphosphate (ATP) and adenosine monophosphate (AMP).26 Activation of AMPK by 
small molecules such as arylpiperazines and metformin has shown to reduce hepatic 
gluconeogenesis, increase oxidation of fatty acids, increase glycolysis, and, most 
importantly, increase the uptake of glucose by skeletal muscles.26,51  
Metformin is one of the most widely used treatments for type 2 diabetes today and it 
can be used as a monotherapy or as a combination therapy with other treatments.30  
Metformin achieves its anti-diabetic role by reducing the activity of complex I of the 
electron transport chain which in turn activates AMPK, inhibits liver gluconeogenesis, 
and antagonises glucagon action.25,27,29 However, metformin is known for causing many 
undesirable side-effects such as diarrhoea, nausea and mild anorexia. Compounds from 
the arylpiperazine family were shown to have a greater anti-diabetic effect than 
metformin and at a lower dose when tested on mice, with no known side-effects.44 
The complex I assay was carried out on isolated rat liver mitochondria which were 
isolated by the method described by Chappell and Hansford (1972).106 Immediately after 
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extraction, liver samples were washed free of excess blood, trimmed of any fat and 
connective tissue, finely chopped, and placed in ice-cold isolation medium containing 
sucrose, tris-hydrochloric acid, and egtazic acid. The tissue was homogenized and 
centrifuged and the supernatant was filtered through a sieve before being centrifuged. 
The resulting mitochondrial pellet was resuspended in ice-cold isolation medium 
supplemented with defatted bovine serum albumin (BSA) and washed twice by 
centrifugation.  The final mitochondrial pellet was resuspended in a small volume of 
isolation medium, and the aliquots were frozen at −20°C. 
Immediately before the assay, the isolated mitochondria were diluted in a hypotonic 
buffer and permeabilized with three cycles of freeze thawing. The assay was carried at 
30°C in a 1 mL cuvette. Permeabilized mitochondria were incubated with potassium 
phosphate dibasic, fatty acid-free BSA, potassium cyanide, and NADH. Baseline activity 
was measured at 340 nm for 1 minute. The reaction was initiated with the addition of 
ubiquinone (60 μmol L-1) and the resulting decrease in absorbance was measured for 
three minutes. Varying concentrations of the test compounds were then added, and 
absorbance was measured for a further three minutes. The effect of the compounds on 
complex I was determined by comparing activity before and after addition, relative to 
the vehicle control, DMSO. Rotenone (1 μmol L-1) was used as a positive control in this 
assay due to its known ability to inhibit complex I.107,108  
To determine the percentage activity of complex I, the slope of the line obtained with 
the addition of ubiquinone was divided by the slope of the line produced with the 
addition of the test compound. This value was then expressed as a percentage, relative 
to the value calculated for the vehicle control, DMSO, and the protein concentration of 
the mitochondrial sample. Compounds were tested at five different concentrations, in 
triplicate, to generate their half maximal inhibitory concentration (IC50) values which is 
a quantitative measure that indicates the concentration of the compound which inhibits 
a biological process by 50%. It is commonly used in pharmacological research as a 
measure of antagonist drug potency and represents the concentration of a drug that is 
required for 50% inhibition in vitro. 
As previously mentioned, all the compounds evaluated in the complex I assay were 
tested by Dr Siobhan Leonard.  
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  Complex I assay results of the active arylpiperazine compounds                    
Complex I assay results for the aryl piperazine compounds that were active in the 
glucose uptake assay are shown in Table 18.  The IC50 value of all the compounds was 
compared to the IC50 value of the parent molecule, RTC1. Rotenone has an IC50 value of 
3.1375 μM.43 The results of the complex I assay showed a range of IC50 values for the 
evaluated compounds in the arylpiperazine family.  
Table 18: Complex I assay results of the active arylpiperazine compounds. 















































































aCompounds synthesised by Dr Robert Devine. 
All the compounds which were active in the glucose uptake assay were found to also be 
active in the complex I assay. The parent molecule, RTC1, had an IC50 value of 27 μM, 
which is the concentration of that compound required to give 50% inhibition of complex 
I activity (Figure 135).  
 
Figure 135: Plot of RTC1-induced inhibition of NADH oxidation in disrupted 
mitochondria showing the IC50 to be 27 μM. 
204 
 
Some compounds had a much higher IC50 value, (e.g. compound 4), where other 
compounds had a lower IC50 value (e.g. compound 22). From the active compounds, the 
compound with the highest IC50 value of 702 μM was compound 30, which contained a 
methyl group instead of the alkyl chain and a thiophene ring. This means it would take 
28 times the concentration of RTC1 for this compound to have the same effect of 
inhibiting 50% of complex I activity. The lowest IC50 value of 4 μM was reported with 
compound 18, the analogue of RTC1 without the carbonyl group. This value was very 
close to the IC50 value of the positive control, rotenone, which had an IC50 value of 3.14 
μM.43 Of all the compounds which were active in the glucose uptake assay with three 
stars significance, twelve of them had a similar or lower IC50 value to RTC1. These 




  Complex I assay results of the inactive arylpiperazine compounds 
A number of the aryl piperazine compounds that I had synthesised were not active in 
the glucose uptake assay. Even though this was the case, they were evaluated in the 
complex I assay as we had material to hand. To our surprise, all of the inactive 
compounds showed some activity in the complex I inhibition assay (Table 19). One 
possible explanation is that in the whole cell glucose uptake assay, the compounds could 
not pass the cell membrane, avoid efflux mechanisms, or survive the cells internal 
“machinery” (e.g. hydrolysis, enzyme catalysed degradation) and hence were 
inactive.96,106  
In an inhibition assay, such as the complex I assay, these barriers and problems are 
removed, and this could allow the compounds to access the complex I active site and 
inhibit its activity. Hollenback et al. have reported a similar trend in their research where 
they tested substrate specificity in membrane and whole cell assays.109 A research by 
Hernandez et al. also compared enzyme assays with a whole cells based assay. They 
concluded that whole cell based assays have the advantage of only selecting compounds 
that are able to penetrate cells and reach the intracellular targets.110 




































As previously mentioned, all the compounds showed activity in the complex I assay. 
However, only three compounds were reported to have an IC50 value lower than RTC1, 
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namely compounds 10, 11, and 21. Compounds 8 and 31 had similar values to RTC1, and 




4.5 Glucose uptake results of the pyrazolopyrimidinone bicycle family 
As mentioned before, a family of pyrazolopyrimidinones, analogues of RTC53 (Figure 
136) were synthesised in order to evaluate their activity in the glucose uptake assay and 
study the affect different structural variations had on activity levels. 
 
     Figure 136: Structure of RTC53. 
The 32 compounds already discussed in chapter 3 were tested by myself for biological 
activity in the glucose uptake assay. These compounds were added to the library of 
compounds synthesised and tested by previous group members. Structural variations in 
this family of compounds were divided into three categories as discussed previously 
(Figure 137). The first subfamily was categorised as variations on both R and R1 sites. 
The second category consisted of variations on the R site only (aromatic bis-CF3 group). 
The third category consisted of varying the R1 site (isopropyl group). The results from 
the glucose uptake assay were divided up into the same three categories.  
 







 Glucose uptake results for pyrazolopyrimidinone category 1: variations 
at both R and R1 sites  
Category 1 consisted of variations at both the R and R1 sites on the bicycle core. 
Variations at the R site consisted of a phenyl ring, substituted aromatic rings with 
electron donating and electron withdrawing groups, and alkyl groups. Variations to the 
R1 site consisted of alkyl groups, heterocyclic rings, phenyl ring, or substituted aromatic 
rings with electron donating and electron withdrawing groups. The effect of these 
variations on glucose uptake in the cells is shown in Table 20). 
Table 20: Glucose uptake results for pyrazolopyrimidinone category 1 variations. 
 
Compound R R1 Glucose Uptake Result 
   
Fold change ± 
SEM 
Active (Y) with 
stars significance 
or inactive (N) 
RTC53a,c 
 
iPr 1.99 ± 0.15 Y (***) 
43 (MK62) Ph Me 0.80 ± 0.11 N 
44 (MK59) Ph tBu 0.79 ± 0.14 N 
41 (MK56) Ph 
 
1.10 ± 0.26 N 
42 (MK55) Ph 
 
0.96 ± 0.16 N 
40 (MK15) Ph Ph 0.90 ± 0.10 N 
45 (MK58) Ph 
 
0.95 ± 0.29 N 
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46 (MK7) Ph 
 
1.10 ± 0.26 N 
47 (MK8) Ph 
 
0.61 ± 0.04 N 
48 (MK9) Ph 
 
0.85 ± 0.18 N 
JW-06-006b,c Me Me 0.76 ± 0.04 N  
52 (MK2) 
 
Me 1.20 ± 0.18 N 
JW-06-012b,c 
 
Me 0.90 ± 0.08 N 
RTC54a,c Et tBu 1.08 ± 0.04 N 
JW-04-053b,c iPr tBu 0.96 ± 0.07 N 
RTC55a,c tBu tBu 0.53 ± 0.05 N 
JW-04-041b,c Me Ph 0.95 ± 0.05 N 
49 (MK61) 
 
Ph 1.16 ± 0.06 N 
50 (MK66) 
 
Ph  1.23 ± 0.07 Y (*) 
51 (MK63) 
 
Ph   1.27 ± 0.07 Y (*) 
aCompounds synthesised by Dr Robert Devin.  
bCompounds synthesised by Dr John Walsh. 
cCompounds tested by Dr Siobhan Leonard. 
The glucose uptake results from category 1 variations showed that very few compounds 
were active meaning that variations at both R and R1 sites resulted a loss in activity 
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compared to RTC53. The first nine compounds after RTC53 in Table 20 had a phenyl ring 
at the R site, with variations at the R1 site that included alkyl groups (e.g. methyl, 
compound 43, and tert-butyl, compound 44), heterocyclic rings (e.g. furan, compound 
41, and thiophene, compound 42), a phenyl ring (compound 40), and substituted 
aromatic rings (compounds 45-48).  
None of these derivatives of RTC53, containing a phenyl ring at the R site, showed 
activity in the glucose uptake assay. This correlates well with the loss of activity for found 
for pyrazolopyrimidinone category 2 variations (section 4.5.2), where the R site 
consisted of a phenyl group and the R1 site remained as an isopropyl group. 
The next three compounds contained a methyl group at the R1 site and a methyl (JW-
06-006), aromatic ring bis substituted with meta methyl groups (compound 52), or an 
aromatic ring, with multiple fluoro substituents, (JW-06-012) at the R site. These three 
compounds also showed a loss of activity in the glucose uptake assay. This correlates 
well with the loss of activity found with a subset of the pyrazolopyrimidinone category 
3 variations, where a methyl group was placed at the R1 site. 
The next three compounds contained a tert-butyl group at the R1 site and an ethyl group 
(RTC54), isopropyl group (JW-04-053) or a tert-butyl group (RTC55) at the R site. All 
these compounds showed loss of activity. Although the tert-butyl group in the R1 site 
resulted in activity in category 3 variations, activity was lost when the aromatic 
bistrifluoromethyl group at the R site was substituted with an ethyl, isopropyl or another 
tert-butyl groups, as was the case in the pyrazolopyrimidinone category two variations.  
The final four compounds contained a phenyl ring at the R1 site, while the R site 
consisted of a methyl (JW-04-041), a para nitro aromatic ring (compound 49), para 
methoxy aromatic ring (compound 50), and a tetrafluoro substituted aromatic ring 
(compound 51). These final two compounds, compounds 50 and 51, were the only 




Figure 138: Structure of active compounds in category 1 variations at the R and R1 site. 
Both compounds had a smaller fold change than RTC53 and one star significance (Figure 
139). This was also interesting as derivatives containing both groups in category 2 
variations showed no activity in the glucose uptake assay when the R1 contained an 










































































Figure 139: Glucose uptake results of RTC53, compound 50, and compound 51 in 
comparison with DMSO as the control and insulin as the positive control. 
In summary, only two compounds were active in the glucose uptake assay of category 1 
variations at the R and R1 site. The glucose uptake results for pyrazolopyrimidinone 
category 1 variations can be better discussed in combination with results for category 2 
and 3 variations.  
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 Glucose uptake results for pyrazolopyrimidinone category 2: variations 
at the R site (the bistrifluoromethyl substituted aryl site) 
The second category consisted of only variations at the R site (the bistrifluoromethyl 
substituted aryl site) of the bicycle core. In RTC53, this group consists of an aromatic ring 
with bistrifluoromethyl groups at both meta positions. Derivatives of RTC53 in category 
2 all had the isopropyl group at R1, with variations at the R site, which included a 
hydrogen, alkyl groups, a phenyl ring, heterocyclic rings, or substituted aromatic rings 
(with electron donating and electron withdrawing groups). The glucose uptake assay 
results for pyrazolopyrimidinone category 2 compounds are shown in Table 21. 
Table 21: Glucose uptake results for pyrazolopyrimidinone category 2 variations. 
 
Compound R Glucose Uptake Result 
  Fold change ± SEM 
Active (Y) with 
stars significance 
or inactive (N) 
RTC53a,c 
 
1.99 ± 0.15 Y (***) 
RTC80a,c H 0.99 ± 0.07 N 
RTC60a,c Me 2.04 ± 0.43 Y (*) 
RTC87a,c Et 1.21 ± 0.09 N 
RTC63a,c nPr 0.99 ± 0.01 N 
RTC58a,c iPr 1.19 ± 0.17 N 
RTC57a,c iBu 0.83 ± 0.15 N 





1.10 ± 0.06 N 
JW-06-011b,c 
 
1.20 ± 0.08 N 
MK26 
 
1.14 ± 0.03 N 
JW-01-023b,c 
 
1.32 ± 0.19 N 
JW-04-063b,c 
 
1.03 ± 0.21 N 
RTC84a,c 
 
2.08 ± 0.20 Y (***) 
JW-01-024b,c 
 
  1.12 ± 0.11 N 
JW-01-018b,c 
 
  1.95 ± 0.22 Y (**) 
JW-01-022b,c 
 
  2.01 ± 0.20 Y (***) 
JW-01-037b,c 
 
  1.01 ± 0.05 N 
JW-06-022b,c 
 
   1.11 ± 0.05 N 
    58 (MK6) 
 





   1.41 ± 0.53 N 
JW-04-067b,c 
 
  1.19 ± 0.19 N 
60 (MK13) 
 
  0.68 ± 0.07 N 
61 (MK49) 
 
  1.19 ± 0.40 N 
JW-04-022b,c 
 
  0.80 ± 0.08 N 
    
aCompounds synthesised by Dr Robert Devin. 
bCompounds synthesised by Dr John Walsh. 
cCompounds tested by Dr Siobhan Leonard.  
The glucose uptake results of category two variations at the R site showed that most 
changes at this site result in the loss of biological activity. The aromatic ring with the 
bistrifluoromethyl groups in the parent molecule RTC53 provides a steric bulk, which 
could be important for binding in the active site of the biological target. Furthermore, 
the trifluoromethyl groups contribute to the overall lipophilicity of a compound, which 
governs the compound’s ability to pass through a lipid membrane and dock within a 
hydrophobic protein cavity. Adequate lipophilicity can help compounds to permeate 
through a lipid membrane.111 The absence of the trifluoromethyl groups could result in 
a drop in lipophilicity and consequently a compound may find it difficult pass through 
the cell membrane and consequently may not reach the active site. The hydrophobic 
nature of the bistrifluoromethyl aryl ring may also play an important role in binding to a 
hydrophobic pocket in the active site.69 Trifluoromethyl groups are also strongly 
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electron withdrawing in nature and this electronic effect may also have a role to play in 
binding at an active site.66  
Replacing the substituted aromatic ring (R site) in RTC53 with a hydrogen (RTC80) 
resulted in a loss in activity, but activity was maintained with a methyl group at the R 
site (RTC60). This positive result may be due to the hydrophobicity of the methyl group. 
However, when other alkyl groups were attempted (RTC87, RTC63, RTC58, and RTC57), 
the same effect was not observed, and loss of activity was reported.  
Loss of activity also occurred with a phenyl ring (RTC61) or a pyridine ring (JW-01-005) 
at the R site, suggesting that substituents on the ring could be important for activity. We 
postulated that these substituents might need to be hydrophobic and/or electron 
withdrawing in nature and hence systematically generated and evaluated a number of 
aryl rings with a variety of substituents. Substituents on the aromatic ring that were 
explored included derivatives with an ortho substituted electron donating 
dimethylamine group (JW-06-011), and meta substituted electron withdrawing 
halogens such as fluorine (MK26), chlorine (JW-01-023), and iodine (JW-04-063). None 
of these derivatives showed activity in the glucose uptake assay. When an aryl ring with 
a single meta substituted trifluoromethyl group was placed at the R site, activity was 
shown with three stars significance.  This result initially supported our theory that a 
hydrophobic substituent was needed and may suggest that both electron withdrawing 
and hydrophobic properties may be required.  
Compounds with para substituted halogens on the aromatic ring were also tested for 
activity. The compound containing the aromatic ring with para chlorine (JW-01-024) did 
not show any activity, whereas activity was reported for para bromine derivative (JW-
01-018) and para iodine (JW-01-022) substitutions.  Perhaps the size of the bromo and 
iodo groups, coupled with their electron withdrawing effect, may be important and the 
activity shown may be due to the steric properties that are not present with chlorine.  
Other compounds that contained a para substituted aromatic ring at the R site consisted 
of the derivative with the para methoxy group (JW-01-037) and para dimethylamine 
group (JW-06-022). These electron donating groups did not show activity in the glucose 
uptake assay.  
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After monosubstituted aromatic rings were tested, bis substituted aromatic rings were 
evaluated at the R site, with substituents in the two meta positions of the aromatic ring. 
The derivatives containing aromatic rings with bis substituted alkyl groups, such as 
methyl (compound 58) or ethyl (compound 59), showed a loss of activity from RTC53. 
This was a little surprising as we thought that the hydrophobic nature of the methyl and 
ethyl substituents may be sufficient to maintain activity. However, methyl and ethyl 
groups are not electron withdrawing in nature and are instead slightly electron 
donating. Loss of activity was also found for derivatives containing bis meta chloro 
substituents (JW-04-067), bis meta methoxy substituents (compound 60), and bis meta 
nitro substituents (compound 61). Compound 61 was particularly interesting as the two 
nitro groups are very electron withdrawing but are not hydrophobic in nature. The loss 
of activity from these five compounds may be due to a loss of hydrophobicity in some 
cases, a loss of electron withdrawing ability in others, and perhaps a combination of 
both effects. The final compound containing a tetrafluoro aromatic ring also showed a 
loss of activity compared to RTC53.  
In summary, five compounds from pyrazolopyrimidinone category 2 were active in the 
glucose uptake assay (Figure 140). The R site of these compounds contained a methyl 
group (RTC60), an aromatic ring with a meta substituted trifluoromethyl group (RTC84), 
an aromatic ring with bis meta trifluoromethyl substituents (RTC53), an aromatic ring 
with a para substituted bromine (JW-01-018), and an aromatic ring with a para 
substituted iodine (JW-01-022). The outlier of this group may be RTC60. The other four 
compounds contained substituted aryl rings with large, electron withdrawing groups. It 
could be suggested that a substituted aryl ring, bearing sterically bulky electron 
withdrawing groups may be important for activity. The hydrophobicity of that 
substituent may have a role to play as the use of the relatively large electron 








 Glucose uptake results for pyrazolopyrimidinone category 3: variations 
at the R1 site (the isopropyl group site) 
The third category consisted of only variations at the R1 site pyrazolopyrimidinone 
bicycle, which is an isopropyl group in the parent molecule, RTC53. Derivatives of RTC53 
were made in where the aromatic bis-CF3 group was maintained at the R site, with 
variations to the R1 site that included alkyl groups, phenyl ring, heterocyclic rings, or 
substituted aromatic rings with electron donating and electron withdrawing groups. A 
summary of the glucose uptake results for the pyrazolopyrimidinone category 3 
compounds can be found in Table 22. 
Table 22: Glucose uptake results for pyrazolopyrimidinone category 3 variations. 
  
Compound R1 Glucose Uptake Result 
  Fold change ± SEM 
Active (Y) with 
stars significance 
or inactive (N) 
RTC53a,c  iPr 1.99 ± 0.15 Y (***) 
JW-04-054b,c Me 0.94 ± 0.06 N 
JW-06-001b,c Et 1.29 ± 0.02 Y (**) 
JW-01-033b,c nBu 1.91 ± 0.10 Y (***) 
JW-01-017b,c  iBu 2.34 ± 0.29 Y (**) 
RTB69a,c tBu 1.28 ± 0.05 Y (***) 
RTC91a,c Ph 1.67 ± 0.09 Y (**) 
62 (MK80) 
 





1.92 ± 0.58 Y (*) 
64 (MK82) 
 
1.67 ± 0.81 Y (*) 
65 (MK81) 
 
1.85 ± 1.00 Y (*) 
66 (MK83) 
 
0.77 ± 0.42 N 
67 (MK71) 
 
1.90 ± 1.19 Y (*) 
68 (MK72) 
 
0.89 ± 0.29 N 
69 (MK75) 
 
3.84 ± 2.23 Y (***) 
70 (MK73) 
 
0.79 ± 0.10 N 
71 (MK74) 
 
1.33 ± 0.61 N 
72 (MK76) 
 
3.13 ± 1.35 Y (*) 
73 (MK78) 
 
1.36 ± 0.97 Y (*) 
74 (MK84) 
 
1.51 ± 1.09 Y (*) 
75 (MK85) 
 
0.86 ± 0.37 N 
76 (MK86) 
 
0.84 ± 0.33 N 
aCompounds synthesised by Dr Robert Devin. 
bCompounds synthesised by Dr John Walsh. 
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cCompounds tested by Dr Siobhan Leonard.  
The isopropyl group at the R1 site in RTC53 could increase the hydrophobicity of the 
compound and bind in a suitable hydrophobic pocket within the target active site. When 
this group was replaced by a methyl group (JW-04-054), it was seen that activity was 
lost, possibly due to the methyl group not binding strongly in a hydrophobic pocket due 
to its shorter chain length and reduced steric bulk in comparison to the isopropyl group. 
However, activity was reported with the derivative containing an ethyl group (JW-06-
001) with a smaller fold change than RTC53 and with two stars significance. This may 
have been due to the smaller reduction in length and steric bulk for the ethyl group. The 
same effect can be seen with the derivative containing n-butyl group (JW-01-033), which 
has a similar fold change to RTC53 and with three stars significance. The other 
compounds with butyl groups, JW-01-017 and RTB69, at R1 also showed similar activity 
to RTC53. These results support the suggestion that a hydrophobic group with sufficient 
steric bulk may be required at R1 for activity.  
Replacing the isopropyl group at R1, with a somewhat hydrophobic and sterically 
substantial phenyl ring did generate an active compound, albeit with a slightly slower 
fold change in activity.  This result could suggest that an alkyl group is not absolutely 
required at R1 and that a suitably hydrophobic and sterically bulky group can generate 
an active compound.  
The next attempts consisted of compounds containing an aromatic ring with 
substituents at the ortho, meta, and para positions. The two derivatives containing an 
aromatic ring with ortho substituents, i.e. ortho chloro (compound 62) and ortho 
methoxy (compound 63), showed activity in the glucose uptake assay with a fold change 
similar to RTC53. The same effect was seen for aromatic rings with chloro and methoxy 
groups in the meta position, compound 64 and compound 65 respectively. For these 
two compounds a fold change similar to RTC53 was observed. Another derivative, 
compound 66, contained a polar electron withdrawing nitro group in the meta position. 
However, this compound showed a loss of activity in the glucose uptake assay and could 
support the theory that polar groups at R1 will lead to loss in activity and that a 
hydrophobic group at the R1 site is preferred. 
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Seven derivatives were tested which contained an aromatic ring with para substituents. 
The first derivative consisted of an aromatic ring with a para methyl group (compound 
67), which is hydrophobic in nature and showed activity similar to RTC53. The same 
effect was not observed when the methyl group was replaced by a fluorine (compound 
68) as activity was lost. However, with the derivative containing an aromatic ring with a 
para chlorine (compound 69), not only did it show activity, but it also had a much higher 
fold change than RTC53 (almost twice). This compound was found to be the most active 
compound of the pyrazolopyrimidinone bicycle family to date. This level of activity for 
compound 69 did not aligned well with our theory that a hydrophobic group is preferred 
at R1.  
The next two compounds consisted of an aromatic ring with a para bromine (compound 
70) and para methoxy (compound 71) groups but neither showed activity. The next 
derivative contained an aromatic ring with a para nitro group (compound 72) was not 
expected to be active due to the polar electron withdrawing nature of the nitro group 
and a similar result was expected as found with compound 66 where the nitro group 
was in the meta position. To our surprise, compound 72 was active and showed a fold 
change higher than that found for RTC53. The final compound containing an aromatic at 
R1 was one with a para trifluoromethyl substituent (compound 73). We had expected 
this compound to be active, and it was albeit with a lower fold change than RTC53.  
The final three compounds tested in the pyrazolopyrimidinone category 3 variations 
consisted of derivatives of RTC53 with a heterocyclic ring instead of the isopropyl group 
at the R1 site. The first compound consisted of a furan ring (compound 74), which 
showed activity with a fold change lower than RTC53. The other two compounds 
contained a thiophene ring (compound 75) and pyridine ring (compound 76) at R1, and 
neither compound showed activity in the glucose uptake assay.  
In summary, fifteen compounds from the pyrazolopyrimidinone category 3 subfamily 
were active in the glucose uptake assay, while seven compounds were inactive. 
Derivatives containing an alkyl group at the R1 site were all active, except the derivative 
which contained the smaller methyl group. Derivatives containing a phenyl ring or a 
substituted aromatic ring at the R1 site were also all active, with initial results suggesting 
that a hydrophobic non-polar nature being preferred.  However, this theory did not 
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always ring true as compounds with a para chloro and para nitro aryl ring at R1 showed 
significant levels of activity in the glucose uptake assay, with fold changes greater than 
that found for RTC53.  Finally, heterocyclic ring substitutions at R1, did not appear to be 
that well tolerated with only the furan derivative showing activity, and both the 
thiophene and pyridine derivatives proving to be inactive.  
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4.6 Complex I assay results for the pyrazolopyrimidinone bicycle family 
Only three compounds have been tested so far in the complex I assay to check whether 
they can inhibit complex I. These compounds were tested by Dr Siobhan Leonard. The 
parent molecule (RTC53) was tested along with the derivative containing a tert-butyl 
group instead of the isopropyl group (RTB69), and the derivative containing the isobutyl 
group (JW-01-017) (Figure 140). All three of these compounds were active in the glucose 
uptake assay. 
 
Figure 141: Structure of compounds tested in the complex I assay from the 
pyrazolopyrimidinone bicycle family. 
These three compounds were shown to be inactive in the complex I assay which 
suggested that this family may increase the uptake of glucose from the cells through a 
different mechanism, other than the inhibition of complex I. It is suspected that 
pyrazolopyrimidinones may still result in AMPK activation through a different 
mechanism. Future work in this project can focus on determining the pathway by which 




4.7 Conclusion  
A structure activity relationship study was performed through the biological evaluation 
of compounds from both the arylpiperazine and pyrazolopyrimidinone families using the 
glucose uptake assay and NADH : ubiquinone oxidoreductase (complex I) assay. The goal 
of this study, and indeed this project, was to explore the relationship between chemical 
structure and biological activity, and how changes in structure can generate more or less 
active compounds. The biological evaluation involved a whole cell functional assay to 
determine a given compounds ability to stimulate glucose uptake, as well as the enzyme 
inhibition assay to determine if compounds could inhibit complex I activity. Using both 
these assays, we were able to establish active compounds, which have the potential of 
developing into anti-diabetic agents. 
The glucose uptake assay, i.e. the whole cell assay, measured the amount of tritiated 
(3H) deoxy-2-glucose taken up by C2C12 mouse muscle cells and quantified the fold 
change using a protein assay to determine the number of cells present. The complex I 
assay, i.e. the enzyme inhibition assay, determined a compound’s ability to inhibit NADH 
dehydrogenase, complex I of the electron transport chain, by measuring the change in 
ubiquinone absorbance.  
The arylpiperazine family consisted of analogues of the hit compound RTC1, where 
structural variation occurred at five sites (A-E) (Figure 142).  
 
Figure 142: Structure of RTC1 with variations sites, A-E. 
Site A consisted of variations of the aryl group of RTC1. Three of the four active 
compounds from site A variations contained a trifluoromethyl group. This suggests that 
this group is important for biological activity. Trifluoromethyl groups are large, electron 
withdrawing, and hydrophobic. It was interesting to note that removal of the CF3 group 
resulted in a reduction in activity, as did moving it from the para to the ortho position.  
Replacement of the para CF3 group with a para NO2 group, which like the CF3 group is 
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electron withdrawing but less hydrophobic, also resulted in loss of activity, which might 
point to an important hydrophobic role for the CF3 group. This theory might gain some 
support from the compound where the entire para CF3 aryl ring was replaced with the 
hydrophobic cyclohexyl ring. This cyclohexyl derivative was active in the glucose uptake 
assay, albeit with reduced activity. The trifluoromethyl group could play a key role by 
binding to a hydrophobic pocket of the target protein and may also have a very 
important role in aiding transport across cell membranes and cellular uptake.68 
Variations at the piperazine ring (site B) of RTC1 showed some mixed results as 
replacement of the piperazine ring with either a piperidine ring or a hydrazine motif 
generated active compounds in the glucose uptake assay. Although, the hydrazine 
containing compound was significantly less active than the parent RTC1. Replacement 
of the piperazine with a simple amide bond motif resulted in complete loss of activity. It 
is therefore suggested that site B should be a saturated six membered heterocyclic ring, 
such as a piperazine or piperidine ring. Replacing the carbonyl group (site C) of RTC1 
with a CH2 also appeared undesirable, as while the resulting compound was active, its 
activity levels were lower than RTC1. It was concluded that the carbonyl group improves 
biological activity and its presence is important, but perhaps not absolutely essential. 
Compounds synthesised with variations on the alkyl chain (site D) contained alkyl chains 
of different lengths and various substituents on the γ-CH2. It was concluded that the 
alkyl chain in RTC1 is important for biological activity as removal of it resulted in a loss 
of activity. An optimal alkyl chain length appeared to be three carbons in length. The 
addition of motifs to the chain, such as a carbonyl or hydroxyl groups, could result in 
additional substrate-target interactions and this may be the reason behind their drop in 
activity. 
Two compounds were synthesised with variations at site E of RTC1, the thiophene ring. 
One compound contained a pyrazole ring and the other a methyl group. Both 
compounds showed activity, but at lower levels than that of RTC1. It was concluded that 
a thiophene ring may be important, but not be essential, for activity, and that 
alternatives to a thiophene ring may result in reduced activity. 
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Combinations of structural variations on multiple sites were carried out on a few 
compounds. Although nine compounds maintained activity, they all resulted in a lower 
activity than RTC1. Overall, RTC1 still remained the most active compound in this family.  
All the active and inactive compounds of this family were tested in the complex I assay 
to test their ability to inhibit complex I. All the active compounds from the glucose 
uptake assay were also found to be active in the complex I assay, with some variation in 
activity levels. To our surprise, some of the inactive compounds from the glucose uptake 
assay were found to have some activity in the complex I assay. This apparent 
contradiction may be as a result of the difference between a whole cell functional assay 
and an inhibition/binding assay. With a whole cell assay, the compound being tested 
must pass through the cell membrane barrier, get taken up by the cell, and survive the 
internal workings of the cell in order to reach the protein target and exert its biological 
effect. These barriers are not in place for inhibition/binding assays, where the 
compounds have direct access to the protein target. As such, some compounds that are 
not active in a whole cell assay, for reasons of cell permeability or enzymatic 
degradation, may show a positive result in an inhibition/binding assay where these 
challenges are not present. The two compounds which were active in the glucose uptake 
assay and had the lowest IC50 values were compounds 18 and RTC194.  
The pyrazolopyrimidinone bicycle family consisted of analogues of RTC53 where 
variations were carried out on the bis-CF3 aryl ring (R site) and the isopropyl group (R1 
site). Compounds were categorised as variations on both sites (category 1), variations 
on the R site (category 2), and variations on the R1 site (category 3) (Figure 143).  
 




The glucose uptake results from category 1 variations showed that compounds which 
contained a phenyl ring at the R site and various substituents at the R1 site did not show 
activity. Similarly, compounds containing a methyl group or a t-butyl group at the R1 site, 
while varying the R site, also reported a loss in activity. Four compounds contained a 
phenyl ring at the R1 site, with variations at the R site. Two of these compounds were 
inactive, where two were active. Therefore, the only two active compounds in this 
category were compounds 50 and 51 (Figure 144). Compound 50 contained a para 
methoxy aromatic ring on the R site, and a phenyl ring on the R1 site. Compound 51 
contained a tetrafluoro substituted aromatic ring on the R site, and also a phenyl ring 
on the R1 site.  
 
Figure 144: Structure of compounds 50 and 51. 
It was observed from the glucose uptake results of category 2 variations at the R site 
that most changes at this site resulted in the loss of biological activity. This could be due 
to the loss of steric bulk provided by the aromatic ring with the bistrifluoromethyl groups 
in the parent molecule RTC53, which could be important for binding in the active site of 
the biological target. As was previously mentioned with the arylpiperazine family, the 
absence of the trifluoromethyl groups could also result in a drop in 
hydrophobicity/lipophilicity and consequently a compound may lose some ability to 
bind in a hydrophobic pocket of the target active site and/or find it difficult to pass 
through the cell membrane. Trifluoromethyl groups are also strongly electron 
withdrawing in nature and this electronic effect may also have a role to play in binding 
at an active site.  
All the compounds containing an alkyl group at the R site in category 2 variations, similar 
to category 1 variations, showed a loss of activity, except for the compound containing 
a methyl group (RTC60, Figure 145). This was surprising as compounds with a methyl 
group at the R site in category 1 variations, (compound 43 and JW-06-006, Figure 145) 
229 
 
did not show activity. The compound containing a phenyl ring at the R site in category 2 
(RTC61) also showed a loss in activity, which correlated with compounds from category 
1 that also contained a phenyl ring at the R site.  
 
Figure 145: Structure of RTC60, compound 43, and JW-06-006. 
Out of the remaining compounds in category 2, those containing a substituted aryl or 
pyridine ring at the R site all showed a drop in activity with the exception of three 
compounds (RTC84, JW-01-018, JW-01-022, Figure 146). Compound RTC84 contained 
an aryl ring with a single meta substituted trifluoromethyl group at the R site and 
showed strong activity. This result supported the theory that a hydrophobic substituent 
was needed and may suggest that both electron withdrawing and hydrophobic 
properties may be required. Compounds containing para substituted aromatic rings 
with bromo (JW-01-018) and iodo (JW-01-022) groups at the R site were also active 
(Figure 146). It could be suggested that the steric properties of these halogens, coupled 
with their electron withdrawing effect, were important for biological activity. 
 
Figure 146: Structure of RTC84, JW-01-018, and JW-01-022. 
More compounds were active in category 3 than category 2. This suggested that 
variations at the R1 site are a lot more tolerable than those at the R site. In RTC53, the 
isopropyl group at the R1 site could increase the hydrophobicity of the compound and 
bind in a suitable hydrophobic pocket within the target active sites. Activity was 
reported with compounds where this group was replaced by alkyl groups such as an 
ethyl, n-butyl, t-butyl, and isobutyl groups, but not with a methyl group. These results 
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support the suggestion that a hydrophobic group with sufficient steric bulk may be 
required at R1 for activity.  
Replacing the isopropyl group at R1 with a somewhat hydrophobic and sterically 
substantial phenyl ring in category 3 variations did generate an active compound, albeit 
with a slightly lower fold change in activity than RTC53. This correlated with the two 
active compounds from category 1 variations which also had a phenyl ring at the R1 site. 
This result could suggest that an alkyl group is not absolutely required at R1 and that a 
suitably hydrophobic and sterically bulky group can generate an active compound. 
Compounds containing aromatic rings with methoxy or chloro groups, in the ortho or 
meta position, in the R1 site in category 3 also showed activity in the glucose uptake 
assay. 
The same result was not observed with an aromatic ring containing a polar electron 
withdrawing nitro group in the meta position as it resulted in a loss of activity. This result 
supported the theory that polar groups at R1 could lead to loss in activity and that a 
hydrophobic group at the R1 site is preferred. However, this theory was not supported 
with the derivatives containing an aromatic ring with a para chlorine or para nitro 
groups, which showed activity and had a higher fold change than RTC53. The compound 
containing a para chlorine substituted aromatic ring (compound 69, Figure 147) was 
found to be the most active compound of the pyrazolopyrimidinone bicycle family to 
date. The derivatives containing an aromatic ring with a para methyl group and para 
trifluoromethyl group at R1 also showed activity, as did the derivative containing a furan 
ring at the R1 site. This was the only category 3 compound with a heterocycle at R1 that 
showed activity, those with a thiophene or pyridine ring at R1 were inactive.  
 
Figure 147: Structure of compound 69. 
Three compounds of the pyrazolopyrimidinone bicycle family (RTC53, RTB69, and JW-
01-017), which were active in the glucose uptake assay, were tested in the complex I 
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assay and shown to be inactive. This suggests that this family may increase the uptake 
of glucose from the cells through a different mechanism other than the inhibition of 











5.1 General information 
Reagents and reactants which were commercially available were purchased from Sigma 
Aldrich, Fluorochem or Alfa Aesar, and used without further purification.  
NMR spectra were recorded using Bruker Ascend 500 spectrometer at 293 K operating 
at 500 MHz for the 1H nucleus, 126 MHz for the 13C nucleus, and 471 MHz for the 19F 
nucleus. All chemical shifts were referenced relative to the relevant deuterated solvent 
residual peaks or TMS. Deuterated solvents used were CDCl3, MeOD, CD3CN and DMSO. 
Assignments of the NMR spectra were deduced using 1H NMR, 13C NMR, and 19F NMR, 
along with 2D-NMR experiments; 1H-1H COSY, 1H-13C HMBC, 1H-13C HSQC, and 1H-19F 
HOESY. The following abbreviations were used to explain the observed multiplicities; s 
(singlet), d (doublet), t (triplet), q (quartet), m (multiplet), bs (broad singlet), pt (pseudo 
triplet). Chemical shifts were given in ppm downfield from the internal standard and 
coupling constants were given in Hz. 13C NMR spectra were recorded with complete 
proton decoupling. 19F NMR spectra were recorded with proton and carbon decoupling. 
Microwave reactions were carried out using a CEM Discover Microwave Synthesizer with 
a vertically focused floor mounted infrared temperature sensor, external to the 
microwave tube. The 10 mL reaction vessels used were supplied from CEM and were 
made of borosilicate glass. Melting point analyses were carried out using a Stewart 
Scientific SMP11 melting point apparatus and are uncorrected.  
High-resolution mass spectrometry (HRMS) was performed in Maynooth University 
(MU) and the University of Bath (UoB). HRMS in MU was conducted on an Agilent-LC 
1200 Series coupled to a 6210 or 6530 Agilent Time-Of-Flight (TOF) mass spectrometer 
equipped with an electrospray source in both positive and negative (ESI+/−) modes.  
In UoB, HPLC-ESI-TOF analysis was conducted using an electrospray time-of-flight 
(MicrOTOF) mass spectrometer (Bruker Daltonik GmbH, Bremen, Germany), which was 
coupled to an Agilent HPLC stack (Agilent, Santa Clara, CA, United States) consisting of 
Agilent G1312A binary pump with G1329A autosampler and G1316A column oven. 
Analyses were performed in ESI positive and negative mode. The capillary voltage was 
set to 4500 V, nebulizing gas at 2.2 bar, drying gas at 10.2 L/min at 220°C in each case. 
The TOF scan range was from 50 – 500 or 50 -1500 mass-to-charge ratio (m/z). In each 
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case 10 µL injections were made. Data processing was performed using the Compass 
Data Analysis software scripts (Bruker Daltonik GmbH, Bremen, Germany). Samples 
were dissolved first in 1000 µL of MeOH (LC-MS grade, VWR), and then to aid additional 
solubilisation 200 µL H2O (LC-MS grade, VWR) was added. From this solution, 10µL was 
added to 990 µL of 70% MeOH to get to effective 8.33 µg/ml concentration (or 4.16 
µg/ml for the 0.5 mg initial sample). 
Infrared spectra were recorded on a Perkin Elmer Spectrum 100 FT-IR 
spectrophotometer using a smart endurance single bounce diamond, attenuated total 
reflection (ATR) cell or potassium bromide (KBr) disks. Spectra were recorded in the 
region of 4000–600 cm−1 and were obtained by the co-addition of 4 scans with a 
resolution of 4 cm-1.  
Scintillation counts were obtained using a Wallac MicroBeta scintillation counter (Perkin 
Elmer). Reactions were monitored with thin layer chromatography (TLC) on Merck Silica 
Gel F254 plates. Developed sheets were visualised using a portable UVltec CV-006 lamp 






5.2 Experimental procedures 
 General procedure for arylpiperazine synthesis using HOBt and TBTU 
coupling reagents  
Carboxylic acid, HOBt, TBTU, NEt3 and DMF were placed in a round-bottom flask and 
stirred at rt for 15 minutes. A second round-bottom flask was prepared containing amine 
and DMF. The resulting solution was transferred to the first round-bottom flask 
containing the carboxylic acid. The solution was stirred overnight. The DMF was 
removed under reduced pressure. The residue was purified using column 
chromatography. 
 Synthesis of 4-(thiophen-2-yl)-1-(4-(4-
(trifluoromethyl)phenyl)piperazin-1-yl)butan-1-one RTC1 (MK24) (1)  
     
Prepared from 1-(4-(trifluoromethyl)phenyl)piperazine (compound 2) (100 mg, 0.43 
mmol) and 4-(2-thienyl)butyric acid (50 µL, 0.34 mmol), using HOBt (58 mg, 0.43 mmol), 
TBTU (140 mg, 0.43 mmol), NEt3 (100 µL, 0.69 mmol) and DMF (3 mL) and following the 
general procedure described in section 5.2.1. The reaction mixture was stirred at rt 
overnight. DMF was removed under reduced pressure and the residue was purified 
using column chromatography (3:2, EtOAc:n-hexane) to give a white solid, 112 mg 
(86%).  
1H NMR: (500 MHz, CDCl3) δ 7.50 (d, J = 8.5 Hz, 2H, H2), 7.13 (d, J = 4.9 Hz, 1H, H11), 
6.94 – 6.89 (m, 3H, H3, H10), 6.81 (d, J = 2.2 Hz, 1H, H9), 3.85 – 3.72 (m, 2H*), 3.64 – 
3.49 (m, 2H*), 3.31 – 3.17 (m, 4H*), 2.93 (t, J = 7.2 Hz, 2H, H7), 2.40 (t, J = 7.4 Hz, 2H, 
H5), 2.13 – 2.00 (m, 2H, H6).*Piperazine. 1H NMR matches literature data.45 13C NMR: 
(126 MHz, CDCl3) δ 171.1 (C=O), 152.9 (C4), 144.4 (C8), 126.9 (C10), 126.6 (q, J = 3.7 Hz, 
C2), 125.6 (q, J = 271.3 Hz, CF3), 124.6 (C9), 123.3 (C11), 121.2 (q, J = 32.8 Hz, C1), 115.0 
(C3), 48.3 (C*), 48.1 (C*), 45.0 (C*), 41.1 (C*), 32.0 (C5), 29.3 (C7), 27.0 (C6). *Piperazine. 
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13C NMR matches literature data.45 19F NMR: (471 MHz, CDCl3) δ -61.4 (CF3). HR-MS: 
calcd for C19H21F3N2OSNa m/z: [M + H]+, 405.1219; found: 405.1228 [Diff(ppm) = 2.2]. 
Rf: 0.5 (3:2, EtOAc:n-hexane). IR (ATR): 2925 (C-H), 2853 (C-H), 1652 (C=O), 1611 (C=C), 
1328 (C-F), 1068 (C-N) cm-1. 
 Synthesis of 1-(4-(trifluoromethyl)phenyl)piperazine (MK17) (RD269) 
(2)  
    
Prepared from 1-chloro-4-(trifluoromethyl)benzene (1.59 mL, 11.91 mmol) and 
piperazine (2.00 g, 23.82 mmol) dissolved in NMP (5 mL) and heated at 200 °C for 30 
mins in a microwave reactor. The reaction mixture was purified using column 
chromatography (9:1, DCM:MeOH) to give a white solid, 417 mg (15%). 
1H NMR: (500 MHz, CDCl3) δ 7.48 (d, J = 8.8 Hz, 2H, H2), 6.92 (d, J = 8.8 Hz, 2H, H3), 3.28 
– 3.21 (m, 4H*), 3.07 – 3.00 (m, 4H*), 2.01 (bs, 1H, NH).*Piperazine. 1H NMR data 
matches literature data.112 13C NMR: (126 MHz, CDCl3) δ 153.7 (C4), 126.4 (q, J = 3.8 Hz, 
C2), 124.7 (q, J = 270.9 Hz, CF3), 120.6 (q, J = 32.6 Hz, C1), 114.6 (C3), 49.1 (C*), 45.9 
(C*).*Piperazine. 13C NMR data matches literature data.112 HR-MS: calcd for C11H14F3N2 
m/z: [M + H]+, 231.1104; found: 231.1106 [Diff (ppm) = 0.87]. Rf: 0.2 (9:1, DCM:MeOH). 
IR (ATR): 3257 (Ar C-H), 2836 (alkane C-H), 1668 (N-H), 1613 (C-C), 1323 (C-N), 1101 (C-




 Synthesis of methyl 9-oxo-9-(4-(4-(trifluoromethyl)phenyl)piperazin-1-
yl)nonanoate (MK16) (RTC56) (3)  
     
Anhydrous method:45 Prepared from methyl hydrogen azelate (48 mg, 0.23 mmol), BOP 
(114 mg, 0.26 mmol), anhydrous NEt3 (51.2 μL, 0.36 mmol) and anhydrous DCM (10 mL) 
in an oven-dried two-neck flask under a N2 atmosphere, and stirred at rt for 15 mins. 1-
(4-(trifluoromethyl)phenyl)piperazine (compound 2) (60 mg, 0.26 mmol) was added and 
the reaction mixture stirred under a N2 atmosphere. After 17 hrs, DCM was removed 
under reduced pressure and the resulting oil was acidified to pH = 3 using a 0.1 M 
aqueous HCl. The aqueous mixture was extracted with DCM (3 x 10 mL) and the organic 
layer washed with a saturated aqueous solution of NaHCO3 (3 x 10 mL) and brine (3 x 10 
mL). The organic layer was dried over MgSO4. Volatiles were removed under reduced 
pressure and the residue was purified using column chromatography (3:2, 
EtOAc:Pet.Ether) to give an off white solid, 41 mg (43%).  
Non-anhydrous method: Prepared from methyl hydrogen azelate (48 mg, 0.23 mmol), 
BOP (114 mg, 0.26 mmol), NEt3 (51.2 μL, 0.36 mmol) and DCM (10 mL) in a round-bottom 
flask and stirred at rt for 15 mins. 1-(4-(trifluoromethyl)phenyl)piperazine (compound 
2) (60 mg, 0.26 mmol) was added and the reaction mixture stirred for 17 hrs. Volatiles 
were removed under reduced pressure and the residue was purified using column 
chromatography (3:2, EtOAc:Pet.Ether) to give an off white solid, 53 mg (55%).  
1H NMR: (500 MHz, CDCl3) δ 7.49 (d, J = 8.6 Hz, 2H, H2), 6.92 (d, J = 8.7 Hz, 2H, H3), 3.85 
– 3.71 (m, 2H*), 3.72 – 3.52 (m, 2H*, 3H, OCH3), 3.39 – 3.14 (m, 4H*), 2.32 (dt, J = 29.1, 
7.5 Hz, 4H, H5, H11), 1.69 – 1.58 (m, 4H, H6, H10), 1.36 – 1.32 (m, 6H, H7, H8, 
H9).*Piperazine. 1H NMR matches literature data.45 13C NMR: (126 MHz, CDCl3) δ 174.3 
(ester C=O), 171.7 (amide C=O), 149.2 (C4), 126.5 (q, J = 3.3 Hz, C2), 124.5 (q, J = 269.7 
Hz, CF3), 121.2 (q, J = 32.8 Hz, C1), 115.0 (C3), 51.5 (OCH3), 48.5 (C*), 48.2 (C*), 45.2 (C*), 
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41.1 (C*), 34.1 (H11), 33.2 (H5), 29.3 (C8), 29.1 (C6), 29.0 (C7), 25.2 (C10), 24.9 (C6). 
*Piperazine. 13C NMR matches literature data.45 HR-MS: calcd for C21H30F3N2O3 m/z: [M 
+ H]+, 415.2203; found: 415.2217 [Diff (ppm) = 3.37]. Rf: 0.65 (3:2, EtOAc:Pet. Ether). IR 
(ATR): 2934 (Ar C-H), 1736 (ester C=O), 1614 (amide C=O), 1157 (C-N), 1102 (C-O) cm-1. 
 Synthesis of 1-(4-cyclohexylpiperazin-1-yl)-4-(thiophen-2-yl)butan-1-
one (MK43) (RTC13) (4)  
 
Prepared from 1-cyclohexylpiperazine (150 mg, 0.89 mmol) and 4-(2-thienyl)butyric acid 
(118 µL, 0.81 mmol) using HOBt (120 mg, 0.89 mmol), TBTU (285 mg, 0.89 mmol), NEt3 
(180 µL, 1.29 mmol) and DCM (6 mL) and following the general procedure described in 
section 5.2.1. The reaction mixture was stirred at room temperature overnight for 17.5 
hours. DCM was removed under reduced pressure and the residue was purified using 
column chromatography (9:1, DCM:MeOH) to give a red solid, 213 mg (82%). 
1H NMR: (500 MHz, CDCl3) δ 7.11 (dd, J = 5.1, 1.0 Hz, 1H, H11), 6.91 (dd, J = 5.1, 3.4 Hz, 
1H, H10), 6.79 (dd, J = 3.4, 1.0 Hz, 1H, H9), 3.70 – 3.55 (m, 2H*), 3.45 – 3.31 (m, 2H*), 
2.90 (t, J = 7.3 Hz, 2H, H7), 2.67 – 2.40 (m, 4H*), 2.40 – 2.32 (m, 2H, H5), 2.32 – 2.25  (m, 
1H, H4), 2.07 – 1.96 (m, 2H, H6), 1.90 – 1.73 (m, 4H, H3), 1.69 – 1.56 (m, 1H, H1), 1.31 – 
1.14 (m, 4H, H2), 1.14 – 1.04 (m, 1H, H1). *Piperazine. 1H NMR matches literature data.45 
13C NMR: (126 MHz, CDCl3) δ 170.8 (C=O), 144.5 (C8), 126.8 (C11), 124.6 (C10), 123.1 
(C12), 63.6 (C4), 49.3 (C*), 48.7 (C*), 45.9 (C*), 41.9 (C*), 32.0 (C5), 29.3 (C7), 28.8 (C3), 
27.1 (C6), 26.2 (C1), 25.8 (C2). *Piperazine. 13C NMR matches literature data.45 HR-MS: 
calcd for C18H29N2OS m/z: [M + H]+, 321.1995; found: 321.2005 [Diff(ppm) = 3.1]. Rf: 0.56 





 Synthesis of 4-(1H-Pyrazol-4-yl)-1-(4-(4-
(trifluoromethyl)phenyl)piperazin-1-yl)butan-1-one (MK69) (RTC193) 
(5)  
    
Prepared from 1-(4-(trifluoromethyl)phenyl)piperazine (compound 2) (100 mg, 0.43 
mmol) and 4-(1H-pyrazol-4-yl)butanoic acid (52 mg, 0.34 mmol), using HOBt (58 mg, 
0.43 mmol), TBTU (140 mg, 0.43 mmol), NEt3 (100 µL, 0.69 mmol) and DCM (3 mL)  and 
following the general procedure described in section 5.2.1. The reaction mixture was 
stirred at rt for 24 hours. DCM was removed under reduced pressure and the residue 
was purified using column chromatography (3:2, EtOAc:n-hexane) to give a brown solid, 
116 mg (93%). 
1H NMR: (500 MHz, CDCl3) δ 7.50 (d, J = 8.5 Hz, 2H, H2), 7.43 (s, 2H, H9 and H10), 6.91 
(d, J = 8.6 Hz, 2H, H3), 5.57 (bs, 1H, NH), 3.85 – 3.72 (m, 2H*), 3.64 – 3.54 (m, 2H*), 3.26 
(s, 4H*), 2.59 (t, J = 7.4 Hz, 2H, H7), 2.44 – 2.35 (m, 2H, H5), 2.00 – 1.90 (m, 2H, H6). 
*Piperazine. 1H NMR matches literature data45. 13C NMR: (126 MHz, CDCl3) δ 171.4 
(C=O), 152.9 (C4), 132.9 (C9 and C10), 126.5 (q, J = 3.9 Hz, C2), 124.6 (q, J = 271.3 Hz, 
CF3), 121.4 (q, J = 32.6 Hz, C1), 120.3 (C8), 115.0 (C3), 48.4 (C*), 48.1 (C*), 45.1 (C*), 41.2 
(C*), 32.3 (C5), 26.2 (C6), 23.6 (C7). *Piperazine. 13C NMR matches literature data45. HR-
MS: calcd for C18H21F3N4ONa m/z: [M + Na]+, 389.156; found: 389.1563 [Diff (ppm) = 
0.9]. Rf: 0.1 (3:2, EtOAc:n-hexane). IR (ATR): 3055 (N-H), 2947 (Ar C-H), 1649 (C=O), 1614 




 Synthesis of 1-(2-chloro-4-(trifluoromethyl)phenyl)piperazine (MK21) 
(RD20) (6)  
   
Prepared from 3-chloro-4-fluorobenzotrifluoride (100 μL, 0.75 mmol) and piperazine 
(129 mg, 1.5 mmol) dissolved in NMP (3 mL) and heated at 200 °C for 30 mins in a 
microwave reactor. The reaction mixture was purified using column chromatography 
(100% DCM to 8:2, DCM:MeOH) to give an orange oil, 124 mg (63%). 
1H NMR: (500 MHz, CDCl3) δ 7.61 (d, J = 1.4 Hz, 1H, H5), 7.47 (dd, J = 8.4, 1.4 Hz, 1H, H2), 
7.08 (d, J = 8.4 Hz, 1H, H3), 3.10 (s, 8H*), 2.78 (bs, 1H, NH).*Piperazine. 1H NMR data 
matches literature data113. 13C NMR: (126 MHz, CDCl3) δ 152.5 (C4), 128.6 (C-Cl), 127.9 
(q, J = 3.8 Hz, C5), 125.3 (q, J = 33.3 Hz, C-CF3), 124.7 (q, J = 3.9 Hz, C2)  123.6 (q, J = 272.2 
Hz, CF3),  120.2 (C3), 51.9 (C*), 51.4 (C*), 50.9 (C*), 45.9 (C*).*Piperazine. 13C NMR 
matches literature data45.  HR-MS: calcd for C19H20F3N2OSClNa m/z: [M + Na]+, 439.0829; 





 Synthesis of 1-(4-phenylpiperazin-1-yl)-4-(thiophen-2-yl)butan-1-one 
(MK38) (RTC162) (7)  
 
Prepared from 1-phenylpiperazine (100 µL, 0.64 mmol) and 4-(2-thienyl)butyric acid (84 
µL, 0.58 mmol) using HOBt (86 mg, 0.64 mmol), TBTU (205 mg, 0.64 mmol), NEt3 (129 
µL, 0.93 mmol) and DMF (5 mL) and following the general procedure described in section 
5.2.1. The reaction mixture was stirred at rt for 16.5 hrs. DMF was removed under 
reduced pressure and the residue was purified using column chromatography (3:2, 
EtOAc:n-hexane) to give a dark red oil, 142 mg (78%). 
1H NMR: (500 MHz, CDCl3) δ 7.30 – 7.23 (m, 2H, H3), 7.11 (d, J = 5.1 Hz, 1H, H11), 6.95 –  
6.85 (m, 4H, H1, H2, H10), 6.83 – 6.77 (m, 1H, H9), 3.81 – 3.70 (m, 2H*), 3.59 – 3.48 (m, 
2H*), 3.16 – 3.08 (m, 4H*), 2.92 (t, J = 7.3 Hz, 2H, H7), 2.43 (t, J = 7.3 Hz, 2H, H5), 2.05 
(p, J = 7.3 Hz, 2H, H6).*Piperazine. 1H NMR matches literature data45. 13C NMR: (126 
MHz, CDCl3) δ 171.0 (C=O), 151.0 (C4), 144.4 (C8), 129.2 (C3), 126.8 (C2), 124.5 (C9), 
123.2 (C11), 120.5 (C10), 116.6 (C1), 49.7 (C*), 49.4 (C*), 45.4 (C*), 41.5 (C*), 32.0 (C5), 
29.3 (C7), 27.0 (C6).*Piperazine. 13C NMR matches literature data45. HR-MS: calcd for 
C18H23N2OS m/z: [M + H]+, 315.1526; found: 315.1531 [Diff (ppm) = 1.59]. Rf: 0.65 (3:2, 




 Synthesis of 4-(thiophen-2-yl)-1-(4-(2-
(trifluoromethyl)phenyl)piperazin-1-yl)butan-1-one (MK41) (RTC20) (8)  
 
Prepared from 1-(2-(trifluoromethyl)phenyl)piperazine (83 µL, 0.43 mmol) and 4-(2-
thienyl)butyric acid (57 µL, 0.39 mmol) using HOBt (58 mg, 0.43 mmol), TBTU (139 mg, 
0.43 mmol), NEt3 (60 µL, 0.62 mmol) and DMF (4 mL) and following the general 
procedure described in section 5.2.1. The reaction mixture was stirred at rt for 22 hrs. 
DMF was removed under reduced pressure and the residue was purified using column 
chromatography (3:2, EtOAc:n-hexane) to give a colourless oil, 122 mg (82%). 
1H NMR (500 MHz, CDCl3) δ 7.64 (d, J = 7.9 Hz, 1H, H2), 7.56 – 7.48 (m, 1H, H4), 7.33 – 
7.21 (m, 2H, H3, H5), 7.12 (dd, J = 5.1, 1.1 Hz, 1H, H13), 6.92 (dd, J = 5.1, 3.4 Hz, 1H, H12), 
6.82 (dd, J = 3.3, 0.9 Hz, 1H, H11), 3.76 (bs, 2H*), 3.59 – 3.48 (m, 2H*), 2.97 – 2.82 (m, 
2H, H7, 4H*), 2.41 (t, J = 7.5 Hz, 2H, H9), 2.06 (p, J = 7.4 Hz, 2H, H8).*Piperazine. 1H NMR 
matches literature data45. 13C NMR: (126 MHz, CDCl3) δ 171.0 (C=O), 151.7 (d, J = 1.1 Hz, 
C6), 144.4 (C10), 132.8 (C3), 127.4 (q, J = 28.7 Hz, C1), 127.2 (q, J = 5.4 Hz, C2), 126.7 
(C12), 125.3 (C13), 124.4 (C11), 124.0 (C4), 123.9 (q, J = 273.7 Hz, CF3), 123.1 (C5) 53.7 
(C*), 53.0 (C*), 46.0 (C*), 42.0 (C*), 32.1 (C9), 29.3 (C7), 27.0 (C8).*Piperazine. 13C NMR 
matches literature data45. HR-MS: calcd for C19H22F3N2OS m/z: [M + H]+, 383.1399; 
found: 383.1406 [Diff (ppm) = 1.8]. Rf: 0.74 (3:2, EtOAc:n-hexane). IR (ATR): 2916 (C-H), 
1642 (C=O), 1312 (C-F), 1107 (C-N) cm-1.  
243 
 
  Synthesis of 1-(4-(3,5-bis(trifluoromethyl)phenyl)piperazin-1-yl)-4-
(thiophen-2-yl)butan-1-one (MK44) (RTC26) (9)   
    
Prepared from 1-(3,5-bis(trifluoromethyl)phenyl)piperazine (194 mg, 0.65 mmol) and 4-
(2-thienyl)butyric acid (85 µL, 0.58 mmol) using HOBt (87 mg, 0.65 mmol), TBTU (207 
mg, 0.65 mmol), NEt3 (129 µL, 0.92 mmol) and DMF (5 mL) and following the general 
procedure described in section 5.2.1. The reaction mixture was stirred at rt for 14.5 hrs. 
DMF was removed under reduced pressure and the residue was purified using column 
chromatography (3:2, EtOAc:n-hexane) to give a clear oil, 223 mg (86%). 
1H NMR: (500 MHz, CDCl3) δ 7.33 (s, 1H, H1), 7.24 (s, 2H, H3), 7.12 (dd, J = 5.0 Hz, H11), 
6.96 – 6.89 (m, 1H, H10), 6.81 (s, 1H, H9), 3.86 – 3.76 (m, 2H*), 3.65 – 3.55 (m, 2H*), 
3.34 – 3.21 (m, 4H*), 2.93 (t, J = 7.2 Hz, 2H, H7), 2.41 (t, J = 7.2 Hz, 2H, H5), 2.11 – 2.02 
(m, 2H, H6).*Piperazine. 1H NMR matches literature data45. 13C NMR: (126 MHz, CDCl3) 
δ 171.1 (C=O), 151.3 (C4), 144.3 (C8), 132.5 (q, J = 32.8 Hz, C2), 126.8 (C10), 124.6 (C9), 
123.5 (q, J = 273.3 Hz, CF3), 123.2 (C11), 115.1 (m, C3), 112.7 (m, C1), 48.4 (C*), 48.3 (C*), 
44.9 (C*), 41.0 (C*), 31.9 (C7), 29.2 (C5), 26.9 (C6).*Piperazine. 13C NMR matches 
literature data45. 19F NMR: (471 MHz, CDCl3) δ -60.5 (CF3). HR-MS: calcd for 
C20H20F6N2OSNa m/z: [M + Na]+, 473.1093; found: 473.1107 [Diff (ppm) = 2.96]. Rf: 0.78 




  Synthesis of 1-(4-(4-nitrophenyl)piperazin-1-yl)-4-(thiophen-2-
yl)butan-1-one (MK39) (RTC22) (10)  
    
Prepared from 1-(4-nitrophenyl)piperazine (150 mg, 0.72 mmol) and 4-(2-
thienyl)butyric acid (95 µL, 0.66 mmol) using HOBt (97 mg, 0.72 mmol), TBTU (232 mg, 
0.72 mmol),  NEt3 (146 µL, 1.05 mmol) and DMF (6 mL) and following the general 
procedure described in section 5.2.1. The reaction mixture was stirred at rt for 22.5 hrs. 
DMF was removed under reduced pressure and the residue was purified using column 
chromatography (7:3, EtOAc:DCM) to give an orange solid, 199 mg (84%). 
1H NMR: (500 MHz, CDCl3) δ 8.14 (dd, J = 9.1, 1.4 Hz, 2H, H2), 7.13 (dd, J = 5.1, 1.1 Hz, 
1H, H11), 6.95 – 6.90 (m, 1H, H10), 6.86 – 6.78 (m, 3H, H3, H9), 3.84 – 3.76 (m, 2H*), 
3.65 – 3.56 (m, 2H*), 3.47 – 3.39 (m, 4H*), 2.93 (t, J = 7.2 Hz, 2H, H7), 2.40 (t, J = 7.2 Hz, 
2H, H5), 2.10 – 2.03 (m, 2H, H6). *Piperazine. 1H NMR matches literature data45. 13C 
NMR: (126 MHz, CDCl3) δ 171.2 (C=O), 154.4 (C4), 144.3 (C8), 139.1 (C1), 126.9 (C9), 
126.0 (C2), 124.6 (C10), 123.3 (C11), 112.9 (C3), 47.0 (C*), 46.9 (C*), 44.7 (C*), 40.8 (C*), 
31.9 (C5), 29.2 (C7), 26.8 (C6).*Piperazine. 13C NMR matches literature data45. HR-MS: 
calcd for C18H21N3O3SNa m/z: [M + Na]+, 382.1196; found: 382.1212 [Diff (ppm) = 4.2]. 





  Synthesis of 1-(4-(4-aminophenyl)piperazin-1-yl)-4-(thiophen-2-
yl)butan-1-one (MK70) (RTC23) (11)  
    
Prepared from 1-(4-(4-nitrophenyl)piperazin-1-yl)-4-(thiophen-2-yl)butan-1-one 
(compound 10) (143 mg, 0.39 mmol) dissolved in MeOH (10 mL) in a round bottom flask 
with PtO2 (10 mg, 0.04 mmol). The resulting mixture was degassed and purged with H2 
(x3), stirred vigorously at rt for 16.5 hrs under an atmosphere of H2 gas and monitored 
by TLC (7:1, EtOAc:DCM). The reaction mixture was passed through a bed of Celite and 
the filtrate was concentrated under reduced pressure. The residue was purified using 
column chromatography (7:1, EtOAc:DCM) to give a brown solid, 23 mg (35%). 
1H NMR: (500 MHz, CDCl3) δ 7.12 (dd, J = 5.1, 1.2 Hz, 1H, H11), 6.92 (dd, J = 5.1, 3.4 Hz, 
1H, H10), 6.82 – 6.77 (m, 3H, H2, H9), 6.67 – 6.63 (m, 2H, H3), 3.77 – 3.74 (m, 2H*), 3.56 
– 3.52 (m, 2H*), 2.99 – 2.90 (m, 6H, 4H*, 2H, H5), 2.42 – 2.38 (m, 2H, H7), 2.08 – 5.2.1 
(m, 2H, H6). *Piperazine. 1H NMR matches literature data45. 13C NMR: (126 MHz, CDCl3) 
δ 171.0 (C=O), 144.5 (C4), 144.0 (C1), 140.9 (C8), 126.8 (C10), 124.5 (C9), 123.2 (C11), 
119.3 (C2), 116.2 (C3), 51.6 (C*), 51.2 (C*), 45.7 (C*), 41.7 (C*), 32.1 (C7), 29.3 (C5), 27.1 
(C6).*Piperazine. 13C NMR matches literature data45. HR-MS: calcd for C18H24F3N3OS 
m/z: [M + H]+, 330.1635; found: 330.1649 [Diff (ppm) = 4.3].  Rf: 0.4 (7:1, EtOAc:DCM). 
IR (ATR): 3337 (N-H), 2815 (C-H), 1638 (C=O), 1510 (C=C), 1223 (C-N) cm-1.   
246 
 
  Synthesis of 1-(4-(2-chloro-4-(trifluoromethyl)phenyl)piperazin-1-yl)-
4-(thiophen-2-yl)butan-1-one (MK20) (RTC8) (12)  
     
Prepared from 1-(2-chloro-4-(trifluoromethyl)phenyl)piperazine  (compound 6) (90 mg, 
0.34 mmol) and 4-(2-thienyl)butyric acid (46 µL, 0.32 mmol) using HOBt (47 mg, 0.34 
mmol), TBTU (111 mg, 0.34 mmol), NEt3 (47 µL, 0.51 mmol) and DMF (3 mL) and 
following the general procedure described in section 5.2.1. The reaction mixture was 
stirred at rt overnight. DMF was removed under reduced pressure and the residue was 
purified using column chromatography (3:2, EtOAc:Pet. Ether) to give a grey oil, 111 mg 
(83%). 
1H NMR: (500 MHz, CDCl3) δ 7.64 (d, J = 1.7 Hz, 1H, H5), 7.48 (dd, J = 8.4, 1.7 Hz, 1H, H2), 
7.13 (dd, J = 5.1, 1.0 Hz, 1H, H12), 7.05 (d, J = 8.4 Hz, 1H, H3), 6.95 – 6.91 (m, 1H, H9), 
6.84 – 6.79 (m, 1H, H10), 3.86 – 3.76 (m, 2H*), 3.64 – 3.56 (m, 2H*), 3.09 – 3.02 (m, 4H*), 
2.93 (t, J = 7.3 Hz, 2H, H8), 2.42 (t, J = 7.5 Hz, 2H, H6), 2.06 (p, J = 7.4 Hz, 2H, H7). 
*Piperazine. 1H NMR matches literature data45.  13C NMR: (126 MHz, CDCl3) δ 171.2 
(C=O), 151.6 (C4), 144.4 (C9), 128.8 (C-Cl), 128.0 (q, J = 3.8 Hz, C5), 126.8 (C11), 126.0 (q, 
J = 33.4 Hz, C1), 124.9 (q, J = 3.7 Hz, C2), 124.6 (C10), 123.5 (q, J = 272.2 Hz, CF3), 123.3 
(C12), 120.4 (C3), 51.2 (C*), 50.7 (C*), 45.6 (C*), 41.6 (C*), 32.1 (C6), 29.3 (C8), 27.0 (C7). 
*Piperazine. 13C NMR matches literature data45. HR-MS: calcd for C19H20F3N2OSClNa 
m/z: [M + Na]+, 439.0829; found: 439.085 [Diff (ppm) = 4.8]. Rf : 0.7 (3:2, EtOAc:Pet. 





  Synthesis of 4-(thiophen-3-yl)-1-(4-(5-(trifluoromethyl)pyridin-2-
yl)piperazin-1-yl)butan-1-one (MK42) (RTC5) (13)  
     
Prepared from 1-(5-(trifluoromethyl)pyridin-2-yl)piperazine (99 mg, 0.43 mmol) and 4-
(2-thienyl)butyric acid (50 µL, 0.34 mmol) using HOBt (58 mg, 0.43 mmol), TBTU (140 
mg, 0.43 mmol), NEt3 (100 µL, 0.69 mmol) and DMF (3 mL) and following the general 
procedure described in section 5.2.1. The reaction mixture was stirred at room 
temperature overnight. DMF was removed under reduced pressure and the residue was 
purified using column chromatography (3:2 EtOAc:n-hexane) to give a white solid, 119 
mg (91%). 
1H NMR: (500 MHz, CDCl3) δ 8.41 (s, 1H, H2), 7.66 (dd, J = 9.0 Hz, J = 2.2 Hz, 1H, H5), 7.14 
– 7.10 (m, 1H, H12), 6.94 – 6.91 (m, 1H, H11), 6.82 – 6.80 (m, 1H, H10), 6.64 (d, J = 9.0 
Hz, 1H, H4), 3.79 – 3.68 (m, 4H*), 3.66 – 3.56 (m, 2H*), 3.56 – 3.49 (m, 2H*), 2.93 (t, J = 
7.4 Hz, 2H, H8), 2.41 (t, J = 7.4, 2H, H6), 2.06 (p, J = 7.4 Hz, 2H, H7).*Piperazine. 1H NMR 
matches literature data45. 13C NMR: (126 MHz, CDCl3) 171.3 (C=O), 160.1 (C3), 145.8 (q, 
J = 4.3 Hz, C2), 144.3 (C9), 134.7 (q, J = 3.2 Hz, C5), 126.8 (C11), 124.6 (C10), 124.5 (q, J 
= 270.9 Hz, CF3),  123.2 (C12), 115.9 (q, J = 33.1 Hz, C1), 105.7 (C4), 45.0 (C*), 44.7 (C*), 
44.4 (C*), 41.0 (C*), 32.0 (C6), 29.3 (C8), 26.9 (C7).*Piperazine. 13C NMR matches 
literature data45. HR-MS: calcd for C18H21F3N3OS m/z: [M + H]+, 384.1352; found: 
384.1355 [Diff(ppm) = 0.8]. Rf: 0.5 (3:2, EtOAc:n-hexane). IR (ATR): 2912 (C-H), 1645 




  Synthesis of 1-(4-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)piperazin-1-
yl)-4-(thiophen-2-yl)butan-1-one (MK45) (RTC6) (14)   
     
Prepared from 1-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)piperazine (114 mg, 0.43 
mmol) and 4-(2-thienyl)butyric acid (50 µL, 0.34 mmol) using HOBt (58 mg, 0.43 mmol), 
TBTU (140 mg, 0.43 mmol), NEt3 (100 µL, 0.69 mmol) and DMF (3 mL) and following the 
general procedure described in section 5.2.1. The reaction mixture was stirred at room 
temperature overnight. DMF was removed under reduced pressure and the residue was 
purified using column chromatography (3:2, EtOAc:n-hexane) to give a grey solid, 123 
mg (87 %). 
1H NMR: (500 MHz, CDCl3) δ 8.40 (s, 1H, H2), 7.79 (s, 1H, H4), 7.14 – 7.10 (m, 1H, H11), 
6.95 – 6.89 (m, 1H, H10), 6.83 – 6.78 (m, 1H, H9), 3.81 – 3.74 (m, 2H*), 3.60 – 3.53 (m, 
2H*), 3.51 – 3.44 (m, 4H*), 2.93 (t, J = 7.2 Hz, 2H, H7), 2.41 (t, J = 7.4 Hz, 2H, H5), 2.06 
(p, J = 7.3 Hz, 2H, H6).*Piperazine. 1H NMR matches literature data45. 13C NMR: (126 
MHz, CDCl3) 171.2 (C=O), 159.6 (C3), 144.4 (C8), 143.0 (q, J = 4.2 Hz, C2), 136.1 (q, J = 3.3 
Hz, C4), 126.8 (C10), 124.5 (C9), 123.23 (q, J = 272.3 Hz, CF3), 123.21 (C11), 121.1 (C-Cl), 
120.6 (q, J = 33.5 Hz, C1), 48.6 (C*), 45.2 (C*), 41.3 (C*), 32.0 (C5), 29.3 (C7), 27.0 
(C6).*Piperazine. 13C NMR matches literature data45. 19F NMR: (471 MHz, CDCl3) δ -61.3 
(CF3). HR-MS: calcd for C18H20F3N3OSCl m/z: [M + H]+, 418.0971; found 418.0963 
[Diff(ppm) = 0.24]. Rf: 0.78 (3:2, EtOAc:n-hexane). IR (ATR):  3036 (N-H), 2852 (C-H), 1646 
(C=O), 1600 (C=C), 1438 (C=C), 1317 (C-F), 1117 (C-N), 847 (C-Cl) cm-1.  
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  Synthesis of 1-(4-methylpiperazin-1-yl)-4-(thiophen-2-yl)butan-1-one 
(MK36) (RTC32) (15)  
    
Prepared from 1-methylpiperazine (71 µL, 0.65 mmol) and 4-(2-thienyl)butyric acid (85 
µL, 0.59 mmol) using HOBt (87 mg, 0.65 mmol), TBTU (207 mg, 0.65 mmol), NEt3 (90 µL, 
0.94 mmol) and DCM (4 mL) and following the general procedure described in section 
5.2.1. The reaction mixture was stirred at room temperature overnight for 18 hours. 
DCM was removed under reduced pressure and the residue was purified using column 
chromatography (3:2, EtOAc:n-hexane) to give a yellow oil, 104 mg (70 %). 
1H NMR: (500 MHz, CDCl3) δ 7.11 (dd, J = 5.1, 1.2 Hz, 1H, H7), 6.91 (dd, J = 5.1, 3.4 Hz, 
1H, H6), 6.80 (ddd, J = 3.4, 2.1, 1.2 Hz, 1H, H5), 3.65 – 3.61 (m, 2H*), 3.43 – 3.39 (m, 
2H*), 2.90 (t, J = 7.3 Hz, 2H, H3), 2.38 – 2.33 (m, 4H*, 2H, H1), 2.29 (s, 3H, CH3), 2.02 (p, 
J = 7.4 Hz, 2H, H2). *Piperazine. 1H NMR matches literature data45. 13C NMR: (126 MHz, 
CDCl3) δ 170.9 (C=O), 144.5 (C4), 126.8 (C6), 124.5 (C5), 123.1 (C7), 55.2 (C*), 54.7 (C*), 
46.0 (CH3), 45.4 (C*), 41.5 (C*), 32.0 (C1), 29.31 (C3), 27.0 (C2). *Piperazine. 13C NMR 
matches literature data45. HR-MS: calcd for C13H21N2OS m/z: [M + H]+, 253.1369; found 
253.1367 [Diff(ppm) = -0.8]. Rf: 0.56 (100% DCM). IR (ATR): 2936 (Ar C-H), 2792 (alkane 




  Synthesis of 4-(thiophen-2-yl)-1-(4-(4-
(trifluoromethyl)phenyl)piperidin-1-yl)butan-1-one  (MK19) (RTC196) 
(16)  
    
Prepared from 4-(4-(trifluoromethyl)phenyl)piperidine.HCl (100 mg, 0.38 mmol) and 4-
(2-thienyl)butyric acid (50 μL, 0.34 mmol) using HOBt (51 mg, 0.38 mmol), TBTU (122 
mg, 0.38 mmol), NEt3 (55 µL, 0.54 mmol) and DMF (2 mL) and following the general 
procedure described in section 5.2.1. The reaction mixture was stirred for 24 hrs at rt. 
DMF was removed under reduced pressure and the residue was purified using column 
chromatography (3:2, EtOAc:n-hexane) to give an off-white solid, 87 mg (67%). 
1H NMR: (500 MHz, CDCl3) δ 7.56 (d, J = 8.0 Hz, 2H, H2), 7.30 (d, J = 8.0 Hz, 2H, H3), 7.12 
(d, J = 5.1 Hz, 1H, H14), 6.97 – 6.87 (m, 1H, H13), 6.83 – 6.79 (m, 1H, H12), 4.82 (d, J = 
13.2 Hz, 1H, H7), 3.92 (d, J = 13.5 Hz, 1H, H7), 3.10 (t, J = 12.9 Hz, 1H, H7), 2.93 (t, J = 7.3 
Hz, 2H, H10), 2.85 – 2.74 (m, 1H, H5), 2.63 (t, J = 12.7 Hz, 1H, H7), 2.41 (t, J = 7.4 Hz, 2H, 
H8), 2.06 (p, J = 7.4 Hz, 2H, H9), 1.93 – 1.84 (m, 2H, H6), 1.68 – 1.52 (m, 2H, H6). 1H NMR 
matches literature data45. 13C NMR: (126 MHz, CDCl3) δ 170.9 (C=O), 149.2 (C4), 144.5 
(C11), 128.9 (q, J = 32.5 Hz, C1), 127.1 (C3), 126.8 (C13), 125.6 (q, J = 3.8 Hz, C2), 124.5 
(C12), 124.2 (q, J = 272.3 Hz, CF3), 123.1 (C14), 46.0 (C7), 42.7 (C5), 42.2 (C7), 33.7 (C6), 
32.6 (C6), 32.2 (C8), 29.4 (C10), 27.1 (C9). 13C NMR matches literature data45. HR-MS: 
calcd for C20H22F3NOSNa m/z: [M + Na]+, 404.1266; found 404.1279 [Diff (ppm) = 3.2]. 




  Synthesis of 4-(thiophen-2-yl)-N-(4-
(trifluoromethyl)phenyl)butanamide (MK90) (17)  
     
Prepared from 4-(trifluoromethyl)aniline (69 mg, 0.43 mmol) and 4-(thiophen-2-
yl)butanoic acid (50 μL, 0.34 mmol) using HOBt (58 mg, 0.43 mmol), TBTU (140 mg, 0.43 
mmol), NEt3 (100 µL, 0.51 mmol) and DCM (6 mL) and following the general procedure 
described in section 5.2.1. The reaction mixture was stirred at rt for 20 hrs. DCM was 
removed under reduced pressure and the residue was purified using column 
chromatography (3:2, EtOAc:n-hexane) to give a white solid, 96 mg (90%). 
1H NMR: (500 MHz, CDCl3) δ 7.62 (d, J = 8.6 Hz, 2H, H2), 7.56 (d, J = 8.6 Hz, 2H, H3), 7.29 
(bs, 1H, NH), 7.14 (ddd, J = 5.1, 1.2, 0.5 Hz, 1H, H9), 6.93 (dd, J = 5.1, 3.4 Hz, 1H, H10), 
6.81 (dd, J = 2.2, 1.1 Hz, 1H, H11), 2.94 (t, J = 7.2 Hz, 2H, H7), 2.42 (t, J = 7.4 Hz, 2H, H5), 
2.12 (p, J = 7.2 Hz, 2H, H6). 13C NMR: (126 MHz, CDCl3) δ 171.0 (C=O), 143.8 (C8), 140.8 
(C4), 126.9 (C10), 126.3 (q, J = 3.8 Hz, C2), 126.1 (q, J = 33.0 Hz, C1), 124.8 (C11), 124.1 
(q, J = 272.1 Hz, CF3), 123.4 (C9), 119.3 (C3), 36.4 (C5), 29.0 (C7), 27.0 (C6). HR-MS: calcd 
for C19H23NOSNa m/z: [M + H]+, 336.1393; found 336.1393 [Diff (ppm) = 0.0]. Rf: 0.6 (3:2, 
EtOAc:n-hexane).  IR (ATR): 3304 (N-H), 2926 (Ar C-H), 1670 (C=O), 1514 (Ar C=C), 1319 





  Synthesis of 1-(4-(thiophen-2-yl)butyl)-4-(4-
(trifluoromethyl)phenyl)piperazine (MK34) (RTC46) (18)  
    
Prepared from a suspension of 4-(thiophen-2-yl)butyl methanesulfonate (compound 20)  
(29 mg, 0.12 mmol) and Na2CO3 (26 mg, 0.24 mmol) in acetonitrile (5 mL), with 1-(4-
(trifluoromethyl)phenyl)piperazine (compound 2) (110 mg, 0.48 mmol). The mixture 
was heated at reflux for 22 hrs under vigorous agitation and a N2 atmosphere. The 
solvent was removed under reduced pressure and the residue was purified using column 
chromatography (3:2, EtOAc:n-hexane) to give a white solid, 34 mg (77%).  
1H NMR: (500 MHz, CDCl3) δ 7.48 (d, J = 8.7 Hz, 2H, H2), 7.12 – 7.10 (m, 1H, H12), 6.94 – 
6.90 (m, 3H, H3, H11), 6.81 – 6.78 (m, 1H, H10), 3.32 – 3.24 (m, 4H*), 2.87 (t, J = 7.5 Hz, 
2H, H5), 2.62 – 2.54 (m, 4H*), 2.42 (t, J = 7.5 Hz, 2H, H8), 1.74 (dt, J = 15.2, 7.5 Hz, 2H, 
H6), 1.66 – 1.57 (m, 2H, H7).*Piperazine. 1H NMR matches literature data45. 13C NMR: 
(126 MHz, CDCl3) δ 153.3 (C4), 145.3 (C9), 126.7 (C11), 126.3 (q, J = 3.3 Hz, C2), 124.7 (q, 
J = 269.4 Hz, CF3), 124.1 (C10), 122.9 (C12), 120.4 (q, J = 32.4 Hz, C1), 114.4 (C3), 58.3 
(C8), 53.0 (C*), 48.0 (C*), 29.8 (C5), 29.7 (C6), 26.3 (C7).*Piperazine. 13C NMR matches 
literature data45. HR-MS: calcd C19H24F3N2S m/z: [M + H]+, 369.1067; found 369.1608 
[Diff(ppm) = 0.3]. Rf: 0.8 (3:2, EtOAc:n-hexane).  IR (ATR): 2839 (C-H), 1613 (C=C), 1325 
(C-F), 1099 (C-N) cm-1.  
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  Synthesis of 4-(thiophen-2-yl)butan-1-ol (MK32) (RD28) (19)  
   
Prepared from a solution of 4-(2-thienyl)butyric acid (500 μL, 3.43 mmol) in anhydrous 
THF (2.5 mL) added to a suspension of LiAlH4 (130 mg, 3.43 mmol) in anhydrous THF (2.5 
mL) in an oven-dried two-necked round-bottom flask, over ice and with a positive flow 
of argon. The suspension was allowed to reach rt slowly and was stirred for 6 hrs at rt. 
The reaction mixture was quenched with H2O (2 mL) added slowly dropwise. The 
solution was neutralised with 10% aqueous HCl (2 mL) and the aqueous layer extracted 
with EtOAc (4 x 10 mL). The combined organic layers were dried over MgSO4 and the 
residue dried under reduced pressure to give an orange oil, 309 mg (58%). 
1H NMR: (500 MHz, CDCl3) δ 7.11 – 7.05 (m, 1H, H8), 6.92 – 6.87 (m, 1H, H7), 6.79 – 6.74 
(m, 1H, H6), 3.60 (t, J = 6.6 Hz, 2H, H1), 2.83 (t, J = 7.6 Hz, 2H, H4), 2.35 (bs, 1H, OH), 1.77 
– 1.68 (m, 2H, H2), 1.64 – 1.55 (m, 2H, H3). 1H NMR matches literature data45. 13C NMR: 
(126 MHz, CDCl3) δ 145.3 (C5), 126.8 (C7), 124.2 (C6), 123.0 (C8), 62.4 (C1), 32.1 (C4), 
29.7 (C2), 28.0 (C3). 13C NMR matches literature data45. HR-MS: calcd for C8H12OSNa 
m/z: [M + Na]+, 179.0501; found: 179.0509 [Diff (ppm) = 4.47]. Rf: 0.2 (100% DCM). IR 




  Synthesis of 4-(thiophen-2-yl)butyl methanesulfonate (MK33) (RD31) 
(20)  
   
Prepared from a solution of 4-(thiophen-2-yl)butan-1-ol (compound 19) (124 μL, 0.86 
mmol), methanesulfonyl chloride (71 μL, 0.91 mmol), NEt3 (142 μL, 1.01 mmol) in 
anhydrous DCM (3 mL) and kept at 0 °C. The reaction mixture was maintained at 0 °C for 
1 hr followed by allowing it to reach rt slowly. It was maintained at rt under vigorous 
stirring and a N2 atmosphere for 3 hrs. Volatiles were removed under reduced pressure 
and the product was purified by column chromatography (3:2, EtOAc:Pet. Ether). 
Residual NEt3 remained which required additional work-up. The product was neutralised 
with 10% aqueous HCl (2 mL) and the aqueous layer extracted with EtOAc (4 x 10 mL). 
The combined organic layers were dried over MgSO4 and the residue dried under 
reduced pressure to give a colourless oil, 92 mg (46%).  
1H NMR: (500 MHz, CDCl3) δ 7.18 – 7.07 (m, 1H, H8), 6.95 – 6.88 (m, 1H, H7), 6.81 – 6.76 
(m, 1H, H6), 4.27 – 4.20 (m, 2H*, H1), 2.98 (s, 3H, CH3), 2.92 – 2.83 (m, 2H, H4), 1.87 – 
1.75 (m, 4H, H2, H3). 1H NMR matches literature data45. 13C NMR: (126 MHz, CDCl3) δ 
144.3 (C5), 126.8 (C7), 124.5 (C6), 123.2 (C8), 69.6 (C1), 37.4 (CH3), 29.2 (C4), 28.4 (C2), 
27.6 (C3). 13C NMR matches literature data45. HR-MS: calcd for C9H14O3S2Na m/z: [M + 
Na]+, 257.0277; found: 257.0271 [Diff (ppm) = -2.0]. Rf: 0.7 (3:2, EtOAc:Pet.Ether). IR 





  Synthesis of thiophen-2-yl (4-(4-(trifluoromethyl)phenyl)piperazin-1-
yl) methanone (MK37) (RTC93) (21)  
    
Prepared from 1-(4-(trifluoromethyl)phenyl)piperazine (compound 2) (76 mg, 0.33 
mmol) and thiophene-2-carboxylic acid (38 mg, 0.30 mmol) using HOBt (45 mg, 0.33 
mmol), TBTU (107 mg, 0.33 mmol), NEt3 (75 µL, 0.48 mmol) and DMF (4 mL) and 
following the general procedure described in section 5.2.1. The reaction mixture was 
stirred at rt for 21 hours. DMF was removed under reduced pressure and the residue 
was purified using column chromatography (1:1, EtOAc:Pet. Ether) to give a green solid, 
70 mg (69%). 
1H NMR: (500 MHz, CDCl3) δ 7.55 – 7.45 (m, 3H, H2, H6), 7.35 (d, J = 3.2 Hz, 1H, H8), 7.13 
– 7.02 (m, 1H, H7), 6.93 (d, J = 8.6 Hz, 2H, H3), 3.98 – 3.86 (m, 4H*), 3.42 – 3.27 (m, 4H*). 
*Piperazine. 1H NMR matches literature data45. 13C NMR: (126 MHz, CDCl3) δ 163.7 
(C=O), 152.8 (C4), 136.6 (C5), 129.1 (C8), 129.0 (C6), 126.8 (C7), 126.5 (q, J = 3.8 Hz, C2), 
124.5 (q, J = 271.3 Hz, CF3), 121.3 (q, J = 32.8 Hz, C1), 114.9 (C3), 48.2 (C*). *Piperazine. 
13C NMR matches literature data45. HR-MS: calcd for C16H15F3N2OSNa m/z: [M + Na]+, 
363.0749; found: 363.0762 [Diff (ppm) = 3.58]. Rf: 0.6 (1:1, EtOAc:Pet.Ether). IR (ATR): 





  Synthesis of 2-(thiophen-2-yl)-1-(4-(4-
(trifluoromethyl)phenyl)piperazin-1-yl)ethanone (MK47) (RTC536) (22)   
      
Prepared from 1-(4-(trifluoromethyl)phenyl)piperazine (compound 2) (100 mg, 0.43 
mmol) and 2-(thiophen-2-yl)acetic acid (48 mg, 0.34 mmol) using HOBt (58 mg, 0.43 
mmol), TBTU (138 mg, 0.43 mmol), NEt3 (87 µL, 0.63 mmol), DMF (4 mL) and following 
the general procedure described in section 5.2.1. The reaction mixture was stirred at rt 
overnight. Purified using column chromatography (3:2, EtOAc:n-hexane) to give an 
orange solid, 98 mg (82%). 
1H NMR: (500 MHz, CDCl3) δ 7.49 (d, J = 8.7 Hz, 2H, H2), 7.21 (dd, J = 5.1 Hz, J = 1.2 Hz, 
1H, H9), 6.97 – 6.88 (m, 4H, H3, H7, H8), 3.96 (s, 2H, H5), 3.84 – 3.78 (m, 2H*), 3.72 – 
3.64 (m, 2H*), 3.29 – 3.23 (m, 2H*), 3.21 – 3.12 (m, 2H*). *Piperazine. 1H NMR matches 
literature data45. 13C NMR: (126 MHz, CDCl3) δ 168.5 (C=O), 152.8 (C4), 136.2 (C6), 127.0 
(C7), 126.5 (q, J = 3.3 Hz, C2), 126.1 (C8), 124.9 (C9), 124.6 (q, J = 271.3 Hz, CF3), 121.4 
(q, J = 32.8 Hz, C1), 115.0 (C3), 48.2 (C*), 47.9 (C*), 45.8 (C*), 41.5 (C*), 35.2 (C5). 
*Piperazine. 13C NMR matches literature data45. HR-MS: calcd for C17H17F3N2O2SNa m/z: 
[M + Na]+, 377.0906; found: 377.0915 [Diff (ppm) = 2.4]. Rf: 0.9 (3:2, EtOAc:n-hexane). 
IR (ATR): 2826 (C-H), 1614 (C=O), 1409 (C=C), 1336 (C-F), 1229 (C-N) cm-1.  
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  Synthesis of 5-(thiophen-2-yl)-1-(4-(4-
(trifluoromethyl)phenyl)piperazin-1-yl)pentan-1-one (MK18) (RTC195) 
(23)  
    
Prepared from 5-(thiophen-2-yl)pentanoic acid (72 mg, 0.39 mmol) using HOBt (58 mg, 
0.43 mmol), TBTU (138 mg, 0.43 mmol), anhydrous NEt3 (86 µL, 0.62 mmol) and 
anhydrous DMF (4 mL) in an oven-dried Schlenk tube under a N2 atmosphere. The 
resulting solution was stirred at rt for 15 mins. A second Schlenk tube was prepared 
containing 1-(4-(trifluoromethyl)phenyl)piperazine (compound 2)  (100 mg, 0.43 mmol) 
and DMF (4 mL) under a N2 atmosphere. The resulting solution was transferred, via a 
cannula, to the first Schlenk tube containing the carboxylic acid. The reaction mixture 
was stirred overnight at rt under a N2 atmosphere. DMF was removed under reduced 
pressure. The resulting oil was acidified (pH = 3) using a 0.1 M aqueous HCl solution and 
purified using column chromatography (3:2 EtOAc:n-hexane) to give an orange solid, 
113 mg (73 %).  
1H NMR: (500 MHz, CDCl3) δ 7.50 (d, J = 8.8 Hz, 2H, H2), 7.09 (dd, J = 5.1, 1.2 Hz, 1H, 
H12), 6.94 – 6.86 (m, 3H, H3, H11), 6.81 – 6.74 (m, 1H, H10), 3.82 – 3.70 (m, 2H*), 3.66 
– 3.53 (m, 2H*), 3.27 – 3.20 (m, 4H*), 2.87 (t, J = 6.7 Hz, 2H, H8), 2.39 (t, J = 7.0 Hz, 2H, 
H5), 1.81 – 1.68 (m, 4H, H6, H7). *Piperazine. 1H NMR matches literature data45. 13C 
NMR: (126 MHz, CDCl3) δ 171.4 (C=O), 152.9 (C4), 145.0 (C9), 126.7 (C11), 126.5 (q, J = 
3.8 Hz, C2), 124.6 (q, J = 271.3 Hz, CF3), 124.2 (C10), 123.0 (C12), 121.3 (q, J = 32.9 Hz, 
C1), 115.0 (C3), 48.4 (C*), 48.1 (C*), 45.1 (C*), 41.1 (C*), 33.0 (C5), 31.4 (C7), 29.7 (C8), 
24.6 (C6). *Piperazine. 13C NMR matches literature data45. 19F NMR: (471 MHz, CDCl3) δ 
-61.8 (CF3). HR-MS: calcd for C20H24F3N2OS m/z: [M + H]+, 397.1556; found: 397.1572 
[Diff (ppm) = 4.00]. Rf: 0.66 (3:2, EtOAc:n-hexane). IR (KBr): 2862 (C-H), 1634 (C=O), 1612 
(C=C), 1438 (C=C), 1326 (C-F), 1107 (C-N) cm-1. 
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  Synthesis of 1-(thiophen-2-yl)-1-(4-(4-
(trifluoromethyl)phenyl)piperazin-1-yl)butan-1,4-dione (MK40) (RTC2) 
(24)  
    
Prepared from 1-(4-(trifluoromethyl)phenyl)piperazine (compound 2)  (100 mg, 0.43 
mmol) and 4-oxo-4-(thiophen-2-yl)butanoic acid (63 mg, 0.34 mmol), using HOBt (58 
mg, 0.43 mmol), TBTU (140 mg, 0.43 mmol), NEt3 (100 µL, 0.69 mmol) and DMF (3 mL) 
and following the general procedure described in section 5.2.1. The reaction mixture 
was stirred at rt for 17 hrs. DMF was removed under reduced pressure and the residue 
was purified using column chromatography (3:2 EtOAc:n-hexane) to give an off-white 
solid, 114 mg (84%). 
1H NMR: (500 MHz, CDCl3) δ 7.81 (d, J = 3.6 Hz, 1H, H8), 7.63 (d, J = 4.9 Hz, 1H, H10), 
7.50 (d, J = 8.6 Hz, 2H, H2), 7.13 (t, J = 4.3 Hz, 1H, H9), 6.92 (d, J = 8.6 Hz, 2H, H3), 3.83 – 
3.70 (m, 4H*), 3.34 – 3.32 (m, 4H*), 3.27 – 3.25 (m, 2H, H6), 2.82 (t, J = 6.5 Hz, 2H, 
H5).*Piperazine. 1H NMR matches literature data45. 13C NMR: (126 MHz, CDCl3) 191.9 
(C=O), 170.1 (N-C=O), 152.9 (C4), 143.9 (C7), 133.6 (C10), 132.1 (C8), 128.2 (C9), 126.5 
(q, J = 3.8 Hz, C2), 124.6 (q, J = 271.3 Hz, CF3), 121.2 (q, J = 32.6 Hz, C1), 115.0 (C3), 48.2 
(C*), 48.0 (C*), 45.0 (C*), 41.4 (C*), 34.2 (C5), 27.0 (C6). *Piperazine. 13C NMR matches 
literature data45. HR-MS: calcd for C19H20F3N2O2S m/z: [M + H]+, 397.1192; found: 
397.1179 [Diff(ppm) = -3.3]. Rf: 0.5 (3:2, EtOAc:n-hexane). IR (ATR): 2948 (C-H), 1647 





  Synthesis of  3-(thiophen-2-ylthio)-1-(4-(4-
(trifluoromethyl)phenyl)piperazin-1-yl)propan-1-one (MK22) (RTC7) 
(25)  
    
Prepared from 1-(4-(trifluoromethyl)phenyl)piperazine (compound 2) (50 mg, 0.22 
mmol) and 3-(thiophen-2-ylthio)propanoic acid (37 mg, 0.19 mmol) using HOBt (30 mg, 
0.22 mmol), TBTU (70 mg, 0.22 mmol), NEt3 (44 µL, 0.32 mmol) and DMF (2 mL) and 
following the general procedure described in section 5.2.1. The reaction mixture was 
stirred at rt overnight. DMF was removed under reduced pressure and the residue was 
purified using column chromatography (3:2, EtOAc:Pet. Ether) to give a colourless oil, 45 
mg (60%).  
1H NMR: (500 MHz, CDCl3) δ 7.50 (d, J = 8.7 Hz, 2H, H2), 7.36 (dd, J = 5.4, 1.2 Hz, 1H, 
H10), 7.15 (dd, J = 3.6, 1.2 Hz, 1H, H8), 6.99 (dd, J = 5.4, 3.6 Hz, 1H, H9), 6.91 (d, J = 8.7 
Hz, 2H, H3), 3.81 – 3.74 (m, 2H*), 3.61 – 3.54 (m, 2H*), 3.30 – 3.23 (m, 4H*), 3.12 (t, J = 
7.3 Hz, 2H, H6), 2.68 (t, J = 7.3 Hz, 2H, H5). *Piperazine. 1H NMR matches literature 
data45. 13C NMR: (126 MHz, CDCl3) δ 169.4 (C=O), 152.9 (C4), 134.0 (C8), 134.0 (C7), 
129.6 (C10), 127.7 (C9), 126.5 (q, J = 3.8 Hz, C2), 124.6 (q, J = 271.3 Hz, CF3), 121.4 (q, J 
= 32.8 Hz, C1), 115.0 (C3), 48.3 (C*), 48.1 (C*), 45.0 (C*), 41.3 (C*), 34.1 (C5), 33.2 (C6). 
*Piperazine. 13C NMR matches literature data45. 19F NMR: (471 MHz, CDCl3) δ -61.4 (CF3). 
HR-MS: calcd for C18H19F3N2OS2Na m/z: [M + Na]+, 423.0783; found: 423.0797 [Diff 
(ppm) = 3.3]. Rf: 0.75 (3:2, EtOAc:Pet. Ether). IR (ATR): 2837 (C-H), 1640 (C=O), 1614 
(C=C), 1331 (C-F), 1103 (C-N) cm-1.  
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  Synthesis of N,N-dimethyl-4-(thiophen-2-yl)butanamide (MK46) (26)   
     
Prepared from dimethylamine (29 µL, 0.43 mmol) and 4-(2-thienyl)butyric acid (50 µL, 
0.34 mmol) using HOBt (58 mg, 0.43 mmol), TBTU (139 mg, 0.43 mmol), NEt3 (100 µL, 
0.69 mmol) and DMF (3 mL) and following the general procedure described in section 
5.2.1. The reaction mixture was stirred at rt for 16 hrs. DMF was removed under reduced 
pressure and the residue was purified using column chromatography (3:2, EtOAc:n-
hexane) to give a grey oil, 29 mg (43%). 
1H NMR: (500 MHz, CDCl3) δ 7.16 – 7.03 (m, 1H, H7), 6.95 – 6.88 (m, 1H, H6), 6.83 – 6.76 
(m, 1H, H5), 3.11 – 2.74 (m, 4H, H1, 2 x CH3), 2.39 (dt, J = 25.2, 7.4 Hz, 2H, H3), 2.10 – 
1.96 (m, 2H, H2). 13C NMR: (126 MHz, CDCl3) δ 178.8 (C=O), 173.0 (C=O*), 144.6 (C4*), 
143.9 (C4), 126.8 (C6), 126.8 (C6*), 124.6 (C7), 124.5 (C7*), 123.3 (C5), 123.1 (C5*), 37.3 
(CH3), 35.5 (CH3), 33.0 (C3), 32.2 (C3*), 29.3 (C1*), 29.0 (C1), 26.9 (C2*), 26.6 (C2).*other 
tautomer. HR-MS: calcd for C10H16NOS m/z: [M + H]+, 198.0947; found: 198.0944 [Diff 




  Synthesis of 1-(4-phenylpiperidin-1-yl)-4-(thiophen-2-yl)butan-1-one 
(MK89) (27)  
     
Prepared from 4-phenylpiperidine (69 mg, 0.43 mmol) and 4-(thiophen-2-yl)butanoic 
acid (50 μL, 0.34 mmol) using HOBt (58 mg, 0.43 mmol), TBTU (140 mg, 0.43 mmol), NEt3 
(100 µL, 0.51 mmol) and DCM (6 mL) and following the general procedure described in 
section 5.2.1. The reaction mixture was stirred at rt for 18 hrs. DCM was removed under 
reduced pressure and the residue was purified using column chromatography (3:2, 
EtOAc:n-hexane) to give a clear oil, 105 mg (98%). 
1H NMR: (500 MHz, CDCl3) δ 7.32 (pseudo t, J = 7.6 Hz, 2H, H3), 7.25 – 7.16 (m, 3H, H1, 
H2), 7.13 (dd, J = 5.1, 1.2 Hz, 1H, H14), 6.93 (dd, J = 5.1, 3.4 Hz, 1H, H13), 6.89 – 6.78 (m, 
1H, H12), 4.82 (d, J = 13.2 Hz, 1H, H7), 3.91 (d, J = 13.5 Hz, 1H, H7), 3.09 (td, J = 13.2, 2.1 
Hz, 1H, H7), 2.94 (t, J = 7.4 Hz, 2H, H10), 2.73 (tt, J = 12.2, 3.6 Hz, 1H, H5), 2.63 (td, J = 
13.0, 2.1 Hz, 1H, H7), 2.46 – 2.38 (m, 2H, H8), 2.07 (p, J = 7.4 Hz, 2H, H9), 1.93 – 1.84 (m, 
2H, H6), 1.67 – 1.54 (m, 2H, H6). 13C NMR: (126 MHz, CDCl3) δ 170.8 (C=O), 145.3 (C4), 
144.6 (C11), 128.6 (C3), 126.8 (C13), 126.8 (C2), 126.5 (C1), 124.5 (C12), 123.2 (C14), 
46.2 (C7), 42.8 (C5), 42.4 (C7), 34.0 (C6), 32.9 (C6), 32.3 (C8), 29.4 (C10), 27.2 (C9). HR-
MS: calcd for C19H23NOSNa m/z: [M + H]+, 336.1393; found 336.1393 [Diff (ppm) = 0.0]. 
Rf: 0.6 (3:2, EtOAc:n-hexane).  IR (ATR): 3026 (alkene C-H), 2933 (Ar C-H), 2850 (alkyl C-




  Synthesis of 1-(thiophen-2-yl)-4-(4-(4-
(trifluoromethyl)phenyl)piperidin-1-yl)butane-1,4-dione (MK88) (28)  
     
Prepared from 4-(4-trifluoromethyl)phenyl)piperidine (99 mg, 0.43 mmol) and 4-oxo-4-
(2-thienyl)butanoic acid (63 mg, 0.34 mmol) using HOBt (58 mg, 0.43 mmol), TBTU (140 
mg, 0.43 mmol), NEt3 (100 µL, 0.51 mmol) and DCM (6 mL) and following the general 
procedure described in section 5.2.1. The reaction mixture was stirred at rt for 19 hrs. 
DCM was removed under reduced pressure and the residue was purified using column 
chromatography (4:1, EtOAc:n-hexane) to give a white solid, 117 mg (87%). 
1H NMR: (500 MHz, CDCl3) δ 7.82 (d, J = 3.2 Hz, 1H, H11), 7.63 (d, J = 4.9 Hz, 1H, H13), 
7.57 (d, J = 8.1 Hz, 2H, H2), 7.32 (d, J = 8.1 Hz, 2H, H3), 7.17 – 7.08 (m, 1H, H12), 4.79 (d, 
J = 11.6 Hz, H7), 4.13 (d, J = 14.3 Hz, H7), 3.37 – 3.28 (m, 2H, H9), 3.23 – 3.14 (m, 1H, H7), 
2.90 – 2.77 (m, 3H, H5, H8), 2.71 – 2.60 (m, 1H, H7), 1.91 (dd, J = 31.5, 13.1 Hz, 2H, H6), 
1.75 – 1.57 (m, 2H, H6). 13C NMR: (126 MHz, CDCl3) δ 192.2 (C=O), 169.9 (N-C=O), 149.2 
(C4), 144.1 (C10), 133.6 (C13), 132.2 (C11), 128.9 (q, J = 32.4 Hz, C1), 128.2 (C12), 127.2 
(C3), 125.6 (q, J = 3.8 Hz, C2), 124.3 (q, J = 272.4 Hz, CF3), 46.0 (C7), 42.8 (C5), 42.5 (C7), 
34.4 (C9), 33.6 (C6), 32.7 (C6), 27.3 (C8). HR-MS: calcd for C20H21F3NO2S m/z: [M + H]+, 
396.124; found 396.1251 [Diff (ppm) = 2.8]. Rf: 0.3 (4:1, EtOAc:n-hexane).  IR (ATR): 2935 






  Synthesis of 5-phenyl-1-(4-(4-(trifluoromethyl)phenyl)piperazin-1-
yl)pentan-1-one  (MK30) (RTC16) (29)  
      
Prepared from 1-(4-(trifluoromethyl)phenyl)piperazine (compound 2)  (150 mg, 0.65 
mmol) and 5-phenylpentanoic acid (105 mg, 0.59 mmol) using HOBt (87 mg, 0.65 mmol), 
TBTU (208 mg, 0.65 mmol), NEt3 (131 µL, 0.94 mmol) and DMF (5mL) and following the 
general procedure described in section 5.2.1. The reaction mixture was stirred at rt for 
21 hours. DMF was removed under reduced pressure and the residue was purified using 
column chromatography (4:1, EtOAc:n-hexane) to give an orange oil, 150 mg (65%). 
1H NMR: (500 MHz, CDCl3) δ 7.48 (d, J = 8.7 Hz, 2H, H2), 7.26 – 7.23 (m, 2H, H10), 7.19 – 
7.13 (m, 3H, H11, H12), 6.88 (d, J = 8.7 Hz, 2H, H3), 3.81 – 3.68 (m, 2H*), 3.62 – 3.49 (m, 
2H*), 3.24 – 3.17 (m, 4H*), 2.68 – 2.61 (m, 2H, H8), 2.40 – 2.32 (m, 2H, H5), 1.75 – 1.65 
(m, 4H, H6, H7). *Piperazine. 1H NMR matches literature data45. 13C NMR: (126 MHz, 
CDCl3) δ 171.5 (C=O), 153.0 (C4), 142.2 (C9), 128.5 (C10), 128.4 (C11), 126.5 (q, J = 3.8 
Hz, C2), 125.8 (C12), 124.7 (q, J = 271.3 Hz, CF3), 121.2 (q, J = 32.8 Hz, C1), 115.0 (C3), 
48.3 (C*), 48.1 (C*), 45.1 (C*), 41.1 (C*), 35.7 (C8), 33.1 (C5), 31.1 (C6), 24.9 
(C7).*Piperazine. 13C NMR matches literature data45.  HR-MS: calcd for C22H26F3N2O m/z: 
[M + H]+, 391.1992; found: 391.1996  [Diff (ppm) = 1.00]. Rf: 0.7 (4:1, EtOAc:n-hexane). 
IR (ATR): 2857 (C-H), 1636 (C=O), 1610 (C=C), 1436 (C=C), 1331 (C-F), 1068 (C-N) cm-1.  
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  Synthesis of 1-(4-(4-(trifluoromethyl)phenyl)piperazin-1-yl)ethanone 
(MK29) (RTC12) (30)  
     
Prepared from 1-(4-(trifluoromethyl)phenyl)piperazine (compound 2) (150 mg, 0.65 
mmol) and acetic acid (33 µL, 0.59 mmol) using HOBt (87 mg, 0.65 mmol), TBTU (208 
mg, 0.65 mmol), NEt3 (131 µL, 0.94 mmol) and DMF (3 mL) and following the general 
procedure described in section 5.2.1. The reaction mixture was stirred at rt for 23 hours. 
DMF was removed under reduced pressure and the residue was purified using column 
chromatography (4:1, EtOAc:n-hexane) to give an off-white solid, 117 mg (73%). 
1H NMR: (500 MHz, CDCl3) δ 7.50 (d, J = 8.6 Hz, 2H, H2), 6.92 (d, J = 8.7 Hz, 2H, H3), 3.84 
– 3.71 (m, 2H*), 3.70 – 3.57 (m, 2H*), 3.35 – 3.19 (m, 4H*), 2.14 (s, 3H, CH3). *Piperazine. 
1H NMR matches literature data45. 13C NMR: (126 MHz, CDCl3) δ 169.1 (C=O), 152.9 (C4), 
126.5 (q, J = 3.3 Hz, C2), 124.6 (q, J = 277.2 Hz, CF3), 121.2 (q, J = 32.8 Hz, C1), 115.0 (C3), 
48.3 (C*), 48.0 (C*), 45.8 (C*), 41.0 (C*), 21.3 (CH3).*Piperazine. 13C NMR matches 
literature data45. HR-MS: calcd for C13H15F3N2ONa m/z: [M + Na]+, 295.1029; found: 
295.1037 [Diff (ppm) = 2.9]. Rf: 0.5 (4:1, EtOAc:n-hexane). IR (ATR): 3222 (C-H), 1614 




  Synthesis of 1-methyl-4-(4-(trifluoromethyl)phenyl)piperazine (MK35) 
(RTC31) (35)  
    
Prepared from 1-(4-(trifluoromethyl)phenyl)piperazine (compound 2) (70 mg, 0.30 
mmol) dissolved in absolute EtOH (3 mL) before formic acid (200 µL, 5.23 mmol) and 
formaldehyde (147 µL, 1.54 mmol) were consecutively added. The solution was heated 
at reflux for 3 hrs after which the EtOH was removed under reduced pressure and the 
residue dissolved in minimal H2O (2 mL). The aqueous solution was neutralised to pH ~ 
13 using saturated aqueous NaHCO3 (4 mL) and extracted with DCM (4 x 10 mL). The 
organic layers were dried over MgSO4 and concentrated in vacuo. The residue was 
purified using column chromatography (1:1, EtOAc: Pet. Ether) to give a white solid, 51 
mg (70%). 
1H NMR: (500 MHz, CDCl3) δ 7.47 (d, J = 8.7 Hz, 2H, H2), 6.92 (d, J = 8.7 Hz, 2H, H3), 3.33 
– 3.26 (m, 4H*), 2.59 – 2.52 (m, 4H*), 2.35 (s, 3H, CH3).*Piperazine. 1H NMR matches 
literature data45. 13C NMR: (126 MHz, CDCl3) δ 153.3 (C4), 126.4 (q, J = 3.8 Hz, C2), 124.8 
(q, J = 271.1 Hz, CF3), 120.5 (q, J = 32.7 Hz, C1), 114.5 (C3), 54.8 (CH3), 48.0 (C*), 46.1 
(C*). *Piperazine. 13C NMR matches literature data45. HR-MS: calcd for C12H16F3N2 m/z: 
[M + H]+, 245.1260; found: 245.1257 [Diff (ppm) = -1.22]. Rf: 0.1 (1:1, EtOAc:Pet. Ether). 




  General procedure of microwave synthesis of aminopyrazoles  
A microwave tube (10 mL) was charged with ketonitrile (2.0 mmol), MeOH (1 mL), and 
hydrazine monohydrate (2.6 mmol) and subjected to microwave irradiation (100 W, 150 
°C) for 5 minutes. Volatiles were subsequently removed under reduced pressure. The 
mixture was purified by either trituration with cold MeOH or cyclohexane, or by using 
column chromatography to give the final product. 
  General procedure of one-pot synthesis of pyrazolopyrimidinones  
A microwave tube (10 mL) was charged with ketonitrile (0.9 mmol), MeOH (1 mL), and 
hydrazine monohydrate (1.2 mmol) and subjected to microwave irradiation (100 W, 150 
°C) for 5 minutes. Subsequently, to this solution was added ketoester (0.9 mmol) and 
acetic acid (0.5 mmol), and the mixture was subjected to microwave irradiation (100 W, 
150 °C) for 2 hours. Volatiles were removed under reduced pressure. The mixture was 
purified by either trituration with cold MeOH or ethyl acetate, or by using column 




  Synthesis of 3-phenyl-1H-pyrazol-5-amine (MK12, MK60, MK64, 
MK67) (32)  
 
MK12: Prepared from benzoyl acetonitrile (290 mg, 2.0 mmol), hydrazine monohydrate 
(130 mg, 2.6 mmol) and solvent (1 mL) and following the general procedure described 
in section 5.2.33 to perform a solvent screen. Purified by column chromatography (1:1, 
EtOAc: Pet.Ether). Reaction with MeOH as solvent gave a white solid, 316 mg (99%).  
MK60: Prepared from benzoyl acetonitrile (290 mg, 2.0 mmol), hydrazine monohydrate 
(130 mg, 2.6 mmol) and MeOH (2 mL) in a round-bottom flask and heated at reflux for 
17 hours. Volatiles were removed under reduced pressure and the product was purified 
by column chromatography (7:3, EtOAc, Pet.Ether) to give a white solid, 191 mg (60%).  
MK64: Prepared from benzoyl acetonitrile (290 mg, 2.0 mmol), hydrazine monohydrate 
(130 mg, 2.6 mmol) and MeOH (2 mL) and following the general procedure described in 
section 5.2.33, except for temperature set at 130 °C. Volatiles were removed under 
reduced pressure and the product was purified by column chromatography (1:1, EtOAc, 
Pet.Ether) to give a brown solid, 169 mg (53 %). 
MK67: Prepared from benzoyl acetonitrile (290 mg, 2.0 mmol), hydrazine monohydrate 
(130 mg, 2.6 mmol) and MeOH (2 mL) in a round-bottom flask and heated at reflux for 
5 mins. Volatiles were removed under reduced pressure and the product was purified 
by column chromatography (1:1, EtOAc, Pet.Ether) to give a green solid, 94 mg (30%).  
1H NMR: (500 MHz, CDCl3) δ 7.53 (d, J = 7.3 Hz, 2H, H3), 7.37 (t, J = 7.4 Hz, 2H, H2), 7.30 
(t, J = 7.3 Hz, 1H, H1), 5.90 (s, 1H, CH), 3.80 (bs, 1H, NH). 1H NMR data matches literature 
data94. 13C NMR: (126 MHz, CDCl3) δ 154.5 (C7), 145.6 (C5), 130.3 (C4), 128.9 (C2), 128.3 
(C1), 125.4 (C3), 90.5 (C6). 13C NMR data matches literature data94. HR-MS: calcd for 
C9H10N3 m/z: [M + H]+, 160.0869; found: 160.0872 [Diff (ppm) = -1.9]. MS data matches 
literature data94. Rf: 0.42 (7:3, EtOAc:Pet.Ether). IR (ATR): 3296 (N-H), 1564 (N-H), 1506 
(C-C), 1467 (C-C), 759 (N-H) cm-1.   
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  Synthesis of 3-(3-chlorophenyl)-1H-pyrazol-5-amine (MK14) (33)  
 
Prepared from 3-(3-chlorophenyl)-3-oxopropanenitrile (162 mg, 0.9 mmol), hydrazine 
monohydrate (59 mg, 1.2 mmol) and MeOH (1 mL) and following the general procedure 
described in section 5.2.33. Volatiles were removed under reduced pressure and the 
product was purified by column chromatography (1:1, EtOAc:Pet. Ether) to give a red 
solid, 364 mg (94%).  
1H NMR: (500 MHz, CDCl3) δ 7.53 (m, 1H, H3), 7.42 (dt, J = 7.2, 1.8 Hz, 1H, H5), 7.35 – 
7.27 (m, 2H, H1 & H6), 5.91 (s, 1H, CH).  1H NMR data matches literature data114. 13C 
NMR: (126 MHz, CDCl3) δ 154.0 (C9), 144.8 (C7), 134.9 (C4), 132.2 (C2), 130.2 (C6), 128.3 
(C1), 125.5 (C3), 123.4 (C5), 90.8 (C8). HR-MS: calcd for C9H9ClN3 m/z: [M + H]+, 
194.0480; found: 194.0480 [Diff (ppm) = 0.06]. MS data matches literature data114. Rf: 
0.11 (1:1, EtOAc:Pet.Ether). IR (KBr): 3325 (N-H), 2928 (C-H), 2850 (C-H), 1621 (N-H), 





  Synthesis of 3-(3-methoxyphenyl)-1H-pyrazol-5-amine (MK50) (34)  
 
Prepared from 3-(3-methoxyphenyl)-3-oxopropanenitrile (350 mg, 2.0 mmol), hydrazine 
monohydrate (130 mg, 2.6 mmol) and MeOH (2 mL) and following the general procedure 
described in section 5.2.33. Volatiles were removed under reduced pressure and the 
product was purified by column chromatography (3:2, EtOAc:Pet. Ether) to give a red 
solid, 278 mg (74%).   
1H NMR: (500 MHz, CDCl3) δ 7.18 (pseudo t, J = 8.2 Hz, 1H, H1), 7.12 – 7.07 (m, 2H, H3 & 
H5), 6.80 – 6.76 (m, 1H, H6), 5.79 (s, 1H. CH), 3.68 (s, 3H, OCH3).   1H NMR data matches 
literature data114. 13C NMR: (126 MHz, CDCl3) δ 159.8 (C2), 153.8 (C9), 146.1 (C7), 131.9 
(C4), 129.9 (C1), 118.0 (C3), 113.9 (C6), 110.9 (C5), 90.1 (C8), 55.2 (CH3). HR-MS: calcd 
for C10H12N3O m/z: [M + H]+, 190.0979; found: 190.0975 [Diff (ppm) = 1.97]. Rf: 0.18 (3:2, 
EtOAc:Pet.Ether). IR (ATR): 3401 (N-H), 3203 (Ar C-H), 3001 (alkene C-H), 2942 (alkane 




  Synthesis of 3-(3-nitrophenyl)-1H-pyrazol-5-amine (MK57) (35) 
 
Prepared from 3-(3-nitrophenyl)-3-oxopropanenitrile (190 mg, 1.0 mmol), hydrazine 
monohydrate (65 mg, 1.3 mmol) and MeOH (1 mL) and following the general procedure 
described in section 5.2.33. Volatiles were removed under reduced pressure and the 
product was purified by column chromatography (3:2, EtOAc:Pet. Ether) to give a yellow 
solid, 137 mg (67%).   
1H NMR: (500 MHz, CDCl3) δ 8.47 (pseudo t, J = 1.8 Hz, 1H, H1), 8.10 (ddd, J = 8.2, 2.3, 
1.0 Hz, 1H, H6), 7.98 (ddd, J = 7.9, 1.6, 1.0 Hz, 1H, H5), 7.57 (pseudo t, J = 7.9 Hz, 1H, H3), 
5.98 (s, 1H, CH).   1H NMR data matches literature data. 13C NMR: (126 MHz, CDCl3) δ 
152.3 (C9), 148.6 (C2), 146.3 (C7), 133.8 (C4), 130.8 (C5), 129.6 (C3), 121.8 (C6), 119.4 
(C1), 88.3 (C8). HR-MS: calcd for C9H9N4O2 m/z: [M + H]+, 205.0720; found: 205.0729 
[Diff (ppm) = -4.4]. Rf: 0.1 (3:2, EtOAc:Pet.Ether). IR (ATR): 3149 (N-H), 1607 (N-H), 1524 
(N-O), 1504 (C-C), 1346 (N-O), 737 (C-H) cm-1.   
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  Synthesis of 3-(4-bromophenyl)-1H-pyrazol-5-amine (MK52) (36)  
 
Prepared from (4-bromobenzoyl)acetonitrile (448 mg, 2.0 mmol), hydrazine 
monohydrate (130 mg, 2.6 mmol) and MeOH (2 mL) and following the general procedure 
described in section 5.2.33. Volatiles were removed under reduced pressure and the 
product was purified by column chromatography (3:2, EtOAc:Pet. Ether) to give a yellow 
solid, 280 mg (59%).   
1H NMR: (500 MHz, DMSO) δ 7.61 (d, J = 8.5 Hz, 2H, H3), 7.55 (d, J = 8.5 Hz, 2H, H2), 5.76 
(s, 1H, CH), 4.88 (bs, 2H, NH2). 13C NMR: (126 MHz, DMSO) δ 166.0 (C7), 151.2 (C5), 140.1 
(C4), 132.7 (C1), 131.9 (C2), 127.2 (C3), 120.5 (C6). HR-MS: calcd for C9H9BrN3 m/z: [M + 
H]+, 237.9974; found: 237.9973 [Diff (ppm) = -0.37]. Rf: 0.1 (3:2, EtOAc:Pet.Ether).  IR 




  Synthesis of 3-(thiophenyl-2-yl)-1H-pyrazol-5-amine (MK51) (37)  
 
Prepared from 3-oxo-3-(thiophen-2-yl)propanenitrile (302 mg, 2.0 mmol), hydrazine 
monohydrate (130 mg, 2.6 mmol) and MeOH (2 mL) and following the general procedure 
described in section 5.2.33. Volatiles were removed under reduced pressure and the 
product was purified by column chromatography (4:1, EtOAc:Pet. Ether) to give a yellow 
solid, 267 mg (81%).   
1H NMR: (500 MHz, CDCl3) δ 7.22 (dd, J = 5.1, 1.1 Hz, 1H, H1), 7.19 (dd, J = 3.6, 1.1 Hz, 
1H, H3), 6.99 (dd, J = 5.1, 3.6 Hz, 1H, H2), 5.78 (s, 1H, CH). 13C NMR: (126 MHz, CDCl3) δ 
152.8 (C7), 141.6 (C5), 133.6 (C4), 127.7 (C2), 124.9 (C1), 124.1 (C3), 90.1 (C6). HR-MS: 
calcd for C7H8N3S m/z: [M + H]+, 166.0433; found: 166.043 [Diff (ppm) = -2.3]. Rf: 0.1 
(4:1, EtOAc:Pet.Ether).  IR (ATR): 3366 (N-H), 3122 (Ar C-H), 2852 (alkene C-H), 1597 (N-





  Synthesis of 3-ethyl-1H-pyrazol-5-amine (MK54) (38)  
 
Prepared from 3-oxopentanenitrile (194 mg, 2.0 mmol), hydrazine monohydrate (130 
mg, 2.6 mmol) and MeOH (2 mL) and following the general procedure described in 
section 5.2.33. Volatiles were removed under reduced pressure and the product was 
purified by column chromatography (3:2, EtOAc:Pet. Ether) to give a red solid, 109 mg 
(49%).   
1H NMR: (500 MHz, CDCl3) δ 5.45 (s, 1H, CH), 2.57 (q, J = 7.5 Hz, 2H, CH2), 1.23 (t, J = 7.5 
Hz, 3H, CH3). 13C NMR: (126 MHz, CDCl3) δ 154.7 (C3), 147.3 (C1), 91.2 (C2), 19.4 (CH2), 
13.1 (CH3). HR-MS: calcd for C5H10N3 m/z: [M + H]+, 112.0869; found: 112.0874 [Diff 
(ppm) = 4.19]. Rf: 0.13 (3:2, EtOAc:Pet.Ether).  IR (ATR): 3181 (N-H), 2972 (alkane C-H), 




  Synthesis of 3-(tert-butyl)-1H-pyrazol-5-amine (MK53) (39)  
 
Prepared from pivaloylacetonitrile (250 mg, 2.0 mmol), hydrazine monohydrate (130 
mg, 2.6 mmol) and MeOH (2 mL) and following the general procedure described in 
section 5.2.33. Volatiles were removed under reduced pressure and the product was 
purified by column chromatography (3:2, EtOAc:Pet. Ether) to give a red solid, 216 mg 
(77%).   
1H NMR: (500 MHz, CDCl3) δ 5.42 (s, 1H, CH), 1.26 (s, 9H, 3 x CH3). 13C NMR: (126 MHz, 
CDCl3) δ 155.2 (C4), 154.1 (C2), 89.3 (C3), 31.0 (C1), 30.0 (CH3). HR-MS: calcd for C7H14N3 
m/z: [M + H]+, 140.1182; found: 140.1185 [Diff (ppm) = 1.65]. Rf: 0.12 (3:2, 
EtOAc:Pet.Ether). IR (ATR): 3360 (N-H), 3323 (N-H), 3115 (Ar C-H), 2962 (alkane C-H), 




  Synthesis of 2,5-diphenylpyrazolo[1,5-a]pyrimidin-7(4H)-one (MK15, 
MK65, MK68, MK91, MK92) (40)  
   
MK15: Prepared from benzoylacetonitrile (131 mg, 0.9 mmol) and ethyl benzoylacetate 
(173 mg, 0.9 mmol) and following the general procedure described in section 5.2.34. 
The reaction mixture was purified by recrystallization using EtOH to give a white solid, 
75 mg (29%). 
MK65: Prepared by heating 3-phenyl-1H-pyrazol-5-amine (compound 12) (143 mg, 0.9 
mmol), ethyl benzoylacetate (173 mg, 0.9 mmol), AcOH (27 mg, 0.5 mmol), in MeOH (2 
mL) in a round-bottom flask at reflux for 18 hours. Volatiles were subsequently removed 
under reduced pressure. The resulting residue was subjected to column 
chromatography (1:1, EtOAc:Pet. Ether) to give crude product that was further purified 
by trituration with EtOAc. The remaining residue, which contained the product, was 
dissolved in DCM (15 mL) and washed with aqueous NaHCO3 (conc, 15 mL). The resulting 
organic layer was separated, and the solvent removed under reduced pressure to give 
the white solid, 64 mg (25%).  
MK68: Prepared by heating 3-phenyl-1H-pyrazol-5-amine (compound 12) (143 mg, 0.9 
mmol), ethyl benzoylacetate (173 mg, 0.9 mmol), AcOH (27 mg, 0.5 mmol), in MeOH (2 
mL) in a round-bottom flask at reflux for 2 hours. Volatiles were subsequently removed 
under reduced pressure. The resulting residue was subjected to column 
chromatography (1:1, EtOAc:Pet. Ether) to give crude product that was further purified 
by trituration with EtOAc. The remaining residue, which contained the product, was 
dissolved in DCM (15 mL) and washed with aqueous NaHCO3 (conc, 15 mL). The resulting 
organic layer was separated, and the solvent removed under reduced pressure to give 
the white solid, 27 mg (11%).  
MK91: Prepared from benzoyl acetonitrile (131 mg, 0.9 mmol), hydrazine monohydrate 
(59 mg, 1.2 mmol) and MeOH (4 mL) in a round-bottom flask and heated at reflux for 5 
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minutes.  To this solution, ethyl benzoylacetate (173 mg, 0.9 mmol) and AcOH (27 mg, 
0.5 mmol) were added and heated at reflux for 2 hours. Volatiles were subsequently 
removed under reduced pressure. The resulting residue was subjected to column 
chromatography (1:1, EtOAc:Pet. Ether) to give a complex mixture with mostly starting 
material.  
MK92: Prepared from 3-phenyl-1H-pyrazol-5-amine (compound 12) (143 mg, 0.9 mmol), 
ethyl benzoylacetate (173 mg, 0.9 mmol), AcOH (27 mg, 0.5 mmol), in MeOH (2 mL) in a 
MW reactor tube (10 mL) and subjected to MW irradiation for 2 hours. Volatiles were 
subsequently removed under reduced pressure. The resulting residue was subjected to 
column chromatography (1:1, EtOAc:Pet. Ether) to give a white solid, 137 mg (53%).  
1H NMR: (126 MHz, DMSO) δ 12.61 (bs, 1H, NH), 8.02 – 7.94 (m, 2H, H11), 7.91 – 7.82 
(m, 2H, H3), 7.63 – 7.55 (m, 3H, H1 & H2), 7.48 – 7.40 (m, 3H, H12 & H13), 6.67 (s, 1H, 
CH), 6.10 (s, 1H, CHCO). 13C NMR: (126 MHz, DMSO) δ 156.2 (CO), 153.3 (C7), 149.8 (C5), 
143.2 (C9), 132.4 (C4), 132.3 (C10), 131.1 (C1), 129.0 (C2), 128.9 (C13), 128.7 (C12), 127.2 
(C3), 126.2 (C11), 94.0 (C6), 86.6 (C8). HR-MS: calcd for C18H14N3O m/z: [M + H]+, 
288.1131; found: 288.1118 [Diff (ppm) = -4.5] IR (KBr): 3126 (N-H), 3033 (C-H), 1669 




  Synthesis of 2-(furan-2-yl)-5-phenylpyrazolo[1,5-a]pyrimidin-7(4H)-
one (MK56) (41)  
   
Prepared from 2-furoylacetonitrile (136 mg, 0.9 mmol) and ethyl benzoylacetate (173 
mg, 0.9 mmol) and following the general procedure described in section 5.2.34. Volatiles 
were removed under reduced pressure and the product was purified by column 
chromatography (9:1, DCM: MeOH) to give a brown solid, 200 mg (50%). Product was 
recrystallized using 4:1 EtOH:H2O and a X-ray crystal structure was obtained.  
1H NMR: (500 MHz, DMSO) δ 12.58 (bs, 1H, NH), 7.90 – 7.85 (m, 2H, H3), 7.84 (dd, J = 
1.7, 0.6 Hz, 1H, H13), 7.64 – 7.56 (m, 3H, H1 & H2), 7.04 (dd, J = 3.3, 0.6 Hz, 1H, H11), 
6.66 (dd, J = 3.4, 1.7 Hz, 1H, H12), 6.45 (s, 1H, CH), 6.10 (s, 1H, CHCO). 13C NMR: (126 
MHz, DMSO) δ 156.7 (CO), 150.5 (C5), 148.3 (C10), 146.2 (C9), 144.2 (C13), 143.6 (C7), 
133.0 (C4), 131.5 (C1), 129.5 (C2), 127.7 (C3), 112.4 (C12), 109.0 (C11), 94.5 (C6), 86.8 
(C8). HR-MS: calcd for C16H11N3O2Na m/z: [M + Na]+, 300.0743; found: 300.0757 [Diff 
(ppm) = 4.70]. Rf: 0.5 (9:1, DCM: MeOH). IR (KBr): 3122 (N-H), 3059 (Ar C-H), 1669 (C=O), 




  Synthesis of 5-phenyl-2-(thiophen-2-yl)pyrazolo[1,5-a]pyrimidin-
7(4H)-one (MK55) (42)  
   
Prepared from 3-oxo-3-(thiophen-2-yl)propanenitrile (136 mg, 0.9 mmol) and ethyl 
benzoylacetate (173 mg, 0.9 mmol) and following the general procedure described in 
section 5.2.34. Volatiles were removed under reduced pressure and the product was 
purified by column chromatography (3:2, EtOAc:Pet. Ether) to give a yellow solid, 105 
mg (40%).  
1H NMR: (500 MHz, DMSO) δ 7.98 (d, J = 6.8 Hz, 2H, H3), 7.61 (d, J = 3.5 Hz, 1H, H13), 
7.53 (d, J = 5.0 Hz, 1H, H11), 7.51 – 7.38 (m, 3H, H1 & H2), 7.13 (dd, J = 5.0, 3.5 Hz, 1H, 
H12), 6.46 (s, 1H, CH), 6.09 (s, 1H, CHCO). 13C NMR: (126 MHz, DMSO) δ 158.4 (CO), 
155.6 (C5), 150.8 (C7), 148.3 (C10), 138.4 (C4), 137.7 (C9), 129.6 (C1), 128.9 (C2), 128.1 
(C12), 127.2 (C3), 126.2 (C11), 125.7 (C13), 90.7 (C6), 89.4 (C8). HR-MS: calcd for 
C16H12N3OS m/z: [M + H]+, 294.0696; found: 294.0696 [Diff (ppm) = 0.3]. Rf: 0.43 (3:2, 
EtOAc:Pet.Ether). IR (KBr): 3402 (N-H), 1667 (C=O), 1661 (Ar C-H), 768 (C-H) cm-1.   
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  Synthesis of 2-methyl-5-phenylpyrazolo[1,5-a]pyrimidin-7(4H)-one 
(MK62) (43)  
   
Prepared from 3-oxobutanenitrile (75 mg, 0.9 mmol) and ethyl benzoylacetate (173 mg, 
0.9 mmol) and following the general procedure described in section 5.2.34. Volatiles 
were removed under reduced pressure and the product was purified by trituration with 
EtOAc to give an off-white solid, 66 mg (33%).  
1H NMR: (500 MHz, DMSO) δ 12.34 (bs, 1H, NH), 7.86 – 7.81 (m, 2H, H3), 7.62 – 7.55 (m, 
3H, H1 & H2), 6.05 (s, 1H, CH), 6.00 (s, 1H, CHCO), 2.32 (s, 3H, CH3). 1H NMR matches 
literature data.115  13C NMR: (126 MHz, DMSO) δ 156.6 (CO), 152.6 (C9), 149.7 (C5), 142.9 
(C7), 132.9 (C4), 131.5 (C1), 129.5 (C2), 127.6 (C3), 94.1 (C6), 89.7 (C8), 14.6 (CH3). HR-
MS: calcd for C13H12N3O m/z: [M + H]+, 226.0975; found: 226.0979 [Diff (ppm) = -1.8]. IR 
(KBr): 3441 (N-H), 3088 (Ar C-H), 1674 (C=O), 1327 (alkane C-H), 771 (C-H) cm-1.   
280 
 
  Synthesis of 2-(tert-butyl)-5-phenylpyrazolo[1,5-a]pyrimidin-7(4H)-
one (MK59) (RTC81) (44)  
   
Prepared from pivaloylacetonitrile (113 mg, 0.9 mmol) and ethyl benzoylacetate (173 
mg, 0.9 mmol) and following the general procedure described in section 5.2.34. Volatiles 
were removed under reduced pressure and the product was purified by column 
chromatography (3:2, EtOAc:Pet.Ether) to give a white solid, 41 mg (17%).  
1H NMR: (500 MHz, DMSO) δ 12.45 (bs, 1H, NH), 7.95 – 7.89 (m, 2H, H3), 7.72 – 7.64 (m, 
3H, H1 & H2), 6.18 (s, 1H, CH), 6.09 (s, 1H, CHCO), 1.42 (s, 9H, 3 x CH3). 13C NMR: (126 
MHz, DMSO) δ 165.2 (C=O), 156.9 (C7), 149.9 (C5), 142.8 (C9), 133.0 (C4), 131.4 (C1), 
129.5 (C2), 127.7 (C3), 94.1 (C6), 86.5 (C8), 32.9 (C10), 30.6 (CH3). HR-MS: calcd for 
C16H18N3O m/z: [M + H]+, 268.1444; found: 268.1442 [Diff (ppm) = -0.9]. Rf: 0.2 (3:2, 
EtOAc:Pet.Ether). IR (KBr): 2966 (Ar C-H), 1659 (C=O), 1611 (C=C), 1324 (alkane C-H), 




  Synthesis of 2-(2-methoxyphenyl)-5-phenylpyrazolo[1,5-a]pyrimidin-
7(4H)-one (MK58) (45)  
    
Prepared from 2-methoxybenzoylacetonitrile (158 mg, 0.9 mmol) and ethyl 
benzoylacetate (173 mg, 0.9 mmol) and following the general procedure described in 
section 5.2.34. Volatiles were removed under reduced pressure and the product was 
purified by column chromatography (4:1, EtOAc:Pet.Ether) to give a white solid, 92 mg 
(32%).  
1H NMR: (500 MHz, MeOD) δ 7.99 (bs, 1H, H11), 7.85 (m, 2H, H3), 7.48 (m, 3H, H1 & H2), 
7.30 (pseudo t, 1H, H13), 7.05 – 7.02 (m, 1H, H14), 6.98 – 6.95 (m, 1H, H12), 6.73 (s, 1H, 
CH), 6.12 (s, 1H, CHCO), 3.89 (s, 3H, CH3).  13C NMR: (126 MHz, DMSO) δ 159.1 (CO), 
157.4 (C10), 156.4 (C5), 152.0 (C9), 149.4 (C7), 140.1 (C4), 129.4 (C13), 129.3 (C1), 128.9 
(C11), 128.7 (C2), 127.0 (C3), 123.3 (C15), 120.8 (C12), 112.3 (C14), 94.5 (C8), 89.0 (C6), 
56.0 (CH3). HR-MS: calcd for C19H16N3O2 m/z: [M + H]+, 318.1237; found: 318.1241 [Diff 
(ppm) = 1.3]. Rf: 0.43 (3:2, EtOAc:Pet.Ether). IR (KBr): 3444 (N-H), 1657 (C=O), 1602 (N-




  Synthesis of 2-(3-chlorophenyl)-5-phenylpyrazolo[1,5-a]pyrimidin-
7(4H)-one (MK7) (46)  
 
Prepared from 3-(3-chlorophenyl)-3-oxopropanenitrile (162 mg, 0.9 mmol) and ethyl 
benzoylacetate (173 mg, 0.9 mmol) and following the general procedure described in 
section 5.2.34. The reaction mixture was purified by trituration using cold MeOH to 
remove impurities and give a green solid, 131 mg (45%). 
1H NMR: (500 MHz, DMSO) δ 12.69 (bs, 1H, NH), 8.07 (s, 1H, H14), 8.00 (d, J = 7.5 Hz, 
1H, H13), 7.91 – 7.84 (m, 2H, H3), 7.67 – 7.56 (m, 3H, H1 & H2), 7.56 – 7.46 (m, 2H, H11 
& H12), 6.76 (s, 1H, H8), 6.12 (s, 1H, H6). 13C NMR: (126 MHz, DMSO) δ 158.9 (C-Cl), 
156.8 (CO), 152.3 (C9), 150.7 (C5), 135.0 (C7), 134.1 (C4), 131.6 (C1), 131.2 (C2), 129.6 
(C14), 129.2 (C13), 128.1 (C10), 127.8 (C3), 126.2 (C12), 125.3 (C11), 94.5 (C8), 87.7 (C6). 
HR-MS: calcd for C18H13N3O m/z: [M + H]+, 322.0742, found 322.0744 [Diff (ppm) = 0.72]. 
IR (KBr): 3062 (N-H), 1662 (C=O), 1607 (N-H), 1321 (Ar C-N), 772 (C-Cl) cm-1.  
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  Synthesis of 2-(4-fluorophenyl)-5-phenylpyrazolo[1,5-a]pyrimidin-
7(4H)-one (MK8) (47)  
 
Prepared from 3-(4-fluorophenyl)-3-oxopropanenitrile (147 mg, 0.9 mmol) and ethyl 
benzoylacetate (173 mg, 0.9 mmol) and following the general procedure described in 
section 5.2.34. The reaction mixture was purified by trituration using cold MeOH to 
remove impurities and give an orange solid, 183.7 mg (67%). 
1H NMR: (500 MHz, DMSO) δ 12.61 (bs, 1H, NH), 8.12 – 8.02 (m, 2H, H11), 7.91 – 7.84 
(m, 2H, H3), 7.66 – 7.56 (m, 3H, H1 & H2), 7.37 – 7.31 (m, 2H, H12), 6.67 (s, 1H, H8), 6.10 
(s, 1H, H6). 13C NMR: (126 MHz, DMSO) δ 163.1 (d, JCF = 246.3 Hz, C13), 156.7 (CO), 152.9 
(C9), 150.3 (C5), 143.7 (C7), 132.8 (C4), 131.6 (C1), 129.6 (C2), 129.4 (d, JCF  = 3.0 Hz, C10), 
128.8 (d, JCF = 8.4 Hz, C11), 127.8 (C3), 116.2 (d, JCF = 21.5 Hz, C12), 94.6 (C8), 87.1 (C6). 
HR-MS: calcd for C18H13FN3O m/z: [M + H]+, 306. 1037, found 306.1043 [Diff (ppm) = 
1.92]. Matches literature MS data.116 IR (KBr): 3060 (N-H), 1667 (C=O), 1609 (N-H), 1528 




  Synthesis of 5-phenyl-2-(p-tolyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one 
(MK9) (48)  
 
Prepared from 4-methylbenzoylacetonitrile (143.3 mg, 0.9 mmol) and ethyl 
benzoylacetate (173 mg, 0.9 mmol) and following the general procedure described in 
section 5.2.34. The reaction mixture was purified by trituration using cold MeOH to 
remove impurities and give a white solid, 122.3 mg (45%). 
1H NMR: (500 MHz, DMSO) δ 12.57 (bs, 1H, NH), 7.96 – 7.82 (m, 4H, H11 & H3), 7.65 – 
7.56 (m, 3H, H1 & H2), 7.30 (d, J = 7.8 Hz, 2H, H12), 6.62 (s, 1H, H8), 6.09 (s, 1H, H6), 2.37 
(s, 3H, CH3). 13C NMR: (126 MHz, DMSO) δ 156.7 (CO), 153.8 (C9), 150.2 (C5), 143.6 (C7), 
138.9 (C13), 132.8 (C4), 131.5 (C1), 130.1 (C10), 129.8 (C2), 129.5 (C11), 127.7 (C12), 
126.6 (C3), 94.5 (C8), 86.9 (C6), 21.4 (CH3). HR-MS: calcd for C19H16FN3O m/z: [M + H]+, 
302.1288, found 302.1291 [Diff (ppm) = 1.1]. IR (KBr): 3019 (C-H), 1667 (C=O), 1609 (N-





  Synthesis of 5-(4-nitrophenyl)-2-phenylpyrazolo[1,5-a]pyrimidin-
7(4H)-one (MK61) (49)  
   
Prepared from benzoylacetonitrile (131 mg, 0.9 mmol) and ethyl 4-nitrobenzoylacetate 
(213 mg, 0.9 mmol) and following the general procedure described in section 5.2.34. 
Volatiles were removed under reduced pressure and the product was purified by 
trituration with cold MeOH to give a yellow solid, 67 mg (22%).  
1H NMR: (500 MHz, DMSO) δ 8.40 (d, J = 8.8 Hz, 2H, H2), 8.14 (d, J = 8.8 Hz, 2H, H3), 8.01 
(d, J = 6.9 Hz, 2H, H11), 7.57 – 7.36 (m, 3H, H12 & H13), 6.67 (s, 1H, CH), 6.19 (s, 1H, 
CHCO). 13C NMR: (126 MHz, DMSO) δ 155.9 (CO), 153.6 (C7), 148.9 (C5), 147.7 (C1), 
143.3 (C9), 138.6 (C4), 132.4 (C10), 128.9 (C13), 128.8 (C12), 128.7 (C3), 126.3 (C11), 
123.9 (C2), 95.6 (C6), 86.9 (C8). HR-MS: calcd for C18H12N4O3Na m/z: [M + Na]+, 
355.0802; found: 355.0818 [Diff (ppm) = 4.6]. IR (KBr): 3122 (N-H), 3032 (Ar C-H), 1667 




  Synthesis of 5-(4-methoxyphenyl)-2-phenylpyrazolo[1,5-a]pyrimidin-
7(4H)-one (MK66) (50)  
   
Prepared from benzoylacetonitrile (131 mg, 0.9 mmol) and ethyl 4-
methoxybenzoylacetate (200 mg, 0.9 mmol) and following the general procedure 
described in section 5.2.34. Volatiles were removed under reduced pressure and the 
product was purified by column chromatography (1:1, EtOAc:Pet. Ether) to give a white 
solid, 47 mg (16%).  
1H NMR: (500 MHz, DMSO) δ 8.00 (m, 2H, H11), 7.85 (d, J = 8.8 Hz, 2H, H2), 7.47 (m, 3H, 
H12 & H13), 7.14 (d, J = 8.8 Hz, 2H, H3), 6.63 (s, 1H, CH), 6.05 (s, 1H, CHCO), 3.86 (s, 3H, 
OCH3). 13C NMR: (126 MHz, DMSO) δ 161.5 (C1), 156.3 (CO), 153.0 (C9), 149.6 (C7), 132.5 
(C10), 130.7 (C5), 128.9 (C13), 128.8 (C12), 128.7 (C3), 126.1 (C11), 124.4 (C4), 114.4 
(C2), 92.8 (C6), 86.5 (C8), 55.5 (O-CH3). HR-MS: calcd for C19H15N3O2Na m/z: [M + Na]+, 
340.1056; found: 340.1071 [Diff (ppm) = 4.4]. Rf: 0.59 (1:1, EtOAc:Pet.Ether). IR (KBr): 
3128 (N-H), 3061 (Ar C-H), 1662 (C=O), 1598 (N-H), 1575 (C=C), 1428 (alkane C-H), 770 




  Synthesis of 2-phenyl-5-(2,3,4,5-tetrafluorophenyl)pyrazolo[1,5-
a]pyrimidin-7(4H)-one (MK63) (51)  
   
Prepared from benzoylacetonitrile (131 mg, 0.9 mmol) and ethyl (2,3,4,5-
tetrafluorobenzoyl)acetate (323 mg, 0.9 mmol) and following the general procedure 
described in section 5.2.34. Volatiles were removed under reduced pressure and the 
product was purified by trituration with cold MeOH to give a yellow solid, 71 mg (22%).  
1H NMR: (500 MHz, DMSO) δ 8.05 – 8.01 (m, 2H, H9), 7.94 – 7.87 (m, 1H, H1), 7.53 – 
7.48 (m, 2H, H10), 7.46 – 7.42 (m, 1H, H11), 6.74 (s, 1H, CH), 6.01 (d, JHF = 0.8 Hz, 1H, 
CHCO).  13C NMR: (126 MHz, DMSO) δ 156.2 (C3), 154.1 (C5), 143.5 (C2), 142.8 (C7), 
132.7 (C8), 129.6 (C11), 129.2 (C10), 126.8 (C9), 113.3 (d, JCF = 19.3 Hz, C1), 97.9 (C4), 
87.4 (C6). 19F NMR: (471 MHz, MeOD) δ -140.2, -141.8, -154.8, -156.9. HR-MS: calcd for 
C18H10F4N3O m/z: [M + H]+, 360.0755; found: 360.0745 [Diff (ppm) = 2.8]. IR (KBr): 3124 
(N-H), 3066 (Ar C-H), 1664 (C=O), 1608 (C=C), 1089 (C-F), 769 (C-H) cm-1.   
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  Synthesis of 5-(3,5-dimethylphenyl)-2-methylpyrazolo[1,5-
a]pyrimidin-7(4H)-one (MK2) (52)  
 
Ethyl 3-(3,5-dimethylphenyl)-3-oxopropanoate (compound 1) (0.56 mL, 3.0 mmol) was 
added to a solution of 3-amino-5-methylpyrazole (132 mg, 1.0 mmol) dissolved in AcOH 
(5 mL) and refluxed overnight for 21 hours. Volatiles were removed under reduced 
pressure. The product was purified by column chromatography (100 % DCM) to give a 
beige solid, 204 mg, (59%). 
1H NMR: (500 MHz, MeOD) δ 7.42 (s, 2H, H3), 7.26 (s, 1H, H1), 6.13 (s, 1H, H8), 6.05 (s, 
1H, H6), 2.53 – 2.34 (m, 9H, CH3 x 3). 13C NMR: (126 MHz, MeOD) δ 138.9 (C2), 132.3 
(C1), 124.5 (C3), 19.9 (CH3). HR-MS: calcd for C13H16N3O m/z: [M + H]+, 254.1293; found: 
253.1207 [Diff (ppm) = 3.3]. Rf: 0.11 (100% DCM). IR (KBr): 3251 (N-H), 2917 (C-H), 1665 
(C=O), 1618 (N-H), 1597 (Ar C-C) cm-1. m.p.: 220-227 °C.  
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  Synthesis of ethyl 3-(3,5-dimethylphenyl)-3-oxopropanoate (MK1) (53)  
 
A solution of 3,5-dimethylbenzoic acid (255 mg, 2.0 mmol), Meldrum’s acid (299 mg, 2.0 
mmol), and DMAP (425 mg, 3.0 mmol), in anhydrous DCM (2.5 mL), was cooled to 0 °C. 
The reaction mixture was treated with a solution of DCC (386 mg, 2.0 mmol) in DCM (1.9 
mL) and was allowed to stir at rt for 5.5 hrs. The white precipitate was removed by 
gravity filtration and the filtrate was concentrated at reduced pressure. The residue was 
dissolved in absolute EtOH (10 mL) and treated with a solution of p-TSA.H2O (799 mg, 
4.0 mmol) in absolute EtOH (2.5 mL).  
The solution was heated at reflux under N2 for 1 hr. The EtOH was removed under 
reduced pressure and EtOAc was added until the residue dissolved. The solution was 
washed sequentially with H2O (2 x 10 mL), saturated aqueous NaHCO3 (2 x 5 mL), 1 M 
aqueous HCl (2 x 5 mL), and brine (2 x 5 mL). The organic layer was dried over MgSO4 
and evaporated at reduced pressure. The residue was purified by column 
chromatography (5:95, EtOAc:Pet.Ether) to give a yellow oil, 251 mg (67%).  
1H NMR: (500 MHz, CDCl3) (Keto form) δ 7.55 (s, 2H, H3), 7.22 (s, 1H, H1), 4.22 (q, J = 7.1 
Hz, 2H, OCH2CH3), 3.96 (s, 2H, CH2), 2.37 (s, 6H, Ar-CH3 x 2), 1.26 (t, J = 7.1 Hz, 3H, OCH-
2CH3). 1H NMR data matches literature data 117. 13C NMR: (126 MHz, CDCl3) (Keto form) 
δ 192.9 (C5), 167.7 (C7), 138.4 (C4), 135.4 (C2), 126.3 (C1), 123.9 (C3), 61.4 (C6), 46.0 
(CH2), 21.2 (Ar-CH3), 14.1 (CH3, C1). 13C NMR data matches literature data117 HR-MS: 
calcd for C13H16O3 m/z: [M + H]+, 221.1178; found: 221.1172 [Diff (ppm) = 1.15]. Rf: 0.27 
(5:95, EtOAc:Pet.Ether). IR (ATR): 2963 (C-H), 1738 (C=O ester), 1682 (C=O ketone), 1595 





  Synthesis of ethyl 3-(3,5-diethylphenyl)-3-oxopropanoate (MK4) (54)  
 
A solution of 3,5-diethylbenzoic acid (compound 57) (356 mg, 2.0 mmol), Meldrum’s 
acid (340 mg, 2.0 moles), and DMAP (480 mg, 3.0 mmol), in anhydrous DCM (10 mL), 
was cooled to 0 °C. The reaction mixture was treated with a solution of DCC (442 mg, 
2.0 mmol) in DCM (5 mL) and was allowed to stir overnight at rt. The white precipitate 
was removed by gravity filtration and the filtrate was concentrated at reduced pressure.  
The residue was dissolved in absolute EtOH (15 mL) and treated with a solution of p-
TSA.H2O (914 mg, 5.0 mmol) in absolute EtOH (5 mL).  
The solution was heated at refluxed under N2 for 2 hrs. The EtOH was removed under 
reduced pressure and EtOAc was added until the residue dissolved. The solution was 
washed sequentially with H2O (2 x 25 mL), saturated aqueous NaHCO3 (2 x 10 mL), 1 M 
aqueous HCl (2 x 15 mL), brine (2 x 20 mL). The organic layer was dried over MgSO4 and 
evaporated at reduced pressure. The residue was purified by column chromatography 
(elution gradient 5:95 DCM:Pet.Ether to DCM:Pet.Ether 4:6) to give a yellow oil, 359 mg 
(74%).  
1H NMR: (500 MHz, CDCl3) (Keto form) δ 7.61 (s, 2H, H3), 7.28 (s, 1H, H1), 4.25 (q, J = 7.1 
Hz, 2H, OCH2CH3), 3.99 (s, 2H, CH2), 2.69 (m, 4H, Ar-CH2CH3 x 2), 1.27 (m, 9H, OCH2CH3 
& Ar-CH2CH3 x 2). 13C NMR: (126 MHz, CDCl3) (Keto form) δ 192.9 (C5), 167.7 (C7), 144.9 
(C2), 136.3 (C4), 133.1 (C1), 125.4 (C3), 60.8 (OCH2CH3), 46.1 (C6), 28.7 (Ar-CH2CH3), 15.5 
(Ar-CH2CH3), 14.1 (OCH2CH3). HR-MS: calcd for C15H20O3 m/z: [M + H]+, 248.1412; found: 
248.142 [Diff (ppm) = 3.16]. Rf: 0.29 (3:7, DCM:Pet.Ether).  IR (ATR): 3322 (OH), 2928 (Ar 






  Synthesis of ethyl 3-(3,5-dimethoxyphenyl)-3-oxopropanoate (MK10) 
(55)  
 
A solution of 3,5-dimethoxybenzoic acid (1.439 g, 7.9 mmol), Meldrum’s acid (1.368 g, 
9.5 moles), and DMAP (1.93 g, 15.8 mmol), in anhydrous DCM (10 mL), was cooled to 0 
°C. The reaction mixture was treated with a solution of DCC (1.79 g, 8.7 mmol) in DCM 
(5 mL) and was allowed to stir overnight at rt. The white precipitate was removed by 
gravity filtration and the filtrate was concentrated at reduced pressure.  The residue was 
dissolved in absolute EtOH (10 mL) and treated with a solution of p-TSA.H2O (3.68 g, 19 
mmol) in absolute EtOH (5 mL).  
The solution was heated at refluxed under N2 for 2 hrs. The EtOH was removed under 
reduced pressure and EtOAc was added until the residue dissolved. The solution was 
washed sequentially with H2O (2 x 15 mL), saturated aqueous NaHCO3 (2 x 10 mL), 1 M 
aqueous HCl (2 x 10 mL), brine (2 x 10 mL). The organic layer was dried over MgSO4 and 
evaporated at reduced pressure. The residue was purified by column chromatography 
(1:1, EtOAc:Pet.Ether) to give a yellow oil, 748 mg (37%). 
1H NMR: (500 MHz, CDCl3) (Keto form) δ 7.05 (m, 2H, H3), 6.65 (m, 1H, H1), 4.22 (m, 2H, 
OCH2CH3), 3.94 (s, 2H, CH2), 3.81 (s, 6H, OCH3 x 2), 1.25 (t, J = 7.2 Hz, 3H, OCH2CH3). 1H 
NMR data matches literature data118. 13C NMR: (126 MHz, CDCl3) (Keto form) δ 192.1 
(C5), 167.4 (C7), 160.9 (C2), 137.8 (C4), 106.1 (C3), 105.9 (C1), 61.3 (CH2), 55.4 (OCH3 x 
2), 46.0 (C6), 14.0 (CH3, C1). 13C NMR data matches literature data118. HR-MS: calcd for 
C13H16O5Na m/z: [M + Na]+, 275.0890; found: 275.0888 [Diff (ppm) = - 0.7]. Rf: 0.73 (1:1, 
EtOAc:Pet.Ether). IR (KBr): 2917 (C-H), 1737 (C=O), 1591 (Ar C-C), 1152 (C-O) cm-1. IR 




  Synthesis of ethyl 3-(3,5-dinitrophenyl)-3-oxopropanoate (MK11) (56)  
 
A solution of 3,5-dinitrobenzoic acid (1.51 g, 7.1 mmol), Meldrum’s acid (1.227 g, 8.5 
moles), and DMAP (1.735 g, 14.2 mmol), in anhydrous DCM (10 mL), was cooled to 0 °C. 
The reaction mixture was treated with a solution of DCC (1.61 g, 7.8 mmol) in DCM (5 
mL) and was allowed to stir overnight at rt. The white precipitate was removed by gravity 
filtration and the filtrate was concentrated at reduced pressure.  The residue was 
dissolved in absolute EtOH (10 mL) and treated with a solution of p-TSA.H2O (3.31 g, 17.4 
mmol) in absolute EtOH (5 mL).  
The solution was heated at refluxed under N2 for 2 hrs. The EtOH was removed under 
reduced pressure and EtOAc was added until the residue dissolved. The solution was 
washed sequentially with H2O (2 x 15 mL), saturated aqueous NaHCO3 (2 x 10 mL), 1 M 
aqueous HCl (2 x 10 mL), brine (2 x 10 mL). The organic layer was dried over MgSO4 and 
evaporated at reduced pressure. The residue was purified by column chromatography 
(1:1, EtOAc:Pet.Ether) to give a yellow solid, 211 mg (11%). 
1H NMR: (500 MHz, CDCl3) (Keto form) δ 9.22 (m, 1H, H1), 8.90 (m, 2H, H3), 4.32 (q, J = 
7.0 Hz, 2H, OCH2CH3), 4.12 (s, 2H, CH2), 1.36 (t, J = 7.0 Hz, 3H, OCH2CH3). 13C NMR: (126 
MHz, CDCl3) (Keto form) δ 193.3 (C5), 172.3 (C2), 165.5 (C7), 148.8 (C4), 127.9 (C1), 125.8 
(C3), 61.3 (CH2), 45.9 (C6), 14.0 (CH3). HR-MS: calcd for C11H10O7N2Na m/z: [M + Na]+, 
305.0380; found: 305.0388 [Diff (ppm) = 2.6]. Rf: 0.8 (1:1, EtOAc:Pet.Ether). IR (KBr): 




  Synthesis of 3,5-diethylbenzoic acid (MK3) (57)  
 
Magnesium turnings (170 mg, 7.0 mmol) were added under a N2 atmosphere to an oven-
dried 2-necked round bottom flask via the septum, followed by a crystal of iodine and 
anhydrous THF (10 mL). 1-Bromo-3,5-diethylbenzene (0.82 mL, 5.0 mmol) was added to 
another 2-necked round bottom flask followed by anhydrous THF (5 mL). This solution 
was added dropwise to the flask containing magnesium and iodine via a cannula. THF (2 
mL) was added to the flask to rinse any remaining 1-Bromo-3,5-diethylbenzene solution, 
and transferred again via the cannula. The reaction was heated at reflux for 1 hr.  
Carbon dioxide was added by sublimation of crushed crystals of dry ice. The resulting 
gaseous carbon dioxide was bubbled into the reaction solution using a cannula. The 
reaction was added to hot water to remove the remaining THF. A few drops of 6 M HCl 
were added to the solution until pH paper indicated sufficient acidity. Crystallization was 
achieved by cooling the solution on ice. The product was purified by filtration to give a 
white solid, 781 mg (93%).  
1H NMR: (500 MHz, CDCl3) δ 7.77 (s, 2H, H3), 7.27 (s, 1H, H1), 2.69 (q, J = 7.6 Hz, 4H, CH2 
x 2), 1.27 (t, J = 7.6 Hz, 6H, CH3 x 2). 1H NMR data matches literature data119. 13C NMR: 
(126 MHz, CDCl3) δ 170.7 (CO), 144.7 (C2), 133.2 (C1), 129.0 (C4), 127.0 (C3), 28.7 (CH2), 
15.5 (CH3). 13C NMR data matches literature data119. HR-MS: calcd for C11H15O2 m/z: [M 
+ H]+, 179.1072; found: 178.0986 [Diff (ppm) = 4.45]. IR (KBr): 2968 (O-H), 1688 (C=O), 
1601 (Ar C-C), 1460 (C-H), 1241 (C-O), 936 (O-H) cm-1. IR data matches literature data119. 




  Synthesis of 5-(3,5-dimethylphenyl)-2-isopropylpyrazolo[1,5-
a]pyrimidin-7(4H)-one (MK6) (58)  
 
Ethyl 3-(3,5-dimethylphenyl)-3-oxopropanoate (compound 53) (28 mL, 1.4 mmol) was 
added to a solution of 3-isopropyl-1H-pyrazol-5-amine (176 mg, 1.4 mmol) dissolved in 
AcOH (5 mL) and refluxed for 5.5 hrs. Volatiles were removed under reduced pressure. 
The product was purified by trituration using EtOAc (10 mL) to remove impurities and 
give a white solid, 165.4 mg (42%). 
1H NMR: (500 MHz, CDCl3) δ 9.51 (bs, 1H, NH), 7.25 (s, 2H, H3), 7.13 (s, 1H, H1), 6.00 (m, 
2H, H6 & H8), 3.10 (septet, 1H, H10), 2.34 (s, 6H, Ar-CH3 x 2), 1.28 (d, J = 7.0 Hz, 6H, CH3 
x 2). 13C NMR: (126 MHz, CDCl3) δ 157.7 (C4), 141.6 (C2), 139.1 (C7), 132.8 (C5), 132.7 
(C1), 124.5 (C3), 94.6 (C6), 86.7 (C8), 28.6 (iPr-CH, C10), 22.5 (iPr-CH3), 21.3 (Ar-CH3). HR-
MS: calcd for C17H20N3O m/z: [M + H]+, 281.1528 ; found: 281.1528 [Diff (ppm) = 0.06]. 





  Synthesis of 5-(3,5-diethylphenyl)-2-isopropylpyrazolo[1,5-
a]pyrimidin-7(4H)-one (MK5) (59) 
 
Ethyl 3-(3,5-diethylphenyl)-3-oxopropanoate (compound 54) (50 mg, 0.2 mmol) was 
added to a solution of 3-isopropyl-1H-pyrazol-5-amine (25 mg, 0.2 mmol) dissolved in 
AcOH (5 mL) and refluxed overnight. Volatiles were removed under reduced pressure. 
The product was purified by trituration using EtOAc (5 mL) followed column 
chromatography (elution gradient 7:3 EtOAc:DCM to EtOAc: DCM 9:1) to give a light 
brown solid, 12.2 mg (20%). 
1H NMR: (500 MHz, CDCl3) δ 11.00 (bs, 1H, NH), 7.37 (s, 2H, H3), 7.12 (s, 1H, H1), 6.03 
(m, 2H, H6 & H8), 2.98 (bs, 1H, H10), 2.60 (q, J = 7.5 Hz, 4H, CH2CH3 x 2), 1.16 (m, 12H, 
CH3 x 4). 13C NMR: (126 MHz, CDCl3) δ 145.4 (C2), 132.8 (C5), 130.5 (C1), 123.8 (C3), 94.3 
(C6), 87.0 (C8), 28.7 (CH2CH3), 28.5 (iPr-CH, H10), 22.4 (iPr-CH3), 15.3 (CH2CH3). Rf: 0.44 
(7:3 EtOAc:DCM). IR (KBr): 2963 (N-H), 2924 (C-H), 1661 (C=O), 1619 (N-H), 1564 (Ar C-




  Synthesis of 5-(3,5-dimethoxyphenyl)-2-isopropylpyrazolo[1,5-
a]pyrimidin-7(4H)-one (MK13) (60)  
   
Ethyl 3-(3,5-dimethoxyphenyl)-3-oxopropanoate (compound 55) (200 mg, 0.79 mmol) 
was added to a solution of 3-isopropyl-1H-pyrazol-5-amine (100 mg, 0.79 mmol) 
dissolved in AcOH (5 mL) and refluxed for 20 hrs. Volatiles were removed under reduced 
pressure. The product was purified by column chromatography (100% EtOAc) to give a 
yellow-brown solid, 45 mg (18%).  
1H NMR: (500 MHz, DMSO) δ 10.19 (s, 1H, NH), 7.08 (s, 2H, H3), 6.60 (s, 1H, H1), 6.07 (s, 
1H, H6), 6.03 (s, 1H, H8), 3.83 (s, 6H, O-CH3 x 2), 3.13 – 3.06 (m, 1H, H10), 1.24 (d, J = 6.8 
Hz, 6H, CH3 x 2). 13C NMR: (126 MHz, DMSO) δ 162.4 (C9), 161.0 (C2), 153.7 (C4), 147.5 
(C7), 138.8 (C5), 105.4 (C3), 102.1 (C1), 91.0 (C6), 88.5 (C8), 55.9 (O-CH3 x 2), 28.2 (C10), 
23.2 (CH3 x 2). HR-MS: calcd for C17H20N3O3 m/z: [M + H]+, 314.1499; found: 314.1511 
[Diff (ppm) = 3.8]. Rf: 0.59 (100% EtOAc). IR (KBr): 2962 (C-H), 1660 (C=O), 1595 (N-H), 




  Synthesis of 5-(3,5-dinitrophenyl)-2-isopropylpyrazolo[1,5-
a]pyrimidin-7(4H)-one (MK49) (61)  
   
Prepared from 4-methyl-3-oxopentanenitrile (50 mg, 0.45 mmol) and ethyl 3-(3,5-
dinitrophenyl)-3-oxopropanoate (compound 56) (127 mg, 0.45 mmol) and following the 
general procedure described in section 5.2.34. Volatiles were removed under reduced 
pressure and the reaction mixture was purified by column chromatography (1:1, 
EtOAc:Pet.Ether) to give a red solid, 20 mg (13%). 
1H NMR: (500 MHz, DMSO) δ 12.56 (s, 1H, NH), 9.07 (s, 2H, H3), 8.92 (s, 1H, H1), 6.09 (s, 
1H, H8), 6.01 (s, 1H, H6), 2.79 (s, 1H, H10), 1.26 (d, J = 6.9 Hz, 6H, 2 x CH3). 13C NMR: (126 
MHz, DMSO) δ 127.3 (C3), 119.8 (C1), 96.9 (C6), 22.7 (2 x CH3), 18.9 (C10). Rf: 0.43 (1:1, 





  Synthesis of 5-(3,5-bis(trifluoromethyl)phenyl)-2-(2-
chlorophenyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one (MK80) (62)  
   
Prepared from 3-(2-chlorophenyl)-3-oxopropanenitrile (162 mg, 0.9 mmol) and ethyl 3-
(3,5-bis(trifluoromethyl)phenyl)-3-oxopropanoate (295 mg, 0.9 mmol) and following the 
general procedure described in section 5.2.34. Volatiles were removed under reduced 
pressure and the product was purified by column chromatography (3:2, EtOAc:DCM) to 
give a green solid, 12 mg (3%).  
1H NMR: (500 MHz, DMSO) δ 8.73 (s, 2H, H3), 8.15 (s, 1H, H1), 8.03 (d, J = 8.4 Hz, 1H, 
H14), 7.61 (d, J = 7.2 Hz, 1H, H11), 7.56 – 7.42 (m, 2H, H12, H13), 6.69 (s, 1H, CH), 6.33 
(s, 1H, CHCO). 13C NMR: (126 MHz, DMSO) δ 152.9 (C4), 144.8 (C15), 131.6 (C14), 130.6 
(C11), 129.6 (C12), 128.5 (C5), 127.5 (C13), 127.2 (C3), 122.1 (C1), 94.8 (C8), 89.4 (C6). 
HR-MS: calcd for C20H10ClN3OF6Na m/z: [M + Na]+, 480.0309; found: 480.0314 [Diff 
(ppm) = 1.04]. Rf: 0.3 (3:2, EtOAc:DCM). IR (ATR): 2923 (aromatic C-H), 1609 (C=C), 1540 




  Synthesis of 5-(3,5-bis(trifluoromethyl)phenyl)-2-(2-
methoxyphenyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one (MK79) (63)  
   
Prepared from 3-(2-methoxyphenyl)-3-oxopropanenitrile (158 mg, 0.9 mmol) and ethyl 
3-(3,5-bis(trifluoromethyl)phenyl)-3-oxopropanoate (295 mg, 0.9 mmol) and following 
the general procedure described in section 5.2.34. Volatiles were removed under 
reduced pressure and the product was purified by column chromatography (3:2, 
EtOAc:n-hexane) to give a yellow solid, 66 mg (16%).  
1H NMR: (500 MHz, DMSO) δ 8.67 (s, 2H, H3), 8.15 – 8.04 (m, 2H, H1, H14), 7.34 (pseudo 
t, J = 7.8 Hz, 1H, H12), 7.13 (d, J = 8.2 Hz, 1H, H11), 7.02 (t, J = 7.4 Hz, 1H, H13), 6.72 (s, 
1H, CH), 6.31 (s, 1H, CHCO), 3.91 (s, 3H, CH3). 13C NMR: (126 MHz, DMSO) δ 159.1 (C=O), 
157.5 (C15), 152.9 (C4), 152.1 (C7), 149.6 (C9), 130.9 (q, J = 32.7 Hz, CF3), 129.7 (C12), 
129.5 (C14), 127.2 (C3), 124.0 (q, J = 273.2 Hz, C2), 123.1 (C10), 122.1 (C1), 120.8 (C13), 
112.4 (C11), 95.4 (C8), 89.1 (C6), 56.1 (CH3). HR-MS: calcd for C21H13N3O2F6Na m/z: [M + 
Na]+, 476.0804; found: 476.0817 [Diff (ppm) = 2.8]. Rf: 0.13 (3:2, EtOAc:n-hexane). IR 




  Synthesis of 5-(3,5-bis(trifluoromethyl)phenyl)-2-(3-
chlorophenyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one (MK82) (64)  
   
Prepared from 3-(3-chlorophenyl)-3-oxopropanenitrile (162 mg, 0.9 mmol) and ethyl 3-
(3,5-bis(trifluoromethyl)phenyl)-3-oxopropanoate (295 mg, 0.9 mmol) and following the 
general procedure described in section 5.2.34. Volatiles were removed under reduced 
pressure and the product was purified by column chromatography (3:2, EtOAc:DCM) to 
give a green solid, 34 mg (8%).  
1H NMR: (500 MHz, DMSO) δ 8.65 (s, 2H, H3), 8.09 (s, 1H, H1), 8.02 (s, 1H, H15), 7.92 (d, 
J = 7.9 Hz, 1H, H13), 7.48 (pseudo t, J = 7.8 Hz, 1H, H12), 7.39 (d, J = 7.0 Hz, 1H, H11), 
6.67 (s, 1H, CH), 6.23 (s, 1H, CHCO). 13C NMR: (126 MHz, DMSO) δ 152.9 (C4), 130.8 
(C12), 127.8 (C11), 127.2 (C3), 125.8 (C15), 125.1 (C2), 124.9 (C13), 121.9 (C1), 90.8 (C8), 
89.6 (C6). HR-MS: calcd for C20H10ClN3OF6Na m/z: [M + Na]+, 480.0309; found: 480.0317 
[Diff (ppm) = 1.7]. Rf: 0.25 (3:2, EtOAc:DCM). IR (ATR): 2924 (aromatic C-H), 1603 (C=C), 




  Synthesis of 5-(3,5-bis(trifluoromethyl)phenyl)-2-(3-
methoxyphenyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one (MK81) (65)  
   
Prepared from 3-(3-methoxyphenyl)-3-oxopropanenitrile (158 mg, 0.9 mmol) and ethyl 
3-(3,5-bis(trifluoromethyl)phenyl)-3-oxopropanoate (295 mg, 0.9 mmol) and following 
the general procedure described in section 5.2.34. Volatiles were removed under 
reduced pressure and the product was purified by column chromatography (3:2, 
EtOAc:DCM) to give a green solid, 28 mg (7%).  
1H NMR: (500 MHz, DMSO) δ 8.65 (s, 2H, H3), 8.12 (s, 1H, H1), 7.61 – 7.49 (m, 2H, H13, 
H15), 7.36 (pseudo t, J = 7.8 Hz, 1H, H12), 6.92 (dd, J = 8.6, 2.1 Hz, 1H, H11), 6.67 – 6.59 
(m, 1H, CH), 6.29 – 6.21 (m, 1H, CHCO), 3.84 (s, 3H, CH3). 13C NMR: (126 MHz, DMSO) δ 
159.9 (C14), 152.6 (C7), 152.4 (C4), 135.6 (C10), 130.0 (C12), 128.5 (C5), 127.3 (C3), 122.4 
(C1), 118.7 (C15), 114.2 (C11), 111.5 (C13), 90.9 (C8), 89.8 (C6), 55.6 (CH3). HR-MS: calcd 
for C21H13N3O2F6Na m/z: [M + Na]+, 476.0804; found: 476.0795 [Diff (ppm) = -1.89]. Rf: 
0.27 (3:2, EtOAc:DCM). IR (ATR): 2939 (aromatic C-H), 1603 (C=C), 1540 (C=C), 1476 




  Synthesis of 5-(3,5-bis(trifluoromethyl)phenyl)-2-(3-
nitrophenyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one (MK83) (66)  
   
Prepared from 3-(3-nitrophenyl)-3-oxopropanenitrile (171 mg, 0.9 mmol) and ethyl 3-
(3,5-bis(trifluoromethyl)phenyl)-3-oxopropanoate (295 mg, 0.9 mmol) and following the 
general procedure described in section 5.2.34. Volatiles were removed under reduced 
pressure and the product was purified by column chromatography (100% EtOAc) to give 
a yellow solid, 28 mg (7%).  
1H NMR: (500 MHz, MeOD) δ 8.42 (s, 1H, H15), 8.37 (s, 2H, H3), 7.96 (s, 1H, H1), 7.93 – 
7.82 (m, 2H, H11, H13), 7.38 (pseudo t, J = 7.9 Hz, 1H, H12), 6.27 (s, 1H, CH), 6.20 (s, 1H, 
CHCO). 13C NMR: (126 MHz, MeOD) δ 155.9 (C=O), 141.9 (C4), 132.5 (C13), 131.5 (C14), 
129.1 (C12), 127.3 (C3), 127.2 (C2), 124.4 (CF3), 122.3 (C11), 122.1 (C1), 120.4 (C15), 91.4 
(C8), 90.5 (C6). HR-MS: calcd for C20H10N4O3F6Na m/z: [M + Na]+, 491.0549; found: 
491.0562 [Diff (ppm) = 2.5]. Rf: 0.16 (100% EtOAc). IR (ATR): 3353 (N-H), 2923 (aromatic 
C-H), 1607 (C=C), 1533 (C=C), 1347 (N-O), 1277 (C-F), 1123 (C-F) cm-1.  
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  Synthesis of 5-(3,5-bis(trifluoromethyl)phenyl)-2-(p-tolyl)pyrazolo[1,5-
a]pyrimidin-7(4H)-one (MK71) (67)  
   
Prepared from 4-methylbenzoylacetonitrile (72 mg, 0.45 mmol) and ethyl 3-(3,5-
bis(trifluoromethyl)phenyl)-3-oxopropanoate (148 mg, 0.45 mmol) and following the 
general procedure described in section 5.2.34. Volatiles were removed under reduced 
pressure and the product was purified by column chromatography (3:2, EtOAc:DCM) to 
give a white solid, 17 mg (9%).  
1H NMR: (500 MHz, DMSO) δ 12.83 (s, 1H, NH), 8.56 (s, 2H, H3), 8.35 (s, 1H, H1), 7.92 (d, 
J = 7.9 Hz, 2H, H11), 7.32 (d, J = 7.9 Hz, 2H, H12), 6.68 (s, 1H, CH), 6.39 (s, 1H, CHCO), 
2.38 (s, 3H, CH3). 13C NMR: (126 MHz, DMSO) δ 153.9 (C10), 147.4 (C4), 143.9 (C9), 138.9 
(C13), 135.7 (C5), 129.8 (C12), 128.9 (C3), 126.7 (C11), 124.6 (C1), 122.4 (C2), 95.8 (C6), 
87.2 (C8), 21.4 (CH3). HR-MS: calcd for C21H12N3OF6 m/z: [M - H]+, 436.0890; found: 
436.0902 [Diff (ppm) = 2.7]. Rf: 0.14 (3:2, EtOAc:DCM). IR (ATR): 3481 (N-H), 2923 




  Synthesis of 5-(3,5-bis(trifluoromethyl)phenyl)-2-(4-
fluorophenyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one (MK72) (68)  
   
Prepared from 4-fluorobenzoylacetonitrile (75 mg, 0.45 mmol) and ethyl 3-(3,5-
bis(trifluoromethyl)phenyl)-3-oxopropanoate (148 mg, 0.45 mmol) and following the 
general procedure described in section 5.2.34. Volatiles were removed under reduced 
pressure and the product was purified by column chromatography (3:2, EtOAc:Pet. 
Ether) to give a yellow solid, 12 mg (6%).  
1H NMR: (500 MHz, DMSO) δ 8.62 (s, 2H, H3), 8.36 (bs, 1H, NH), 8.19 (s, 1H, H1), 8.02 
(dd, J = 8.5, 5.7 Hz, 2H, H11), 7.27 (pseudo t, J = 8.8 Hz, 2H, H12), 6.65 (s, 1H, CH), 6.33 
(s, 1H, CHCO). 13C NMR: (126 MHz, DMSO) δ 162.7 (d, JCF = 245.6 Hz, C13), 152.2 (C9), 
150.7 (C4), 149.7 (C7), 134.0 (C5), 131.1 (q, JCF = 33.0 Hz, C10), 128.6 (d, JCF = 8.0 Hz, 
C11), 127.9 (C3), 123.8 (q, J = 273.6 Hz, C2), 122.7 (C1), 115.80 (d, JCF = 21.6 Hz, C12), 
92.1 (C6), 89.4 (C8). HR-MS: calcd for C20H10F7N3ONa m/z: [M - H]+, 464.0604; found: 
464.0604 [Diff (ppm) = -0.1]. Rf: 0.1 (3:2, EtOAc:DCM). IR (ATR): 1672 (C=O), 1607 (C=C), 




  Synthesis of 5-(3,5-bis(trifluoromethyl)phenyl)-2-(4-
chlorophenyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one (MK75) (69)  
   
Prepared from 4-chlorobenzoylacetonitrile (162 mg, 0.9 mmol) and ethyl 3-(3,5-
bis(trifluoromethyl)phenyl)-3-oxopropanoate (295 mg, 0.9 mmol) and following the 
general procedure described in section 5.2.34. Volatiles were removed under reduced 
pressure and the product was purified by column chromatography (3:2, EtOAc:DCM) to 
give a yellow solid, 30 mg (7%).  
1H NMR: (500 MHz, DMSO) δ 8.65 (s, 2H, H3), 8.12 (s, 1H, H1), 7.97 (d, J = 8.4 Hz, 2H, 
H12), 7.48 (d, J = 8.4 Hz, 2H, H11), 6.63 (s, 1H, CH), 6.28 (s, 1H, CHCO). 13C NMR: (126 
MHz, DMSO) δ 128.9 (C11), 128.1 (C12), 127.4 (C3), 122.9 (C1), 90.4 (C8), 90.1 (C6). HR-
MS: calcd for C20H10ClN3OF6Na m/z: [M + Na]+, 480.0309; found: 480.0312 [Diff (ppm) = 
0.62]. Rf: 0.14 (3:2, EtOAc:DCM). IR (ATR): 3091 (aromatic C-H), 1603 (C=C), 1541 (C=C), 




  Synthesis of 5-(3,5-bis(trifluoromethyl)phenyl)-2-(4-
bromophenyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one (MK73) (70)  
   
Prepared from 4-bromobenzoylacetonitrile (202 mg, 0.9 mmol) and ethyl 3-(3,5-
bis(trifluoromethyl)phenyl)-3-oxopropanoate (295 mg, 0.9 mmol) and following the 
general procedure described in section 5.2.34. Volatiles were removed under reduced 
pressure and the product was purified by column chromatography (3:2, EtOAc:n-
hexane) to give a green-yellow solid, 47 mg (10%).  
1H NMR: (500 MHz, DMSO) δ 8.66 (s, 2H, H3), 8.09 (s, 1H, H1), 7.94 (d, J = 8.3 Hz, 2H, 
H12), 7.62 (d, J = 8.3 Hz, 2H, H11), 6.65 (s, 1H, CH), 6.28 (s, 1H, CHCO). 13C NMR: (126 
MHz, DMSO) δ 153.4 (C7), 152.7 (C4), 151.3 (C9), 143.1 (C5), 134.1 (d, JCBr = 5.9 Hz, C13), 
131.8 (C11), 128.5 (C12), 127.2 (C3), 124.0 (q, JCF = 273.2 Hz, C2), 122.1 (C1), 121.4 (C10), 
90.9 (C8), 89.6 (C6). HR-MS: calcd for C20H10BrN3OF6Na m/z: [M + Na]+, 523.9804; found: 
523.98526 [Diff (ppm) = 4.2]. Rf: 0.12 (3:2, EtOAc:n-hexane). IR (ATR): 1604 (C=C), 1541 




  Synthesis of 5-(3,5-bis(trifluoromethyl)phenyl)-2-(4-
methpxyphenyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one (MK74) (71)  
   
Prepared from 4-methoxybenzoylacetonitrile (158 mg, 0.9 mmol) and ethyl 3-(3,5-
bis(trifluoromethyl)phenyl)-3-oxopropanoate (295 mg, 0.9 mmol) and following the 
general procedure described in section 5.2.34. Volatiles were removed under reduced 
pressure and the product was purified by column chromatography (3:2, EtOAc:n-
hexane) to give a yellow-brown solid, 77 mg (19%).  
1H NMR: (500 MHz, DMSO) δ 8.66 (s, 2H, H3), 8.10 (s, 1H, H1), 7.86 (dd, J = 8.6, 4.6 Hz, 
2H, H12), 6.94 (dd, J = 11.8, 8.7 Hz, 2H, H11), 6.53 (s, 1H, CH), 6.32 (d, J = 16.1 Hz, 1H, 
CHCO), 3.76 (d, J = 8.4 Hz, 3H, CH3). 13C NMR: (126 MHz, DMSO) δ 159.6 (C13), 159.2 
(C7), 153.4 (C4), 152.8 (d, J = 20.7 Hz, C10), 142.8 (C5), 127.9 (d, J = 8.2 Hz, C12), 127.2 
(C3), 127.0 (C9), 124.0 (q, JCF = 273.6 Hz, C2), 122.2 (C1), 114.2 (d, J = 7.2 Hz, C11), 90.5 
(C8), 89.3 (C6), 55.5 (d, J = 4.1 Hz, CH3). HR-MS: calcd for C21H13N3O2F6Na m/z: [M + Na]+, 
476.0804; found: 476.0813 [Diff (ppm) = 1.9]. Rf: 0.1 (3:2, EtOAc:n-hexane). IR (ATR): 




  Synthesis of 5-(3,5-bis(trifluoromethyl)phenyl)-2-(4-
nitrophenyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one (MK76) (72)  
   
Prepared from 5-(4-nitrophenyl)-2H-pyrazol-3-amine (184 mg, 0.9 mmol) and ethyl 3-
(3,5-bis(trifluoromethyl)phenyl)-3-oxopropanoate (295 mg, 0.9 mmol) in a microwave 
tube (10 mL) with AcOH (27 mg, 0.5 mmol) in MeOH (2 mL) and subjected to microwave 
irradiation (100 W, 150 °C) for 2 hours. Volatiles were removed under reduced pressure 
and the product was purified by trituration with cold MeOH to give a yellow solid, 330 
mg (78%).  
1H NMR: (500 MHz, DMSO) δ 12.99 (s, 1H, NH), 8.56 (s, 2H, H3), 8.46 – 8.24 (m, 5H, H1, 
H11, H12), 6.91 (s, 1H, CH), 6.46 (s, 1H, CHCO). 13C NMR: (126 MHz, DMSO) δ 156.4 
(C=O), 151.9 (C9), 148.0 (C13), 147.6 (C4), 143.8 (C7), 139.1 (C10), 135.3 (C5), 131.4 (q, 
J = 33.4 Hz, C2), 129.1 (C3), 127.8 (C11), 125.0 (C1), 124.5 (C12), 123.5 (q, J = 273.6 Hz, 
CF3), 96.6 (C6), 88.5 (C8). HR-MS: calcd for C20H10N4O3F6Na m/z: [M + Na]+, 491.0549; 
found: 491.0544 [Diff (ppm) = -1.2]. IR (ATR): 2927 (aromatic C-H), 1667 (C=O), 1612 




  Synthesis of 5-(3,5-bis(trifluoromethyl)phenyl)-2-(4-
trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one (MK78) 
(73)  
   
Prepared from 4-trifluoromethylbenzoylacetonitrile (192 mg, 0.9 mmol) and ethyl 3-
(3,5-bis(trifluoromethyl)phenyl)-3-oxopropanoate (295 mg, 0.9 mmol) and following the 
general procedure described in section 5.2.34. Volatiles were removed under reduced 
pressure and the product was purified by column chromatography (3:2, EtOAc:n-
hexane) to give a green solid, 49 mg (11%).  
1H NMR: (500 MHz, DMSO) δ 8.71 (s, 2H, H3), 8.20 – 8.14 (m, 3H, H1, H12), 7.77 (d, J = 
8.1 Hz, 2H, H11), 6.74 (s, 1H, CH), 6.36 (s, 1H, CHCO). 13C NMR: (126 MHz, DMSO) δ 159.0 
(C=O), 153.3 (C4), 153.1 (C7), 151.8 (d, J = 32.8 Hz, C10), 150.9 (C9), 142.9 (C5), 137.5 (q, 
J = 313.3 Hz, CF3), 130.9 (q, J = 32.8 Hz, CF3), 127.3 (m, C3), 126.9 (C11), 125.6 (d, J = 6.9 
Hz, C12), 125.1 (C2), 124.9 (q, J = 274.8 Hz, C13), 122.9 (C-CF3), 122.2 (C1), 91.6 (C8), 
89.8 (C6). HR-MS: calcd for C21H10N3OF9Na m/z: [M + Na]+, 514.0572; found: 514.0576 
[Diff (ppm) = 0.8]. Rf: 0.12 (3:2, EtOAc:n-hexane). IR (ATR): 1604 (C=C), 1527 (C=C), 1322 




  Synthesis of 5-(3,5-bis(trifluoromethyl)phenyl)-2-(furan-2-
yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one (MK84) (74)  
   
Prepared from 3-(furan-2-yl)-3-oxopropanenitrile (122 mg, 0.9 mmol) and ethyl 3-(3,5-
bis(trifluoromethyl)phenyl)-3-oxopropanoate (295 mg, 0.9 mmol) and following the 
general procedure described in section 5.2.34. Volatiles were removed under reduced 
pressure and the product was purified by column chromatography (3:2, EtOAc:DCM) to 
give a red-brown solid, 28 mg (8%).  
1H NMR: (500 MHz, MeOD) δ 8.49 (s, 2H, H3), 8.10 (s, 1H, H1), 7.48 (s, 1H, H13), 6.89 (s, 
1H, H11), 6.50 (s, 1H, CH), 6.47 (s, 1H, H12), 6.33 (s, 1H, CHCO). 13C NMR: (126 MHz, 
MeOD) δ 154.0 (C4), 146.3 (C9), 142.5 (C13), 132.5 (C7), 129.8 (C10), 127.3 (C3), 124.5 
(CF3), 122.5 (C1), 110.1 (C12), 107.6 (C11), 91.3 (C6), 89.0 (C8). HR-MS: calcd for 
C18H10N3O2F6 m/z: [M + H]+, 414.0672; found: 414.0654 [Diff (ppm) = -4.35]. Rf: 0.22 (3:2, 
EtOAc:DCM). IR (ATR): 3111 (aromatic C-H), 1613 (C=C), 1542 (C=C), 1277 (C-F), 1169 (C-




  Synthesis of 5-(3,5-bis(trifluoromethyl)phenyl)-2-(thiophen-2-
yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one (MK85) (75)  
   
Prepared from 3-oxo-3-(thiophen-2-yl)propanenitrile (136 mg, 0.9 mmol) and ethyl 3-
(3,5-bis(trifluoromethyl)phenyl)-3-oxopropanoate (295 mg, 0.9 mmol) and following the 
general procedure described in section 5.2.34. Volatiles were removed under reduced 
pressure and the product was purified by column chromatography (3:2, EtOAc:DCM to 
100% EtOAc) to give a yellow solid, 29 mg (8%).  
1H NMR: (500 MHz, DMSO) δ 8.64 (s, 2H, H3), 8.08 (s, 1H, H1), 7.89 (bs, 1H, NH), 7.55 (s, 
1H, H13), 7.51 (d, J = 4.8 Hz, 1H, H12), 7.16 – 7.10 (m, 1H, H11), 6.47 (s, 1H, CH), 6.22 (s, 
1H, CHCO). 13C NMR: (126 MHz, DMSO) δ 153.2 (C7), 152.9 (C4), 148.0 (C9), 143.1 (C5), 
138.5 (C10), 130.9 (q, J = 32.6 Hz, CF3), 128.0 (C11), 127.2 (C3), 125.8 (C12), 125.0 (C13), 
124.0 (q, J = 273.2 Hz, C2), 122.0 (C1), 90.3 (C8), 89.7 (C6). HR-MS: calcd for C18H9N3OF-
6SNa m/z: [M + Na]+, 452.0263; found: 452.0272 [Diff (ppm) = 1.99]. Rf: 0.36 (3:2, 
EtOAc:DCM). IR (ATR): 2924 (aromatic C-H), 1604 (C=C), 1533 (C=C), 1275 (C-F), 1125 (C-
F) cm-1.  
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  Synthesis of 5-(3,5-bis(trifluoromethyl)phenyl)-2-(pyridin-3-
yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one (MK86) (76)  
   
Prepared from 3-oxo-3-(pyridin-3-yl)propanenitrile (132 mg, 0.9 mmol) and ethyl 3-(3,5-
bis(trifluoromethyl)phenyl)-3-oxopropanoate (295 mg, 0.9 mmol) and following the 
general procedure described in section 5.2.34. Volatiles were removed under reduced 
pressure and the product was purified by column chromatography (9:1, DCM:MeOH) to 
give an off-white solid, 12 mg (3%).  
1H NMR: (500 MHz, DMSO) δ 9.20 (s, 1H, H14), 8.67 (s, 2H, H3), 8.55 (dd, J = 4.7, 1.6 Hz, 
1H, H11), 8.37 – 8.31 (m, 1H, H13), 8.10 (s, 1H, H1), 7.63 – 7.59 (m, 1H, NH), 7.48 (ddd, 
J = 7.9, 4.8, 0.7 Hz, 1H, H12), 7.34 – 7.29 (m, 1H, NH), 6.74 (s, 1H, CH), 6.27 (s, 1H, CHCO). 
13C NMR: (126 MHz, DMSO) δ 153.3 (C7), 152.9 (C4), 150.5 (C10), 149.7 (C9), 149.2 (C11), 
147.6 (C14), 133.4 (C13), 127.1 (C3), 125.0 (C2), 124.1 (C12), 122.1 (C1), 90.8 (C8), 89.5 
(C6). HR-MS: calcd for C19H11N4OF6 m/z: [M + H]+, 447.0651; found: 447.0652 [Diff (ppm) 
= 1.65]. Rf: 0.38 (9:1, DCM:MeOH). IR (ATR): 3094 (Ar C-H), 1607 (N-H), 1541 (C=N), 1364 





6.01 Spectra for 4-(thiophen-2-yl)-1-(4-(4-(trifluoromethyl)phenyl)piperazin-











































6.03 Spectra for methyl 9-oxo-9-(4-(4-(trifluoromethyl)phenyl)piperazin-1-
yl)nonanoate (MK16) (RTC56) (3) 
 
Wavenumbers [1/cm]



































































6.04 Spectra for 1-(4-cyclohexylpiperazin-1-yl)-4-(thiophen-2-yl)butan-1-one 






6.05 Spectra for 4-(1H-Pyrazol-4-yl)-1-(4-(4-
(trifluoromethyl)phenyl)piperazin-1-yl)butan-1-one (MK69) (RTC193) (5) 
 
Wavenumbers [1/cm]

































































6.07 Spectra for 1-(4-phenylpiperazin-1-yl)-4-(thiophen-2-yl)butan-1-one 






6.08 Spectra for 4-(thiophen-2-yl)-1-(4-(2-
(trifluoromethyl)phenyl)piperazin-1-yl)butan-1-one (MK41) (RTC20) (8) 
 
Wavenumbers [1/cm]






























































6.09 Spectra for 1-(4-(3,5-bis(trifluoromethyl)phenyl)piperazin-1-yl)-4-






6.10 Spectra for 1-(4-(4-nitrophenyl)piperazin-1-yl)-4-(thiophen-2-yl)butan-
1-one (MK39) (RTC22) (10) 
 
Wavenumbers [1/cm]


































































6.11 Spectra for 1-(4-(4-aminophenyl)piperazin-1-yl)-4-(thiophen-2-






6.12 Spectra for 1-(4-(2-chloro-4-(trifluoromethyl)phenyl)piperazin-1-yl)-4-
(thiophen-2-yl)butan-1-one (MK20) (RTC8) (12) 
 
Wavenumbers [1/cm]




























































6.13 Spectra for 4-(thiophen-3-yl)-1-(4-(5-(trifluoromethyl)pyridin-2-






6.14 Spectra for 1-(4-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)piperazin-1-
yl)-4-(thiophen-2-yl)butan-1-one (MK45) (RTC6) (14) 
 
Wavenumbers [1/cm]































































6.15 Spectra for 1-(4-methylpiperazin-1-yl)-4-(thiophen-2-yl)butan-1-one 






6.16 Spectra for 4-(thiophen-2-yl)-1-(4-(4-
(trifluoromethyl)phenyl)piperidin-1-yl)butan-1-one (MK19) (RTC196) (16) 
 
Wavenumbers [1/cm]





























































6.17 Spectra for 4-(thiophen-2-yl)-N-(4-(trifluoromethyl)phenyl)butanamide 






6.18 Spectra for 1-(4-(thiophen-2-yl)butyl)-4-(4-
(trifluoromethyl)phenyl)piperazine (MK34) (RTC46) (18) 
 
Wavenumbers [1/cm]








































































































































6.21 Spectra for thiophen-2-yl (4-(4-(trifluoromethyl)phenyl)piperazin-1-yl) 






6.22 Spectra for 2-(thiophen-2-yl)-1-(4-(4-
(trifluoromethyl)phenyl)piperazin-1-yl)ethanone (MK47) (RTC536) (22) 
 
Wavenumbers [1/cm]


































































6.23 Spectra for 5-(thiophen-2-yl)-1-(4-(4-







6.24 Spectra for 1-(thiophen-2-yl)-4-(4-(4-



































































6.25 Spectra for 3-(thiophen-2-ylthio)-1-(4-(4-






6.26 Spectra for N,N-dimethyl-4-(thiophen-2-yl)butanamide (MK46) (26) 
 
Wavenumbers [1/cm]



























6.27 Spectra for 1-(4-phenylpiperidin-1-yl)-4-(thiophen-2-yl)butan-1-one 


































6.28 Spectra for 1-(thiophen-2-yl)-4-(4-(4-(trifluoromethyl)phenyl)piperidin-






6.29 Spectra for 5-phenyl-1-(4-(4-(trifluoromethyl)phenyl)piperazin-1-
yl)pentan-1-one  (MK30) (RTC16) (29) 
 
Wavenumbers [1/cm]
























































6.30 Spectra for 1-(4-(4-(trifluoromethyl)phenyl)piperazin-1-yl)ethanone 
















































































































































6.35 Spectra for 3-(3-nitrophenyl)-1H-pyrazol-5-amine (MK57) (35) 
 
Wavenumbers [1/cm]

































































6.37 Spectra for 3-(thiophenyl-2-yl)-1H-pyrazol-5-amine (MK51) (37) 
 
Wavenumbers [1/cm]



























































6.39 Spectra for 3-(tert-butyl)-1H-pyrazol-5-amine (MK53) (39) 
 
Wavenumbers [1/cm]

























































6.40 Spectra for 2,5-diphenylpyrazolo[1,5-a]pyrimidin-7(4H)-one (MK15, 







































































6.42 Spectra for 5-phenyl-2-(thiophen-2-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-

































































6.44 Spectra for 2-(tert-butyl)-5-phenylpyrazolo[1,5-a]pyrimidin-7(4H)-one 






6.45 Spectra for 2-(2-methoxyphenyl)-5-phenylpyrazolo[1,5-a]pyrimidin-
7(4H)-one (MK58) (45) 
 
Wavenumbers [1/cm]































































6.46 Spectra for 2-(3-chlorophenyl)-5-phenylpyrazolo[1,5-a]pyrimidin-







6.47 Spectra for 2-(4-fluorophenyl)-5-phenylpyrazolo[1,5-a]pyrimidin-
7(4H)- one (MK8) (47)  
 
Wavenumbers [1/cm]



















































6.48 Spectra for 5-phenyl-2-(p-tolyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one 






6.49 Spectra for 5-(4-nitrophenyl)-2-phenylpyrazolo[1,5-a]pyrimidin-7(4H)-
one (MK61) (49) 
 
Wavenumbers [1/cm]























































6.50 Spectra for 5-(4-methoxyphenyl)-2-phenylpyrazolo[1,5-a]pyrimidin-






6.51 Spectra for 2-phenyl-5-(2,3,4,5-tetrafluorophenyl)pyrazolo[1,5-
a]pyrimidin-7(4H)-one (MK63) (51) 
 
Wavenumbers [1/cm]



































6.52 Spectra for 5-(3,5-dimethylphenyl)-2-methylpyrazolo[1,5-a]pyrimidin-
7(4H)-one (MK2) (52) 
 
Wavenumbers [1/cm]



































































6.54 Spectra for ethyl 3-(3,5-diethylphenyl)-3-oxopropanoate (MK4) (54) 
 
Wavenumbers [1/cm]


































































6.56 Spectra for ethyl 3-(3,5-dinitrophenyl)-3-oxopropanoate (MK11) (56)  
 
Wavenumbers [1/cm]































































6.58 Spectra for 5-(3,5-dimethylphenyl)-2-isopropylpyrazolo[1,5-
a]pyrimidin-7(4H)-one (MK6) (58) 
 
Wavenumbers [1/cm]



























































6.59 Spectra for 5-(3,5-diethylphenyl)-2-isopropylpyrazolo[1,5-a]pyrimidin-






6.60 Spectra for 5-(3,5-dimethoxyphenyl)-2-isopropylpyrazolo[1,5-
a]pyrimidin-7(4H)-one (MK13) (60) 
 
Wavenumbers [1/cm]




















































6.61 Spectra for 5-(3,5-dinitrophenyl)-2-isopropylpyrazolo[1,5-a]pyrimidin-






6.62 Spectra for 5-(3,5-bis(trifluoromethyl)phenyl)-2-(2-
chlorophenyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one (MK80) (62) 
 
Wavenumbers [1/cm]
































































6.63 Spectra for 5-(3,5-bis(trifluoromethyl)phenyl)-2-(2-





6.64 Spectra for 5-(3,5-bis(trifluoromethyl)phenyl)-2-(3-
chlorophenyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one (MK82) (64) 
 
Wavenumbers [1/cm]


































6.65 Spectra for 5-(3,5-bis(trifluoromethyl)phenyl)-2-(3-
methoxyphenyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one (MK81) (65) 
 
Wavenumbers [1/cm]































































6.66 Spectra for 5-(3,5-bis(trifluoromethyl)phenyl)-2-(3-






6.67 Spectra for 5-(3,5-bis(trifluoromethyl)phenyl)-2-(p-tolyl)pyrazolo[1,5-
a]pyrimidin-7(4H)-one (MK71) (67) 
 
Wavenumbers [1/cm]


































































6.68 Spectra for 5-(3,5-bis(trifluoromethyl)phenyl)-2-(4-






6.69 Spectra for 5-(3,5-bis(trifluoromethyl)phenyl)-2-(4-
chlorophenyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one (MK75) (69) 
 
Wavenumbers [1/cm]



























































6.70 Spectra for 5-(3,5-bis(trifluoromethyl)phenyl)-2-(4-






6.71 Spectra for 5-(3,5-bis(trifluoromethyl)phenyl)-2-(4-
methoxyphenyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one (MK74) (71) 
 
Wavenumbers [1/cm]





























































6.72 Spectra for 5-(3,5-bis(trifluoromethyl)phenyl)-2-(4-






6.73 Spectra for 5-(3,5-bis(trifluoromethyl)phenyl)-2-(4-
(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one (MK78) (73) 
 
Wavenumbers [1/cm]


































































6.74 Spectra for 5-(3,5-bis(trifluoromethyl)phenyl)-2-(furan-2-


































6.75 Spectra for 5-(3,5-bis(trifluoromethyl)phenyl)-2-(thiophen-2-
































6.76 Spectra for 5-(3,5-bis(trifluoromethyl)phenyl)-2-(pyridin-3-





































X-Ray Crystallographic Data 
An Oxford Diffraction Xcalibur system was used to collect X-ray diffraction data at room 
temperature. The crystal structures were solved using ShelxT and refined using ShelxL 
within the Oscail package.120,121 
Crystallographic data (excluding structure factors) for MK56b (compound 41) have been 
deposited with the Cambridge Crystallographic Data Centre as supplementary 
publication CCDC 1588686. Copies of the data can be obtained, free of charge, on 
application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK, (fax: +44-(0)1223-336033 
or e-mail: deposit@ccdc.cam.ac.uk). 
 
Table 1.  Crystal data and structure refinement for mk56b. 
Identification code  mk56b 
Empirical formula  C16 H11 N3 O2 
Formula weight  277.28 
Temperature  298.5(9) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 6.6464(6) Å = 82.880(10)°. 
 b = 7.0114(9) Å = 86.962(8)°. 
 c = 15.0626(16) Å  = 72.352(10)°. 
Volume 663.64(13) Å3 
Z 2 
Density (calculated) 1.388 Mg/m3 
Absorption coefficient 0.095 mm-1 
F(000) 288 
Crystal size 0.50 x 0.40 x 0.02 mm3 
Theta range for data collection 3.723 to 29.168°. 
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Index ranges -8<=h<=7, -9<=k<=9, -16<=l<=20 
Reflections collected 4838 
Independent reflections 3011 [R(int) = 0.0233] 
Completeness to theta = 25.242° 99.7%  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.00000 and 0.69643 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3011 / 1 / 195 
Goodness-of-fit on F2 1.048 
Final R indices [I>2sigma(I)] R1 = 0.0593, wR2 = 0.1313 
R indices (all data) R1 = 0.1145, wR2 = 0.1614 
Extinction coefficient 0.010(4) 





Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) 
for mk56b.  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
O(1) 1978(2) 2474(3) 5142(1) 69(1) 
N(2) 5084(2) 2450(3) 5702(1) 43(1) 
N(1) 8044(2) 2440(3) 4783(1) 42(1) 
N(3) 4405(3) 2463(3) 6565(1) 55(1) 
O(2) 7624(5) 2616(4) 8381(2) 112(1) 
C(1) 6930(3) 2451(3) 4051(2) 42(1) 
C(2) 4879(3) 2453(3) 4156(2) 46(1) 
C(3) 3826(3) 2448(3) 4985(2) 47(1) 
C(4) 6113(4) 2433(4) 7007(2) 56(1) 
C(5) 7855(4) 2418(4) 6447(2) 50(1) 
C(6) 7159(3) 2425(3) 5612(2) 40(1) 
C(7) 8036(4) 2469(4) 3182(2) 50(1) 
C(8) 9609(4) 3399(4) 3023(2) 62(1) 
C(9) 10656(5) 3352(5) 2210(2) 89(1) 
C(10) 10129(7) 2453(6) 1545(2) 110(1) 
C(11) 8543(7) 1565(6) 1691(2) 107(1) 
C(12) 7509(5) 1561(5) 2504(2) 75(1) 
C(13) 5920(5) 2488(4) 7964(2) 74(1) 
C(14) 4379(7) 2428(6) 8561(3) 112(1) 
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C(15) 5162(11) 2539(8) 9408(3) 148(2) 




 Table 3.   Bond lengths [Å] and angles [°] for mk56b. 
_____________________________________________________  
O(1)-C(3)  1.233(2) 
N(2)-N(3)  1.354(2) 
N(2)-C(6)  1.374(2) 
N(2)-C(3)  1.400(3) 
N(1)-C(6)  1.352(3) 
N(1)-C(1)  1.358(3) 
N(1)-H(1N1)  0.898(16) 
N(3)-C(4)  1.340(3) 
O(2)-C(13)  1.356(4) 
O(2)-C(16)  1.363(4) 
C(1)-C(2)  1.363(3) 
C(1)-C(7)  1.468(3) 
C(2)-C(3)  1.399(3) 
C(2)-H(2)  0.9300 
C(4)-C(5)  1.395(3) 
C(4)-C(13)  1.444(4) 
C(5)-C(6)  1.361(3) 
C(5)-H(5)  0.9300 
C(7)-C(12)  1.380(3) 
C(7)-C(8)  1.387(3) 
C(8)-C(9)  1.374(4) 
C(8)-H(8)  0.9300 
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C(9)-C(10)  1.360(4) 
C(9)-H(9)  0.9300 
C(10)-C(11)  1.373(4) 
C(10)-H(10)  0.9300 
C(11)-C(12)  1.373(4) 
C(11)-H(11)  0.9300 
C(12)-H(12)  0.9300 
C(13)-C(14)  1.334(4) 
C(14)-C(15)  1.422(6) 
C(14)-H(14)  0.9300 
C(15)-C(16)  1.314(6) 
C(15)-H(15)  0.9300 































































Symmetry transformations used to generate equivalent atoms:  
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 Table 4.   Anisotropic displacement parameters  (Å2x 103) for mk56b.  The anisotropic 
displacement factor exponent takes the form:  -22[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
O(1) 26(1)  87(1) 100(2)  -6(1) -5(1)  -26(1) 
N(2) 29(1)  46(1) 58(1)  -7(1) 2(1)  -15(1) 
N(1) 23(1)  48(1) 56(1)  -1(1) -7(1)  -14(1) 
N(3) 52(1)  52(1) 65(2)  -10(1) 11(1)  -21(1) 
O(2) 174(3)  130(2) 63(2)  -3(1) -20(2)  -94(2) 
C(1) 34(1)  40(1) 54(1)  -1(1) -7(1)  -14(1) 
C(2) 33(1)  49(1) 59(2)  -3(1) -12(1)  -14(1) 
C(3) 26(1)  42(1) 74(2)  -5(1) -9(1)  -12(1) 
C(4) 65(2)  45(2) 62(2)  -6(1) 0(1)  -23(1) 
C(5) 46(1)  49(2) 59(2)  -1(1) -14(1)  -20(1) 
C(6) 27(1)  37(1) 57(2)  -2(1) -5(1)  -12(1) 
C(7) 46(1)  49(2) 54(2)  3(1) -6(1)  -16(1) 
C(8) 54(2)  68(2) 66(2)  6(1) 1(1)  -26(1) 
C(9) 88(2)  102(3) 82(2)  11(2) 13(2)  -49(2) 
C(10) 143(3)  134(4) 68(2)  -8(2) 34(2)  -72(3) 
C(11) 156(4)  128(3) 60(2)  -13(2) 11(2)  -80(3) 
C(12) 93(2)  86(2) 59(2)  -3(2) 2(2)  -50(2) 
C(13) 111(2)  60(2) 59(2)  -10(1) 6(2)  -36(2) 
C(14) 148(4)  120(3) 72(3)  -26(2) 33(3)  -45(3) 
438 
 
C(15) 255(7)  127(4) 71(3)  -25(3) 41(4)  -73(5) 




 Table 5.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for mk56b. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(2) 4140 2458 3649 60 
H(5) 9191 2407 6607 65 
H(8) 9954 4055 3465 81 
H(9) 11739 3942 2114 115 
H(10) 10838 2439 996 143 
H(11) 8168 963 1235 139 
H(12) 6448 943 2599 97 
H(14) 3054 2332 8447 146 
H(15) 4450 2523 9956 192 
H(16) 7958 2783 9706 199 




 Table 6.  Hydrogen bonds for mk56b [Å and °]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 N(1)-H(1N1)...O(1)#1 0.898(16) 1.879(19) 2.7064(19) 152(2) 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
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